var title_f31_24_32128="Dermatitis herpetiformis vesicles on elbow";
var content_f31_24_32128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 438px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG2AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5jUDBOaCMn2oLbeB1oLErjGDQAgPGKTnoKNtOUcmgBQcYzSEAtnFLxyBzSE45oAM460qHAOaDzgmlUjI4oAbnmnbTt60PjPApT0x60AHT3pxIwO5puOaVOO1AAvOeKFUntRuUHNAYnvQAd6UECmkdT3oTIXNADiwQe9N3Fvemk7s56UvPAHFAAQFwMUhwO9PJUEhvzqFtp4WgB+NxIxniu9+D2gDVfERvZ41e0sAHIYZDSH7o/Dr+FcBEGLhUBLE7QB1JPavpzwF4fXw94ctbJlH2kjzbhgPvSHrz7dPwrDEVOSPmzehDmlfsdHAmASeh7+hq7GAF4GfpzUcS88gemTVhBgdPm74715TZ3jot2MlcegzU4UnkkflTEznpUgIJ/WgTYoHIxzUgx34zQBwPT+tPUAZb09aVxiMBtzg9cYprBVAPU+tSEq2QBk/ypuMHd+gouAzDMMltvrSMMdB0708BscDH15qM7udxBHqKm4yJwQepx6VGRgluc9s1MwxkkmomUEgscjsKLgMyCCetQFuSMZP5YqdmXI5B254FQsVJycZ+tFwuRSctlsZ7Cms21DtXPalYZk5OD1pCM8jkUAIucH1+lOAyozgfUUm4LjfxUoxnnnNAEe1uflBHsaCqn/CpDkdj9KjLBicr/wDXpiGuAMgYqvIQg6ZOO3pUrsi596gChm3Zzn170wIZCpiLAED+VQKpGNx5x1zUshbIXAxnqKjPyn5/u+vajcZVnMfKsRk1n3KkD5cHA9avyHe7Y7DPTtVSfbtGQOf1pgzGMZ+XdgZJyCOtZl7lN6YBY8ZramXYrKvLdh6Vj3ijO1mOT1q4shnmPjG3WPUnZAdzoHOex6GuZ5B7iu58dRCNIZVwpLFGHU46j9c1xXsf0r1aTvFHnVFaTEQ5zxxSv16cUjAgcfrQr7gOBwK0IGnjoOtTWsrW8qsOoOSAajYDHXmmqxHOBz3oA7+ykE0CSDgMAcVbQY5xn2rD8P3MYiji3qHK8Ln061uo3zYx9akQ4AZ6kelPGM8/e/nSLwMHr/SnryBQA4AEEdRnjPrThgZXpxgZoUcEY4AzTwOu3Bzxz0zQA115OeCOCKKduJYY/LFFAHloweO9B4owSaM449KoYhyaeOx7U0nIpVPHNABjrSEcj0ozzxmgDJOTQANjilJGMD86COB7Uv1oAAM9KCfmwTSg479aQDPA60AKCM+tOyB0puAvHelxnk0AHU0nQGlLAD3pB81ACKc9acM8npUiBfLYbRnsfSmFTnk0ANxge1NY7jjoPSnZxjJxS7QMHrmgBjLxyCBTQgzxUpOWOTwKaqlnCR5ZmOAB3J6CgDvfg9oC6n4h+3Txq1pYYb5hkNKfuj8OT+Ar6Ct0Pfn+tcv4B0BfD/hy1smVftBHm3BA6yN1/LgfhXXQDJ6cV5OIqc8/I9GlDkjYkCngAc1ZRcCo0BJFSd8E1hctkgycY6+tPRRnvj3qMc8D/wDXUyqc8ClcBw6jJ/8ArU7juR700gdzxUg5460rjAABeOlNBAyWp7cHg9qj467Tn3pXGBk3AkDAHqKYynb3B60Slu3HcnrTS25sA4GM5pAMkyOnOemajIIUb+T7VI/BzgZNROxx0yfQUwGsnG5hz29qjdATk9MVI7tsG79KiJ3AsOKVwK7spHIOelImFXCjg0+UjZwPbBpgfCEsBkcDFNMY4Ak5zz9KkVD13H6ZqFV+bd/Ef5VMg3/eHTrQIcE2q3f1yagkbGePxqWTGABnHoKiZlLbRkn0piRCxz2+bv7VC6DhdxHqBU7bh0AOajcYOR1/nQhlaUqgwQcDv1qu/wA5GQdnYVZYAZbkn+VQMcDA4P0p3GV7hQvTg+tZ06kHOc46g/0rSmbgE9M81RucMDkYB6Gi4jPkycEKBn19Kyr5RvxtyzHAH+Na9wQEZuwrLmOQzP8AM3t29qqLJZyPi2zNxpc/y8ryoB64rzUg7uD9RXslyofcsnAYHI+oryjVLY297LCy8qT1OCa9PDSvGxxV463KRA2KT05qIDHIqduqgdMdDUbAAkg/hXSYDlIK4/i70xhgEU0MUYEU+QA4II5oA0fD+DqaEgsQPyPrXbRZOGJya4rw/NHb6grSZww2j612yBs57euKl7iJlHGRwven5I78+lNJIzinA5+73FIBwJ35/Q96QMeB17EVIIzsDevBpHUbiCfccUwEHUEnI/lRSk8qfxoouB5eSQPrSIPWkK5IGeKkPCYxVDEJx9KTHGKDg4zSnGc0AAGD1pTx1pMZHvS89QOKAF69KOgNAPpSFs8DrQAEAmlBwOKQKQeacACeaAAZ25OKAeMmnEDOD0pjAZx+VAC4zyaFwO1B5A9qAwJoAASxPOBS9+vTtSNwRSE4OD+BoAJPmORx9aYoJcDORUjrnq1N4C8UAKEG7rXc/Cfw/wD2p4oS5uIs2lgBM24cM/8AAPz5/CuNitiFDNk7uhHINfQ3w50M6L4cto5UAuZ/38oHZj0H4DFc+IqckNDahDml6HXwocZPU8k1bjGBmoYVwDu6+1Wo16dhXks7yRCQvIwe1O25zk8mgDOc8CngHjApCFVdpFWUPHpUMakjLdf6VMABSTBi9OtBYE4UdKXGTzQQc8CgBDnGT+AFRyknBU4pxz+Hc0jHLHHQflSGROx7YA71GzAH5vvdacSGJ69aikHXHakMazZfI646/wCFIuMEg+3HalRQfmbn+lJIABwAM0XEMdsAl2qJjuBbd8vrTmBBGMk9801mJySoApDKzMx6Dj3GKWIcEnOfenKxY4+XinAjOGB4ouMUIW55+maftLHkYoQKWODzT8t6j6U7iEcgABQT2qB9g9Nx61LJuJ29V71Hs7AAD2qriIJC3RQfx4qHDEkMOMfhVrZgHJz71FI2BjBz2pjuV5cqOCMdqhZAM5Jye9TuSAMj61VLAvz64GfWgCvIvLbu3IPrWfcFmYkfN7dhWjckEYyeeapS4EanYQfShAZ8ybwRtIHQZrOnUgjOQg7gda1JmySBksOCfSqUi9QxyDk81SJZkXYJ4UAtx8w7Z7VwHja08u7iuQADN8o+o616HMEEbE9zn61geJrP7bpsmOXiG5QB1x1rrw87SOerG6PMmxwDwcVG33snvViRNrlcjj3zUL4wRxmvSOMjYDkD8KU48vOOhpOvHSnJjJGKAJ9OZEvIGkPyhgTivRLdt6AjkHkEV5pt+YKB1r0bS/ltIgRjaoyKmW4mXM54IqSL1PTqMUzdn5jSqOOD0pASgk5x90ilIJpq5X7p7dKc2MjGduMc0AN/h5GfrRS5+XJ5x6UUwPKixx0p2SfpQQQvTn3oTIHNUMVRSNjp3p2Mc+9IR6nNABu7c0oJz7UmOfWlJzx0oAXIApq/Mc9BTgOKBwwoAX+Kg88CkZhu+UUbjjgUALx0poPNKvHUfjQenHWgAAPU0YweBSjAxnrQBk80AKhB5NLwxOelNYjbgAZpQOPegBuBnHUU5UBbAPSkPHNSxKAhYnBJ4zSA6z4caQdX8SQxMM20H7+f0Kg8L+JxX0PaLg5PrXBfCXQzp3hsXMsZW6vm80g9VjH3B/M/jXosKgIM15eJqc07djvox5Y+pMg+bParIGBjqahQZwfTpUyjH1rmNGOUc8DipV4GaYDjjqalTHfipY0SR/dDUuOST3oA38Dp607scmpGKcAYzRtwcjqetJj27UhbBwOtMLBkbeRx71GORjIweaHwxA/P60fKARj2FIZG3QFBjPGaYSAQoB96cWwxpjN14J70gGuT60w855oJYnOOKjJO7oMeh60ANb5QxXNQsxIztIzUkpYDCgfQ1GxYDpj2NIBvHQEZ9OlBcD+IfSjBP38c/pTdpB5xTsMsAgqD1PakAyw2t83amL2GMY4p6lQflH0piHPuBxgc+lRldrZ4yetPO7cMHA70jldhyaYEErhBls8elRStlcqf/rU9sk/Nyv8AKq8ksYBVTn2pjsV5GfnABHv1qLjYMAfUmrJ+YAL+Iqs4GD8vPegCCYlkP97NU5wwHynP19auEEFmwD2qBwxbf0X0piM9lx19Ko3BaNemS3T3rSkIAbHJ9DVCQqR8w6DIH1polmS8Jc5Y5yPyqpOq4w/3COea1LlOCASRnHoQazbsNhhjKj8zW0WRJXR5Xrlu1pqc6Mikbzt57e/vWeeeoXPt2rrvF1mDcxzt/Eu3gfxAZH6Vx7HnAIxnmvVpy5opnBNWdhGxnuPShh0PcUSL39KRe2askliBe4jUdWYCu8sg0cSK7b2A5OMVyGiQ+dqUZxkJ8xrtUTP41LEWEfcMd6ljI79elRRADipV2gDHrSAkI4zzQB2AxmjcA2cdKDggkD64oAQhienJ5ooducH7o9aKAPMCct60dcmmgFj0pSpHarGHJORS455pQMDmg0AHGCKTG33zR70AHqaAFXPPNJjvnBpQVHFIACc0APXHU0hJOccUmTSlsjgUAICaUHBFGCD0o6HJoAXaWJPajae9CtgH0NLnKgdqQDRjNOY44HUUh5HtSHJoAfHjPz9SeK3vDmktq+u2OmxjCTNukcDOIxyx+mBj8awQBkHvXsnwX0fbaXGrzD55/wBxDn+4p+Y/icflWVafJFs0pR5pWPTbSFQihBtUABVX+EDoK0FUkAE/Wq8AA4I5q3Hx1ryGd7JAMcZGKlTAFRAbuD3qZRkjP1NSwHAZbI7VMo4GOvpSDGcU9ODz+FS2UPQkZGOKcQcjjp2pN3TFByBkmkMeAQD9Kafu00yZHHFIR1JPt+FA7DH+UEgZPXjuaaxOPen7t272P50yTP49qNhERDFuTx3HrSYbduzgdBSrlWOSSevPamuwwcsM9eKQxhb5sAZNMf0x1p+8bjgHHrimMxKk4xmkBCcgnnNIcle2acpXoDkDqaHQk5BwaYiDYR8wPvSEk4DdfWpMjcc8elNCg5yP/r0DAYyD6CngnAyPw701Ux1z+NALBvu5UfnTAfnjHrUFxv24Q4B708MCDgnJpCWw3OQf0pgVmDlQCRmmMpznjj2qdzuXaMfU1GW6cdKAK8hbOe46Gq8rAAnke1TSOXzxgfzqtIMgbuccimMaSPKyOT6etVHYhQpPPep5WBj9+gAqtIuCyjH+9TEVLjOTswO1U8LvOeNvQg1euFCAEctjA96omIqoUD3polkNy+cFBjPX2rNdS4LZB5wAavMVww3bCDwD2qvKduAvPH5VaZLRzut2gurN0IyyHcOPzx+deZPGVdgxClTg56165c5MnB6Z6mvLtbg+z6jMhGMMTXo4aV00cdeNncok5XGaYv3sGn7QQSCRn2pihVPrXUYGz4bSQ3xZQSgXk12KZxxnNYnhiMLZFuRuPQ1tIRwKhiJ0xjnqKcOeSR0pqgY4GCafnGPXvQA9chuDzSgALn1pqnHPQGkZvTA+lACM3cn8aKacZ6570UwPNk5Y5pzNzj0qMgkcGnKMA+tUMVTnrQR605Rhc4pMd6AA9MUjfoKU/KM0fw80ANAxTsUDJ/Clzn1oAUEDjvSFsU3BBJpVI75zQAFgTgUEAketBAJAHBp5QjB4xSAacDjFH49aVqaeTxQAoGTgUoAzSHI6U5FLSAHpQBZ023mv76G1t1Ek0rCNBjPJOB/jX09othFp2n29nCF8uCMRqVGAcdTj65NePfBvSFu9XuNQkjDx2KARt/00bp+S5/OvcYFwnqK8/Fzu1HsdmHjZcxPEODmrCrwB0qJVOAT1NToK4Tceo5FSryOOMVGuDUiHjApDsTrjOaUDJ59aavTntS5GDnqaljRIpB4GfrSlgAcVGDwBkD+tK/C8f/rpFERJ3EA5HpTxkDkn6VXhQ7ySc554qxzgcZPXmhFPQQZfBxtGeRSthjjpjrinZwMEioTgphThepPrQydxuVwSOaYwHJ54pxdQvsByajJ34znHWkBGScYAIHtURO485OO1WHYE4GMe3aoAwbJBFAwU5UZGDQSc47etNUOxIOfXNOZXCnHX0piGvGGOe9QrlDgnj+VSsQDkg8UjKJDk445FAhD0GCcDtSg7uoI4pDtyB39KYwIJ2sQfWmA5lAGc4qJu3BwfSnkkYVsZNMZsLxz/ACpjGyMA4BHUdfSoZfl+b17UoZmLE4BHFMbC8cnvimIgkG/Izg+3Sq7gouSx+hqw5J4A596rPk/eHPTNOwyoS8jHIIx27UgOGPy4FSPuLBT371FIxHB5FCArT7Vkz+ntVZyWOF6Z/L61K+WlZgCR09OPSomZk+6oyO2afUllWaBRuLhd1UcAR5J47e5rQuGLHJYknqAO1Z29PKwvIHc1SeotWVHj25yMYHIHPFcL46svLuIblOkg2t9RXoEuAg+Uj3Pc1zni22+1WDkceS27PbHSuvDytJGFaN4nmzfKwAqzptoLu6VGbC9W+lRSKQxz94HBrf8AD9rsRpWGN3SvQbOI2oIxFGqqOAMCp1OcfpUKdetSq3AFSIsxncRT25YeoqGI8jAqU+3rQgF59aRj8uQMU1mG6nAgigBv+0RjJzRSc5HcUUwPOdvGe9OzgY703IA5pBjOetUMcxJoOABgk0KTml6UAJgsQKceTtHUUm7b9aRcgk9SaAJF5PSkbhsg4FNXLHBOBQy4PHQUALgkZFAXg+tMJOQM09s7fWgAbjjH40mSTmgkcAdaUZx1pAAyW6UuQCBjnvSbtppQu5sk8GgAHXOamhHEhzggAg/SoxweBx0rofBGjtrPiSytWBMCSiWYqeiLyf6D8aTdldjSu7Htfw/0k6V4YtI5FAuZh9onwMfM3OPwGBXXp0x2qvCMg8AHrxVtR8vHavGnLmbbPRSsrEiA7s/kKn6cHmok4Puf0qVOetQVYeAPSpkAA96jHSpV9+KkYmDipOmPfrSA/KcdaTOc5pMY7PJz+dOzu5YfhTOaVmypxjIpDA5ycDAzTWbaAOT60x2J4HX3pu4hfegYr/N8o64701lABB6AdKake0M2T609UDKN3Q9c96W4PQidQWHoe1OdVXHfnApwYb/93jIpDlhwpHpmgVyFwFB296h2/J6HNTvGDgnPHTmoWwSRnNFhocvAJHJ7e9Kx447U0siKBx0xTAz9yMelAhWORyMGo+M5GM0shz0PzUwYLcnn2piHMABk00Bj1Py9vao7ncdgU96mj6dee9NbgRyANyMEnvUWwk/L09PWppEAyQDj60wkgYPSnsFyNu2DgVGxJyRjFI5ITnB55pQUA56Gmhke0DJHT3qtOD2GcVK7nd/s981XkkAPTI9qYrETYCDP/wCqqUrA5wQf5VNKzFgrkDnp61DLIoPfPsDSGQhTkYxjvUUoChs/d9DVjcPujv68VTulMp2kYA9D1pklR8tnbgDoTVYKqLsHJHJHvVyRVjjAHbgVWPDbj1IqkIr3Cbzgj5V4Iz1NZ99AJIHik+7IpHPf61qSBtoBIyeSRVK5By2DworSD1IlqjynU4Al6EPyljz7HpXS2MapboiMCoHWsjxXAY79+DgksOc9ccVq2CsLSMDj5RmvUTukzz5KzLijtipFHPQ1EnTmpkb3xTJJEwAeMH3p2ajNODdc0AOABOaeDjOMDvUS9TzzRI2OBTAceBn1oqtK5wOfwooA4LbuxilxtBz0oUADNNY56VQwPPSlIwBSKuBSmgB2QFGevrSDLEYo25GKd24NACAZbB6ign86FQ560qgY5HNIAAyc8CkNH8QpzYxhaYCBcvnNDHj3pRyPSkAycUgBQSwLCpSAevAHNRsScUh5IwaAJkQtnGQPUivXfgrpCRWl5qZGXmf7PG/+yvLfTnH5V5Naq7cJyxIVR6knA/nX0r4X0xdJ0SysABugiCuwHVurE/iTXLip8sLdzehG8rmzGuOKtqOn1qCIYwT9asLycgfSvNZ2ki8t0qZV4zUcfcipAeOKm4yVfvY7U7JPvio0OevA71IvTgjFK47BnsOtKDxzxQeuelKBkUkMUZbIX65NKeAR3NIGC8Lz9KMndz+tJgNlG1R3PtUbABCXwKk3dWc8n0pm3ewDDK+lDGgZS6HJ4PbPWkZhj0UVLxxgdQR9KjJDZIPHsKQbiJ06dqZub7o4GMU8H5eRyegqFt2OoBOelA7DXZyTnGMYwPSq024DKdO9Plb5cLyfWgjK88tjpQNKxXOSBv6U7O7kNwB2qNnOW3DHOKaCAmF4poTQ6R8Yxn60zJAyvBpcjgfxDtTlweG4HrQSCHcPm4anBsMSeR2phGc9vQ0RgnCseP71ABJNk4AIPSkOS2/PA4qR41XAGT35qNm2huarbcRXmJHUE88n0qPcQM9afIxZDt5yKgLcHP5YoKGSsScpnbntUMy+igY6CpSfUYxUUzfNnGR0xTApuGUhl5J65pkm1k5BDVYYjb8tVpQ2Qy8sOx70CKzu2eFAOMcnNRMjsclx15A9KsTAA8dRUWdxyvUdMd/rTQirdlQFCgcdB/U1DEmVLP8ATHrU8ijJPGc4J9aYDlWJwMDqaaJK0mVx0wDjAqheDC9ge2B1rQcnGSSR6GqNz87Env2PP0q4ks4zxbEPMSTqxA7dwef0otQwjTcMccirHiON5FhI+9GxB3HHBqGFvl5NelSd4o4KnxMmHU4p8Zx15NRryaePvVqZkinnipNo259ajzxyMUobr6UIB/A5B6VC5z3pS3U1GxHP1pgNzk8GimtjnPeigZwx4HWnD1PWkxgZoYZFUArfXNKNuM+lMxmnjhcYoAEbqSaMZOR0pCMUrD5cCgBrMT07VJycZpi8YAFOwyn1oAUAZPYU49OMdaYwI6UdB3pAOxxSOctxSqeBxml2jd0oAbtOOetOVeacUwpPX2pYcbuBwBk0Add8M9NXUfEtsJFUpbH7QVb+IDoPzINfQNup29ST3rzD4L6eE0+8v2QZnlEKHHO1Ov8A48f0r1SEcV5mKledux3UI2iToOQPaplGQMUyMYyRUiA4wOtcpuh+OOBT0Q49qRck1KnIpDHKOPakyD8uCBUg5GBSHAWpYJh3wetK3XORUYySc0p4IzQMeAAePvGlIBIJ6CkVjnPf1NOIGAfegBp+YAY5NMTcrZcgsKkJCuMGlIGM/wAVIYxhjjOeKFA28cD0pHyx4OOck03nIUH60hpC9cn15xVaQMCdzZycYqyc4Pbjj3qA54LYzRYcSg5InZs8Y6UPLsDFvrxU0kXzbs8Z6VDKQTyMkjpRYu6ZDK4cYx1FQRkqTk5H9KWU8n8qiyUK55FFwaLW3dg9D607O0jP4YpqtnkHj3p/BXP61RkwDE4b1pVwGyTTThuvNRu+zALDHb2o2EPmlO4FeR6VG7YBY/lSbxkDB+uKhlkJypU4HemNIXzBnpUZHzbu54pN6qCQCSPamuzMoYcZoQEb9SAaYQwGetKuQxyePTFMnORgEAHrimBXZGZySeB26VDJnPy8mrDEgnnP1qs+VOT+A9aQiF+h3cCoHZgCFXvUkuWPX64qPop254prclkMi5b27mmMQy7VzgdT2NKckHd19KRuV4G3I5NUhFadsjK/SqM5bazjg4zV6TkgEfgKoXO3DHJOBzVxE9jC1eNZQSy9CCBWYmOBitfVW32xYrtI7VlL056+lehQfunDWXvDh04qVPujPXNRZp45rcyJd1N3D0qMnB5pM+maBEjdOtRNyT65wadu4pjMMcj60wGOetFNfAJooA4sMxFHJPXpRnApRwKoYo7UMeeKRDjrRnJ4FAB3HpUnrTcgYoDZ7UAKDngCnHJHvTRwCO9GM9TQAA8cnmndTimjhzTlHzA9RSAVwQevSjGBk/lSyEA8U3JY5GKAF3Y4xzVmFgABg5HT1J9KrgfPkkE10HhHThqXinTLR1zE0gkkx/cX5if0pN2V2NK7se6+EtOGl6FYWapt8uEBgP7x5OffJrpoulUbYE4J6tWhHwK8aTbdz00rKxLyBj35qQH5uKYO3YU8D5qhlIlXgZqROQahOSR6U9DgUgJ84wBTWOelC9z60u3NIA49e1OABPTigALz3pAeuR360hj3+6ADSDPbr3pCwA9jSbsnr17UgHdB656mkPzgE8Ck2HqTx6UODnrxQMaQSDzgGmheetLnI5FNBUAKpySOaQwDH5uOAOKqyOQVJbA9KmnBKMAcd6qSkBcHndxzTKiriPITjDDA4pkn3cr19KiuCqKApGQM5ohcFNwOaL3HJWQwANzjH1pjgA5HWrD46npURALEnvQRccpB4PTrTjgcdKZgg5HI9Kkx3NMTIwuHySelMIJz+hpx+9weKY4BPB6UxDWOFGBnFMkyeacSQPYdqjLccDrQMbtK5OQfaomcqORnPanu2AeearuzAj1oASQ9e4qrJkL8pwc1YbLMBjjHWoWX36etFgIZJPcfWoGbIBZskd6lbbjOAeaicZbaASD3PagTItwyFHfpSMNoAB6dakZETjr71C5BDY5qkSQuR1ApjsdpAFPI3DAyaikbYvAAAoQiCVtzYUjJI59qoXIG9jyQP1q48i7iAvtmqV1kEdSOnHrWiJZj6jt+zsRnIHOayCxNa+o5KsCO/pWUQFHSu+hscdbccvPJpWJB4NJnj6CkPXiugxDPFGR9KaTkZBpp9uKYDyTjrTGOTQW4+lRlvzoEIx5zRUUjcZooGckelKTmjj8aOlUAuOMUDpSZOeKXPGKAFxkU7bxTVIzzTmbLcdKAAHB96aMknHWlXilOM8UAKBxweaduKjHFNUY5pTxwelIBGY55pV4HNGRnGKFGTmgBynHQc16d8GLEy395fOB/o8fkqO4LnJ/QV5siAqpAznOa9w+Ell5Hg+CVl2tdSvNk9SucKfyFYYiXLBm1CN5newA8GrqD5R61WgBwPWrS9sDpXlnePHI7etSqOlRqDtqRAdtIB2AWGakAC1Fj5s5+lPBJAPek0BKh4yaeBz9KiXrxUoLH7vHqfSpZQMQGxS5OcY+X+dISFwf508YI+bilcCI9aRSd2acct0Hy0wnBAI5pMZIGITgEnNISQOc0E9h1NJId3GTSASRgcDsBzUa9cfnTiQc46DqajVf7x68mkULIRzhuKq3KB8cH1p8i7idxI54xUUzELjktQNaMpXAGDgA5pE+WMBBSMh3KffmpVGD600VJ6ADkDNICGyR24oQ5B7fWnLgZB6+3emZMRWVcKTz2oJ4xmggZzgU18AAgUxA2FAC1HncD2pcg9cj2prDnOaaAY3I4qM5wR3FOdhuGKgckuTyKBiEHPHSo+M8jnvTnZQ2c9KY5Bx2+lMBkjAHAAIqCUgj2+tOZvm9RTWGSOMevvQBCckdOTUbnaDk89BUkhOODgnvVaQA9yaSJEkPXLGmmM7MlgD7GgBsYzTHPqSSKoTGliOF5qrMuXLHr0HtUzfKDj1qKQ8DjmmhFVxtXb1z1NVJvlxj8qtSt8xBH/wBaqtw3yEgc1cSWzF1ByAcd/WspiMdc1pagQEJA5PSsvoc+tehR+E4qu5Ip9etKSMHnmoye9Jn1rdGQ8njimkEmkFKW9KBDTxULkAk808k54qCVsH3pgRSvx70VDI2eM0UDMA9aU+nak96Op4qgFIpDS+lL16UAJ/Ojp+NBPFGM9aAHDr7UmecGgcD3pc5FADgcdKOuCRSDj60jHnrQA/aCTzQG4wtM6UqjPPpzSAsRBz8kfLOcKvqe1fTnh+zGn6VZ2aj/AI94Uj/EDn9c18+eCbJdQ8UabbyDKGdXYY7Llj/IV9IW43fMxJbqa4cZLaJ14ZaNl2MDGDVhBUMQ7nrVlRjOK4DqFUcVJ0ApqnnHtS8Y9qQwXJbJzipFIpvagnp79aBMkXPGO9SA4A6DPSot/wAuF5pwXkEnLUmO491JANGM8elDNjGaQOBk0hjm9BTDjOaQtuGBTSc8d6kY85OMGmbgQTmhmwOOSaYTtHPrQNDlIxz79aQ544+tIzEHHamSyDO09TyaBhIcDNVm++dxFSZOSSe2ag3bhn1osAyVhkAdaaBjknk05iMZFMU5OCRxQSCkljkYppGGBwfrSlsA0hycZ4qkIaW5+fpSl8j601zngdKYWwQB0p2AG+bIJpjHCY5pxAGTmmBgVO3p60IBuF2E8/hUXzY+Y0rEAcGmSPtwWGQadgGkjnI/CoWJPC0+QjqAeaiY7eRRYZG465OSKifqOc/jUrnPOQPWoJAcErjNFhMa3zZI5qAZIyRhqkySOnPpUWSD97n0oERyMQ4APB/OmuQOnBPpRK4LZzz0wKh3EcsOp4FMkR+p7YNNOOSe9NYlm5OB6Ch9u0Z7dMVSEyvMu459+9UJ2OCDye1XrhgMelZd2xYEdOxFaRJZk6k2Rj3/ACrOYZOSe+Pxq1fNhgCc55qluzx1r0KStE4qj94c3yimqxJpMnHHAoyOCDg1qjMdu9DSMevamn1qNz29aAFd8CqssnFOkfH1qvyzADrTAdEhc5PQdaKtwqEAX86KzbKSOXbFJilPsOKG6VsSGRigH0pAOOaXOOlABikxSjp15o+hoATtmgUGk70ASZxTSDnNNY/lTkNADuo9qVSNw9KbjHGKenX3pAeifBmzMviG7uyBi2tymSO7nH8ga9utQOleZ/BWzaPQry6bH+kXOF+iLj+ZNeoW4wAPzry8TK9RnoUFaCLSDgfSp161BEeBUoP45rmZsOQZ5z2qTn1qMEjIx0/Wngkke1AxTkHljmnN8xGf/wBdIeW4p2DznikIeMKCaZ5hHTvS8YOP1pMgfU0gsOJ/PFHUe1NpQRupDF3baCpPzZpnVuakGWNKwCE0xsEZI4FKw5zSHgAEDHekykxquNvv3qGU9WI61JkYIaoJssBjjJ/SkUhm7KnPB6Ux5BnAIPamT5TBB4JxVOZ9khZeh4p3K5blvcDwKhkVtwwajW4PGePen7+fwpkNWJQ+F5xmmOTnAphHIOc55pSQoJz2pkCyMAnNVujHJyD61IW3Lk1C2cEg0wRJn1NMdgOnQ8YqEknHOCKduyPWmA3PzAdqa554GcU7IxwKiZju+XigBkrN04qJmK8GpHxgknNV2Ykc5oAbIxzjqKjZti/WkkkAxjJoJz2oQiF3JXnI9KrSsdvU5+tTSZGcc57VAw5OTxTAXfhQNoBHp3qKY8n8qa0h3Y6YqLdkEt1NMkd27D6VG/fFPDAA46+wqFye35UxEM7gdOnTNZUzcHvzyK0LhsAg/jWTdPjI6ehraCIkZN6QZ8g5A7VX7+lOkYs7555phHHNehHRHDJ3YNwT60wn3pxGenWmNxwaskQtTHb1pGaoJG4oAbI+TU9qmF3HqelVoxubnpVtWwKTGiUe/SiouT7UVNhnNL0OKAcNzzSEUY71sSL9O9GM4pRx1pCeaABsAUg9hQeozQDxxQAv86T60hOBmkDZzQA7gc0ZPOKTtntQM0AKD708fKT3wMnFR8g81ZtIjcTRwqcNI6xgj3IH9aQH0N8PrQWPhDSolGC0IlYH1b5j/MV10XQelULOEW8UcKjCxKIx9FGP6VoQ9Qa8Wbu2z1IqysWU5IHtT8kEYxTEp4HFQWiRTwcdzSryPl6imonHX8PWpRgZpAKAFOSacTTGAzknJpSwxjPNJgDNjg01Tgn1qPJJ9akbAxjmkOwvXOT+FOHBpmfzpQDnjr6Uhi55zQJCSQAeKXaTTPusevvQmIV3C7R700ttGS2aryM27cR9KrzuRjcwy3pQy4xuWixJ5+pqOSQ9cfQVVWfLAZ+ppTLvJYd+KCrWI5zu5zjHI+tVpyFQgEbu2Kkm3sOp4quVOcHrU2HcRDketShg3B6dajRQM4pOjg1SM3qSlypGfu1JncvFQ7t4Hf3p2SBx09KohilsA1E7gdOKa7YyTkGoGfIJ600BIDntxTmIIwtQKTjGaHY8cUDY8nk461AXyelPdwBwagY5JFAh24EEZqBuvFKPve5prNkYFAEb9R9abI+zJ60MxXng1BI2T9aaExsjBuhqBm64I+tK2c4PIqJtoXAIANNCGMAwyG61GQN4JNPAXGFyOKjORkdaYgPqKhlb04NOMgXOR+lV5CQee9UkJlW5fJY8En9KyruUrvzgj3q/dOBnuPSsi+Jx3OTmuimrsxqPQobjnJFM3ZNOkyDlTxTG967UcYM2DxTGJxS5/E1G74piGOagYktTnamKSZMUN2AeODxU8ZzSYHHFN5EntUlE+flxRUZbHFFFhHOHpSfWg5PSkOcc1sIXOKPc0g6YNI1AD3bgelMOetIePejORigAPIx3pOnWlIFGM0AHbrQTzSge9Jg0ALmuh+H9ut34z0eN13KLgOw9lBP9K58IT05PpXdfB+13+MFlZT+5t5GGfU4UfzqKj5Ytl01eSR7xb8jnqatxEfrVS3B2c9elWo+oHbrXis9RFpTwPU1KpweBUKHAz36VKpOOakRIHPPH4U5XYAlgB6U0Edc81HK/B20hpB5gzjPFSEjAxVFQcE5qaFiqZwfqaRbViYEgnPSnE8dahU569ev0p4PbtQxD8gEVMnT9ahRR25NTjC4HrUgxS4x8vSoGOEJHU1YfG3AFQbD04x2p2BFO8ZhHjOAe9ZUxVnURZ45JNad383y9h+tUtgDY7mho3johI0C53HJNWOAo45pm3B569qUsDkMaDGTuMc56d6rscsRUzN82T+VQyNkn1oJuRnhutDsCMjqaQt13DOaMDcO9NDBQQCelOwccnPemO+3tz60uSTx0qkSN9AT1phAUEgU7bhie1M3AnjtQBGTjBxUbSMSeOKfIah53HPSgY7ryTzUZPtmlkYcD9RUbP8vFAhGYAZPWoXfilLAjionOc0xEbsSelMd89DSuSenFQs4GPlz+PWgQhJ7nJz2qN1+bLEU92A5NQs4LHr0piuNkbaP6VC24nrgU9+Oe9MBOD0qkBGWAODgVVnkzkA8/youmZV+UZOfyqCRwo6k9hVpEMrTnb+PSse6fdJgjIFaN2/ycVkP7kc110Y9Tmqy6DGODwRTTgjkgGkz/APrpjnA45NdJzgxAHGarSNT3YjpxUByxoAUfMeacU53Z6UAcUpyRjtU3KQ5WyoBpxwQD3pAvy0Y7UADYPSilQYPPWimBzmTTST60oJzml7k1qSIAaDkdaUDIzSnn6UAN/GjOAaUgA8UHGOKAGhc9afjFKtD44oABjBxSCgdaX+tABjHSvTvgnADf6tcuo3LHHEpPUZJJ/kK8yX0P4V658EYcaZqkx6tcIg/BP/r1hiHamzagrzR6pD90c81Zj/U96qx9B9Ktp0ryWeiTJz/WplPFVkJVhjpipkP4g1IiQkZpNoAJPXrSAncemKUdPwoYxowvXFOLAcflTGOSMcU7qATU3KE7jH40/r7AVGCKcoP4UAWIMY9KkJweOaYm4LwOalVdgO7t1oENG/aM8e1RSyhTt6VMCSu89KpSyBt7t2/WmVFXIphg9cn+VV9yb+CCRTJbl1QkBSPY1SlaRI/NLDnqKVzZR0LzkEEdagOBgVXhud4JJ4p7sGHtQjKUbMex9DUJ65Jp6HAOenpUR68GkyROWb2FODBmxUeT+VLuA7cmmgY8+nam7+ccYpGHqcU0YVsdapEjmJOahZhyelPkbOajPTJ/KmAyRiTUbsMcVKxAFV3bAxjrSAaW3DNROeSOlKXPTtUTt+dOwhrMRwPzqKRuOKJXwarvJx15p2ESZ9TUUjAnHNRmQjnimmT/APXTAeQAhycnPFQknPHfvQz8U3dzxTENbOeaY7MOM44xxSM3JqCRsDAHFNCZHMTknPQfnVSV6mmbavJ71QuXIyelaxRnJlK+k5wetUnYZ6U64ctMT6DioWJxz1ruhGyOObuxjfpUTMKezVBIfQ1ZAxzk0Rrjk0iqWOfSpSOOKTfQaQgFBBpzDApAcj61IwDUZ+cU4YBApBwxoGKB3oo/GiqEc3RwBQoJpMHPPatSRcnOaXk0dTQTzQAcnqacQKaozmlI7A0AGcYpTzSAGjqck0AGT07UmPSg9eKQ+tADx15r2z4PRCPwmJB1luZGP4YArxEYPrmvdPhMSfBtscAZnlP/AI9XNinamb4b4zvUOABVlCcfWqqfh1qdTgGvKZ6BZj65pw6nrxUAOQKlB5qGxjw3P64qTquSe9QgjcfenbufpRcB/wDGMUMdozTCxzwaQnPHapKFHLDNTRsFHXpUarjLHp2qKWToB3NMpK+howy7lyegqbO5eeveqUDqijcc47U8TME3MOSePYVQpR7Ek8gC4/Ssm8fIKjPPWr0soLgEckZqpKAVJHWgqOhkSqqZ5/OqE0zY2EmtK5TceDxVB7clyTUM3Ul1EgJXrVoPgYFQIgB+lPY9AOtUtEZSdyffhOaYZF7VG2TgCmjg0GdiUHJwKcp56VHHwMkkZqQZ7UIli8g4IyaYwyeRilDbScmmue/NUhCOcL70xunpQc+9MZqYhjHqM1FIR2p7kZziq0h96BCO4qBmz1NI7kcGq7t3PFMQSMTUMhGfU0M+aiJyOOtMBWIxyc0wsfwpjHH1pGYc4607CHMR3qF5BtwOT7UPgnPamMdop2EAY9xUM75PpTicnvUErAHrzVolkE8iisu+mO3g49BVy6cdKx7l98hJropRuzCpKyIsZPJprHPtihmIqJ5K6zlI5DUJOTjvTpHz3pEXnJoAeMIKQNu+70pXGRjtQihOnSpKHZBHPWlXBB9abtz9KkxgcdaAGHigHLDPSnHkU1yBigEPbHQUUgPA/WimFzmsnGOlKTwKMcdKD9K1JFB+WgdKO3FISaAFHFJnHFIRSGgBzE9qFOKQHFJQArnPAoAGOaBxzRnNACqOK91+FQC+CrMDJzJKTkf7VeFJXuvwtP8AxRlj9ZB/4+a5cX/D+Z0Yb4ztVJGDnPFWUPBFU0YHHU1Zjbg57V5TPQJw2B+lP3HgdKhQ5OaeW49+lZtlJEo6e9OWTC4PWoQwCfpSr0H0oCxLu3N7U8YzUQYDilVst7UFEpbJ2+lJ8ok3sBgU9Tg4A69TUcqFwcDihFRGSzbTlRgtwKDOQwSQc4zVa4BByOo5pkLZkLyHLVZry6XNBZBkZ61HKQc9hUHmb87R16U8k7ORSZnJEDqOpNVHXLZ/KrUhIH1qGRSQMGkRcrbeT6ClJGORzTnzzUTjrzmi4rjS3Veuaa3BFKF5ppPOD+dNATAHGTUiDH1pgJC8A/jTlHQtxzTIYhDFsYwKH496cRyMUjfepiuRMx6ConA/GlckNnrmopSetAEUjZzjpVSQ8delTzEgZqhLJgk1SENZ8Zz1qrI+Xzmlmk/Oqsj5OT2qkhEjSdRTGcj05qEvkU3fn/GqsTckZunHNN3YGKj3ZXg5NNZjkDFOwXJWf/IqN2AHzHmkz2P40xzj+lCRNxJXycZqpM+3oefenyMAapzyBVatIxJbK91ISQo7/wAqzpD8xParE5Krk/ebmqrH0rrpo5ajuyNzVd2zzUkhqBjngVsZCAFj9KmB4pcBUGKQj0qWMcvvS5XoKa3ApIznJxSGOOM4ozxwaXGOvWgjuKAG7eM96NjHkjIqRAe9LhuQDxQBDkrxiipQvrRSA5nPrQO3NBNHQc1uSO6Hr1ppOe1Ax1OaUDjjvQA0nI4oC5HNOGKOfwoAbt4oA6c04jsKQA5OaAFxz60mOcYp1KBnrQA0DB9q9x+GJ/4o6yBYH5nGR/vGvEDXtHwrb/ikLcHp50o/8erlxf8ADOjDfGd1D6GpoyQcHuarwnBOelTqT17jivKZ6BY3YGBSqMr9aj3ZA9akTAFZMtCnA6/TFP3cY9ajA3EZzj1qZF6nHbpQUxvJA9+tWIlwuT3qNFx1qcMCCKAHKDhucUqjCnn6UqAMME8VNjkAcVSFcptFnJdcYqBoAeSMZq7I2SckEelQOw6c4p3KUmVQjK3HalLN2GB0p7nPSoGdh1NIG7hIeTkVDIwwSKcXycGopCp+tBDRGTmoTz0609iQeelMdwPamSJjLUFRmk3ZHBpvzZ68UICwmQM0oOfvDk01e2RipMgkd/arEMI7AdaRjt6nmnnPOOOahfljmkIY3Ukmq8hqeQjaM9qozPxx3piuQzuMnNZ1y3Zehqed6z7iWrSJIZHx3z7VXMmegqOWQluDTA+elapEtkoYgnml3eoqEHpzT8/L15oYh3Prj2pGODTc800nnNAXFY5PtTHcCmyOcYWq8jDI700rktiSycZqnKd3LdBUkhGCc1SuJeMA4/wraEbmUpWIZn3MTVV2xzUjdOtV5DXWlZWOZu7I5G96SNe9N6nJ6U8HjihgPII4pcY60gbjmnFt2BipACQRTkwAcUzGKcpw1AwwWOafnGAe1ISD0OKCD3pAL34pc4A44poyTxSE4AHemBKwAPFFMyD35ooA5c/KBR170p6dMEUdevStiQfqMUDHelGCTgUDj6UAB4HTml6ikznpSg/nQAmcD3oPWjPejfg0AKQQM0HoDSbmIyaYTnrQBIGHQivX/hRKG8MKoP3LiQH9DXjg6Zr1T4TTH+xLtMfduMj8VH+Fc+KV6bNqHxnpsD8D9asI+fpWdbybhircbYYAV48j0kXIhxkVKASuTUaHHPYdKmXJ4rNloeg49qkHJGaZ0wD0zTs/MeOKQxS21ScfSn243cn8aaV3cHgVHEHV8c4z1pouK0L4yCMd6U/cxnmo1PtQ7d880yGhrjBGOlMdhigE/ebp2qF5AT2FMLDXK/SoCNwIFLIQwyB0qJ8+tIY1iUHTPvULHd92pWOBionPrTRLZE744NQMQWqRuelRtwP61W4h+Mj5aQcHmow2enSpADtxxQInDZHAqRQAvPFV0+U8c1ZH3cn8aaExGOV4qGQ4HvUh4+lQzOMU0SV5DgHNZ87deatyms+4frzzVIRTuZMd6ybqchsZ5q3eSdqxpXy1axRDY8tlsU5T1xUKHvUgO2rZJITj0ozkVEG55xigvzxz6UguSE8VGz+pppc96id/WmkS2K0mcmq8r55J49KSWQgHHHuaqT3AUYHWtYxuRKSQk8wXp+FU3YsMnqetBYkkmoWfk+9dMY8pzylcHYVWdtxwKc7elMUHNWQKQcYpVABpM4PNOAqRknBoAyaUcCm9DSGOHU0bSTzSAgdqN3pQAv6Clznr+dMchselSHGzIoEKCQcg04DJpiD93uB+tLTAVkAHSignPSigZzA5pQRnpSHJPFAO2tSRc/lS9qR+wH40ZwOtAAcY4pAPSjuc0pNACHpSEikbmkHSgBxYjimKOeadjvQPegBAMtXo3wnkwt/Gzd0bH5155jJ5rtvhjOF1W6iA4aENnPcN/wDXrGur02aUXaaPW7c8D61ei5bJrMtGyR+ZrThGSMV4smepFl6AZGTU/v61FEMCpVArIpEoHXNPQDH0pEzkcVIF5IpjuO75pu8cACgE4+btUZk2E5oKRKHYfw0jAdz+FQvcf3eabu3cE8+9MLD5ZTjA6VUlz1x0qST7vXmoJGz3oDYarFsikbjmkDgHjrTXbnFAMGYD61BKevY0St+dQOSRnNMkUn1NMY54ppPY03dweTTQiWMCpFOO1RxcDinnI5piJFJz7VKTlRUMeTTwwzzVIliOc8niqszHBxU7vuOKrScdadiblWZvl69azbhsA55q5O3PtWTeOOTVJCbM+9lznmszdkn1qe6fORVePqK6IrQybJlHGSOaRpPmx+lNlk2jA61VMgz1ppXBuxZ8yk3461DuGKa0mO/FPlJuTF6rySeh/GoZZwvfJ9Kpyys/sPQVrGm2ZSmkSy3HXByfU9Kqk5ySaCcCmZAreMUjByb3FZqru3FPY1BIeKoQ0tzT15IJpmOlOUjNJjHuMUDOBTQctTwcmkA5W4waM4FN7mpFUbcmkMap9qZK2FwOKeABk00rnigBsbZGM9anAwvAqGNQsgBq0rBW9qGG4W+BJsb7pp7IquwyWNNkUkfLwc8GmrJyd3BoATHoOc0U4KXbiigRyw60oxjHegEYpOCRjFbCFAxSHIB4pRweaU5PTjNADTwtAzik6HB6UE++KADtSkY75pvOPelAoAX0zRznBpf4gDSHrQAuTuz2rovAk5g8S2+ekqtHn3I/+tXO96vaJd/Y9VtJSRtEi59h0qZq8WiouzTPdrJ8nvW5a8gY6muZ0yT5yOororIkEeleDPc9VbGmlSgHg1XQkCrKNnA9azK2JgcYPpTkbJpFI2kCm7uCB0oKWo9zyecVVlAzkkkVK5z0HSq8hY8AVVjSIBgDwcUuWIzg/Wk2xqQXOTSNOBkA8UAwOMdTmo3KjtTWJcZXios/3uaRLBiME96hMhNOd+MDpUDsMdKYgdx1qJnz0pJD8uTVcNyRzigLEjSDPPWjOelRs/Y05HqrEsljJFTB8iqqscjPSpFYA5FFhMmR8U7PcVHuGPrQSDxVIhsHeq1xIMetOkbHANU5pOue1WkQyC5bg81jXkmAeetX7mTg1gXs+WNaQVyWypcPlqVBgZzUAO5yxpZphHHkmt7dDO/UZcSc7RTAcCqr3C54BY+pqFpnfgnj0FbKmzF1EXJJwvU5PoKqtcM3TgVGTimE1pGmkZubY4mmbu1BJ9aYc1ZArNTc8U1utMZsDAoAV2wOKg6tmhjmnbcCgBcDrSZpCT0FKe1IY5MU7HUmo0U54qbjGB1pAItP3fwg00DC8ikyB8x60gJSoQc1H79KXdvpMGgBQN2KWVygXinhStKVzyecUAHmELletRSuDg5y1OwWB4pvlfuuF5FMCSAEodpIPvRSRvhdo60UAcz1oHTp0o5oyNuBya1ECnPNOLZ6A5pFGVoUgHFACE9j1pR9KDzkjrQg9TQAuR1NJnuKD0OKMHGKAFOAN1IeaMYOeM0mc9RQAp9KMcZU80L60hPUjpQB7D4Vvvten2s2eXQA/UcGu3s3yoA4PWvHfh5qACyWjE7lbzFz6HrXqtjOHQDoa8fEw5Zs9KjLmijdik5I71YVzgY4xWbEWDZHJqws3rkVxnSkXg5BNPQjAxVQSjp2NKr7eKYy0744IxUMjgEYpiyBmIJpkq8EjrQUtBjtuYg0igDJPNIocjOOtNkDAZzigq/QV5MComYsOBSZwDnqajeXAwaYhshINQsxyfakluMDiq/nAk5poTRK7lqYBg8Goy9MLYPBp2IZOxpgIqIPluTTScHrmqJLKyCpEYEGqisuKeGGDigTLZfgZqJ5cZxUJYgdajcjbwapIhjnlqnPJxSzPtzms+5m4NWkQyve3HBFYcz7m4qzeS5Y4ql0BzXRCNkZNgWCjmsy7nMrYB+UfrSapcSFdkPT+I/0rPjuecSAqa6qcOrOec76ItBucGnA1FkEZFKretamRKW55prdaXqtIM96AExTSQKdkY5prc8igBjGoW71IxqJ+lABEu5/apjtAPrUMLYznrTzz2qRjCMc+tKeooPv0pcHFAC7gB70KMZPem9Vx3pVBpASA/Lik20Jx+NKSM0AIO46Uu8g4xTCQaF3MfegCUSZODToyRndTXiIXOc00kqV3UATKcI3XNMhZypLDjNLI2ACOhpFyVODgGgBxZT90YaigIOOefWigGcxnbwKTtgCjndjHTtTifzrUQhH4ClI6Y7Ug5HsKM4OcUAH44pzbcLimilP8qAFyAx4pD14NA7mkzxg0AKAPWm9+KO9BPORxQAueeKByuOOKaOlNz196ALul3raffQ3KdUbJA7juK9t0i5Se3iliOVZQwPtXgpPSvRfh3rAezNi7fvIeU91rkxdPmjzLodOGnaXL3PVYZjs9KnSTctYlpcksN/QirJnMbdeOteS1Y9KC1NVJMH2FSiQHp0rNS4VkJB5NPEoAHPWlYtl9nG7cCKDP6c1RWXHH5VKsg70WEWBMMcGopJge9V5ZQuSKrSTDHtSGlcszTrjjrVCWXc3J4qGS4B6VWmmxgitIo1jEneTPOaA4xxVD7QAetPWXPQ1XKRNNFtmbPPNMZsGofNUd+aQygNRYxJ/N5wBSl8AkVWMnXBxSeb70WJZZD5FKJMc1V8zj3pBJxx1ppCbLZkxyTmopJuPaoTJhetV5HI5Bq0jNsdPLk1mXUo55xU08uAec1mXMnNaxRlJleZ9zVENpbDNgVXurlYzjI3noKrJcEH5xXXCHVnPOfRGk9krglMHNZl5p/qtX4LrGMGrPmpKMMOTW2qMTlWhlgOUJIHaljuFJw/ymuhuLNXGUxWZc6fnOVp3AhDZHByKkVqoyQTQH5CSPShLsZw4KmgC62M4prDHemJKjjgihw7H5RxQAj4qGQ1HK0gbB601EkY8q2KAJIzluKn6D2psS5GAOakbI61LGMzxT1YYxim9egpq5B5pADqfpSZIIFT/AClR61Ey4bJFACq3r1pwwVpOOtJnJ4pDHMNoBFEY+YY6GnFNwGaaPkbjtQBYI2Lg4IqCRgWBY8UrHK57+lRleBnpQLYczbgoxxQGPTbR/CM04nKMO/rVACkg44I9aKj2kDqaKAOfBIbGKXHsKQZGc0hyTgYrQQY2jmlFKBzg/rQwwff1oATPWhsigdKSgA3Z4HFIfrmg9aTOOMUAG6gnikByeaRjzxQAu7gjvTRRSgc0AKOas6ddyWF7HcQkhkOceo7iq2OKcBxz1o3BOx7Nouqx3tpHPCwKnqM9PatpZFkUAnArxTw/rEmlXQwSYXPzr/UV6XZalHPCskLB0boQa8yvQ5HdbHp0K3P6nRrNsOO1Oa4Ax7Vkx3GT14NTtMNuOK5eU67pl9LrPXrSvcOeVzis9ZABk0ouGxwMijlHoXnlZhyaiLAH5jVJ5WZfl4x61ESSOW5pqIItSyKOVqlJKWHoKZLIVHTiqkkxI6HFUkWpFgsPrT0kJXrgVQZySNmamTO0ZPNVYiU7l6MjPrSmQKc8AVV83aBg1GWycmlYxcrlrzMknGRR5vHSqplIFN8wkE5pqJm2WvMy1BmwOvPvVMyY/GmvLxwc46VViGy20wqGWfPTgVTabAqGWfAOTiqUSJSJZpetZlzMTkL1pJpy5wtV+evf1rqp0ras5p1OiKs0O4ktz71CN8XA+YehrQbpUbJmugxK0bqx+Q7W9DU6zsjfPUckKnPHNRfvI+GG9KBGrDcYHBqyJUkADVho4bmI4P8AdNSxzMpw3BpWA1ZbRHHGKz7jTVbOVqxBcHI5q2swI+bmgZzkmlkcoSKRILuE/Kdw966Jth5Uion2imIxD9oDZeAE+tXLVd5/e5B6YFW2dApJ7VSact9wYHrSAjvFVLk+XjGKiPJp+MnPr3pvQ1DdykGOtR4qZjgcCoWODQAAEU5hkdeaAOhpxGR70wIVB5FSRLtByaTpTec8UhkqsM4HSkkyTnPAqPaQD605OevIoAWJx0zk1IFyM1C6hBlBzT1beuevrQAuBjrUmAI+B0/Wmg7mx0pTgLj0ouBHkgEkZ/pRT8/NgDiincDmQM89qBtLZB4oGT7UYA6VqSOVvvdDTCSzCkOMHilGMcmgBCM5xxRnJ5/SmlvYUHI5oAcSAKjJNO7UnUYoAB0pO9OxiigBOM0vpS4obmgAJzgUo5NJ2oNAByDV/TNTn06UNA5K55Q9DVA8Gjoc0mr6MabWqPRtJ12C/UAHy5e6E/yrYWU46nNeRLIysCpII6EVuad4kurYBZ/3qe/UVy1MNfWJ2U8VbSR6LHM44yCKeLlh7e1czY6/a3IAEnlv6PxWos28Aowb6HNc0qbT1OqNZS2NM3JPI4qJpjVFn9c0jSn3qeQvnRdefpxk9qhmlLY3LgVV84496RpCRzk1SiLmLCydu3oKcZAB1qopyeOKVpFXvk07CZcEnHv60x5OvNVPPJ78UhfijlM3IsPKAKi85vwqEuM8GlGT0BP0qlEzckSNIx5zTTJjvViCwubgZCbV9W4rRtNIjjAaTEj9s9BVKJlKokY7K/kmVgVjHc9/pWbLIznJ4HpWrrs4eYRKfkT0rJI3V0xgonPKbkNOcikz60MCKTB71ZA7oDSDtQOmBSFscfrQA7H503YDR796cDjmgCtLagkEZB9qiO9OJBuX171orz1pkiA9elAipExAzGcj0q1DOG4Y4NVZodrZQ4qPeVIEg59RTAvyuUPHSoxOD1NNSUFQJDkdjUE0WDkHj1FAx1026MgHrUUZ/d1GyyL0OQaVMipYIeWxwaCQVzTG5zTlPGKkoM8YNMYZxinkDpikXAODzQgGpndhvwp/Rs54oc/N0pOvWmIXbuzio+QacGIGOgpG/wBnNAC5BYUKTkrjrTCeBxS5zx3pWC44FVOCc5p0QUN8o61HIgKgDtTlwq4yeKBjuScrxTwxOCcc1GewycelIOAR78UASDIznpRSbsrxz/SigTZzZOWGRSHnnoPSkB28d6Rmz04rYQrYAznk0mR1700jjnigHPAoAM+1A560ck80vHrnNACj7ue1C0nXrRj0oAAMn3p3GM0DhaSgAo9hSnr6UnQ0AHQ0d+KCcdhSdOaAAd6MZNKMZ9qQdc0AKevvS9jSY5JpQcDmgBASKsQ3dxDzHM6/Q1X+tBGRQBrQ6/foMGQOP9oVZHii4A+aGM1z5JpD0xUuEX0LVSS6nTL4nO0E24z7GpovEkbH5oGH41ygqeEc1Pso9h+2n3Otj1pJOBEw/GrMV4sh+5+ZrnLMdK2bVCSD3qXTiP2s31Nu2iE3J4FaKaYhGSSar6YhGM1twqAuSciocULnk+pXt9Nttw/dg/Wrv2SND+7VR64FWIogxGOKttEEHHOR1oshXbKixDHUVX1Em2tGkJxkYFXlwrYOd3oawPEl35sqRJ91Ov1q0hGDMCzEnnvUewBfep2GRxzTCARVklZkzz3qLZVsimsPWgCqV5pjLzkfhVllphU0wIQcnml29aeYsDNIMCgBUBz1p7ADFMXg0pOTzQIc8YK1CYkYEMKcZD0FB4WgCq6IjAK2DU9uImO2QYJ9OhqterkAr1FUt75+ViKBlyfbFcsqkFO1QM25yV6dKz72UxR5DEs1WrFsWqbup5pPYETEccGo2bb061KcHpUR4apQx4fIGeKkwMA96gb6UofgDqaAJnxs461XkJGMdqmU1G685oQCocjPen8+mKiYFcY5qcy5jAI5xQBFjjikPqDzSEjOCcClA4zQAvOzg9aQNwQeKRcZ4PFD55P507ANDuGI6j1qYHIBPBqAckY61LCcnB4NJjQ9uFAzjnNFEjAqSe1FJAc1nAHvSHpxRRWxInJ60oOM0UUAHUUAYoooAXryaD2oooAC2cDsKB0OKKKAEHzA56ijoMmiigA7+9BoooAVulIO9FFADs/LQOVoooAQnikNFFACE8Up5oooAOnFWohRRQBpWnGK6DTkzjNFFZsaOks0Bx9K1bVcjrxRRUFGnCgVcmpgcjjgelFFIRBKSkUkjYO0Vx1wpldmJ+8c0UVSEyAR4BGabtxkUUVQDWWmbeKKKBEZXmmnjpRRTACAahf5TRRTAMjGMVG5IoooAOg96aXyCKKKAIJapSjBoooYGRcN594F6AHFbCAJH07UUUpDQ1DTpB09aKKhgSRYZcEUx48Z2miimBECQc1IrbhnFFFDAM8k4qQx5hD56dqKKAK5yzcGnj7p9qKKGCEH3cikJBU8UUU0A1fmb0qRSEP4UUUMEJLnGR+I9aKKKlA9z//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A few vesicles are present near the elbow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32128=[""].join("\n");
var outline_f31_24_32128=null;
var title_f31_24_32129="Patient information: Bronchopulmonary dysplasia (The Basics)";
var content_f31_24_32129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/62/8163\">",
"         Patient information: What to expect in the NICU (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bronchopulmonary dysplasia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bronchopulmonary-dysplasia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H113836535\">",
"      <span class=\"h1\">",
"       What is bronchopulmonary dysplasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bronchopulmonary dysplasia (called &ldquo;BPD&rdquo; here) is a serious disease that causes breathing problems. It happens in babies who are born early and have a lung condition called &ldquo;respiratory distress syndrome,&rdquo; or &ldquo;RDS.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113836550\">",
"      <span class=\"h1\">",
"       How do doctors usually find BPD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Babies who get BPD are already in a part of the hospital called the &ldquo;neonatal intensive care unit,&rdquo; or &ldquo;NICU.&rdquo; That&rsquo;s because they have RDS. Doctors and nurses in the NICU take care of newborn babies who are sick or were born too early. They watch babies with RDS for signs that their breathing problems are not going away.",
"     </p>",
"     <p>",
"      Doctors know a baby has BPD if the breathing problems are still happening 4 weeks before the baby&rsquo;s original due date. Signs that a baby still has problems include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Needing extra oxygen",
"       </li>",
"       <li>",
"        Needing a machine to help with breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113836567\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If the doctors and nurses in the NICU think your baby might have BPD, they will do an exam and order a chest X-ray. The X-ray can show signs of BPD.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113836582\">",
"      <span class=\"h1\">",
"       How is BPD treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most babies who have BPD get better in 2 to 4 months. Depending on your baby&rsquo;s situation, doctors might keep giving treatments to make sure he or she gets enough oxygen. These treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using a breathing machine",
"       </li>",
"       <li>",
"        Giving extra oxygen through a special hood, tubes in the nose, or a face mask",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Giving breast milk or formula that has extra nutrition &ndash; Babies who have BPD can use up more energy than other babies.",
"       </li>",
"       <li>",
"        Giving the baby less fluid &ndash; This can help the lungs work better because it can lower the amount of fluid in the lungs. If this does not work well, doctors can also give medicines called &ldquo;diuretics&rdquo; to help pull fluid out of the lungs. This makes breathing easier. But these medicines are not usually needed.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your baby has BPD, he or she might be in the hospital for several weeks or months after birth. The doctors and nurses in the NICU can help you spend time with your baby while he or she is there.",
"     </p>",
"     <p>",
"      Babies with BPD can have other medical problems after they leave the hospital. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        High blood pressure &ndash; This usually lasts about 4 months.",
"       </li>",
"       <li>",
"        Eye and ear problems",
"       </li>",
"       <li>",
"        Heart problems",
"       </li>",
"       <li>",
"        Development problems &ndash; Babies who had BPD might not learn to do normal activities as quickly as other babies the same age.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The doctors and nurses in the NICU will watch for these problems and help you get treatment if they happen to your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113836596\">",
"      <span class=\"h1\">",
"       Can BPD be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can do some things to lower the risk that a baby will get RDS. This is important because having RDS is what puts a baby at risk for BPD. Doctors can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Give steroid medicines to a pregnant woman who might have her baby early - This lowers the risk of RDS that can lead to BPD.",
"       </li>",
"       <li>",
"        Give your baby treatments to lower the risk of RDS, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Using a device called a &ldquo;continuous positive airway pressure&rdquo; machine (or &ldquo;CPAP&rdquo;) to help the baby breathe",
"       </li>",
"       <li>",
"        Giving the baby a medicine called &ldquo;surfactant&rdquo; to help the lungs work better",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H113836611\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/62/8163?source=see_link\">",
"       Patient information: What to expect in the NICU (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/24/32129?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83626 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32129=[""].join("\n");
var outline_f31_24_32129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113836535\">",
"      What is bronchopulmonary dysplasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113836550\">",
"      How do doctors usually find BPD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113836567\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113836582\">",
"      How is BPD treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113836596\">",
"      Can BPD be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113836611\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/62/8163?source=related_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_24_32130="Construction of an ileostomy - suture to abdominal wall";
var content_f31_24_32130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Construction of an ileostomy - suture to abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 505px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH5AdIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKoaxrGn6NFbyapdR20dxOltGz5w0jnCrntk+tAF+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK5n4i+Jz4T8LXGoQW/wBr1B3S2srXvPcOdqJ+ZyfYGuhtDObSE3aotyUUyrGcqGxyBntmgCWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfGXh208V+GNQ0XUMiC7iKb1+9G3VXHurAEfStqigDifhd4iuNU0ufRtccDxNojC01FP75x8ky+quuGB9cjtXbVwHxD8OX8Wp2/jLwmo/4SHTojHNa9F1G2zloW/2h1Q9j9a6bwh4k07xZoNtq2kS+ZbyjDKww8Tj7yOOzA8EUAbNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNkdYo2kkYIigszMcAAdSadXlWvX938S9Zu/DGhSyW/hW0fytY1SM4Nyw+9awn9HYdBx9QCTwq8vxD8ax+LHDL4X0nfDoqOMfapj8sl1j+6BlU/E8V6jUNnawWVpDa2kSQ20KCOOOMYVFAwAB2AFTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFebeKvDmo+GNZm8W+BbYzTyndqujI21NQXvIg6LMOx/i6Hnr6TRQBieEPFGl+LdJXUNGn8xM7JYnG2WBx1SRDyrD0NbdcH4w8D3M+r/APCSeDL1NI8TIu2Qsube/UdEuEHX2cfMKf4a+IVtc6pHoPii2bQfE+P+PS4P7q4/2oJfuyA+n3h3HFAHc0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFRXNxDaW8k91LHDBGu55JGCqoHck8AVy/izx/ovhy8j05nl1DXJv8AU6XYp51w57ZUfcH+02BXOw+D9d8bXkd98SGhg0qJw9v4ctX3xZHRriT/AJasP7o+X60AQXWqap8Ubx7HwzcXGmeDY2KXmrqpSW/9Y7YnonYyflXpGh6RYaFpNtpmkWsdrY267Iooxwo/qe5PerkUaQxJFCipGgCqijAUDoAOwp1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUyeaO3gkmmYJFGpd2PQADJNPooAwPD3jPw14jH/Ej13Tr5v7kM6lx9VzkflW/XMa/4A8J6/J5mr+H9OuJv+e3khJB/wNcN+tYM/wAPdU0sB/BfjDV9MCfcs75vt1t/u4k+dR9GoA9ForzMeM/Fvhk7fHHhc3NmvB1TQC1xGPd4D+8UepG6uz8M+KNE8T2puNB1O2vUX76xv88Z9GU/Mp9iBQBs0UUUAFY/inw1pHinTGsNesYru3PK7xho27MjDlW9wRWxRQB5n/Z/jfwPD/xJ7lvGOjJ/y530gjv4l9Em+7Jj0cA+9bPhf4k+HdfuTYm4k0vWF4fTNTT7NcKfZW+99VJrs6xvEnhfQ/E1usPiDSbPUI1+758QZk/3W6j8DQBs0V55L8NZLFceE/FniDQ1X7luJxd26ewjmDYHsCKi/s/4q6fxba54X1hB3vbKW2c/jGxH6UAekUV5udX+KcAAk8LeGrs9zBqsiD8mjo/4SH4m/wDQi6Tn/sNj/wCN0AekUV5uut/FGQ8eD/D8Q9X1hj/KOnm/+Kh5XQfCSj0bUZz/AO06APRaK84bWvihbkGXwj4fu17i21dkJ+m+Ok/4WXfaWR/wl3grX9Ii/iubdFvoE9y0RLAf8BoA9IorK8OeItH8SWP2vQtRtr6DoWhcEqfRh1U+xANatABRRRQAUUUUAFFFFABRRRQAUUVW1K/tNLsZr3UbmG1tIV3yTTOFVB6kmgCzRXmK+MPFXjFyPh/pUFnpOcDWtZR1WX3hgGGYejNgGrcHgDXLo+Zr/wAQPENxK33ksPKsoh7AKpb/AMeoA9Dorg1+GGklcT6v4puD6ya5c5/RwKd/wrDR1XEWqeJ4/ddduv6vQB3VFcD/AMKxswcp4m8Yp7DWpj/Mmg/DO3PDeK/GRH/YYkFAHfVR1PWNM0mIy6pqFnZxjktcTLGPzJrkP+FV6FKAL6/8R3wHa51q5YH8A4FT2Pwq8DWc4mj8MadLMORJcoZ2z9XJoAz7v4u+H5pmtfC0OoeKL4HHlaTbtIgP+1KcIB75phsfH/i6EjVLuDwdpz9YNPcXN66+hmI2R/8AAQT716JbW8NrCsVtDHDEvCpGoVR9AKloA53wh4N0PwlbyJo1mEnmO6e7lYyTzt3aSQ/Mx/SuioooAKKKgvry2sLSW6vriK2tohueWVwiqPUk8CgCeo7ieK2hea4lSKFBlnkYKqj1JPSvNpvHet+K5WtfhrpPnW2cNrupo0VmvvGvDzH6YHvVm0+F9rqG2fx5ql54quwdwS6Pl2kZ/wBi3TC/99bjQAX3xZ0SS6ksvC1rqPim+Q7SmkwGSJT/ALUxxGB75NLBN8S9bUk2ug+F4G6GV2v7hR9F2Jn8TXeWNna6fax21hbw21tGMJFCgRVHsBwKnoA5/wAJaLqukLdNrXiO71yadlIM0EUKRYzwioB1zzknoK6CiigAooooAKKKKACiiigAooooAKKKKACiiigArjvF3w70PxHdLqGyfTNbjH7rVNOk8i4T6sOGHswNdjRQB5iniPxT4FQx+N7Y61ocfA13Tov3sa+txAORju6ZHtXomlajZ6tp8F9pl1Dd2c6745oXDK49iKskBgQwBB4IPevMtW8I6h4JvbrxB8Ood8Mh8y+8O7tsFz6vD/zzl9hw3TFAHp1FYng/xPpvi3Q4dV0iUtC5KPG42yQyD70br/CwPUVt0AFFFFABRRRQAUUUUAFFFFABRRRQBwfjL4fx6hff294Wuf7C8VxDKXkK4juP+mdwg4kU+p5Hb0rR8AeLD4jtru01K3Fj4i0xxBqVjnPlvjIdD/FGw5U+n0rq681+KVhL4f1Gz+IOjoftWmKIdUhUf8fViSN+fVo/vg+xoA9KoplvNHcQRzQOskUih0dTkMpGQRT6ACiiigAooooAKKKKAEZgqlmICgZJPavKNLib4reIhq96m7wNpkxGn2zj5dSuFODcOO8akEKD1PPtWx8YdSujpWm+GdKkMep+JLkWCyL96KDBaeQfSMEfVhXbaVp9rpOmWun6fCsNpaxLDFGvRVUYAoAtABQABgDoBRRRQAUUUUAFFFFABRRRQAUUUUAFFFc54+8UxeEfDz37W8l5dySLb2dnF9+5nc4SMfU8k9gCaAI/G3jPT/CkdtFNHNe6tesY7LTbVd09y/sOyjux4Fc1pvgS/wDE9/FrXxLlS6kRvMtdCibNnZ+m7/ntJ6sePQVq+APCNzp1zceIfFE6X3ivUFHnSgfu7SPqLeH0Qdz1Y8mu3oARVCqFUAKBgAcAUtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5d43gl8AeIl8a6THjRbl1i8Q2sa8FScLdgf3kz82Oq/TNenQyxzwxzQuskUih0dTkMCMgg+lNvLaG8tJrW6jWW3mRo5I2GQykYIPsQa8++E92+jXGp+A79n+1aGQ1k7nmewckxMD3K8of90etAHo1FFFABRRRQAUUUUAFFFFABRRRQAVDe20V7Zz2tygeCeNopFPRlYYI/I064nitomluJEijXks7YArldQ8cWaFo9NhkvJOgb7qfn1P5VnUqwp/E7G1HD1Kz/dxuZfwMuZ/+EIbR7yRpLrQb240h3bqVifCH/vgpXezzxQLunlSNfV2ArwHwHea3e+IvHQtrg2kMur75Fi4+cwx5wevp3rrk8Oea/mXc8krnqWYk1y1MbZ2hG53UsuTV6k7emp30/iTRoDh9Rtyf9ht/8s1WbxjoanH23P0if/CuSXw7AOjYFTJoFt3yax+uVnskb/UcKt5P8P8AI6qLxbocmMX6KT/fVl/mK0LfVdPuQPIvraTPZZVJ/nXDnw7antVafwzEfu4H4U1jKq3iiXgcNL4ZtHp3WivMINJ1Cy50/UJ4MdFVzt/LpWlb694gseLqG3vox3H7t/04/Sto42P24tfiYTy2X/LuSf4f195TUf2r+0C/mfNFoehAxqf4ZbiU5P12RgfjXpNeLeHPFdlbfG3xJLqKS2YvtKtGQOu7HlvIrcjtyK9fstQs75d1ndQzj/YcEj8K6Y1YT+FnFOhUp6yiWqKKK0MgooooAKKKKACiiigAooooAK8w8Ks3jr4iXviaQl9A0Jn0/SF/gmn6T3A9cfcU+gNa3xb1250/QoNH0c517Xpf7PsQOqbh+8lPsiZbPriun8NaLZ+HNAsNH0yMR2dnCsMY7kAdT7k5J9yaANKiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvOPi5ZT6VJpfjrS0LXugsftaKP9fYuQJlPrtHzj0KmvR6juYIrq2lt7hBJDKhjdG6MpGCD+FABbTxXVvFcW7rJDKodHU5DKRkEfhUleb/AAbuJtLj1rwVfys9z4duPLtmc/NJZSDdA3vgZT/gNekUAFFFFABRRRQAUUUUAFYniPxBb6NFtx5124/dwqefqfQVS8XeJl0wfY7HEmoSD6iIep9/QVzmj6cZZGur1mlmc5Z3OSTXFXxNnyU9/wAj0sLgk4+1rfD0Xf8A4BVuINS8Qzi41SYiMH5Il4RfoP61pLb2Ol2rSyFQsalmZuwA5NJquoCIeTBgY6kV5T8Rdaub54PDWnzsb7UsrO6n/UW3/LRz6ZHyj1Jrzbrn7vuexaTp9l0SN/4S6hH/AMIzd6vcArLreoT6jtPVUZtqD/vlV/Ouuk1kSMNgwtcZCI7W1jtrdQkEKCNFHRVAwAPwqZbkqM8VlUxLk3Y6KWBjCKT1Z2C6gDgZ/Wpo74gAnoOtchHc8DBOKupeEA/McYxis1XY5YVdjqo78jHTpViO+VuGHSubt5GZetXI2wvWt41mcs8PE2zIM5U8U5WVwM85rFSRiTg4qxFKQcZrRVLmUqNji/iTZw6T4r8NeJmT/Q/MOlXx/uxzEeW59lkA/wC+q37zw0UfzbGV4pRyCDjFamsabaa7ol5pmooHtbqIxuO4z3HuDyPcVzHgDX7yOeXwr4nk/wCKg09cRzNwL+3H3Zk9Tjhh2NayhGpG/YyhVnRk0nozUtfEfiHRXEdyftcI4xKMn8GHP55rs9A8V2OrFIXzbXZ/5ZSHhj/snv8AzrJleItsmAIPrWJremxvH5tsNpHIK8YNEK1Sls7rsy6mHo4j4o8r7o9Torl/AWtyarprw3TFru2IV2PV1PQ/XjBrqK9WnNVIqS6nhVqUqM3TlugoooqzIKKKKACiiuS+KviGXwz4D1S/sudQZBbWSDq1xIQkYA7/ADMD+FAGD4OhbxV8SNb8V3OGsNKZ9G0leoJU/wCkTD3LjYD6Ka9LrC8C6CnhfwfpOjI282luqSP/AH5Ort+LFj+NbtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB514ugGifFTwn4iU7IdQSTQrsjuWBkgJ/wCBqw/4FXotcB8drWWb4ZapeWmftelNFqcBHZoJFk/krV22m3ceoada3kBzFcRJMh9VYAj+dAFmiiigAooooAKyPFmtR+HvD15qkqF1gUfKO5LBR+GSM+1a9Z3iHSoNc0O+0y6yIbqJomI6rkcEe4OD+FKV7aFQcVJc2x4/ok97dv8A2lLYXFyZ/wB5vLIm7PcZOf0rY/4SCFpWt54p7O4C5EUq43D1UgkH8DXAX1zqOjXVxZ6rclJrSQQzKGKFSfuunPKsMEflWvaO3i7TJtO1PMF3CBNA6nlxj5XP5jIHrXguMo6M+ylTjJKotV5dCp4k8ZJHeSaVodtJqeuYz5CDEcGejSv0Ue3U1leH9IbSI7i5v5lutYvW8y8ucfePZF9EHQCtGzkV45JQgiu2+SbA5DLwQfoarTNKXJZwfwrjqVtOVK3c6aWH97mk79vL+u5Ye4OTjrTFlbJyarlsChXzXM2diiadu5zyTWnbNyKxLZ8Ec1fSUrg0uaxEo30N+BsHOQOKs+aQRjpWLbzE45rShbcRmt4TucdSFtzUibgVZi5qlH0FXofu11Q1OKoWYj15rB8a+HLTxFp0IllltL+1fzbS+gOJbd/VT6HuOhFbiHFZ2r3QjjIBxit3PkVznVP2kuU5DQda8QQpc2/ihbR2tGCJewZUXC92KH7p9cHFdINQmlthOJoLSycDZJLyz574zgD9awbZG1bV44WyYU/eSfQHgfif0BrF8R3k9zqrfY2xDE5hghx8pIHLj0xxWUJufvHoxw6TUF03Oy8FSzW3xAtILe6jmguYJWlKDghQOCO3JWvX68i+CenQie41q5lCy3Ie1sllf55UQgyyKD1BYAcdl969dr2sLBwppM+ZzOpGeIfL00Ciiiug88KKKKACvN/HqtrXxP8AA2g43W1q82t3I7fulCRf+PyZ/CvSK4LQsah8ZfFF2eRpmnWenp7GQvM/846AO9ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKOu2KanomoWEgyl1byQMPUMpH9a5T4HXz3/wl8LyynMkdmtu/OeYyYz/AOg13BZR1IH1NebfAmaO28G31g7xp9g1i/tgNw4AuHI/9CpXHZs9Koqub23HWVfwph1G2H/LQn6KaXPHuPkk+hboqkdTt/Vvypp1WDssh/AUvaR7j9lPsX64jxx43l0u/i0HwxY/2x4puVylqGxFbJ/z1nf+BPbq3QVQ8feOLq3mg8O+FI0k8UaghaIy8x2kQ4aeT2HYdzxV3wJotj4P0uSC2WW7v7l/Ovr+dszXcp6ux/kOgFDqRXUapTfQ5bxf4H1KHwpHreq3/wDa/iWxLT3MwiCI8J5eFFA4RRyucnOT3rj/AA/cLaaiskTlkh2mMj+OCTp+WTXvNxqIngkieAFJFKsC3UEYr500iMxCxQnGIri1J/3GYL/IV52M5X70T6PJpS5ZUp7HReKII7TxGxjUKLuESnHd1O0n8iv5ViTMd5rV8VSGa28O3YPLKyE/Vf8A61Y87dMV4ldWme5h78iT6BnIpoJBpkbHdUwGTWLOgkhY7q0IiW7VShTPIrStkx1pWJky7brgcVoWue/aqcS1ftcYNa0zlqs0oDkDmtBOMVmW3Dgda0lzXbTPOq7krNhCfauQ1+7IDDPfFdTcnbAx9q4LWpN0gGf4qnEysrGuDheVzQ0WRrXRtTvF/wBYzeXH+AAH6k1zcVo95fGysyfOuZk0+AjqpY5kf8Bk5/2a3PMEPh7TgTgSXDSn3wWP9Ki+GRVfF+kPMu4xWlzdAf7TMqZ/JjW+Gim4pmtebp0alSO56r4h8B6LrWiWNg0T2cunKBp95at5c9owAAaNxyOgyOh71i+EPFGqaPrieEfHssR1NwTpuqKuyLU0HbHRZh3Xv1FdmNVj7xt+dYnjXS9J8YaBPpWqxShGIeKaPiSCQfdkQ9mB/wAK9v2kO58Y6U92jraK87+GnjCe5gu/D/iR2bxJoxWK5kC4FzGf9XOvsw6+jZrtxqdv6t+VVzx7k+zl2LtFUxqNt/fP5U4X9sf+Wo/I0c8e4ezl2LVec/Clzd+JfiLfk7t+um2B9oYI0x/Ou/F3bnpKv51538DZo5ND8RXLMim68Q6hL1HI80qD/wCO0+ZE8rXQ9LopodT0YH6GnUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVk6ndTRXJSNyq4B4FUWup26zP+dYyrJOxvGg5K9zpCQOtRtPEv3pUH/Aq5pmZj8zE/U0lQ8R2RosN3Z0LX1svWUH6Amom1S3HTefoKw6Kl15FLDxNdtWT+GJj9Tiozqz9olH1NZlFT7WfcpUIdjQbVZz0VB+FRNqNy38YH0AqpRS9pJ9SlSguhO13cN1mf8Dio2lkb7zsfqaZRU3bKUUtgrgfhOPKn8awZz5fiK6bHpuCN/Wu+rhPAEf2bxr4/tsYB1CG5Hv5lunP5qaa2Ynuju6KKKksKzPE2sW/h/wAP3+rXh/c2kTSEd2I6KPcnAHua068/+I//ABOPFHhDwz1gubptQu17GG3G4KfYuU/KnFXZMnZF74ceHrnT7W51rXcP4j1gi4vGP/LFcfJAvoqDj65rsqKKG7jSsrBXhgfyYbSTGc3Vyf8AyI1e5mvBA5bTdJB5Z1ll+udx/rWFf4D1cpV6rNvXRnw94dbIOZDyP901iy963L4eZ4R0ByPu3IX/AMdesu5gxyOleTiPiR7dHqvNlWMZarA4IpsUe009hlq5zYswHkVpQHoKoQDCjHWr8DYHNOxnJl5GAq5asKzlbjrVm3k+ari9TCa0Nq1GXFaK1k2s4DDNaiOCvFdtPY86qncZqBxbN9K891Ns3H413moSDyGXPauI1CMBye9Y4lnVgla5LrD+R4d0lgRz5gx65Bp3gE7fF+mkdG0yUf8Aj6GovEnGj6CmOGTP/jopfArf8VL4ef8Av2lxGfw2n+ldlD4hYpXwrfr+bPWqKKWu0+dPO/iLGdD8UeGvFtv8uy4XS7/HR7eZsKT/ALsm0j616HXK/FSz+3fDrxDEPvpZvPGfR4xvU/more0a7GoaPY3g6XEEc3H+0oP9ap7ELRsuUUUVJYZA5PQVwXwN3P8ADmzuG63NzdXGfXdcSGup8V3w0vwvq9+Tj7NaSzZ/3UJ/pWV8K7E6b8N/DVqRtZbCJmHT5mUMf1JqvskP4jqc+9ODsOjEfjTaKkqxKtxMvSV/++jTxeXA6St+PNV6KfM+4uVPoXBqNyP4wfqBT11WcdVQ/hVCiqVSS6kunB9DTGrP3iU/Q09dWH8UR/BqyaKftZ9yXRh2NtdVgPVXH4VKuoWzf8tMfUGufoqlXkS8PE6lGDqGU5U9DS1X0/8A48of92rFdSd1c42rNoKKKKYgooooAwtX/wCP0/QVSq7q/wDx+n6CqVcNT4mejS+BBRRRUGgUUUUAFFFFABRRRQAUUUUAFcTYEWXxh1aHgDUtIguR7tFI6H9HWu2rgPGpOm/EnwPqvSK4e40qU/8AXRA8Y/76jpx7ES7nf0UUUiwrgNP/ANN+OGsSnJGm6NBbr7GWRnJ/JVrv64HwySnxh8aowwXtLCRfcBZB/Oqj1IlujvqKKKksiu5PKtJ5M42IzfkK8C3MsemRgA+Xp4J/Fcn+de3+KJvs3hrVpz/yztJW/JDXjFwPK1OaLtFZbQPyX/CufEv3T2MnXvSZ0WqJ5XgTSWPUTwt+Zx/WslizgKK2dWV5PhqkgwWt1ilA9kdSf0BqkFVFrzMQtUepRl8XqyvHGFGW60kska8ZGaqX12QxSPr61UjJZju61hsb8rerNqGRCOtWIdzHg1QtQCBWrbAKRSbJehKsMmOgqzawuDyetPRhipUfHSmmZNtmlDa5AwRVoRvGuBWL5zq2VYitnT79ZFCT4+tddOUZaHFVhKOu5UvN+w5zXHavM0YlbHKqT+leiagsZgbHpXnniABba5P+w3P4VFeNrG2EmpF3xOv/ABJPD8ijJxGAPqgql4HmC6z4fYgArNcRfnGxrS8T5jt/D8BA2q0f6ACsLws+zUdDLfe/tCRfzikH9BXZS0mFVc2Ef9dz2oSg09WBrNDkVMktdakfOOBU8aMq+DtdZ/uiwnJ/79tUXgFSvgXw6rD5hp1uD/37Wsb4s6gbb4e6tFG2J71FsIh3LzMIxj/von8K7CxgS0soLaL7kMaxr9AMD+VaX90yt7xPRRmikUcJ8bZHPw8vbGDPn6nNBp8fuZZVU/oTXbwQpBBHDEMJGoRR6ADAri/G7Lf+M/BejE5U3cupSD/ZgjO3/wAfkX8q7iqeyJW7ExRRmjNSUFFFFAwooooAKKKKACiiigDotP8A+PKH/dqxVfT/APjyh/3asV3x2R5kviYUUUVRIUUUUAYWr/8AH6foKpVd1f8A4/T9BVKuGp8TPRpfAgoooqDQKKKKACiiigAooooAKKKKACuG+NFvI3gK51C2Um60iaHU4cdQYnDN/wCO7q7moNQtIr+wubS4XdDcRNE49VYEH9DTTs7kyV1YWzuY7yzguYGDQzRrIjDupGQfyNTVxnwgmkPgOxsblibvS2k02cHs0LlP/QQp/Guzoas7BF3Vwrz/AFM/2T8atIum+WDWtLlsc9jLC/mL+JVm/KvQK5D4o6Lc6r4aFzpa51bSp01GzHdpIzkp/wACXcv40R3CWx19GazPDWt2fiPQrLVtNffa3UYdc9VPdT6EHII9RWkxwKT0Huc18Rrgp4UuYV+9cyRW4HrvkUH9M15deAvf63MB8qJHEPzB/oa7z4gzeZJo1tk4e9Dn6JG7fzxXDH5tHvJCebi8P6A/4iuXEO6PfyqPLFvudFbjPw41RpD8r20hAPb93j+YrAubr9wgU/MVH8q1fEU5s/CWl6SMh7xQ0pHaJcM355VfxNc3ncSxrz672R3UFdyl5jO+T1NPi+9TG61JCpJrnOo0LU5xitWLNULJMYxWnCjE9KVjKTLCE4qZMmmrG2BVmGM01ExckLHGT1qylu2MrSohBq7D0raEDnnMyb27kgiKsTtrldUlFzAYwfmldYv++mA/rXUeIwBCT3rgLl3Q7o+XRldR6lSD/Sib1SZ0YeKaujqvHJKazp65+X5cD0wf/r1iWA8m6sieDDrO389w/rWx40lS8TR7+E5ilQsD+R/rWXdfJe3GeAmqW8n5uo/rXbT+Mzl/u1vL9T0pbg+tTJPVFBWD4x8Sp4fs4kt4jd6veMYrGzT700nqfRR1J7Ct43bsjw5WSuyprM3/AAk3xI0vSozv07QcajekfdNwRiBPqPmfH0r0mGb1NcT4G0N9D0bZdSrPqdzI1zezgf62ZuWP0HAHsBXUQsQa0ctbIxUNLvdmwrZFLVWGSpLq5jtbSa5nbbFCjSOfRQMn+VWncyascLoP/E4+MPiLUD80Gj2UOmRHt5j/AL2THuPkBr0CuG+DNtKPBa6pdrtvNbuZdUlB7ea2UH/fASu5q5bkQ2uFFFFSWFFFFAhaKKKACiiimIKMUUUDOhsP+POL/dqxUFh/x5xf7tT13R2R5sviYUUUVRIUUUUAYWr/APH6foKpVd1f/j9P0FUq4anxM9Gl8CCiiioNAooooAKKKKACiiigAooooAKKKKAOA8LO2j/FLxTorkiDUo4tZth7keVKP++lU/jXf15v8Wd+i6z4S8WQ5C2F8LO8I720+EYn2DbT9TXpHeql0ZEdLoKKKKks8y1BX+Geu3Gqwhn8HanPvvolUn+zp2/5bKB/yzY/eHY8j0r0MXMVxbRzW8iSwyKHSRG3KynoQR1FT3EUc0EkU8ayRSKVdHGQwPUEdxXkOvLdfDK5E/hx1vNBlbMuhPJ+8hJPL2xPQdyh49KJNNa7ihFp6LQ2vHRI13QhnjFy/wCSAf1rkQq/2LYgd55iQP8APtUS+OLbxl4gsTax+VHbxzr5UhxKpKjO9e33alAAsdNGDkvM2fX5jXFX2Ppcu/hr+u5peOGzqtmv8K2fy/i3P8hWIqHaK6LxzCBNpM2OSkkRP/fJA/Q1iY4wK4ay986cO/3aK4TmpYxtNIeKVT6VibmzpwB5rWhwDWBYSlWxWzDKuRzTTRhNO5pRgGrUSiqEcgxxVmOXkVpE5pJmiiVbgjAGap28m7FX0Py10QSOSbexznikZQ1wM4w4rvfE54NcPfELE7n+EE1z1fiPSwj9w1L4Y8FaXu/vOy+wLEj+YqjqmI3v2J+7c2h/JkrV8SRm28OaXAfl2QqD9cDNch4vknl0XWhZSeUxmgCXB5B6ZI9SMV20l7xEn+5b9fzPQPFniqDQVhtbeFr/AFm6+W1sIT88h/vN/dQd2NReFvDlzBfy654imjuteuE2ZQfurWPr5UQPb1PUmvO/h/exaFey3lzE97NccT3Up3zt/wACPb/Z6V7TY3ltqNqtxZyrLE3cdvYjsa2U01aJ4k6U4u8yZDg1ciOaong1atm7U0TItLkGuR+LuqyW3g8aXak/bdcuI9KhweR5pw7fgm79K7AdK86vGHiD412VuTusvDVmbmQdvtM3CA+4QZFbU9Hc5quqt3PUbO3is7WC1t1CQwosaKOygYA/KpsUyIfLuPU0+qIFxRSUuaAClxSZpc+1ABRRmjNMQUYozRmgAxRigmkzQB0Vh/x5xfSp6gsP+POL/dqeu6OyPOn8TCiiiqJCiiigDC1f/j9P0FUqu6v/AMfp+gqlXDU+Jno0vgQUUdKTNQaC0UUUAFFFFABRRRQAUUUUAFFFFAGJ430VPEfhDV9IcZN3bPGns+MofwYA/hWZ8LPEX/CT+CtMvpCftiRC3u1bqs6fK4P4jP4111ea+C9C1fw18SvEqQQR/wDCNaq/25GLjMU5++Avoev4CndWsTZ3uj0qgUCsLxhrR0jT1WDBvbgmOEHt6sfYf4VLdldlxi5PlRn+M/FA05XsdOKvqBHzHqsI9T7+gry+QNJO888jTTOctI5ySa0bmMQoQWLOx3O7HJY9yTWRM5lfyo889SK4KtS7uz2KFGNOOhSghtZvE1qwRRLIXieRRhiCjYGfrWrbyTN/Z8U8aqEeQRsG/wBYu48+uR0NZttbfZ9asXJ5Fyi/TPH9a0pvLSTRpXBLJeTWwOcY3Enn8hQpc8EdtC0W2v63Op8ekCw0lvW4Jz/2zauXeUY4rqfHaZ0TTGPVJ1z+KMK44965cR8RthV7nzEZiTUsRxUI61IvFc51F62PzVqQr0rLs+WragXjmhIymyzESBVyBznmoIgKvQICRWsUcs2XrMdzWiOlUoMDGKt7uK6YHFPVnM+JG5Oa4y5AnaOAdZZUj/76YD+tdb4nkAZq5SwHma1pw7G5Q/kc/wBK556zsejQ0p3Nn4nuPsdlagSf6Q/l5j4KgjrXM+LoY7TQLqGJAkYuY0AHbCiuo+ICzNqukBHAhJIdN2Cx4xx3xXL+NJF/stt/Ie/YfgCB/Su+O5hH+Fc53SnBTg8V0+hapcaNdi4gy9uxAmi/vD1HvXPJbKiCa15B6qOhrY09llCleh4INc0J31REkpKzPW7S4hvrWO5tn3xSDKmrcIwa898Kag2k6gtpK2bK5bC5/wCWbnp+B6V6KgrshK55lWHI7DdV1K20jSbrUL6QR2ttE0sjeigZP41xHwYt5b7RrzxDeKFuteu3vnH92PO2NPoFH611cNxZ68NRsJbTz7OI+RKZkBjlb+JcHrjjNa9jbQ2sMUFtEkUMYCoiDAUDoAK3vZWOW13c00+6KdSIPlpcVZkFFLijFAXEopcUuKAEopaKYhKKWjFACUYpcUYoA6DT/wDjyi+lWKgsP+POL6VPXdHZHnT+JhRRRVEhRRRQBhav/wAfp+gqlV3V/wDj9P0FU8Vw1PiZ6NP4EJRS0VBYlFFGKACilxRigBKKXFLigLjaKdil4oC42jFOyKMigLjcUjLkEZwSMZHanZozQBi6dfSWdzDper3KSX8od4ZFQqsqAnAz03gckVw2tXLan4jvLhm3QwMbeEdgB94/ic133iidLbw/qFw+QY4HKkHBBIIGD2614/pk9xp1tawTRyXEHlkvc7hlW5PzD0x3rGq76HXhI2vJjtckxII0P7xzgCnW1oII+Rlz1NXRHa3FvBexukglxtf69qfcLjb9K8qtK8rHoqV1oc3e/Jewt/duoSf++1qa+dleCJHVWTVGJBPVcZOKpanMkU1wXbhHjcjuAHU/0q28LS3l/PIqYjvk8nj5gGQ5z9ePyropfwjqw+rt6HX+O5Aug6eh+89wgH4KSa48oTXUeN5CbTRFP3WZnP1Cf/XNYLHj5RWFfWRvhtIFQoVGTTN/PWrBjd+vApBGi9qwsdNyzaN0rbtXyBWFbD5uK1INw6UGc1c2I+1XoenWsSKSQHkVqWbs4HFXFnNUjoX0YjoauwyEqQapojelW4kIUk1vG5yTscr4nUszVgaKuNe03d/z3/oa6PxBkO2RWBYsq61ppXr9oQfrWX20d1P+E15Gj8R9qanok/lPI8dwqgL2DEAnHeuM8ayB9GsiMHzLmWTI9N1d74xO/W9OTsn7w/hk/wBK8u8YW08PhzSYtNkjSQHzFEuWX5mJI9hXfHW5g/dop/11LOjo32dRjg1et1MNzkcBjyPeue0y98QwxRh9FtrhR3hvAufwYVoWus6kusWVvfeH3iiuH2GUXKvs98AVxqnJSurfejn9tHs/uf8AkdLelPsTvI6oFG4OTjBHfNdfpN5deJ9NEbJc2lrtTfcowUzMPvKvfaf71cX/AGckzTC+Y3KGQOkUijbHjOAB36967vwFeW0ehrbzSqkkUjjaewzkfzrsptJnPiIuUb2OqhAChV6DjrV6CPuaoxXlkD/x8R/nV6O+tCOJ4/8AvquiLXc4Jp9i2OlFQi4hb7sqH/gVPEiHo4P41rdGVmPzRmkyD0paYhc0maSloAM0ZpMUvagBc0maKKAsLmjNNxRigDo7D/jzi+lT1X0//jyh/wB2rFd0dkebP4mFFFFUSFFFFAGFq/8Ax+n/AHRVInHUgVi+Mze/8JEwhuPLh8tePeskwXL/AH7t/wAK82pUtNqx7FGheEXfodcZEA5ZR+NQyXtsn354x/wKuZ+xhlw87n8arTabbH75dvq1ZuozVUF1Z08ms6fH966i/Oq7+JNLTrdJ+FcsdOsAeYs/U04Wlkv3bZPyrN1marDR8zoW8V6Wv/LYn6Com8YaaOjSH/gNY4ht1+7bp/3zTwsY6QL/AN81Pt33H9Wh2NFvGVn/AARTN/wGoW8Zx/8ALO0mb8KrqvpCP++acAw6RAfhS9v5j9hDsPPjCc/6vTpD9ab/AMJTqT/6vTMfU0uW/uUoL9lpe3/vD9jD+UYfEOtMflsYV+ppf7W15x9y3Sn4k9KcElPY0vbruP2UeyIftuut1uIVHstL5urt96/x9BU6wTt0Bp32SfGdrUvboXJHyM67srm+heG+vpZYXGGTPBrlFiKOYckBDtr0zTdLNzazOzlXU8CuG12wm07WZElHyS/OhA6+1ROorXLpTjdwRzvjbQE1jTbGFp5YILe4EpETlGPBHBH1rEk8GWJUK2s+ITxkJ/aDkV3t8m/Typ7gVmQEeXITywXFc/tZxVky/ZQnq0cDbaJZaRc3Jskl8yRlDySyNI7AEHkk12V0dg1L/r8iP6GudvJA88p6EsP5it3VG/5CeP4Z4z/6FXTCTlTbkzvwsVF2irf8OdL4hiW+8IQ3SZD2ZSYe46MPyJ/KsGQKgrW1Gdovh7uU/wCu8uIgdwXAI/LNc1dXDNwucVz190bUE/eXS46e4C8Cq/mlvaosdzyaegrA6rWLMLkYrTtZG4rLjHIrVtFpEyNS2kyAGFbFiwQg4GKxIFywFbMPyoKqG9zlq7WNeKdD1AqxgMuV6Viq5zV+2kOMZrpjK+jOOcLaowfEGN5FYmjW/neJrBF6R7pm+gGB+pFafid2STI6VW8FzK+uXpP3/s67PoGOf5is0r1EdabVFsTxHcpN4gm28iC2kB+u3/69cN4wUrp9mv8AcSIfjyf61v3kpa91aQn7qlfrmQD+VZXja3b+zZ5hjZHJHH+SrXUtvmFb3YKJTsHlVYwGGw9fWt/TIw1yh645yfWuf035oo8dxXQ6a3luCTxmuC+pzyL9yuZSR64rpBocD20W9SHCgMV9cVQ8O2C6nrMSPzDH+8f3rvrmHy12BQAemBXRGrZbHHVqWaicWdDgXo8v/fVJ/Y0faaUf8CrqHtc9F/SqjwMp5FaRqxYlNmD/AGQR926mH/AqP7NnX7l7MPxrXI5pAKu8SrszFtdQT7moyj8akU6wv3dSf8RWhgUuBTTXcTd+hUS61tOl8G+q1Iup64v/AC3ib6pU/FGBVKfmTaL6DV1rW16i2b/gJqRdf1cfet7ZvpkU3AowKftH3J5Ifyko8Sakv3rCE/RzTl8UXQ+/pp/4C9QYFLj3p+1fcTpQ7Fr/AISwJ/rNPuB9MGnL4xsv+Wlvdp9Y81RIpMewp+1fcXsIdj1DQ7mO80m1uIc+XImRkYNXqzvDnGh2eP7laNexB3ij5+orTa8woooqyAooooA8+8aRFtdYgkDy1rLijbABya7jVtMiur4yyE52gYqCPSbdDkA189iIz9rK3c9mlioRpxj2RzkNjI+OKs/2M7feIrpUt406Cn+WKnlb3IeLfQ5c6D3zSjQ+OtdPsFIU9Kh0xLFz7nNLop3AHpV6HR41A+UZrWIx1pykURghSxE2Zy6ZGOw/KnnTosfdFaFBq+RGXtZ9zMOmxNxsFQvo6k8DFbIGKM4pOnHqNV5rZmI+kAfdFWYdORFHyjNaYPFJk0lTjuDrzehUFmB2FBtgByKuc0hquREe0kUbe3CTEjhT1Fcr8RbYNaQTqPmjkx+Brt1IzjFcr49AOksP+mi1lONonRh5t1UzgVaSWCVW5C9DWbN+5RiRnI5xW8UCWrYFYmoL+4J9q5nuezFnFsoeZicgmeNR+LrW1qpIbU8kYa4Q/o1Y6sv26JP713D/AOhrW1q5GL7IB/fD/wBnrup/w/md+G+J/I2tVQr4A0sDoblCfzY1zUvBrrNbwPA2jqDndNH0+jGuXlXAJNc9f4kbYd6S9WVxyefyqZR6VXDZb2qdTxWJ0Fq3TJFbVnGMCsi3PStezPSkzORp26AMOK0VAI4rPg61fgzkVcDlqEqRGrcCbeaVE4FWVTEdbqJyymch4sIyRWf4LU/29K46JauT+LL/AIVf8VcsRVfwUpEutS9NkCKD/wB9GohrUOvagcvES8V1gZMk0a/+PH/Crni2Ev4X1ZsfduAR+BAqDS1DGPrl5wT+H/666C+t1vPBuugj5g0jL+BP+FdDdkvUzxz5bepwvh5WZUJ5AWulSDzY+Oo6VgeGWU2/4V1umR7lJril8RjN21Or+H0W2W7fHOFWvQobdXGZAD7VxHggAT3ajrlTXfQHKVvSVzxcZJ844IgGAqgfSqN7aqxyqjn2rROKYy1pNaHLCTi7nPS6UJeQAppo0VO7E10KrzipAtZqnc2+syRzR0WPsWqtJpDBsKfzrr9lNaJW6im6Q1i5I5MaSO5OaQ6OSflJrq1iVc4FDquMkCl7PQf1uRzq6CxXP8zTW0Fh2P4GumBBFLVezRH1qoclJozqDjI+opkWi3MoyFAHqTXXkAjFKBgYFCpa7lfXJ2OTOgXI/u/nULaTKpwcA12RprRqxywBNDpdmNYyfUt6HGYtJtUbqqYq9UVqALdABgAVLX0dLSnH0R5M3eTYUUUVoSFFFFAFK7/134VDT72TbORjtVfzvavCrzXtJep0xi7IWQ9jQucZVs1Ezgn3pNxxxXNz6mvKWA3qRn60bhVQjPNGD6mn7R9g5EWJGDdOtRZI6GmAnpil+Y9qhu5SVtCQO1KH9SaWMYFOqlF9yG0Jvz93mm+aO4NOJ4quW+Y0O6GtSx5gx0NHmE9BSKRtppGTxTuxWQ/LHq2KXcq85yaj2mkKmldoLDjJg5xXN/EBSdEWRT0kBYeoro/LyOtYHjsqugOrH3pSvyu5tQ0qRscHcTbbZ/pWFeTb7VjnHFbtsQ9oxK9utYmrwgQ7l9DXL1Pbj2OOtxu1qzHrdx/zzWtrMmDqA/6eUH/odZ1oMa1Ysf8An6X+tT63J/pN4q9TdLj/AMeruh/DPQw3xM63W93/AAheikcBbmPI/wCAsK5y4bIIrq/EhCeDNMUADM0P8ia5KXnNc9f4jXD6p+rKw61OlQgc1MtYnQW4TitazfpWPGcVo2jjNJkSN22PNalt94Vi20grXtXBIwaqByVUbMfQVMw+TFVom4FTF8iupM4WtTjfFZ2yVS0GUR6R4ifvtRTj/dNXfF/+tX61U0pFXwZq0x+9LK/6YAqKa9871/DXqjn/AA+d9xaL6yufy211WnfN4a1RezCXP61yfhQhry2PTHmtXS2NwI/Depgj/ljI5P51rP4V6mOYa/15nn3heQrEiYzkV3elq4gz2zXE+F49oXPYY/Su9sVJs2GcVyzd5sxqbHYeAYw/26Q9WbANdvbjamO1cJ8P7jZHOjZ5c8130ODHkGtqZ4uLupscOtSDpUfenhs1omjjZG8gXqKZ5rt9xamYZ6AGm78HkUm/Ma9ADSY5FLljS+YpFNLrRfzD5BsOck0u0HrSg07FFrhcb5YxTCpqYUhFNwQlJkQ4NPBz0pNpJoxg0ldFOzEIYdDSAtmn5FKMZot5hc0rb/UJ9Kkplv8A6lPpT6+ip/AvQ4nuFFFFWIKKKKAMrUVJuTj0FVvLPpV2+fbORjPAqESE/wABr5/ERTqy9TshJ8qINuKOlStubotV5FZTzXNJNGidyZADUmwelQxHA5qbeMc1UGupMrifIDThsIwKpPcYY4Galt5gxIPBq1NN2Bwdrk+3HQ01tw96eTSZptEjEy4yelKYk9Ki89Ucg9Kd58ZH3hUJx6lNPoI6lWAB4NTBeKpzzg4Ef51Nbs7LljSjJXshyi7XZOaSl+tIcCtGQgY4XNcf8QUZ9KZ8njqK60t2A4rn/GKB9GuAem2sajudGG0qJnB27YtCv+yKydZbbaE+tX+Rpisp5AFc9qkkjwuXPC9BXPbU9uK1MCz+fVrEf9PY/kafqvzzzEH5muck+1R6cf8AibWXtdKf0NLqDYE57C4H6g/4V3w/ho78NuztvExZvDukqRjFwoIHsj/4VzzR4Uk1u6xcef4OspiOUuIR+fH9axncMK5q/wARrQ2a8yhKwU4FNRuabOQGNQh+eKxOmxpR8ir9n94VlW0mcZrXsxyKCJGpCOlaFuxGMGqMQ6Vci4po5pGvbXOMBqub9y5BrFU4FXLaQ7Tk1rc5pQ6mF4pBcqfeqlmxj8ATZBJkaUj/AL7NXPEDDPPrWfLdLF4DiH8TKyj67jVUfiZ0fZivMwfCoP2iI9zFIPxrcdo/+ED1dgxE3kkAe1Y3hfi4tz6xOf1b/CtfSFFz4d1aJxkG1P8AI1tUdlEwxur/AK7nN+HMAKDxlc5rtrEfuto+tcN4bG63h7koP5V3+nJiE+uK5GrSZhVZ0XgWPdBK4H3pDj8676FNkYArivAY22jBuqyHP413C8VpTPGxb9+w2gGhlOcioyxHaqbscqVybNRk8800OaXG7qcUm7jSsOAHpSFRTgAB1pwA9aaFcaobHWngt6U4bcUoIrRLzJbGhWPU07IFLketNI9KrbYnfcGPHFICMUoFDIDS1Y9BrKGpACtIQynijJzzU3KNW2/1CfSpKjtv9Qn0qSvoqXwL0OOW7CiiirEFFFFAFC7QG4JPoKjxUl5Iq3BU9cCoN5/CvDrte0l6nTFOyH4qOcDb70vmE9AKidGk6nArCTutCktdRY145pzRg9aci4XGaU0cqHfUpS2hzlDQlsQCW7VdFFTyIftGVrcMRkk/Sp88UhG3JA69qaHBOCCDQrR0B66iSRh1IIqqlm7c5AFXgC3TgU/IXAocFLVjU3HRFJbNh1IqURMi9an3rRuyOAaFTithOcnuVdx9aeoHU81IYu9JikotbjumV55SowFrnPF9zt0aVScF+BXUSqChBFcz4xtA+g3JxmRBuWs5o6MO1zI4C3d5LIIo7cmsbVVAjdfWtzRW8zTGOOelYmrOoR8nvisXue1Hexz0C+VeWbAf8vMf/oWP61FqZA+3g9VmT/2aluJgssAB5WeM/wDj6mneIU239+gGB8sn16f413U9aZ24b4mjo4ZftHgbHHyXKE/gaybqURRkmrekMX8AarjqjCQfgyn+lY2qTAuEU5A61z11eSOiktZLzKk1wzE4qMNIaUAZqdQAKzsdFwgkdDya1Le7cAc1mjFTRNilYl6m9bai6kZNbNrqKSABuDXIq/oat28pBHNBjKCZ2sUivjBq6uEXiuYt7ggDnmti3vEZMOcEU7swlAz/ABC2Iyx7Via9m38G6fE3DONxH+9lv61o6/KJY5FXpg/yrF8VzGXw1o7Hq0a5/wC+a1obs1ivhE8NcTwe1sx/Vq2PDZB0HVTjpbMM/QGsPwtzctu6x2h/XJ/rWz4fDJ4V1mQjA+zyYPr8praqtEceMOV8Kqx8hR1wB+lem28e2HPQ4rgPDCxxvEccjAz+Fehqf9HJHpXLLWTZz1Xsa/g4yGecAfusDJ967uJ/kGetcl4Ii/4l8jj7zyHP4V16KAtVC99DyMVJOYoYHpQVBPNHl45U0eWT1NaWZy3ABR6U8BWHFRiIetBjx0NUr9UJ+oOAveoxuJ4NOMZpUIThhioaTZSdkChu9KFb1qUYI4oquRE8xEM07OBwM0Ec05KcVYGxjSOBwhNILhejZB96e5INRPDv5JFN36ArdSTzUI6immRB/EKaLYYpGh29AKLMa5e5sWjBreMjuKlqGy/49Y8+lTV9DS+Behxy3YUUUVZIUUUUAZl5xdkkcYHNRseKsXhAmOT2qEEeteDX/iS9TqjshiH5emKUkAc04sB1IqGR9xwgyfWsW7ItK4GdRwpp4kBx2qFYB1bk1II1A6VKcnuNqPQk3D1FAI9ary4TntSLLFjnNHtLOzDl0ui1n0qKYELkdaZ9pUHAHFDzqBwCaHOLW4KLTEhchhk1Y3j1qrvjIzyDQmHOFzUxm1oOUb6lrePUU3zVzjNM8kdyaVYtpyv61d5E2iOYlvu8Cm7sDFS0wqfShrqCIXJJGaz/ABOFOh3BP9wj9Kvseax/FjudEmVOPl5rFvR3N6SvOJ5xo7xi1liDAEMa47Wi6PN8+4A5B7VpGSSKSXLY3n8qxPEN1Hb2w34OffFLlbdke9FWdzIdw4aQsCUwx+oNdB4mid71ZktZsTxbV3cAnrx+leU3mqGbUk8liIw4BweDzX0HqUL6p4Xtp7YZurULIoHUjFd9Om4wszopTUZGD4Zt7mTwtq1sLZ23RsOCOMg1x0MpuFDE/MRk13Pg3WFt9Qkjuji1uV8tieArf4c4/GuOvtNm0fUp7G5Uq8Rwp7On8LD2IrmrLZnXTdqjT6jD8vU0qz9qgk6U0MoHJrA3Lqyg1IsijvWcZgOlHnDvmgLGxG6nvVyBwMGufSfB4NW4Lnnk0hNHSxz4AxipGvNo64rCW5AHBqC8uxs5agjkLupamUyqndu4NN1+7t5vD+kQpIN8aDcCCMdqztHsp9c1SCztwSXOWb+6vdjXeeLp7b7XHbxqv2ezQJgDv6fyFdFGO7InJKaijnPD0kCfb5vOjIEKoo3cniug0iNm8A6m684tZAR9QafY6eln4WuZ57eM3tyjSICoJRccfSrXgy3V/Cd5GST56HIJ6cYrStpynnYuV1ddzkPCwWRjuGMEEV3UtwsdmSSBxivPfDF5DNcG0jJjvLddjo38WOCRXUXW2aNUY8nj8a55wcZamcveZ6V8PZFfS2GQSGJrrcelcV4AhKaYzDrnFdomdoyaIPQ8XFL947DS7DvTS5PUmnY7gZFIxyOlNtmFhyMB61IOarg4pwkI6DNCn3E4k+KawBHNM8w91NRvIe2KpzQKLFV/Lcg/dqYOpHWqqoXOXORUw2AYwKmMmOSJMqe4p4GKiXb2xT8j1rRMhoRhzSrxSFhS5FK+oAzECo85px5pMCk22NI1LX/j3T6VLUdt/qE+lSV9HS+CPojjluwooorQQUUUUAZWprm4z7CqmK0L0jzyDjoKrEJ7V89iYXqyfmdlOXuogxSo4DYpzsgGByahKiuZ6PQ1SvuWgRSNIo6kVX8sepoEYFPnfYXIhdpm6nApr2xXkHNTI22h3yOKTjFrXcd2noRxQ5FTrEBTFcKOacZlx1qoqKWpL5mxfKT0p6Kq9BUYmUjJNBlz90VScVqJpsmNLVVi/Umk3t60e08g5C1mmscjAqDzDSbz3NHtENQHLGByTmsrxSANHucD+A1qeYpGc9KwfGd0Y9EuXj5O2ok01ZGtFNzR4ZeXLrdyyZAiVcknoAO9ebeKtVk1MsyuVt0OEH9/3Ndf48uxaafbaepzdXY86fH8Mf8ACv4nmuCu4g8WCcKoz+NdtKnyavc+jjDmVzIh4lQ+jCvqnwywXRNOmQZ3W0e4f3gVFfK8a/vFAGTngDvX1H4Obf4W0o/9O6D8hit2ZooeJPDi7ZL7S03xPzLAOufVfQ+1ZJntdZsobDWSVkjBFrfAfMn+y3qPUf8A669CUNH80Xf7ynoawfEHhuLUVe407EN3954jwHP9D71lOnzbG8KnSf3nmGv6JqGjyKL2P9y3+rnjO6OT6N/Q81mDpzXdxalqGkxvZ3dv5kLfft50yp9RjoRVS5sPDmoMWikuNGn7ptMsWfoeRXHKlbY7I1JJe8r+aOPJA61GZPSuuHgqSYZtNb0mZe25yh/Lmmp4E1Mvg3OlAf3jc5H8qz9nLsV7en1ZyQdj0p4kYetd1B8P9qh73XNPhT/Y+b+ZFSHQfCNhzdandX0g6pEQFP5D+tP2UifrEH8N38jgfOdSPmxn9a6LRfCWrasBNLH9jsxy09z8gx7KeT+g966GDWLGyJ/4R3Q4IZOgnkUyP/n8abI2qawwW6lnvGz8sEX3Qf8AaxwB9TmtI0SZVJ2/l/M0dPu9O0CymtdCCyMB+/vpe59v6CotE0z7ey316rLp6NmJG+9cP6n2q3YeGIoFR9XkEzLytpEcIp9/Wtp3JYM5HAwqjgKPQCuqMOXc5m19n7xmoK81tIz/AHmGMDoB6CqPhAAaZbgd0YVqbxJH9KyvB5P2G3B96xxXQ5cR8NjxDULiaw8XXZgkKSxzuUcdjuP6V6PpOrrrOm/akQLcwnbPEOx/vD2NeZ+MAYPGGoeomc/mf/r1d8Nao+mawlwT/osg8udexU9/wrVxUopMtQ5o3W59NfD2UPoofIyxyfauuQt3HFee/DchNMmWN9yCQ4Oe3UfpXoaODEG7YrhtZtHh4pWmyVBxSlQajSRezCn7x6itE1Y5GncQoPSoJQyn5FzUrzIB1psbhjzUS5XoUrrUrkzHqnFRsWB+ZSK0QVocKykEVLpJ9Rqp5FJN2M1II2IpdpB4HFTp0FKEb7jlLsVmzH94cU9Dv6GpJVDLg02NdoxVWs7C5roULzT8cU2kBOfaq0JF2+hNRvIydcEVI2eg61WnD4xg4qZOxUVdm9anNvGfapagsDmzi/3anr6aj/Dj6I4ZfEwooorQkKKKKAMLWHK3p/3RVEy+9P8AEU6R6gVZwp2jg1jvfRL/ABE/QV8xilL20vU9ajC8EaqSkNz0qXzF9awf7SUHhGNSDU1xymPxrnSkjR0mbQlycU8k9qwv7UXuKDq5PCKxq0pPoS6TNvzT0NLvzWF9uuG6RfrUUmpXKf8ALKnyVF0D2R0WR1JqN3GeK5s61L0MePwpv9syf3V/WpakUqMjp0IHWrAbj7wArkTrUh6KKjfV526foKcU0J0JM657mNAdzVVk1GEH5SK5U3VxJztc/gaN103Ajf8AKq5ZPoUqCW7OlbVEHTFV5NSZ+FFYscN1nJier0E7w/6y3wfWn7OfZj5IrY07cyFMtxn1rB+IF2lp4ZuGbvhRn1NX21i3U4dkB9C4rzz4q+IbK60KSJLmORweI42z+NOFOTeqNKFKU6i0PD9WvH1LV7q7kJJkfA9lHAH5VSmXzGCgZ7Aepp7A4G3qetdj4f0qHSNKOv6nHudf+PWFujN2Y16MVdnt1JqnEp6Z4fg0HyrjUCj38q71h/54g9M+9eu+BSG8K6fjsrD8mNeG3l/PeXclxO5aWRtxNe4fD0EeEtOJ7qx/N2q5Kxy0229TqlGFFSJEsmM9R0Ipg+6Ks245pIcnZFa809LmExXcEdzEezDJrnbnwlZFv9FuLq1HTZneo/Bs/wA67qNQcCpjbIw+YA1bp8xzrEuB5ufBlsQd9yjN2IQJ/KoB4MRTxJC3sZGx+hr0v7BFn7opfscKD/Vr+VT7BdjX6/Luebp4SjXO5rBR6+W7n9WqzD4bsI+ZZy59IYVQfyJ/Wu8eGPGNi/lWXeJtyBSdNIuGJlPRs5/7FpsBGyzaVvWdiR+R4/SrJnfywoKxxjokYwKjvFPUVRaQgYqG7HRGHNqTyTBeFqu8pNRlqaDlqm5so2NCAkRE+1U/C67La1GB0z+lXl4hP0qn4XIeCBjx8gIx9K58TsjhxOx4N48k3eNdTA7SmoLEhx7HIPvWt4u0w3V3e38XM63EqyqO2HP/ANasXSidr57V02tFGtB30Pe/gvef8SZIJHOTGuCf7ykqf5V6xDOirsY4r59+Fz3csc8VujP5MhJCjorc/wA816XHqlzGuyZJMj2rhrRfNdHnYmhzTZ3o2sMg0oA9a4ZNdlThVkx9KlTxDIv8En5Vz2ZyvDS6HaYFOFcQ2us7ZLMp+lSjXJVH+vH40WYvq0jtEYBuTU2c1wy61JuyZUP41bi8REDllP41SbXQiWGl0OuqFpcSEA1z6+IUYYZwpPvSpfqzblcE/WlKo10JWHktzpUORSkViJqWO4p76kSMAgU1VXUn2MjQMh8zb2qyqgisJb0A5JGfrVuPVIwMNTjUj1FOlLoae2kbFUf7SiI4OTTP7QQnmqdSPQlUpdjpLX/j3T6VLUFg4ks4nXoVqevpqP8ADj6I4JfEwooorQkKKKKAPNfHc10PEDpBG7KI0OQOPzrmZ5pIhm5ureEf7cwFYnxye7k8cywQyMsYgjOPMIHT0rzGezkSTE4Y+4Gc14tdQ9o+Z9T6/BYKVSjBrsuh65Lr2lWozPrNvkdky1V28e+HoM7Zbq4YekeB+teViy5ykbMv0wak+yB8KkTI/uODWPNTWyO5Zan8T/I9Kb4oaYpxDpk7e7ECmH4rRqP3ekE/Vq86k050HzRH6rUHlrna25SO4qliEtvyKWVUn0v82ejn4sT9tJTH+8ajPxYu+P8AiUxY7/Ma8/EIAyJG+oPFP8gMhxkt/vVSxHmDyykvs/iegL8V5MYbRoif9+kPxUlJ/wCQPbj6vXn0cKt8pQlqlFl/0x/M0vrD6P8AAf8AZlFbx/E7h/incYOzSrRT7tUY+J2pvjyrGyXPGSa4v7Nt6xRj6tTxCxHCRY/Oj28mH9n0F9lfidkfH3iSU/u1skU+ibqry+NfE2ebyNMf3YK5B4XXOEwfVGxTUubyI4Sdvo3NS60u5awNNbRX3I6VvFGvXm7OtzqV6hU21iXOoXskjGW9uZh6+aeaRNVuF/10Mb47jg1XmltpWLKkkRPUdRWcpzfU6KVGnF/Db5CGWQknzpP+BMar3amS0lzydtKSOxyPerECh4pFLKMqRjPtUxvzam81FQdij4U0k6nrcFs4zGDlz/sjk1e8ear9t1ZrWA4tLT92ijpkdT/StDwdu03R9X1UjDRwlYyf7xOB+uK4hmLMWJJJOSTXpQVkfP1pc0/QWvf/AAOvl+FNLH/TEN+fP9a+f1OTX0L4UXZ4Z0sf9O0f/oIokFPc6FD8oq1bdaoRt8oq5bNg1KCa0NGM4Iq6jAgVQU1IpPatkzgnG5dqOQjFIobHJqC4VscGqbIjHUZJKqjrWdcfMSalbrzUUlZSdzshHlMu6Tg1lTritm66Gsucdaxkd1Jme1Ef3qH6miPrUHQan/LE/wC7VDwYm/TInJOVwo+mK0V5jx7VmeC5AtjsY9xisMT0PPxPwnk2vXB0zxrqqHmBpyHXsQec/rWbqdktjfyCP/UzLvQirXxEG3xtqw/6aA/+OipI2+3+FC+M3Fi2Ce5Q/wCf0rtiuamvQilPkkmafgfxJqHh2S6l03yQZwqv5i5zjOP5126fEvXMfvbKzk446ivMdNk8uyYBCxc9cdOamWT15HqK5JV5xdkz11gKNZc8o6npY+J+pKvzaXaA+z0sXxO1RyT/AGZbso9HrzXaH5Rhn0PBpuWRs8qaX1mYf2Th+x6lF8SbyUZOhwyjvtYf4U8fEi1P/H5oJH+4Af6V5ZHNJE4eNmRv7ynFWEvpA27cQ3cjofwo+sy6kPKKPRfmeqxePPDEhAutOmhz1JjPH5Vow654KvMCO9SFz2LFSPzrye21gL8twCw/PFWbmW1lt/N8hZE7kKMiq9vF7xRzTytJ6Nr5nrS2ei3X/Hnq0J9AZFNSf2HN1t7uJx2Oa8OL6bjiJx9Kt2csQI+yX08DdgXIpOVGW8SHllVbT+9Hsp0zVox8jI//AAKo9mrp962JHsM15lH4h1e3cR/2rMp7FjkVor4o8QxxqVv/ADR6hQan2VB9zF4GuuzO6aXUR1tH/AGo2uL/AP59pB/wE1wd1438QwkFLvcfRoQKW3+IfiYnaIYJSfVOtL6vS7i+p1rXsjuBd6kpyInH1U08X2ojG6Bj9Aa41Pidq0XE1hAx7jOKtRfFN9w+0aZj12tmn9WpfzEvC119g988NO0mhWTupVjHkg9q0qxvBt+uqeF9OvUQos0QcKe3NbNe/TVoJeR8rVTVSSfdhRRRVmYUUUUAfO3xvZo/HUrLbCQ+RH85PtXnzalMOGHl4/2c16/8UfB15rnjOW6hmkjiMMa/IhPIFYtt8LHlH+lXtyw9NoFeNVw051JNdz7bB5jQpYanGW6SPN3u7hxuWZcDsDj9KhF7KGwZ2XPfrXsNp8JNKQhp5bh/XLVfT4b+GLX5rhEwP+esmB+poWCfUuWdUVolf5Hif9pTRnHnqwp0uoW7/wCuSKQ+qnBr2iXTPh9p+PtD6SD/ALUqk/zqpLrnwzswctphx/ch3f0qvqa6sy/te/w02eO+bYEEiWWP2IzTUltQ3+tlYdtiV66/jv4eRk7II3x/csyf6VC3xS8F24xBpszf7toB/Oj6nD+Yf9rVXtTZ5iLq0PGLkn/dqaNFmx5dneP+Fd/J8W/DCnMWgXLn3jjWoH+M9ko/0bw5JjtukQfyo+qRvrIf9p1baU/xORh0m6mP7vS7k5+prQi8MarMAF0ibHuCK05vjbeji10C3Qeslwf6CqM3xn8QuCIrHTYs9zvb+oq1h6SMnjsXL7KXzLEPgbX5D+706OP3c/8A16sp8OPEcwIZraFT6Yrm7j4q+LZicXltDntHbjj8yaozfELxVKMNrdwo/wBgKv8ASn7GiuhP1nFvqkd3B8Hr1yDcaki567VzWlH8J9HtlBv9XkwOTllWvIZ/FGu3Abz9a1B89f37D+VY1zPLcHM800p/25Gb+ZqlGmtokOpipfFU+493bwx8PdO5vNUtyR/z0uM/oKauqfDCx4Se1cj+6rPmvBBGuchFB+lOCE000tkiHTnL4qjfzO48Ya1oZ0O7sdEmLefcBlURkYQHPJPvjivPc1LIhzUZU0jRRsKh+YV9GeHht0DTh6W0f/oIr50jXkV9F+HznQdPPrbx/wDoIqJmtPc0FYjFWIpsVVboKkhQtWaN5JW1NSGfNXYZASKzYkIqymRW0WcVSCexrA5FQTHAOarrM4HWoZZWbqatyOeNJ3GOfmNQSmns1V5mrJnXFFW5PFZs/ers7Vnzng1DOumii/3jSp1/Gmt1pydqzOjoasf3B9KzPD6LEYlXoTmtOP7g+lZuhHzBAydjWGJ2RwYnY8a+IrE+NtVyf+Wn9BSeC7hF1KS1mP7m7iaJh79qf8Rkx401XtmUH/x0Vz9tK9vOksRw6EMD713UvgRz2ujpYLWWJDGCytExVsLnpTvL5+eQA/7hFdj4L+Jej6bbzprGjvJPNJvaWJVYHgDoT7frXVJ8SfAtzxcae0f+/bZ/lms3hYy1udizSpS91QujyVVVTlZkyPfFPkuJSmNySL7kV64viT4a3Z+dbdc9mhKj9ak+wfDTUP8AVyWKk/3Ztv8AWp+pPpItZ0vtU2eOQLITuIiA9GarUSJtZZBEQem0nivWf+EJ8BzcxahGo9BcikPww8KTKTDqUgz3WdTS+pSLedUXvdfI8k+yoW4kAHpU9nvt3bDAqex6GvS5fhhoatsg17Y56K7ITSN8JMrmDWFJ9TGP6VLwdTsV/a+Has5fgeY3kMe7fECmeq9QKqAENgjFenzfCrVE/wBTqEEg9GUis67+HWvQA7IYJf8AdNZyw9RfZOiGY4eWimjhTK4G1jlfzqW3unhPyMQPTqK2LvwprNuT5unTDHdV4rMmsJ4eJbaVP95CKztJbo6VUpTWjROl8SPnAIP5GrC3AZflYge3askIyE7SR7UqyNGc7CfpTUkRKlfbUtva5ywYsCetV5IQpyG/Onx3uDzkGpPMiuB0CSeh6GrvEi01ufUPwxGPAOif9e4/ma6euZ+GgK+A9FBGD5A/ma6avep/AvQ/PMV/Gn6v8woooqzAKKKKAPDfjB8RtW8N+LJNN062tGRYUfzJck5I9K83n+KniuYkteQxA9BDCF/nmtT9ob/kpE3/AF7RfyNeaqma45yfM9T6TC0YOlF26HQXvjXxHek+dq11g9lfaP0rDubm4umLXNxNKx6l3Jpyw04wis7nUopbIphFBztGfpQxxViSPbVV+tAxC2aTNFFABT0NMpV60AS0UCipAQnFNLelBBpyJQMaqsx71Olux7VNbR5rRij46UXCxnLaN3pxgxWusWR0p4tN3UUrjsc88Z3dKa8HHSty4tVQ5qm4A4ouFjJKYNe9eEJRL4X0xvSBVP4DH9K8OmA3V6/8OJ/N8Kwr3id0P57v/ZqUiobnUZyRV637Vnqeav2pyRUI1nsX0WpMUsa8VIFrVI4XIiNRNU8gxUB60McSJxiqk7VeYZrPuhgmoZvDcozNVKc8VamPWqMxrNnXBFc05O1MpydRUmrNZP8AV/hWP4TfMKezsP8Ax41rD/UNj0NYPhhysb4/hkP881hidkcGI2sebfE2P/itb/jGdh/8dH+Fc0kNdb8T1/4rW9/3I/8A0GubjWuyl8CMY7IYIR6UvlipiKTaa0KIfKFHk1YCGnBaAsU2g9qjMbL0JFaJU+lMeIntRcLGY8Zzk8mrVjqmpWBBsr+6t8f88pmX+Rp7wnHSoTDzTuJxudHY/EHxXZkeXrE7gdpQr/qRmt20+MHiaHHnfZZh6lCD/PH6VwIipwip8z7mboQe6PWLT433igC80qKT1Kvite2+MegXOBqOj3CepCq4rw8wmo2jIp+0ZDwtPtY99PjH4c6n/wAfEQhY/wB+3I/UVImlfD3UsfZNTgRm6BZ8foa+eiKQik+V7xQ1TnD4JtfM+ipfhppFx81jq3yn/bVqzrj4TXGSbbUInHbIrwmKe4gOYJ5Y/wDccj+Vatr4s8Q2eBb6tdqF6DzCan2dJ/ZNFVxUdqn3o+y/BOny6V4U0yxnYNLBEEYjoTk1t1y/wwvrjUvAGh3l7IZbia3DO56k5NdRXoQVopI+XrNupJy3uwoooqjMKKKKAPl79oCPd8R5j/07RfyNedqmK9Q+PEe74gTH/p3i/lXmzIVNcFT4mfU4X+DD0GAUUuKXHFQbkMoyKoyrzWiwqpMnNNAyp3oqQx81JHDTuIiVM1MkXPSrMUBJ6VdhtD6VLZSiUVgJHSnfZq1fs5A4FQvGQelTcvlM5rfFCxVdK54xUZTB6UXE4klpGM1pRxjjiqFrwwrUiOaBWJkjAFPwBTkHFOCikMoXy/uye9Ycp+Y10N+P3ZrnpQN5qkJlWbrXpPwln32OoW5P3JFkA/3hj/2WvOJRzXpPwls2js7+8bhZXWJffbkk/wDj36UpbDjuduODV+zPzCqEhG7irNk3zioW5tNXidBDgipcVBAflFSk8VujzJLUilqA9akkPNRHmpZrFDSaoXferzcVn3bdahm1Pczbg4zWfKeau3B61Qk61kzugMp0f3hTafF98Ui+hpZ/cN/umsPw8m3f6MD+YP8A9etsf6pvpWRoAzCCOzH+tYYnZHDiNjzr4mgr41vS38SxkfTYP/r1zkeM9a6j4v8Ay+LlI726fzNcdExrso600YReiNEbe5p6haprk1NGDmrLRZwtKAKQKSKUKR1pFWF2j0p6oPSlUinFuKBkEyD0qqy1cfmq7jBoAjVOakEftTkFPAphYiMdRSR+1XAKCgYUXCxkyJUJXFaU0BByBVV4z6UyGitikxUjKRTcUxH2X8If+SaeHv8Ar2H8zXYVyHwi/wCSa+Hv+vYfzNdfXfH4UfKVv4kvVhRRRVGYUUUUAfOvxuj3ePZT/wBO8f8AKvPpLcGvR/jUP+K6lP8A0wj/AJVwRrz6nxM+rwn8GHoZj2xB4qF4iDWq+M1AwHWoub2M1oyBVWRTk1oXDgcCqh5NMRCqVatrcuRxSwRGRwAK6fS9O+UFhSbKSM+2ssAcVejtcDpW5Faooxtqb7OuOlSO5gmAY6VXmt1I6V0EtsMcCqM8GO1IdznpYMdKi8rPataeHrxVfysdqZRVihANWkXBpVTmpAKBWLUS5Wn7ajgbBq2+PLJpE2Mi/OQRWHKh3E1uzDexzVOWDmqRLMloiegyfT1r23w/YDStDtLPjdGnzn1Y8t+pNec+FtMF9r9tGy5ih/fy/Rfuj8Wx+Rr1KVuKUmaU0Rnk1atuGFVU5NXbde9QjWb0Ne3k+UVOX4rNVivSphLxWqkcMoakzmmEgVE0tRNKaVylFj5ZOKzrhs5qeRiRVGduDUtm8I2Kk561Sbk1YmbNVjWbOuK0EqSDmQVHU9mMyUkN7F5uIm+lc/4cugbQYGSxrdvXEVlPIeiRs35CsnwrEh0hDtGdq/yrDE9DhxGx5/8AGFt3i2MDtbr/ADNcjbxlq634np5vjSQf3YUBrGtoBwAK7KOkEYU1dIjji4FW4LVmOcVetbMHBYVpw24HAFU2bKJmJaYHShrXNbQgHpStbcdKRRzr2xFRmIityaLA6VUdBnFFwsZTIaiZCTWhKoXtUQUGi4WKyoadsNXEiBqdbcHtRcLGaEPpUqxGtNbYdhThbY7UXFYzTDkciq0tt7Vvi3yOlRSWvtTuKxzUtt7VWeAjtXSyW3tVSW19qdybH1T8JRj4b+Hx6Ww/ma66uW+Fq7fh7oS+luP5mupr0Y/Cj5Ot/El6sKKKKoyCiiigDwH4zx7vGsp/6YR/yrz94yM16Z8W4w/jKX/rjH/KuGmgHpXnVPjZ9XhP4MPQxHU1WnO1a2mtqy9QQIdoBZvQVCOhmQ+WY0qRknFWVjDAEdDT4UzKEQZc8+wHqabBI0dIs8sCRXVwxrFFliAorJ0WJlh8yRiQTkZ4wK2rRfPIkcYjHKA9/c1I2T26Fl3Mu0HoD6VKyDHFUHkeZmUMcSttA9FFX3lVY9ygnnaB6mmSQtHzUE0KFlViAzdB60+5mcrEIBhpCOT2BqSKyb5WVskMeW6gc9P50hmNJCTcmNVDDHygdSc/yofTXRPm5bvXSQ2cUJLKvzHgk9celSPErDpRYOY4WeFo2IIqKup1KwDqSBzXNyxlHINItO4kR5qaSYLHt9arg7WB7VBcyZcYpiZJTHFSR8qKivCyxERDMrEKg9WPApkHa+ALPydMnvGHz3Mhwf8AYXgfruP41vytk0zTbQadpdraLyIY1TPqQOTQeTWbZ0U1oSRda0IOlUIRk1dj4ApoUy4rClYAiq4NSBqoxaGnrTTTiaYxxSKI5OBWfcHrVyZuKoTsKTNIIqSdahxUrnNR1mdKENWbIc5qqavWa/KKa3FLYreJJRHol3/tJs/Pj+tM8Lf8gpQfYVS8cS7NMjjB5kf9B/8ArFT6DbTNZQBW2qccVy4h3djgxGxwfj0F/GmobhjaIwv02D+uaq2MAxk1P4scz+NL8+wX8uKlt1wldtP4EKmtEWIV9KuouBUNshOK0IovWqNGMSMmphHxUgUCnYoEZl5HwaypEwcmt2+GFrDuW5wKRSKcy7jxTBEfStCC2Mh6VoR2HHIoC5gqCpq9AQa0JNPGOBVVrVojkUBclUYqQAGoY27GpRQA7bTStSCloArvFkdKqyW5zWjnFOChqdxWPoj4bjb4F0YekA/ma6Suf+H4x4M0kf8ATEfzNdBXpw+FHx9f+LL1YUUUVRkFFFFAHh/xZbHjKT/rjH/KuNchq6/4u/8AI5S/9cY/5Vxea86p8bPq8J/Bh6IkKjFYOr7YwUQ4Zup9B3Nbhbiuauz591ITyN2PwH/16g6Si0xVxgYjC8L3PpWnbKohLAbTJgZ+tZwiJYbx80jc/Tv/AErYtomkliUD5Ack0hmlauZX8s8RA5I9FHQfjWolx5lu2x/vnavHQdM/zrJdGitpMnEkhJJ9PSptLKFFVzlgc+nbGPpQS2aJ/dl2jBJRdiAfqf1qysDyyAsSI9m0c8j/AOuaWMKCWUAE9TViM80xXHxwKgX+Jh/EfyqwgpgqRKBEpXioiKnqNxQIgdQwwa5zWbXYxYDiumNZ2rRh4DQykzjJTtBrPkf5q0L8bWIrJl4cmki2aNrKMYJrY8NWovvEVorDMcIM5+o4H865iGTBruvhxHvnvpyOmyIH8CT/ADFMmx2dwMCquKtXFVqzZ0w2JYeKsqapo2DVhWpomSJs0nmYqJnqFn5ouSoloy0x5qrFqYTSuWoCXExqg8pJqa5PFU+9S2bRih5OaTNJRSKENaVrwg+lZyDcwFakK4FNETOZ8XA3F7bQjnYNxH1z/wDE10mipsgtl9EH8qwShvNenPUKGUfguP5mt7TSRGrfwpDk/lXDVd5s82u76HlOsfvPFmoMOcNj8yauwpwKop++1m/l6hp2A/Dj+la0YxXox+FG0VoXbSMBRVwCq9swwKs9qoGAFKKKZI4UGgClqD8H2rH2FpKvXcm5iKZax7nBpFF6zhCqOKugUQx/IKftxwaZLGkcVE8YOeKsAUFaBGXNbjqBg1VOUOGradMiqN1DwTigpMhjIIp7CqgVkb5Tj2qQSkD5xikMeRT46YDu6GnjIoA+jfAP/Im6T/1xH8zW/XP+AP8AkTNJ/wCuI/ma6CvUh8KPjq/8WXqwoooqjIKKKKAPDfi5/wAjjL/1xj/lXEnivpLUvDmkalcm4v7CGecgKXYHOBVU+DPDp/5hNt+R/wAa5ZUHKTdz2qGZ06dOMGnofOM8wVayXC72KgAscn3r6hbwR4abro9qfwP+NN/4QXwx/wBAa1/I/wCNT9Wl3Nf7Wp/ys+XNg3hscjpWlY8EV9Jf8IL4Y/6Atp+R/wAacvgnw2v3dHtR+B/xpfVpdx/2vS/lZ8537Zj4qjBKY3yK+m28F+HGGG0i2I+h/wAaZ/wg3hn/AKA1r+R/xp/VpdyXmtP+Vng9jdh1AJ5rUhOTxXs6+CvDi/d0i2H4H/Gp18K6Gn3dNgH4Gj6tLuL+1af8rPHF6VInWvYv+Ea0b/oHwfkaUeG9HHTT4fyNH1aXcP7Vp/ys8mQZFI6cV64PD+kjpYw/lR/wj+lH/lxh/Kj6vLuL+1KfZnjTjBqpe4MRFe3Hw5o562EP5GmN4X0RhhtOgI+ho+rS7j/tWn/Kz5e1YYkNYsnU19ZSeCPDchy+j2rH3B/xqI+AfCp66Jafkf8AGj6tLuV/a1P+VnyXkq3FeofDyMJoiSfxTM0h/PA/QCvY/wDhX/hT/oB2f5H/ABq/aeF9EtIUittNgjjUYCqDgCj6tLuH9rUv5WeZT1BXrR0HSz1sofypP+Ef0n/nxh/Kp+qy7mizqkvsv8DyUilDEV6z/wAI/pP/AD4w/lR/wj2k/wDPjD+VL6pLuV/bVL+V/geRs5pAc165/wAI7pH/AD4Q/lR/wjukf8+EP5UfVJdw/tqj/K/wPJKK9b/4R7Sf+fCH8jR/wj2k/wDPhD+VH1SXcP7bpfyv8Dxy4HFUjwa9vPhzRz10+E/gaZ/wi+i/9A6D8jSeDl3KWeUV9l/geJ5oJr2z/hF9E/6B0H5Gj/hF9E/6BsH5Gj6nLuP+3aP8r/A8as03PuPQVfkcRQu56KCTXrKeG9HQYXT4R+Bok8OaRIjI9hCVIwRg0/qkl1M5Z1Sf2X+B4PoDO14ZW6bGJPuSDWzPcRWek3k+4eWqHBz+letR+FNDjBCabAoPXANMm8IaBNavbS6XbtA/LIc4P61y/wBmTe7RySzKm3ezPlLSc+WHf7z/ADH6nk1roa+j18CeGEHy6LaAfQ/408eCfDY6aPa/kf8AGuz6tLub/wBr0v5WfOsT7atpcDHNfQH/AAhXhz/oEW35H/Gl/wCEL8O/9Ai2/I/40fVpdw/tel/Kz59e5AHFVJrjg+tfRh8F+HD10i2/I/400+CPDR66Pa/kf8aPq0u4f2vS/lZ8zElmq/aJgD1r6KHgjw0DkaPa/kf8akHg3w8Omk2w/A/40fVZdw/tel/Kzwu2xsAqR4+MjtXuY8J6EvTTLcfgad/wi2if9A2D8jT+rS7kvNqf8rPCFXJOKUoa92HhXQ16abbj8DS/8Iton/QNg/I0fVpdw/tan/KzwcoT2pGtt45Fe8/8Iton/QNg/I0v/CMaL/0DoPyNH1aXcP7Wp/ys+en0wsxxTf7KlHuK+hx4Y0UdNOg/I0v/AAjej/8AQPg/Kj6tLuH9rU/5WfOR05knCP8ALuHymp/7In7SHH0r6Ek8L6JKuJNNgYA5GQaf/wAI5pGMfYIcfSl9WfcHm8P5WQeBIzF4Q0uMnJWEDP4mt2o7eCO2gSGBAkSDCqOgFSV2RVlY8SpLnk5dwooopkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts suturing the proximal limb of the ileum to the dermis of the abdominal wall. Sutures are placed through the full thickness of the end of the ileum and through the seromuscular layer 3 cm proximal to the end.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32130=[""].join("\n");
var outline_f31_24_32130=null;
var title_f31_24_32131="Dopamine: Patient drug information";
var content_f31_24_32131=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dopamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     see \"Dopamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/54/13157?source=see_link\">",
"     see \"Dopamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700798",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may rarely cause very bad skin irritation. You will be closely watched by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dopamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697032",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to sulfites, talk with your doctor. Some products have sulfites.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12207 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-714CE7359B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32131=[""].join("\n");
var outline_f31_24_32131=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016021\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016023\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016022\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016027\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016028\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016030\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016025\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016032\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=related_link\">",
"      Dopamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/54/13157?source=related_link\">",
"      Dopamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_24_32132="Chikungunya incidence map";
var content_f31_24_32132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Approximate global distribution of chikungunya Virus, by country, 2008*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 311px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE3AjEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3/wCIvjex8CaVY32oWOpX/wBtvY7CC306FZZnldWKgKWXOdhHGTkjiuU/4XJ/1Tj4k/8Agj/+zo+Pv/NOP+xz03/2pXqtAHlX/C5P+qcfEn/wR/8A2dH/AAuT/qnHxJ/8Ef8A9nXqtFAHlX/C5P8AqnHxJ/8ABH/9nR/wuT/qnHxJ/wDBH/8AZ16rRQB5V/wuT/qnHxJ/8Ef/ANnR/wALk/6px8Sf/BH/APZ16rRQB5V/wuT/AKpx8Sf/AAR//Z0f8Lk/6px8Sf8AwR//AGdeq0UAeVf8Lk/6px8Sf/BH/wDZ0h+Myqyq3w6+JALcKDofX6fvK9H1XUVsRGqoJJ5MlIy20EDGSTg8DI7HkisWL/ifRSJqRtoLqGYpbvG56lQxTBILDbtz0zk8DGaAOMt/jhbXDslv4B+Icrr95U0YMR9cSVP/AMLk/wCqcfEn/wAEf/2dd7omnf2ZLM080fmXRXEYYkAqDwCTzx6AdOlSC3uZL+/trtTNplzHldzDCZG1k9eeT6D9AAeaN8dbJThvAvxAU5K4OkL1DBCP9Z13EL9SB1qVPjbBIsjJ8P8A4iMsRxIRooIQ4B5/eccEH6GvQV8P6NZ2t4BaRxxTQtHMxZslMc/NnI+o54HoKo+FrWK1u5UsLpBZYZ/s4i8pmYkYYqVGMcjIwD3GaAOFPx4sBZi7Pgbx/wDZSdom/shdhPpu8zFLbfHaxuohJbeBfH80Z43R6QrD8xJXWeOpJpdR062sbi7Wba6ypbzyReUr4xKxX5Tt2HCsecnHeubsI9Q8NaT9nS0iuLWORI7eK2DMyIzkuWwOgBwMAnjknrQBDP8AHSyt4jLP4E+IMUYxl30dVAycdTJUknxtgjlEcnw/+IiSEbgraKAceuPM6V0Hg+2ttZ1a71C+s7Nbi3EcQtpdks8DKzMrNxhDzkbWYH1yK1vH8OmP4duZNXaWGMIyLPC2x49w5+YkADjncQpwM9qAOI/4Xdb/APRP/iJ/4JR/8co/4Xdb/wDRP/iJ/wCCUf8AxypLJ9bbU7MCC/TTw7CRrqa3ctHtbaSqqGBJ2nAJxznOeOnoA5T/AIXdb/8ARP8A4if+CUf/AByj/hd1v/0T/wCIn/glH/xyurop2A5T/hd1v/0T/wCIn/glH/xyj/hd1v8A9E/+In/glH/xyuroosByn/C7rf8A6J/8RP8AwSj/AOOUf8Lut/8Aon/xE/8ABKP/AI5XV0UWA5T/AIXdb/8ARP8A4if+CUf/ABynw/GmOeGOWH4efEaSKRQyOmiZVgeQQRJyK6W4RZYJI5CVRlKsQ20gEevb61h/DqO2t9QFnb30d7ZO5mtmtbpWSPbu2gxqvGVfBcsQSidMgFAQ/wDC5P8AqnHxJ/8ABH/9nR/wuT/qnHxJ/wDBH/8AZ16rRQB5V/wuT/qnHxJ/8Ef/ANnR/wALk/6px8Sf/BH/APZ16rRQB5V/wuT/AKpx8Sf/AAR//Z1Bc/G+2tniS58A/EOFpTiNZNGClz6DMnNeuVyPxK057zRElhJiaBmMtyhbfBCVO9l2uuei568ZwM4oA48/HOzEjRnwH8QRIsZlK/2OMhB1bHmdBkc1JB8bYJywg+H/AMRJSuN2zRQ2M8jOJK6PwPpwFhqzaZKtrFJGlrbMIm+QhS/mEMck75m+U4xtwfa74Z8OXem3xmvJrYRwjyrdLQMgeMKAokBPOOSBk4J60Acp/wALk/6px8Sf/BH/APZ0f8Lk/wCqcfEn/wAEf/2deq0UAeVf8Lk/6px8Sf8AwR//AGdH/C5P+qcfEn/wR/8A2deq0UAeVf8AC5P+qcfEn/wR/wD2dH/C5P8AqnHxJ/8ABH/9nXqtFAHlX/C5P+qcfEn/AMEf/wBnR/wuT/qnHxJ/8Ef/ANnXqtQzXVvBJHHPPFHJKdsau4Bc+gB60AeYf8Lk/wCqcfEn/wAEf/2dH/C5P+qcfEn/AMEf/wBnXqtFAHlX/C5P+qcfEn/wR/8A2dH/AAuT/qnHxJ/8Ef8A9nXqtFAHlX/C5P8AqnHxJ/8ABH/9nUM/xut4JI45/AHxDjkk+4r6MAW5A4Bk55ZR9WHrXrdQXrwQwm5uFUrb5kBK5KnBGR74JHHrjvQB5j/wuT/qnHxJ/wDBH/8AZ0f8Lk/6px8Sf/BH/wDZ1076zeQXsEk00hSWQboFh3rGmRnlV3cA9c9fQZx1kUiTRJJGwZHUMrDoQehoA8s/4XJ/1Tj4k/8Agj/+zo/4XJ/1Tj4k/wDgj/8As69VooA8q/4XJ/1Tj4k/+CP/AOzo/wCFyf8AVOPiT/4I/wD7OvVaKAPKv+Fyf9U4+JP/AII//s6P+Fyf9U4+JP8A4I//ALOvVaKAPKv+Fyf9U4+JP/gj/wDs6P8Ahcn/AFTj4k/+CP8A+zr1WigDyr/hcn/VOPiT/wCCP/7Oj/hcn/VOPiT/AOCP/wCzr1WigDyr/hcn/VOPiT/4I/8A7Oj/AIXJ/wBU4+JP/gj/APs69VooA8q/4XJ/1Tj4k/8Agj/+zo/4XJ/1Tj4k/wDgj/8As69VooA8q/4XJ/1Tj4k/+CP/AOzroPh78RLHxvf6zY22ka3pN7pPk/abfVrZYJB5oYphQxPRc844IxnNdrXlXw7/AOS7fFz/ALhH/pK1AHqtFFFAHlXx9/5px/2Oem/+1K9Vryr4+/8ANOP+xz03/wBqV6rQAUUUUAFFFFABRRRQAUUVBe3UVlbNPOWEakD5VLHJIAGB7kUAcPr1vqQ86XVI1W1lkKzThxnydxAQAYK5yMcnGWJPeq2l3Ew1U29usccVkdzxzQpITJyMswIIIAUAADAj68kV2MOv2Mi/6UTZq3Cm6KoGz2BzjPsefauf13wtDNZpLpM9wYGmS4CxOHAIBPmAnl+cHGeuCOmKAE1bVRdXGn3kJ3yKD/o2RuV45AXUDqSwU4yB90HjJpdc1jUJ7K01XS47uEW0hS6hADkKVV8smQDhfcEE+nNXdP0K8e3DSXJgJbeAyly2ezAn5R6AHPTnqDp2OhQ2l1Dci4uHnTduJKgPkY5AHA4HTH3RnOKAOG0S5NsgGo3LpFLNExSVn2hZdodXJ+VmyX5HGD071r39oi2KX+lahHc2Kp5arB/dcAplgTnkIOnRuQa35/DlpPqP2qaSaRTL5zW7bDEzbNvIK5xjnGeozWO2hXUDC2geMCKNfLAkCmba6n7vThd/XoWGOuQAYuhaHc6rLPfNr11ZapK8PnWsgSTmNBgOMDJYZ3FCAwC4I2nL5NDigEtxB4lupdUYORIB/opOW2K3yuFVQQDhucbjzzVuTSp7qeRL/QRvdFAZSrlic7hu4AA45J59O1Wkj1E4EumXMIdQI8lXbdzw21iB25Jx1yR3ANfwpZLFBPeuZGurhtjuy7VZEZghVegUglgck4bk8ADamijniaKeNJI24KOuQfqDVPQre4tdItYbwxm4VP3nlghc9eBk/wA6v0AedDSNb0q7isdK0u2ktN7NJclljWQkr0VfuHG7Py7RtwOoB1ptP1WzTzJkhvIurfZVKvH7bSTvA9RgnstdfRQBxkEyTwpLEcowyDgj8weQfY0+q8kKaXrlxpiFjE6G9iJQj78jl13dDhiPfDDOepsUwCiiigAooooAqataLf6Zc2zSCLzEIEhUNsPZsHg4ODg1o+FZZL2+817W2svscL2hto/4V3KUdRtACttbgEgYUZyCFzdYntrbSb2a/VXtEhdpVZN4ZcHI298jjHfpVP4a2sVxtktb2/juLE+XOh4hljLSBE2FiV2gH5W5XPHGKGB6RRRRSAKKKKACkIDAggEHgg0tFAFXS9PttLsY7Owj8q2jLFU3FsZJY8kk9SatUxpFWVIyH3MCQQpI4x1PQde/Wn0AFFFFABRRRQAU2WRIYnkkYLGilmY9AB1NOrjvEepMNZuoJJn/ALPtreOSRVwAJdzHB7k42EDp07mgC1P4gu/NmeOGCC0UAI85O4+rEA9O23g989qhhs7vVCWIYpLgSXDjble+wfQ8cbe+Tzm54csZpV+26hC8TlswQMQdi4GGbH8R578ZHfmuhoAKKKKACmTSxwxtJM6xxr1ZjgD8ajgtYYJrmWJMSXDiSU5zuIUKPpworkVu7jVHN1eKUUOfJtzg+TgbTzgZJIJ55Gccc0Aal54idJp1sbP7VFEgYSebsEh54Tg56denIrO1K+utWZUMctvYOpWSF3CuwKj723POcjAb1znIw6inYBsqeZE6BmTcCNy8EfSoorSGHa0aKso5EigBs+uRU9IRK7CK1iMs7AlVzgcdyew5H/16AN3w1qR1XSIrlzGZMlHaM5QsDg4P+cHI7VqVT0qyFhaCLdvdmLuwGAzHrgdh/nk81cpAFFFFAGTqWtRW7vb22JbxXEbRnI2ZXduP+zjAyO5A45xQtvF1tLfrbvbTJGQVMvXbIv3lx1wMj5u/05q7qumR3chms/JF5G+Xy2A+VAw+M84xgkfoTWRZaBc3TW8s+qwGe3LRz/ZUBAPGV5JwehORxxxQB1kUscqhopEcEAgqwPB6Gn1z994cj3282nbIZrdFjQH5eBnB3DkHk54IPpWvpsdzFZRpfTCa4GSzgDnJJA4A6DA6DpQBZooooAKKKKACiiigAryr4d/8l2+Ln/cI/wDSVq9Vryr4d/8AJdvi5/3CP/SVqAPVaKKKAPKvj7/zTj/sc9N/9qV6rXlXx9/5px/2Oem/+1K9VoAKKKrahf22nw+bdybEPopY+vQAmgCzRUcFxDcIr280cqMAwZGDAg9DkduDUlABRRRQAVkeJpgljFCQf9ImWPOM4xl//ZMZ7ZrXrI8QWc88cc8Dbvs4ZjDtJ8zp09GABA4Oc44zQBg3Ih8sPcqhRCHBcZwR0I96fpeufYJAJkIsbiTbHk/MHIY5AxzuIHp69zhJ9PnurO5maEpAkLFTM+xXyRk9eMKGwWGASD71BaXBui2+2liMeCGfaQSR/CQTn6+9MDobvxDZRptt3E9wVVkjwVBy+zG7GAQQcr14PFU/DmpXkkd9PqkriO3UGQFVIRsFjt2gEgLj1PPqDnGu7BWtJY7RUjlkbJc5zyTuOevRm/PHStrQyp1GeCRVdJ4MkH0U4II7g+Z+nvSA5nUr3bdT6ncXl3crbXLMjQM3lrHgN8qjhWCZTJwNxO44OatzGBrnUCxiurmW5kZY225YhiiKMDP8OATk9a1b3SrqC5W2tQ88UwOySQ4EWByGYDp0wepJ59areFHC6xLM4zFdKI7Ztu3aEQLjbjgMsQbknHT6gE9zd3Flbrp9pcyeZaKsckg2s8kpAIUbgQB8w7fxADAHOTZ+ItZu9MnukYx+QSI1kRd0yr1ZgAcbhyAMcEfUy6vPFHPqVpNdxW12zSOpkYDaDkq3XsMH1HtUGlumo+H0WMmJZI3i+U7thBKnGR2IPagDZ0rxEzXlrDNcLOLjA2FB5qE9CdvGB0ORxnOeMV1dcPHZxJA0XzurAAmRy5OAAOWz6Cr2i+IpI5Ley1iHyJXl+zxzNMrec2MggcE+nTOe2MkAHVUUUUAcx4zR4brSL9F3IkrWsxxnYkoGG45z5iRL6YY59RWrQ8ZwahPY2a6bbPdFblZJoUdE3KqsRksRxvEfQ5zg8jIPK+HdTubm51PTdVSKPVNNn8qYICBIhGUlCnOFcZwMnp2OQADaooopgFFFU9YupLPTLi4h8kyxrlRNII0J7AseBnp9aAOSsfEU2q3LtdRQC2ciL7PJIskHAyW3qpLEkjGAR8p4Ocr6v4d059J0eCzlm85oy53ZJADOWCjJJwAdo56Dt0rySe+s57C91u0tphdCVZLyBrnCyRIVR9pXKlcJnIx2Y8HB9tpAFFFRC5gN0bUTRm4CeYYgw3Bc4yR6ZoAlooooAKKKKACiiobq6t7SMSXc8UEZYIGlcKCx4Aye59KAJqKiguIbgObeaOUIxRijBtrDqDjofapaACiiigCC/uo7GzluZtxSNdxCjLN6ADuSeAPU1wWlac+oa+tteBXWNheSsPmJQZCRyEoA2WyeeTtauq8Xs6aM7Zb7MG/0kAA5iwcjntnGfbNUvCV5FcytKmVFzBG8Ybqcbsj6jcOP8KAOnpk0qQwvLK22NFLMx7Ack0+sbxHcr5S2S/6ybDH0CBhn656fj+YAzTNd+0R6i9yix/Z2d4ol/wBbJCvR9h55/wDrcGtJ7+3Sziui58iUoFYKT98gDOOg5HPauT+0S298Giby3Mflh8Z+VmG4+xBVBz/f9qydP2i/tY5t9tLbwmGAI7IXHDE9eDnd0PI/3aANuG9v7q3Vri7lVjxJHHtUKwPIDAbsAjrnnHekjjWNSFzySxJJJJJySSeTzVJZZo9WWAIGSSNpJHBxlt2d2MYBJY5A4OM8dDfpgFFFFAEF/cNa2ksyRSTOo+WONdzMe3FVPsMst7HcfaLmJECsFLASM4zgtt+XAJBCjIyMknpWlRQBFpk+q29t5E15tSJ2WHy8OTHn5d5ZSd2OOOOB9Tr2WulLcLqMbm5ywBhhOx+TjHJ28Y+8RzWbRQAtjfarDaxBrpJJSAZftEW/DY5xtK45+o7DFdNpt0L2zjn27Scqw9GBIOPbINcxVi11M2WiQx2vlyXomKyxs2dpJZzxxgHBCk9MgnOCCgOjS3hS5luFjUTyKqO46sFzgH6bj+dcsizWOtzsb6xhL3HmSIblkUqcZ+QgjdtweuckHIBAqa/8TyRx4XSLuZHYphHAbHTJx0785xjBzniszS7ZLW2KRwmEF3YIxyQCxxk5PbFAHd0Vw8kBigk/s/8A0eYqdpjZo1zjjdt6iuj0rVo57V/tZ8ia3RTM0hAXnI3A5xglTjOD6gUAatFV4b60nkEcN1BI56KkgJ/IVYoAKKKKACisrVtdtdNmWKTLyEZIDKoUderEc4ycD8cA5rSglSeCOaIkxyKHUkEHBGRweRQA+vKvh3/yXb4uf9wj/wBJWr1WvKvh3/yXb4uf9wj/ANJWoA9VooooA8q+Pv8AzTj/ALHPTf8A2pXqteVfH3/mnH/Y56b/AO1K9PvYWuLSeGOVoXkRkEijJUkdRQBl+I9RubY21tYKPOmbLynBEUY6nBP3j0HBHXPSucs9MtrZbj5BM9w7vNJKAzSbjnDHuBwB7AVaFsLGdrd4o4pQAfkAw45wRj6HjrwfYl9MCCK1jt5Uls/9FmTOHhUDgjGCMYI+o7D0q/DqOoQc/aFuB3WZAM+wKgY+pBqvRQBdXxDLbtEl7bmZpW2obcAc7ScEM3op5z+FX9R16w0/SG1G4lxAPlCgfOz9kA/ve349Oa5e+/4+tO/67n/0VJRqGmWeoRMl1CG3cllJVs4x1HP+RRYC9qHi53vY7XRrYzy5DOZlZF2jG4Z/hODgdTkj5cc0Jr91YW8cc8Ut0/nrulEZbEJIyflHLDJ4x0GabRRYDattctJvluUktMjj7RtAPtuBI/An6VzF3ZBLtoJWltMOwiWN5FDrnjBZiG4x93GM8+12qH2KKG8Bjt9lq4Jl+zKod2H3epAABAbvkgceqAuxqVjVWYuwABYgZb34qldahALB7yCR3MPQwlgwbp25/Tp2NVvELwDTZTJFdR7hiOedw6xt28xEIAXOPmXJ9fSrOl2P9nx/6SkV/wAhnzHscjuikHATuEPGScnnhgdAusXEOh2Ul8qrfXKniDEmwYJD4B+YAAexJA7iufaVrN7a1tvluoFimjZVLr5WdpdTxuG3cMZzz05qTxNdXF59mbTNOljmVtrS+aiEIAcAjnPzdumD1GSKq6CRdWsF60PlTmLyZBub5mVjuJDfd+bdhRwM9TSA6i5tLbWB9p0+9aKYxo5CBcMCAV3qRkZHHY4+gxzMd7e3DwxQ2sUDzEbHuJgFbkZXj+IgnA9RUiyXOjyieyKSSPuXbN0ctImF4xjCBgO3yipIrQRz6YhmlEKXaySnOXkYkkZJ9ZCpPtkUAJZi/WD7ReoI1ZyJbdmVpLXKgruK8YPPqRuXk84nureO6t3hmBaNuoBI/lWl4pjtIbaKNrS1xJMZ90sZKeYB1IBG5jnoTyAeuKybKG5tVEN1C0G5fMSN33lFLH5d3cDgA4HGBjjJAL3grUJWlutMup45ZYCzoRlTtLHgKSThQVHYDgc9a6uuNtJ7nTbmWe1UTxyndLAzbckKACpxwflAweDnqK6rT72DULSO5tJFkicAggg49j6H2oApeK0nk8PX0dss5d49p+zkiUISAxTHO4LkjGTkDg9K87061ax8Rac0sw33VrOkcZjMC+WjRtuVCTyS/RQg++TnivV5ZEhieSV1SNFLM7HAUDqSewrzPRF1fUNTl1nXTF++iAtIOd1pGzMxQgovOCgJPPyCgDeooopgFZHijTLrVtNW2srw2cnmBmlAzhcEHA7kZyPcA9qt6u8i6dMtu0i3EoEMTRgFlkchFIDccMw68etW9H8P67JAv9u6jZwybQGXT4ieQOTvkyME842+2e5AOUn0K61O6ttGtLg3RAze3DgqYI/lJTep43EIVjIJOCc4zn1yqel6ba6XbGCyiEaMxdzklpGPVmY8seByfQVcpAFIFVWYqoBbliB1+tLRQAUUUUAFIzBFLOQqgZJJwAKWsLxtEtx4duYGkkRpMbBFne7jlVXnAJI6ngd+KAMHxN49Szu1t9GjS52KXnuXX9wi8/x7h3x+HtkjCNjdyQNf6vefbZZpY3WMM5jBYgBU3E7FL7TwOBkAVLoGlzy6cjX1y0kM+ybyeHDcAjcWXPZePar9nYQRahMhV3KbZULuTt3FuMZx1XOfU56jNAGdpavoOuokNq8zSIJSLUgyggBcO7sBsOwZ45OTjJyPQNF1y11O1hcsttcuSrWsrr5iMDjBH6j2INcwB5WrE8Hz4ueOV2H9R8/+e1s7ZEHIZWGQQadgOxorB0vVJhcw212VkWQ7Y5RwwIBOG9eB1GOe3NV7W9uodduo/Plk0+FnaTzdp2JtySP4iQ4I7jB9waQG9Z3lvfRM9tIJEBweCP0Pb371Qbw9p6XP2q1t1hulJeMhnEauVxnYCFPbjHXnrzWG4/0T7Lpvm6fanAJViZnUdixyQMccHI9R0ptstxDZx2gumW1RQgijRVBUepwSSe/IznpQBp2WtXdqpttVtJGuIQA8kbKd/Gd2OOOoyByQeB0EOuTxXF1ZXluA8Gx4ZJQnKsSm1W7r/F1HX0JGaFpb/Z4tpkeVum+Q5OMnC+wGcADgUtxAZQdrbCwCvxnemc4/wPUHkUARXjiORnZgqeQVYkgAAzQgnPbjPNWY5EkBMbqwBIJU55HUVBcS4mKwy7J0hkJKH5lVkKr+blMDuR7HFOKE2mtoIoWFtLAQWVc/OCPvHr0x19/emBbe1dtQW4+0MIQozDtGCw3ANnr0dhj6enNqiigAooooAKKKKACiiigAppjQyLIVBkUFQ2OQDjI/QfkKdRQAUUUUAFMaGJ5UlaNGkThXKgkfQ0+igBk+/wAvdFkSqdyEdQfUf4d+hrZHiKFmGLO92ZwXKKMdjxuycewOe2eKyaKALk/iSVpLkWVhJJBFEJfPc7cDJyShw2AAT6nHTkVKNcusc2UOfa4P/wARWZJEkmN6g4ORTqLAdFYXdrfszpHtuFADLIoDgZyPqM9wSM+9Xq4yaMvtaN2imQ5jlT7yH2/qOhHBrY0fWzc3T2V7EYrlE3iVVxFKuQPlOTg5IBU+vGaQG3XlXw7/AOS7fFz/ALhH/pK1eq15V8O/+S7fFz/uEf8ApK1AHqtFFFAHlXx9/wCacf8AY56b/wC1K9F12/fTdPe5jhaQKfmIBbYMH5io5PbgevbrXnXx9/5px/2Oem/+1K9UdFkRkdQyMMFSMgj0oA8+1uzutXtJI7idHlcxsk20o1u6tksnXAIwNvHT72cmr1vF5EKx75JNv8UjZY/U03WLbR5jdWtlHNPexq8DB5phGmR3LZBIO0jHOR2wamUYUAADA7DFMAooooAp33/H1p3/AF3P/oqSrlU77/j607/ruf8A0VJVygAqG7WZogIJViO4FnZc4Xvj3qaigDLgltZoLUXT3M147F0NmFYbcZVmLDCDjoD/ABDIJxjRt0eO3iSVzJIqgM5/iOOTSrGiuzqihn+8QOT9aZ9pi+0GHeBKMfKeM5BPHrwD09KAHzRJNE0cyK8bDDKwyCKcOBgdKgW7t2ufs4mTzsZCZ5IyQcevIP5VPQAUUVR1aW5giSW2uLOFQwVhdAgMSQAAwIwefQ5OBxQBDqV+0Mc8MsU8TsCI5YlZlx2JbGFPsfwzxWr4StxNqF3JcSO4hZfJidvucYOQQC2CMh+hzng5AfBo17d6Ss8hRbuePiByVWIOMHnbu3bCRyOCTweMVBZagbiwZri3tNQb7luxG4EKSzBgG6jIwR07g0gOrvtTtbGSOO5kYSOpZVSNnOBjJ+UHHUVzTTtdXVxPIGyXKIzLtzGCSuB16Hv3zWzeWMV9fRR3aTrMIQzzQybEkw3Kdd3BOenQ9ecVkatp8GgRwPaJHDpfyxMnOITjapHXgkKMepzkk0AUCLv7fctHIXjSNGW2bb+8XJ3lMDcWAwcc9vXjX8IW7ST3GoRhYrSTciIoAMjBjudsHnkcZ55bPWuc1G8/0G6mntw4gjNxbyQDzNygZDA4wp6DOe/UZBr0iPdsXcFDY+YL0z3oAV1V1ZXUMrDBBGQRXnXhdZbfSU0+6Qpdaexs5QVxkoBtb0wylX4/vevFejVwGv6Pa23juPVbgMZLqIR2zMeFlCnzFHuY0Q477WPagC/WZqV1cztPpmhhZtYaB3Qb0CwEbQGfJ6ZdTjBJ9K06j8B773Vtc1RHleycxWtuWDKreWGLsnZk3PgN6q46YJYE/hjw7qMU8F74kuop7u3UCKG3bMSttw0hO1SWOWwMYAPA9OtoopAcv431PVNOjtX05BHbBw89wSh4DD5ApOSSu48DPA98U49d1y9gidIbWxSRSGEkbPIh55AyB/dIBz15A6V0mu6Ymq2EkBKRykYSYpuaPkZK9CD7ggjg9qy10e/80Rs9vs/57gH/ANA7f99H69iAWfDuoTXEt1a3btJNFtdXKgAxsMDp3ypznHt6Dbqnpunw6fGyw7mdzueRzlmP+HsOBnirlABRRRQAVwvia9lvdc+yxblt48WqyDOPMZWeRhj0VVUHsxb6HY8R63PEs9noqQz6gi/OJJNgi3A7TnBye+Mdj7A8/ZQM10xZtgtXKBU6OWVWYknJPLevbJz2ANJVCqFUAKBgAcACqqW1zGw1SeNEtrhI4lXzMuPmbaxGOh3epI4464sxIbw3EcTqkcA/fzOMrGMZxju2DnHp17Aumn+2NC3lukEK7YEk5YcY3H3I49cfUimBSmIXVbXbje0cgZf9kFec+xwMf7R9Km06wgW4mjFw9rbpEZc7gEjwemGGNvJPBGMe4xDqK4a2uD92CXe3qVKsv4/eBx7euKsTRb23qcPsaP5slSrYyCARnoOeoxwaAJLqGS2ubfy7lZXdTLFMiAIo6EjJbc2Dx2GcnPAqt9neeWaW+ZJpXkLB1XZ8u0Lg4PPAGex9B0DbOwitgpVVDhnbKZUHccnPJz9SST1zmrdFgCiiigAooooAoWOmLaSSHz55g5BPmuWJI6Z5wcckccZPti/RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFNeRIyod1UudqgnGT6CgB1FFFAFa+F3IscOnMguXbgMu4lQMnAyBn3JxzTNQ0+K8mWDUbUpLCRIqSbWypyOxIwcMMHnjtwa0/B72wur1bdo5FmPnI6gE9cOu4dQGwcHkFiOmANfXND0/W7cxahAH+UqJFJV1B6gMOcHuOh75pAZ/hIXTJJIEEWluitbIQMtnkuuD8qkY4IznJ478Z8O/8Aku3xc/7hH/pK1egWNzeR3n2KbTXjgXKxTpN5ilB90tnBBIxxyc+3Nef/AA7/AOS7fFz/ALhH/pK1AHqtFFFAHlXx9/5px/2Oem/+1K9OvrqKztmmuJFjQEKGIJ5JwBgcnJIGK8x+Pv8AzTj/ALHPTf8A2pXqciLIjJIqujDBVhkEUAec6Vf+XGtpcM80yyCFJgm3z8qXEmP4cp8xz+BJrYrc1bR4r2DECwW9zmMCfyQzBEcNt7HHBHXjNc3qFrdaVPDHPexzQ4zxETKygAZOP4izAYA5xx1wACtrUrvaT2lqT9rmjKqVbBTd8u/8Cc8c8E9jVaw1i4nuFgexaRlwkptiZSj7dzHAHKDIUNnJORtGKt6QbTWtUm0i7hlZona6kYMVaNlOwRlgOfvE/KflJI6g13UFtBbhRBDHEFRYwEULhFztXjsMnA7ZoA8/1HULNZ7J2u7cLHMWdjIuFHluMnngZIH4itON1ljSSNgyMAykdCD3rqr+xtdQgMN7BHPEc8OM44xkeh56ivK/H1je+FhbXNpdFtNWT90rgt5J+U7cKvIwJMZIwMjju7gdZRWTo15c6npsN0ksCFx86NAwKMOCCN/rV3Zef897f/vyf/i6AJ5Q5icRMqyEHazLuAPYkZGR7ZFUPshmmWS+gjnmRNqOF2IDkEtw27IwMAY6nnvVjZef897f/vyf/i6Ty77/AJ+Lb/wHb/4ugB9taxQFmVF81vvPjk+gz1wAAAOwAqese+0q5vZY5JruAPE26NktyGQ4wcHfkfhjPfOBi3DBexxIguoG2jG5oWJPuTvoAu1a0OzF1qZupGby7M7Y1BIHmMvJPrhWGO3zHuBjL2X3/Pxbf9+G/wDi6u6HdXGn3TJdy272txJuZhGUMbbcZJLEY+VR9T1oA62oRaw/bDdeWPtBQR7/APZBJx7dTUqOsiK6MGRhkMDkEetLSA4zUdNgsb2ytAJHjFsxVpCpLEPkkdwV39R/e9qijujok5u4XhS2YBJopZBGjHPysG7Nk45659hWnr8Ei6tDPM5eMoyQ8YEZO0svuTtB5/un0qjOjSQSIhVWZSAWXcAcdx3HtTA0VtbG4tTqdoDYzgecZCjGMM6bmO3hXyHPzDqc85yK6FGV0V0YMrDIYHIIrg4JdTk02DS7lbdbW2aNTMAd8yIFIwN3yncvOScr2yeNjwZdOkU+lXLM0tod0TMwJeFidvQDoQVxjgAdetIDpayvE2lHWdIkto5RBchllgmIJ8uRTlSQCCRxhgCMqWGea1aKAPNL/Wp9DEB8TWf9nxywtIsqP5w3pjchCg4JBBUDORnuMV2/hi3e20K0WUFZZFM0in+F5CXYfQFiPwrSkRJF2yKrLkHDDIyDkU6gAooooAKKKKACo54En8vzN3yOHXDFeR0zjr9DxUlZ+u6kukac95JHuiRlDkttCKTgsT6D2BoAs3l3FZxLJcMVRpI4gQCfmdwij82FOuzKLWY24zMEbYOOWxx196w9C1839yYbyMQu+3yUEb8nYXI3/dbAxyD1B4roaAPK/Acz3GkGQIq2rEGMmR5ZHYjLM7so3cnGQCODye2xYMGu9RwcgTgEe/lp/wDW/X8Htoi6fpc1nqMn2fTIwwebfvaVTkkKOTk5IwQSO2etM0i0NhZfZGLFoJJEJbGWIc8/j1+hpgavh28sZbCeGRv3lzO6srKQJM5VcHHIKoBn/EVk2F4skSQyFjfIoWaFVJkD45+Uc9c8jitHwTaW1m24yzyahdwC4ffK8iIm442biduc5Izzj2AGTLqWoXVw0t3m5tZHkEUVs+PLVWyGYHbuyGUjqeAep4QDzJ52pfZ7tJLZo23RQy4UzjGd4HdRnp1BHOCBV+s3w/8APZPOzzySyyvvknzvYqSg68gYUYB5HfnNaVMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooq3penDUUM07SC0PCBHKmX/AGsjnHpg8/SgCpSOyojOxwqjJPoK2H8N2Ehw/wBoaPcGMbTMynHY5PI65B6556DFeXwtDJcTN9uvkhdlZYVcEIRjozAsORnrRcCtJpF1PpNzOjzxXflubeEFVBIB27sgnJP5DHGQazLiJVvhJNMWEfDrgbI3H8APVjzzjI3Io6g10Wr6ljzLK2aTzxhZZcY2AgHg92IPbp+QOTotobrXFIxHHYj7jQhg4IG0qSOOQemCNg9TSAhS7jeCOZUm8iUgRyeU21iTgAcdc8fU461saborS4m1MEcnba5BQDkAt/eJHOOg98ZreVFVAqqAowAAOBS0ARQ28EBJhhjjJVVJRQMgcAcdh2qWiigAryr4d/8AJdvi5/3CP/SVq9Vryr4d/wDJdvi5/wBwj/0lagD1WiiigDyr4+/804/7HPTf/aleq15V8ff+acf9jnpv/tSvS9RsLfUbb7PdqzwllYqHK7iDkZwRkZA46HvQBl3usXs119k0SwaZwfmup/lt0HHfOWJzxge/SmaFoMkFx9v1e4+2X7oo5XCxHqcAs3P44HO3G456BVVFCqAqgYAAwAKWgCC0s7e0877NCkZmkaWQqMb3PUn1NT0UUAFUtZ0y31jTZrG8DGCXaTtOCCGDAj3BANXaKAPGvDuk6v4e1x7UREaK9zJCHaQNuIDENjHy5xjj05rtalufB1tPqOrzg+Wt7JFdIyMVaO4RWXdx1BBHfuenWqNldLcCZCU86GR4pFU9CrFc884OMj2poCzRRRQAUUUUANeREKB3VS52qCcbjjOB78GklijmCiWNHCsGAZc4I6H61R1qOIRC6niMq26s6gKG2MCGEnIzxtxgc4Y45xV+N1kjV0OVYBgfY0AOtpJrOUyWTKhbJeNslGz3wCMH3/nWxpuuC7kt4pLO4t5ZR/EUKhtpJGQc9j2rHqrqM09rHHdWzlHt38xiFDfLghuCRngk9fy60gNXXrlb6aGGBnCW8pd3HGXGV2jPUcnJ+mO+KlR/a47zU9RltvmtvNAV8EbmCKGwCOmR17nPpzJTAKgQyWGotqVqjTS+WInhLcMm4E7cnCt+h4z0BE9Vr+ygv4RFcqWjDBsBiucdjjqDyCO4NAHWaRqlrq1qZ7Jy6KxRsjBVsA4P5irtcR4bWC38RQQaeHgjaGR5IFRkjZflAcDG3gqACOxPrz29IAooooAKKKKACiiigArkvGXiWyt4Z9JRvOurmGSNtjqBFkFRnLKckkDaPm56V1tcPb6ZqN3c6vF9lWCCa5lCLKCqqpJBYNyX3HL9ABuxnigDP8K6hLbCye9m+1TWsZhmcxsu/wCcoZVGScjacnB6tzya9HBDKCpBB5BHeuDFzHLq9755lS4V2UJIT+6QtwuR8oJJzwc8+3EkPiOLTfDU1v8AbVlvEHkWaRIZJSAFQOUAJID5+YjHAyaALXxG85LCGSCPzDIJLbG/btLgHcTkYACNk5469M4wPD+o3GqXUx1G5jgkG3eisFkWJdq7zuypHzoSxO5sHA6AT6MZtQUXt7dzXZV/3LNIdhIXazhM7Rlt+DjoccU7Vja2Z0uWU28EMVyAN2FwWR1AX3yw/DJoA09S1fRtJ8OXGn2TyBxatDCpXY0nBGRJJhSctnJPf3556G4s/s0l9FdTrcLIsBZplk82Q42qOduCWxgFRyemAR0dZMjFPEEz/YnncW8e2RAnyDdJ3ZgecngenvimA2NLywhW5lliPmOHuYRHhU3FQSpzwAMsSc55PFbFZWoXrzWUsFtBcreSoY0DwsFRjxktgrgdT16cZ4y/TJWt2Wxng8kqgaNg5dXyWyAcAbhjOBxgjHHQA0qKKKACiqVxqUMM5iVJ5mVgr+TGXEZIz82OnHOPp6jLm1OxWISSXkEak4/eOEwcZIIPQgHkHkUAWnZURndgqKMlicAD1NUxqMcyj7Cj3Rb7rICIzzjO8/Lgd8ZPXAPSqElpb3fisTXEbCW2hxCGQMsnIJbJBxtLKBghs54wQTuUAUrDUY7maa3cLDdwtteEuCeinIx1GGHP8qsw3EMzyrDNHI0TbJAjAlG9Djoahv8ATrXUFQXcIcxncjAlWQ+oYYI6DpTJ4kslWeBVjijAEqIAFKdM+20c/QEelAF2ioYLy2nWMw3EUgkzs2uDuwcHHrg1NQAUUVVluysrKkEsqx8SMmPlOAcYJyeD2z2oAtUU2GRJoUlibdG6hlPqDyKdQAUUV598T/E19pFxa2ml3iwyuheUKgZgM4HJBA6Hpz+lBlXrRoU3Unsj0GivNPh14xvr/VF0zVJVm8xD5UhADbgM4PrkZ/KvS6ETh8RDEw9pT2IVnt2vY7e73iNnCldv+sGMk5PGwDljntiuxW5gbyis0RE3EeHHz8Z49eATXGXdjb3jRNcRB2iJKHJBGRg8jsRkEdCDg1DGH/tu0/eOtvDMjRKHOBKzASHHb5ZAPQ7296Rud9RRRQBxVs263E0h+eUea7E9SeT/AJ7CtPwtbEyXWoGWcmX90IiMRhVJIK8DJOep6HI7VUhsDeareWbO6RRyyPM6Y53ncqcjuHz+HvmutoAhsZ2ubOGZ4ZIHkQM0UgwyHup9xU1FMjEgMnmOjAtlAqkYXA4PJyc554+nqAPoqLzX8tmMEgIDHblSTg8d+/UfriobW6muY4pFtJYVZiHE5Csq4JyAM55wMHHc9sEAt15V8O/+S7fFz/uEf+krV6gVlbyWLCMqcyKvzBvlIxk+5Bz7V5f8O/8Aku3xc/7hH/pK1AHqtFFFAHlXx9/5px/2Oem/+1K9Vryr4+/804/7HPTf/aleq0AFFFFABRRRQAUUUUAFcD4m8NnTXbUNHjVVZyWRWCujO2TtJHIZiMgkbeccfLXfVm+JUEnh7UkLFS9u6qV+8GKkLj3zjHvigDjNNvL+5so5VitpVOQJGlaPzMEjdt2HGcZ696s+ZqH/AD62v/gS3/xFXFGFAJJI7nvRTAp+ZqH/AD62v/gS3/xFHmah/wA+tr/4Et/8RVyigCk7Xzoyta2hVhgj7S3P/jlRwz3duWS4sf3Ixsa2YOqIAOCDhic54VTxjvWjTJ4knheKUExuCrAEjI+ooAghkvbwLJptg01uVJ8yZ/J3cjhFYZbg5zgD0JPAnhlWZN6bsZKkMpUgg4IIPIOQaoX6PbyW8tvNcROqur3JmdzHCqF2GC2TkJgehOQQeap6dvtLe/8AtF5dyXyNFc/ZjPHI22V9m35hk4xkncAWbqoNIDepssiRRPJIwVEBZmPQAdTVH+1Yo7dGuARcEhGhj+dlc4G07cgZJAySByKivZLi9tZIDYy24ccyzSIBH33fKxOR1HTkdR1pgRvqLCJLu7jeO1cgRx7JN3PQvsPy8f3sAZ57Guh0nw8bWJ5NUmkuUCBwryNuQ85VtpCsBxztGeeMcVzdzA8Vtcf2fZQpY3EYjR3Bij8z5vmxjkY53DsvXpWh4b0nxJN9jbUb+eG1jdZWjkO5yVPABPJBHUMBjPQ0gKMmtraXj6sNRtrWeVHka1m2uCgAwMBgQwCoDg4yO9d3oOopq2j2l9FkCZMkEYKsOGGMnoQR1PTqanvLK2vVRbuCKYISVEihsHBHf2JpbG0gsbWO2tYxHBGNqqCTgfU0AT0UUUAFFFFABRRRQAUUVDcXVvbbftE8UW7O3zHC5+maAPHvGvjG28P3FzY2Xh+5gv4Zh5NzqMImS4QPh8M7btjDJBUnOedpJNeV6vruparrD6pdXci3x+7JCTGYx2VMdAAcfnnOTX0J8X7OzvvAF9PcIJDbBZ7dw2Nr52gg98hiPx+lfNNJny+c1K1Ooo82m66HrPwy8UT3dtd22qy2iRW2G+0O4jZ2dmOCPunvyMY44Oc11aTpPqNw2mm2vXKKXLz8R54CggNgEAnAA5GT1rxTR9T11tG1DS9PjnlsI9003lW+/ahwSWYA4GQea6T4c2F5PpWo3Wn6j80LN5th58iFU2ofPAU891+6fu9+lNM9LA4/n5KTu21u9P8Ahzv7O4YxE6WZlyzZiMLzREgkZjdiqhe+AcegBzmxp18Nkk10szzsxH7q2cqAOAARuHbPBPJ9qzoTdxtYWNrcC1t5oJEiRHDtEygYBDKTgYI68HPPQDV0/V7IxGGVorOWFvJaGSRRgjj5eeR6H+RyKZ6xZsdQju22iKaF8E7ZVwSAcHkEjg4z6VPcW8VygSdA4B3DsQfUHtWboeltrHia6eR5V06KMOpjcxMrPwYyOGGSu8nj+HHfNuPRdag1OQKpvrWIbFjubnyFZeCGDqhZ2xwQQBnPPTKArae7f2pcQW8kz2UKAHeCVEhJyquRzjByMnBIHGMVY1kuNPfYsjAsgcR53bCw34xz93PTn0pumWlvpqvbLClvcu7SyxkBWLHqePvADAByeAOTVm8JFuwEvkbsJ53H7rJxv544znnjjmmAzTYoYrKNbVi8RLNuJyWJJJJ98k1JDbQQyySQwRRySnMjKgBc+pPepZ9PsNGSCwXTf7RkkVnae8kz1OWIJBOSSOFAHIrP8+7SSC12Q+dIsjb2csFVSoBPA3H5hxx3oAs2tla2hY2ttBAWGCY4wufy+tT1UW8WH5L54oZB0Jbarj1Gf1Hb8ibEMsc8YkhkSSM9GRsg/jQA+iignAJAz7etAFSfT7aVJAsawyOQxliAVwy/dOfUe+fTpxXIaJ4zsdXvpbOe+aGHcBDIw8tp93bI+7jpxgnjnrXC+OPFD67q0MtqLi1ht4yio7YcMSdx4PGRtHXtXLZZeYztYfdI7GpbPBxOcqnVUKauk9T6TGnWi4McCxEfxRZRj9SuCalt7aO38zyg2ZG3sWcsScAdST2Ark9C+IWk6ncR28qzWc7kKvmgFCx7Bh/UCuxqj2qVaFVc1N3RT/suz3E+TznK/M3yH/Y5+T/gOM0ohvEJCXcbR/w+bCWYfUhgD+X51bqvqN2lhp9zdyKzJBG0rKoySAM8UGj0OT8d3+raLY2c+nTyy3Usu2QrGChGCdoTBx9c59SeMeT+ILq/vNXuJtXVkvSQJEZNm3AGBjtxiuz8T/EeW7gEGiRyWysoLzSY3g+i4JA+tcDd3M15cvcXUrzTyYLSOclsDAyfoAKlnyubYunVfLTm3tp0HadeTaffQXdsQJoXDruGRketeveFPH1rqFjO+ty2ljPCR/y0wJQc8qp54x0Ga8Zra8L+HbrxFcyw2ckMZiAZzISOCccYHNCObLcVXpT9nSV79D3nS7+HU7CK8tdxglyULDBIBIzj8KJrae4axit2WJ74zPDI6lggCxkNgEddmRz3B9qtaTpaSpDYwrts4FVH/wB0AYT6kdfQemRV3xCIH1vTjdG4SO3HnCSCUgq29cB1C5KnaR16bsjoQz7JXtqdDEXMaGUKJMDcFOQD3wadWQmrm/Kf2IkV3F5hjluC5WOPGM4OPnPPGOCQQWFakCukKLLJ5kgUBnxjce5x2oGMs7WKztkgt1YRpnG5ix5OSSSSSSSeTU1FFABRRRQAUUUUAFeVfDv/AJLt8XP+4R/6StXqteVfDv8A5Lt8XP8AuEf+krUAeq0UUUAeVfH3/mnH/Y56b/7Ur1WvKvj7/wA04/7HPTf/AGpXqtABRRRQAUUUUAFFFFABWd4iH/EnnPPylG4HowPPoOOT2GT2rRpk0STwyRSrujdSrDpkEYNAHJU2Xf5T+VtMmDt3dM9s+1NjgntJZ7a7lMskcjFXK43Rk5T64GAT3KmpKYENlJNLZwyXUPkXDIDJEHDhGxyAR1Ge9TUUUAFFFFAEF3A08e1WVQwZHJXJKMpVgORg4PXn6GqepWE91qNrMkgEMSOrJuK8sVIbgZONowAV+vpp0UAULPSbO1Ut5SPKWMjSuNx3ZzkE5I55+vPXJqxbQahqksqWlskNqjYF1cEMsjBsMojU5YcEHJXPIHrWX4vQNp0H77ymF1DtBj8xWJcDDLg5HftyByK9FsraOztIbaAYiiUIueuB6+9ICVlVhhgCMg8juOlLRRQAUUUUAFFFFABRRSMoZSpzgjHBwfzoAWimRiQNJ5jIylsoFUgquBweTk5zzx1AxxkvoAK4nxR50PiBpbaSEB44I2R4yxLF2BwQRjC4OPbPfNdtXKeJtInN/wD2lCYzbw4nlV5SGyqOrEDBH3SO4+7260AZeoaNpuoW8kN5ZQSRyfe+QA+ucjkH3FZnhzwLoGma3bak+yKCYFILO6kEomJwu5Q2TjkHqevYdeijimuLYTrtt7Vhn7VKy7VHrjOfwOPer9vqtjbRxJaWN3LHEoSOTC5ICheC7BugHXrigzlShJqUkm0YvjT7Poh8M6fpdu1ja3msRLKtnGscUgOdyPjGd2c4wchDmuO8QeDNW8B6o3iPwcRPZwqfMt5Mu6IfvAqMb0GAeDuHHXGa73UNZhu7y0juNFjnuIi11bedIp8srgZzg7X+cAYyOvPAzFr8PinVl0++8M6rDaWFzDF51u8aF0DHJdJNrZO1hx0+XIznFBz18Oprme62tujjra7sNb0qHWbTTptL1MOhm2KVjlO2Xa0R6EF0I29yMMDwavHUNSshqEdvYm4MO+YvI23HyB8E7QpYZ+6uSR9MnvNP8NWOneFU0Cz8xLNIjGGJDPySSx4xkkk9Op4xXN6LoEi3uox63qEkDXy+Q9nJLEwuF2BfMUD34GRn5SCMHFB001JRSm7sl8Na5dwQyxNp7Sq5837Qy+RuJ4A2kseABz6e451Bq2pq6kmzdAeU8pkJH+9uOD+BrJ0631C2VrFtNumFu/2eGXIInReA+eNpxgnOATwCaivNVW3LrHa3NxIjrG8cIXerEnAKlgQOCc4xweaCy94gmTWbdFOlxecjKyPclTgAgspxngjjuO+MgA8sbt/7USztzbQEpIJoJrx/urwQEx8nUFSP4cnHptXF9eIq+Vpx8xm2hZZlXdwTwV3dAOc49s1TXTop9TZ9XtYTOZBLA8bMQSE24PA5ABIB9TjvTsB0N9PPqfhi8kMZGp2CbhKiZDsFDHZ0zuHGOmT3HNc3FaahfNbytdn7O0cqGdWVZij7SCoUFR90EHPAb1GT0uhXS6JYrZJavLbozGMwkbhliSG3Nz16559O5ybWyu47WFRdCFo1AWJIl8sADoR1P4EUgHRSXFnKsV2ySWzvsjnZ/nyRkBhtA9QDnn5eMkmodTnfS5ZbxfIMMqgNG7srNIAcbAAdzEYGAM/KOvaU38StLaaj5azBFLL1WVWJUFV5JyeMepxzwTSW01IlHiEJtw6yRQzSEPCBno2wn5sgEHO0bgM54YGTpOqW9/He3OqyF7VHLyOZWWJFwAqmM8YOBjBYls+tZev+O9Jgh26R9tu5yAySGaRI1Pvk5JHpjHvTPG/iGDT5bnS9XszqlxKqvuVPIWNT/Cr8tjjqN3JPP8I8lS6TZiVgkg+8p6j3x6e/pSbPGzLMZ0HyUWm+vdFlmZ2LOcsxyT6mkpAQQCCCDyCKWpPk223dhW2nivXkChdVuvl6ZfP86xKKDSnWqUvgk16M7uD4m6uloY5Le0lm6CUqR+YBwf0rB1fxZrWrWxt729Jgb7yIioG+uBzWFRRc6KmYYmpHllN2CrENncT2tzcxRFoLcL5smQAuSABk9Tz0HOATjANV69X8Da3da/Z6dodp4P068tLB1muWDeREX6LIwxt345KnduIJ4A4BYLDwxE+STs+mlzivDnhK/wBdtZbqJ4be1XhZpzhWbjgY579a9r8EeANL02xaSeGaSWQrtd2aNwASdwwQVJyR/ujHds6HinTpU1OK4hldIrspCxjjUNEUV2UhifXGPlJHPI4x0Wh3ElzpkUkx3SAuhbGN21iufqcZqj6zCZfSwqvFXl3/AK2LNrbxWsIit0CIOcDufUnufc1gxeG5GvL64ub52NzOX2oijEfZS2N2QOAc8V0Eys8TrHIY3IIDgA7T64NPoO4hs7WCzhENrEkUeS2FGMknJJ9STyT1JqaiigAooooAKKKKACiiigAryr4d/wDJdvi5/wBwj/0lavVa8q+Hf/Jdvi5/3CP/AElagD1WiiigDyr4+/8ANOP+xz03/wBqV6rXlXx9/wCacf8AY56b/wC1K9VoAKKKKACiiigAooooAKKKKAKOp6XDqDRPI8scseQrxtg4PUc5B6A8jtXGXF3eWV3LBdWqOI3ZN0Tnc2MENgjaAQQeW4z7Gu/kDGNhGwVyDgkZAPrjvXNeLLZ454b62gkdsFZnVd6BQD95R8xBDMMj157FQDLbUrQLky4bOPL2nfnOPuY3fp71PBMk6loyeDghlKkfUHkVBp8rm2gEsqTbkGJkGFdhkMuOcMCDkZPrmlurJZ5N4lliYgK5jbaXUHIGeo6nkc8mmBaorOa5NjuglPmOf+PcM3Mn+ySe4PU+mCc8muhs/Dv7ktf3Ur3LkMTC5RE4A2qO44zk8/TpQBn5GQM8nnFMmcxxMyoXboqDqxPQD3JwK1rDwtptsbhp4UvZJZDJ5l1EjMuQAVB2jA4ziqWuaeLGSA2QkVXyd0kjOFlXBQ85PY+3HvyAaOm6LskW4v2EkytuSNTmOMjoRwCT3yenYd62apWep210YkSQLNJEsojbhirDPHr+FXaQBRRRQAUUUUAFFFFABRRRQAU2UuImMSq0mPlVm2gn3ODj8jTqZMZBE5hVWl2naHOAT2ycHA/CgB9c5rF691LLaxsFtVOyTA5kI6rn+72I789ur9U1u7sCE+xxSTMgbYswzHywLNnAx93Azz83pXL+abi+e2umubcECXG4J5jO7kjchOOnAyD160ALdpby38ZtbJZrq3nUySCNQI9w5yxxk7WLcZPTPUZ16ZBDHBEI4VCoMnA7k9SfUn1p9MDM1M+Rcm4md0gaBohKoGYD1J/HC9uCo9a2dI1q5tdOt0vrJFSFAhML87RwDsxgcYJAY47Z6Vl60qtZoHQOpnhBVhkHMijkd+tXqAOgutWt47I3Fs6XQL+WvlOCpb0LDp/ngnArKl1LTrpkGtabFvJ2IxjFwp4zgcbuxPTHHWqLQxNMszRIZVGFcqNwHsarX3/H3px/6bMP/Ib/AOFAHVvremIm43sLH+4rbn+m0c5/CuK8T39gZrGz0IQSWnN/dNaEEkIQUAI45JJ2+g47VrVhpplw96Z55HWKDNuZo5cSSK5DJu4yACCuQRk9O4CAfFdF5hcaiGihjbdC+CsQyuMsTyDywy2AeMDNXL9vIaO+yhhhjfzMnGEOCWB9tvT36+tuKNIYkiiUJGihVUcAAcACsq70eV4nhtL+W2tmDHyQilck5xnAO3JORn2BA4pga9FQWNtHHZwiyRzNDGEurdSWII/5aqpOSG+YnGST/tZpEvrd7hYFdvMYZA2MPwzjGfbrQBBCsf8Aa1z5q5mYK0e4E/Io6g9OC7e/PoRVTxL4l07w/au97cR/aNhaK3BJeQ4OAAASASMZxgVjfEiW90yyXVtM1U2c6AQmEqjCUFh90ODgjknA5A9q8f1LUbzVLs3Wo3MlzcFQu98DgdAAAAByegpNnl5hmSwnuJe907FfxJqFzqz3V9qM/mTNh2JGFCrghQB0GBj8yc5NULmNBbKVTy2crliRkfVv079eKljY3IR8AQ/eGDnd6f59fpzYPSpPlJVZOV5O7vdgAAAAMAcACiumSfwzfaPa2kltPpN7CAv2iJRLHJ0yzj73Jz0HGe9Yd7ZpaatBZPqWmSrLGZPtEE7SRr7HapbPtjuPXNFjaeCl8VOSkvJ/mnsVaKimDhpR5oVEYqrx878HAI3DOD1Axn+VNtZXkBEq7XAB44yOecHkdOlByuDV/InooooICvR/gj4mOleJRpFw8v2PUeEUDKLOMYJ9MgEe/wAvpx5xXefBnQLrVfGVvqELyQ2umnzJpFYqW3KQqDjnJ6j+6D6ihHflrmsTDk/pdT6B1XS4dSktftKRyRQuXZHDHdwRjhgPrkMCMjHOawZLnWG1q70jTTZWkcKK0WyMkJERw3IADbgwwAwxjGCDXV3E0dvBJNM4SKNS7seigDJNNiQ7nkkVRK3y5UkgqCdv44NUfbkWmWr2dlHDLPJcOuSZHJJJJJ7knAzgcngVaoooAKKKKACiiigAooooAKKKKACvKvh3/wAl2+Ln/cI/9JWr1WvKvh3/AMl2+Ln/AHCP/SVqAPVaKKKAPKvj7/zTj/sc9N/9qV6rXlXx9/5px/2Oem/+1K9VoAKhiuoZJTEr4kBYbGBUnbjJAPUDcORxyKmqrqdjFqFm8EyoTglGZA3lvggMPcZoAtUVFaRyRW0Uc0pmkVQGkIxuPripaACiiigAooooAKKKKAOcXQGW4ktmKvpzDzopM4mgmACjB6EbSR9Bg5yc0mSWGaSC4AE0Z5I6MOzD2P8AMEc4rsKxdV0maa6a7s5FMrgK8czEKQOmCASvU8YIPtySAYlxHFMsaXCq0Jlj8wN93bvGc+2OtdrXFykA+TdRvCz5XZKu3d6gHo34E1Zj1u+jt3gQ2kssK8ysxyeOAy9jjHO78KAOhbUbJbgQNeWwnLbRGZV3FvTGc5rF1rV/MuJNOGkXd1GD87srRqdu07kwCzYJHKjg4+tYfhS5l1XVrQRW7LZwIZ5pJmUtI5Hy8KSM5bcc4OR7GvQKAOVs9Ts9QupIILuSwkWFYUjZABG4OQY2+7nnDIeSAuQO/SW84m8wbSjo5VkYgkYJweCcAjBHfBGcHisnWtMW/wBTtzLpsc8JjMclx9qaJlUnlSqj5x0wCe56d8e40fxDHqwOnSw2+mhlRI1u2Ztqq+GbdH1yV4yw4A5A4AO0orMsTq8aWkd5HZTHBFxMkzKR6bV2Ybtnlf6VoGWNZkhMiCV1LqhI3FQQCQPQFlz9R60APooooAKKKKACiiigAqG9uYrKznurhtsMEbSu3oqjJP5CniRcsDkbSASQQMn0Pfr2qLUTCun3Ju3SO3ETGV3xtVcHJOeMYz1oA4G8vI9RkSLzbaee6lWSVRIGAC4JGBn+FQOw9Tk8yXtlawWEkcEEMMTunmiNAgK7huzj2zzSaJq9hqUASyvra5ljRfMWKYSFTgdeT+dWNXTzNJvUAJLQOMDvlTTEmnqhEjlslCxl57cfwuxaRR7MeW+h568ngVZhmjnj3xMGXpx2PcH0PtTkdZI1eNgyMMqynII9QazNWtzEUubSZraV5o1lK8hwxCdD8u4ZXDEE/KB0oGWtSMTW7QSM++QfIIsb8joVzwCDjk8DjNQGe/trZWlhilO8LnzsHDNgE/LjjIzj0OPSrdvbrDlstJKw+aR8bm/L+Q4qLVzjS7vgMTEyhcZ3EjAGO+TxjvQAsd3hljuozBKeBk5Rj/st0PsDg+1RapIsU+nuwcgXB+6pY/6qTsOaueUnk+Uy7o9u0q3zZGMYOetUfskceqW21pNiJI6RlztVvlGQPoxGOg7Ac0ATHUIQCSl1x6W0h/8AZaIb+P7YAY7gWkkbJds0LIBGQcHnBJB9M4G7jkVbplw0aW8rz48lVJfIyNuOePpQA4o8M89vI294H2b8Y3AgMD+RGffNLSxMb3Rvt/lSR3dp+7uN55mRVB3depBDc8/w1zEXjvw3IZAmprlFLHdE6g4/ukqAT6Ade1IiVSEPidjYvI7iDULTUbFQ9xBuVkKhgysCOhK8gn1HBPXgVDbNPd6zd3V7DE9wYlQxXUSupQknoGIAyMAckbSTndmuAHxNurrVbaKKzhtrKSVY3ZiZZQpbBYYwAcHphunfpXqOlaPLdMVYTpbGQSTSXKFXmII+ULxgYGCcYx0zk4DOhiaWITdJ3sWj4a0LxDZ21zfaazKMlI5JX2oc4OAGxjjjtj61x/xG+F+ny6C914ai+xXdpGzmNFaXz1AzjGSdwwccHJ4IPb1dVVVCoAqgYAHAApaAq4anWTU4p3Piy2QxIUO4nJY8cDJ9uPX9amr3D496TFDoNheWdvFEou2E3loF3F1J3HA5OV6+9eH1LPjcfhvq1XkvfqFLBpVzqd9FHZ2N1dyspCiCJmJIIPBA7Z59AeeK634f+CL3xbebxug0uJgJ7np/wFOOW/Qd+wP0doGjWWg6VDp+mxeXbx+pyzE9WJ7k/wCeKaR2Zdlc6/7yekfxZ8f3Fld2Oo3GnahH5dxZSFJhncC4z0P5H8qieT7PM7ysohYZ3EEbSMDBP5+le2fH7w9Z2yWmvwbYbmeb7NcL2mOwlW+oCEe4PtXil3BMHmjmjmiuIwrpFKpQjKgqSCM8+/b2pHPjMM6FaUH8P+YkVy0sfmRwvt5zkjP4YJ/pVuBGnMYgVpDIMoEGS/0x1pukXEFlrtneapaLPZo4aaFW/wBYgILdQM8dvQHpX0va6ZPrfi/S/Emn6zBJoNvbMttDbrydwwynjGMhSc8gqBgYzRY1wmXxxSbTtqtF+e5434f+GvibV5IzLp8mnWzkZmu8KVHr5ed3TsQPTI5x6pp/he/0HXPDek6K9xFokAku7+5RtpuZgAuH7c/JhfTOPu5Ho1ch408aR+Gda0LTzaLctqU3luRMVaFd6Lu2hSW++cDjO3A9me9SwOHwceZO22vz2+Z1yggYJLck5NLRRTPSCiiigAooooAKKKKACiiigAooooAK8q+Hf/Jdvi5/3CP/AElavVa8q+Hf/Jdvi5/3CP8A0lagD1WiiigDyr4+/wDNOP8Asc9N/wDaleq15V8ff+acf9jnpv8A7Ur1WgAooooAKKKKACiiigAooooAKKKKACiiigBk0Uc8TRzIkkbcMrjIP1FZ+o6JZXln5AhSHb9xolC7ecke6nuOhrTooA4LVfDeoQXMt4DYXqNgMZYDuhUf3Vycjueec9sVd+Hxtn+2SWNyZ4ZEif8AugEl8/JgbenpngDsK7CuTuPDd3p96Lrw/dvDEEKtak5MhOOd7E9APlBBx0BAOAAdZWJe+KdIs7iKJ7tHLhyWiO9U2qWO4joeMAdSSOKxbpNZt5YrO9u1mtLu3Zp94G4PwGRSOg+Yc/ljrWffW7x6lFdpbz3ChfuxlAUK5xgMR13tyOe3QkUAd9ZXlvfW6z2cyTRH+JDnB9D6H2NLE8V0kNxbzLJERuV42DK4I9e478VxERsL2aQxpDLKoUuTGMjOcZJHXg8dqqizg0fUrG60eytIbpn8niIBNm07sgYwcKMEc8AdKAPR6Ky7XXbCWLM9zDbTKB5kUsgUocZ74yPccGtMEMoKkEHkEd6AFooooAKKKKAI5oI5mjMgLbDuAJOM9iR0OOoz0PNZXjGwm1PwrqtnamUXE1s6xCJ9jM+Mhc9gTgH2JrZooFJcysz4+tn1Hw9rKm+gbdG+JoI32lkDYeJxnocY5GD1x0r2/wAN6joevLcf2dCjmBgJPNi+Y5HDEnk5weTzkGtzxp4M0/VdSh1VtMF3cBSk6I+0yDHytyQCRjHrg+wFee+EPCX9l6/cR6mLW5sp4AI0kiDK8gIJAznlcMMdT1wMUHnYbD1cLU5YW5G/mtP1Oya5ieNQ9xDZ6eRtiw/ltKoA5U5G1eccc9CCK5LxD4usNChNvayG+1NMeQ7zNLESf4m+bqFzwPwwOnXQWcFvraGDcu22YFGlYgAsuNik4AG05xj+H2x5F420K7uNelutM0y6msIkZmmggZ40K8DLAED5MHr0OT60M2x1WpSouVJXZvW3xVuFhUXOkRSSgcvHcFAT/ulTj8zUuk/EGfVvE1hBJZLbxyMIo0VzL8xPzMThcfLwODjnP3sr5e7hQDySTgAd6s6DqC6brNpqM0AlSKVCI2HzEZGccjDdx9Bn0pXPn8PmuIdSKqS92+uiPpas/SPKf7VL8rXHnyRyPgbsBjtBI9F28fnzmvM9c+Jl5dRiPSbf7H/eldg7H2AxgfXmuQtfEOradbvHYXckStOLhypO4sAR9COeQRzgU7nrVM4w8J8sdT6LrPmuoL2JIbd1l8yVkYdiI5NsoPsCCp9c+9eI/wDCZ6/LdR3X9qzMV5CrtCH6qBg11PwZv0F7qdtd3Tve3G2VFkJO8AsXbcerEsCfz55wXLw+aUsRVVOKfzPS7t47ETaiPlkjiKtk8OnXYR05/OvLNA+GF1qdrHf3WoWVjph+eOV33ts6ZxwB1A5PevXayZ7Y2Lq1lHbzSniKGRdrcccSAEhQPUH07iix1YjCUsTb2ivYs+C/B3hTSLqEWWzUNTiUy/apCXwQRyuPkUjI6c8/jXa2E8lzaRzTWk9nI2cwTlC6c45KMy+/BPWsjw5bGSeS+cDABgix6ZG85+qgY/2fet+g2p0oU1ywVkFFFFBZl+J9Gg8QaDeaZdfcnTAbH3GHKt+BAP4V8k3dpcQzTWk8TxXSM0Txnqrjgj86+yq808X/AA7trrWtV8RRlpH+yPLHZouN9yq/K2fT5RxjJY5z2KZ5WZ4F4nllHdfkei2UCW1pDDFBDboigCKEYRPZeBx+AqauT+GGpalqng+0m1mOVbtS0fmSjBmUdHxj04z3xnvXWUz0qc1OCkupSAW9muIrq0UxW8y+WZUyHIVW3rkdi2M+qmvEvih4WuNX+LCWumvm41Cw+0tuU7VMasoBPYHaoz2LD8fdZ50g+abCRBSzSswCrjHBye+f0Ptnz34gy3PhbxXYeNN3maVHAunX8SRAyJGzkh93cbmXjjBXuGOA58ZShVp8s1dXR88axYXel6hcWepiS2vLaUo0WASDzjHHOVIIPI5z0r239m1rlfD+pQzB/ISSIqT08wphxnpnASus1XQPD3xFt9J1USpcWsTbxJEoVpU5/ds2NwGeo+vfkdha28NpAkFrDHBCgwscahVUewHApWOPB5d7Ct7SMvd6EteYfFnTZxqukeI9Muba1k01mhuruUCRYN2PLLR9SAXPTkbwcMOnceKdcsfD+kS3mo3YtUPyI+wyHeeBhRy3rj0B7Vkatb2cvgm7j06NdYbUl+X98A11I+Bv3842gA5A+UJx0FM9KqozTj1Wv+QfD7xd/wAJJb3FvdpGmq2ar9p8nHlNu3bSnzE4wBkHpnqRgnrq8T+Eia1pnju60i5sVt7e1tfKuUiLmNWzlJMuSTu2tgDC4JIHFe2UCoVPaRuFFFFBsFFFFABRRRQA1HWQZRlYAkZBzyDgj8CCKdUJjlCThZ2LuSYy6giPgAAAYyM88889amoAKKKKACvKvh3/AMl2+Ln/AHCP/SVq9Vryr4d/8l2+Ln/cI/8ASVqAPVaKKKAPKvj7/wA04/7HPTf/AGpXqteVfH3/AJpx/wBjnpv/ALUr1WgAooooAKKKKACiiigAooooAKKKKACiiigAoJwMngUVHcwR3NvLBOoeGVCjqe6kYIoAkoqCytYbK1itrVNkEY2ouScD05pmquI9Mu3aVogIm/eKpJTjqAPSgDl9W1e3vNWiVZEjiiBSN3O37QW2fdyOQDgZBOSR+KyOI42diAqgkknFY1rK2saabdYRFbtH5U27KsuV5QKRnIBwSeh9adfmTTLd1t3EsRUlLQwtK5AHKrg8L06g4z6YFNAR2mofabqWf7NeR2txbRtFMI9+7BbP3clThl4IHf3pq2FzPo0b3/ny30YDqjSAFWHddoA3dxnOCcZrX0+J4LC2ilx5kcSq2DkZAANT0WA5+VLuW11KC0sS0VyrussrCEsWUgg9WyOMZC8ccbQT0Hhu5ltdSjimHkwXhZY7cFfkYDduPuQGzgkfd9zRWRrGhQ6ndxXLyFJo08tSUVwFLAtwwODxwRgj36UAej0VxsD3lmYfsV3JtXhkuGaVWXGO5yCPYj3zWpDrswZftNoix5+ZopCxA9du0flnPpmkBvUVDa3VvdoXtZ4plHUxsGx+VTUAFFFFABWfeaLp95cJPcWytIrbsgldxwV+YA4bgkc54rQooAz/AOxNLDq4060VhkZWJRkHqDgcjODg9wD2rQAwMDgUUUAeQfFDwT4Y03whqWq6daLDdWkgbMczN+8chQpBLADLg4A9hjNeByTTuUQwBd5yGD9CORwQPT/9VfXHj/w63ijwzcadHO0ExZZYzk7WZeQGHcH9Dg9q+UtSt7nTtUks9Sje3uoHIa3ZDuHUA59COQfcetJnzWcUeSpGUYaW38/kQRRs8p85y2FBK4GFY+mPTHr3qT7NDnLRhz6v8386dAhWPLf6xvmf64qSkeFKbvoyq8KQ7RBujYnAVSce+B0H5VLaSzW+oxz211Mssakq8blSh5XgrjqCw/Oo7pGdgEQkkbRICR5eSCenqBxn0PXjG54p1u58R6mt9PDbWrRwrbww26bY441yduP94sfxx2oN42jDncve6f8AD+R0/hPxLr+teJNMsLrV5lgZ2L7IowWCoxwSF74x+vUA17FpWjrNI5tYVghY4luQBvcjsD1Y+56e5yK8f+C/h19e8Qtdyu8FvYLukAHMhYFdgz2KlskcjjoSCPpBEWNFRFCoowFAwAPQVSPqMqlVnQ5qrbbfXsNhiSGJIolCRoAqqOgAp9FYen6zLc6hFC8cflzKzKFzujwSMMehI24YcbSVHOc0HoykotJm5RRRQUUtXlmhsJHt9wfcgLIm9lUsAzBe5CknoenQ9KqeFby7vtKWe+SRHbaQJE2sMopIPAzhiy5wM7fxOxRQTyvmvcKKKKCirqllDqOnXNncxJLDPG0bI+dpBHfHP5c14D4hivPBcd/oU3n3HhnUC6Ijg74pFCNuQkKDtYqRj5WAxwc4+iK57xl4Zg8TaXcWs8roWiKxDgokmQVkxjORgjgjKsw70HJi6DqwvD4lt/k/JnC/s+XLrpeq2Xlh4PtH2hJ1YH5iqqyMM5U/KpGeuTjIGa3/AIifEaz8ITGx+yXFzqUluJ4QF/dDLFRuIOf4WOMc4xkZrx/w9J4l8H+MF0ux8m1v7meO3ZblCYpAZAAc4ztPPzDnB9a9T+J3gjUPFdtBdW0djFqdq8qAeY376DJKAttGG6fKeAWb5vVHFh61R4Rxoq046WZ4R4o17UfFerTX2qTTISuFjVyqReyDJxjH4k55r3/wxr/hTwx4d0eHyzpMl3bLMYHt5TL1OS527sbt2Gbg9RxXm2k/C7XE8TWVrq1gsuml0e4mikDRmM9V6g57HA9+R10fiHqGsWnxE1WUXF9BpUYtUujp8xWUW+ODuALD53fgd275zQc+C9vR5qtZO7dv1v6HqVz410uPw3qmt2wuLmxsBy6RMBKeOEJHIycE9q3dLvE1DTLS9jGEuIUmUc9GUHuAe/oK5jWbK5l0GOxsba61nS7q2EQTzYojGgQbSWcZbcRyecbicVy3jnQvE/iLT7nUYdPn03WLV4/JjivlZZYgDwCgBLK2WG7H3jg+jPZnOUE3a7PWqK+e9Y8deLtESwt7iK906+ito4LprtRIk7pkb49wI+YfeIJyc+mT3Pw++Id/4hiuzf6fBm32ZNsxUndnorEjt/eFBlTx1KpV9ir83oel0VVsrkXg86GRTARt2FCHVgTnOT9OMe+TkVXg1e3k1BLDf5l0U3sYlJReARlu2Qcj6fTIdhpUUUUAFFFFABRRRQAV5V8O/wDku3xc/wC4R/6StXqteVfDv/ku3xc/7hH/AKStQB6rRRRQB5V8ff8AmnH/AGOem/8AtSvVa8q+Pv8AzTj/ALHPTf8A2pXqtAHM/wDCwPBv/Q2+Hv8AwZQ//FUf8LA8G/8AQ2+Hv/BlD/8AFVy+n+M7LwR8IPA17qFpfXi3VjZ2kcVmsZfebUvk73UYxG3f0qh/wvfR/wDoW/En/fNp/wDJFBlUxFKm7Tkk/NpHb/8ACwPBv/Q2+Hv/AAZQ/wDxVH/CwPBv/Q2+Hv8AwZQ//FUnw/8AGdl430y8vdPs76zW1ujaSRXixh94jR8jY7DGJF7+ta9zrelWuqQabdanYw6lOoaG1kuEWWQEkAqhOSMg9B2NBpGSkrrYyf8AhYHg3/obfD3/AIMof/iqP+FgeDf+ht8Pf+DKH/4qumooGcz/AMLA8G/9Db4e/wDBlD/8VR/wsDwb/wBDb4e/8GUP/wAVXTZ5x3psrrFG8khwiAsT6AUAc3/wsDwb/wBDb4e/8GUP/wAVR/wsDwb/ANDb4e/8GUP/AMVWjZeIdLvm0lbW63nVbVr2z/dsPNhAQluRxxKnBweenBxq0Acz/wALA8G/9Db4e/8ABlD/APFUf8LA8G/9Db4e/wDBlD/8VXTUUAcz/wALA8G/9Db4e/8ABlD/APFV01cz8UP+SaeLf+wRd/8Aol66agAqO4hjuIJIZlDxSKUdT3BGCKkooA5GaF7W6ltpDu2YZG7shzgn34I/DPesozrZ6nO1wkxa4aNInSNmUL0CkgYBDFjzjhhyccdZ4htS8KXUSM0sJwVUZLISM/l1/AjvWG6xXMBV1SWGReQQGVgf5imBHcXcNu8aSvtZyAvyk8kgDOOnJA5qesjSbKCTScJEsKSyNIjRqFO0OTGfwAXGfxqz5lzaSRrO6TwO4QSH5XXPTIAw3OBkY+lAF6iiigAooprK8skUMUgiaVwgkYZCe/14wPcigDS8OoWvrmZeIwixsR/G2Scf8B/9n9q6Co7eGO2gSGFdsaDAHX9e/wBakpAFFFFABRRRQAUUUUAFcL4m8OaPP4kku7zTbS5nu4QzNPEJDlMLxuzjgrnGOgzXdVzGrTm51SQceXbAxLj+IkKWP8h+B/AE4qWjR5ZJ8MI5tbuJGvPJ0t2Z0jgUCRc9FGQVAGfQ8DGBXmE8L288sEqlZYnMbhuoIOCPzFfTNc2vhnTNQlnlvLCwZHkmBEcGxyTIcsXByW4PIx1NDR5OLyinVX7r3Xe55L4c8Lah4hs7qSwkhAgZcpISCzc9O3TPX16VkajZz6dfz2V5E0VzCQHUj15BB6Ee4r3HRtFtvDmqtHp9wwt7wHbY7fMcyDncp67QoIIP1JrJtvD1nd/Em6tfGWjtnVFL2LLOcnYqgg+W2R8q59OtKxy1cnj7GMb2ltfoP/Z5vLeOPXLV7hFl/dz+UzAfKAQzj2Hygnt8vrXsFpd293GXtLiGdAcFonDAHGcZH1Fc3B4S0TTbgW2l2FvaNcW8qmRUDP8AwDJLZJH6ZJzyxzj6vcSeEZL/AFjWrxpN0imJxIVV1AP7lULMzFi2MYIX72eKZ6dCM8LSjTlql1PQ6jSCJJXlSJFkfG9woBb6nvXEfCXxdc+K9Kv21Ep9rtrjGEAwEYZUH3HzDoOAPWu7oOqlUjWgqkdmFFFFBoFFFFABRRRQAUUUUAYXizwxY+JrJYbzfDPGd0N1CFE0JyDlGIJHIB464rkZvBnjKx01LbRvGkkgjcMiXMOCAB08z52I6fLjFel0UGU6MZu738m1+Rwmly+PNLjZNUsrLXCASJLe7SAkkrwVMajjnHPrnPGIY/EOo3WsSae/g2AavJbB7pZbgBCgbCjzTHiRRuH3c4JxjINeg0EZGDyKB8jWzOL0TxRqes639n03SYTpNrM0FzerKTGSB0jLBScHuFYHscEGusuYHnmRXaNrQo6ywum7zCcY/AfNx3zXI+LviLofhLUIdNuUuJZggaRLVARboem7kc4Gdoycc45GfIPiD40l1bxTcXOhXd3BaR7EilSaVCxXqwUthckkcAZHXqRQclfH0sMnzyu10Pctf0B5vBV/oukLAZJ43RDeszKGdss5PJyCSw98Vw3gnwVr3hmfUrZ4YZxcGHyrpJAYx94MSpIb5c5xjnoD3B8F/Euv+INWvl1jVftVrBbgJC0cStvLD5jtUMeAR3HXODjJ8X/EE+ieNPC1zGz+TZ7p3jXHzhjsYc99gYD/AHu1BMq9GUI4xrbT73Y6LVdPis7xG1iBJ7TncY/lWUkcNych1wcDPQ5BJGB0Hh620WfR2bR4o30+53q2Vb95glWB3c4yGHPv61b0LVbXXNJttR09ma2nUlSy7SMEggj1BBH4VeUBRhQAPQUHoJqSujDFvfaPHIbeZrmxj8srHMGkkVRkOq7FLH+EjO7oRgcGtHSNQTUrFLhEaNslXjf70bg4Kkdjn1q1IgkjdGLBWBUlWKnn0I5H1FCoqsxVVBc5YgY3HAGT+AA/CgY6iobS5iu4fNt2LJuZMkEYKsVYYPPBBH4VNQAUUU2QsEYxhWfB2hjgE+5wcflQA6vKvh3/AMl2+Ln/AHCP/SVq9QtXlkt0a4iEMxHzIH3AH2PGa8v+Hf8AyXb4uf8AcI/9JWoA9VooooA8q+Pv/NOP+xz03/2pXqteVfH3/mnH/Y56b/7Ur1WgD57+Iv8AyQ/4Xf71l/6bp682r3/T/Bll43+EHgay1C7vrNbWxs7uOWzaMPvFqUwd6MMYkbt6VQ/4URo//QyeJP8Avq0/+R6TR4mZZbVxdVTg1ZK2t+78g/Zq/wCRa8Sf9hk/+kltWj408LaxqPj1NWtI3l02OLTFktw8QW58q8kkfOfmBjDJIMFQ2NvzdK6X4f8Agyy8EaZeWWn3l9eLdXRu5Jbxoy+8xomBsRRjEa9vWptZ8SLa6nNpVjZXl5exW4uJ3gEfl2qMWCNIXdepRuFDNhTx0yz1sPTdKlGD3SS+5HkN7Y+OtK08y67e6wzz3lpbyra3Hlrcu93ED5Mn2pjHlSy4EcK4bnpW/Pofjg2cUe7VWnNuy6e6amB9gkNxKym7+cfaMQmBT/rOUbgk7jUu/iner8M7eZftNr4i/syOWSa4to2EjyWFxMkyBX2gM9ux5U9MFACCOxt/iTpf9hwahJBfSQSWF5qCSoiYmitQnmMo3ZG4v8oOM4OcDBIanLHwf4oW/sdUD6lLq4XWUWaXUS8dq8sg+yNsMmPK2IMqobnblePlbaaB4z/sWyi1Qa5ewGS48+0ivVt50Zo4xE3mfanLxBhKSDJnL/cwAo66T4laPDqN1b3VtqEFvbtLG968aeSXjthcsowxfIiJP3ccEZ6Zk0z4g2V74ittEm0vVbG/uPLKLcrFja8U0qsSkjcbbd/cEqMdcAHPweC9TuLHwFBdR3dsdK0Ca0umtb4wPHcGO2CpvjcMRmN+hK/Lz2zh3elfEp/DH2Dbqb6rL/pTXkeoxIqk6WYjDxICCLn5uBsyQwPUjrLD4raXqFsl1aaRrUlq0ltCZhHDhZLiNHiTHm7iT5qLwCATyQOaL34t+HrXTzqDRXb2CpA8k+6BFTzYxIFw8gZnVSpKIGb5hgHnABlP4e8Xadfz3GmyandhLvbFDc6u7JJbtYEsDuc4/wBKwA2Ny9vlFUfDnhrxrd36w69Jq9tpSLdtGqapJG4LR23lKzLcSOcOs+MyNjnoGC17NRQBwniRNRj+BWqJrhY6svhuUXm5gx877Kd+SvB+bPTiu7rmfih/yTTxb/2CLv8A9EvXTUAFFFFABWHr+nRR2V3e2apDcojSkhflfAydygjJ468Hpzjitys7xC2NGul4/eqIjn0chT/OgDk9HLCxCSY3xO8ROME7WIBPuQAfx4pb2VHc2rWj3Xyh3UKpUDPGdxAPIPTPT6VWS2e5vrqRJbmKAkkbWVcyAbNwxzgBejZBPbipIraXT97wGa7D4LrJIC+QAMqTgepxkD0x0pgP0Vt1kcI8aCWQKjgBkAcgrxxgHIGO2KvVjXMiWsDalZyExKzGaKSVlUjnIAPCtux6d+ma2SQASTgDkk0AFT6ZEZ9XtwBlIQZnPUdCqg/UnI/3TTrTTru8VZFMcEB5VnUszD/dyMD3z+HOa29M09LCJ1V3kkkO55H6k4x07Aen9SSUBcooooAKKKKACiiigAooooAK4m+0xrbVLkC4uI3ldplZXyrKzE4CtlRg8cD0P8VdtWP4mQC3t58f6uUKWHUK3y4+m4r+XtQBy99HcW9rLcR3s5aFGcIyoVbAzg4UHH0IrLu7PxBZWVzNp99b3NwuZUt2g2xuxbLDliRxnHzdSOgFaPiWaKHSWa5l8qBpYY5H3FQFaVVOSOgwSM1HrfiTStGin+23tuJ4l3fZhIplbPQBM55/zxTInJJO7seE67qV7qmqy3WpM32tW2FSCvlbSfkAPIwc8eue9fQ3gqAz+GPDVxNGs+rC2ZoricHdHGSNx9TwygDvx0618765qI1TWptSlt4od77zFF8qkA9/Unue/tX1XA0E09iunAG3gBBeMfIE24CA9DzjjttFSjxcoXPUqz5uZef5l22tlhYuXeWVhhpJDkkenGAPwAr5n+Lfz/ETV2aYXBVkCtwdg8tfl9scj+fOa+n6+YdY8IatN46vNLhtL2QyXRInaNmHls/ErNyMYOST3z34oZrnMZzpRhBXuz2f4N6WNN8B2LtHsnvC1y5P8QY/IfpsC/nW3N4gRri2gsYTK9wjSRtNviR1BVcqQrE5Lr2wByTjGde1t4rS1htrdAkMKCNFH8KgYA/KsuLw5pyyq88K3WyPyo1uERwieg4yeMDLZOO/Jyz0I05U4Rpw6GlYXK3ljb3SAqk8ayAEgkAjPb61PSAAAADAHQCloN1tqFFFFAwooooAKKKKACiiigCvfXtrYQGe+uYLaEHHmTSBFz6ZPFea/EP4maTHol7YaBfPcajKpiEtuCEjBOCwfoeM4K55x0615z8Xr2+n8dapb3U10LWKRDDbySlo0HlqNyr0G7k8epriqTZ85js4nGUqNNWtpcOSWZ2Z3YlmdzksT1JPrRRRSPnW23dkltNLa3MdxayyQXEZyksTlXU+xHIq5rOsX+sywS6ncNcSQxCFGYAEKCT26nJJyeefpWfRQWqk1FwT0fQ9f+DHjiw0yyGgatLJCXnLWszZMfzkfuzj7vzZbJ45PI7+3V8YkAgg96+g/hN4+GuWsWk6xNI+tJuxKyDFwuWbPygAFVwDnrgHJJxTTPpMozDnSoVN1t5npdVb/ULTT1ha+uYrdJpBEjSsFBcgkDJ4zgGrVZfiLRoNcsBa3SQvGH37Zo/MQ8EcjIPRjgggg4Pame5O6Xu7lmxWzkaW7sWgdbjBaSHaQ5GRksOp7cntVusvw7pCaLpqWyytPJks8z/eckk5OSSevUkk9yTWpQOLbSvuZenaUbe/nvruc3V5JlEkIK7IsghAuccEZzjPNalFNMaeaJdi+YBtD45x6Z9OBQMdXlXw7/5Lt8XP+4R/6StXqteVfDv/AJLt8XP+4R/6StQB6rRRRQB5V8ff+acf9jnpv/tSvVa8q+Pv/NOP+xz03/2pXqtAHM/C/wD5Jp4S/wCwRaf+iUrpq5n4X/8AJNPCX/YItP8A0SldNQAVj6p4f0u+1GPU7tJUuoY/LMsVzJCGjBLbZAjAOoJJw2RyfU1sVwfiLRvElx4yjOnXdwug3CJc3BF0VMU0KuFiQZ4SQtEWAGP3TZ+9QBdHgTwjqel2wSwjubBrOG3haO5kKtAkMsUeGDcjy55QGzk7s5JAIkv/AIe+GL+CSG405/KdpmZYrqaMfvQBKPlcYV9qllHBI3EZ5ri9D8OeM7PQnubqbVJNSgfSSlp/aWRLFDFbG5Rfn2BmdJgSSA3POGyb/hXTvF8XiPSLnVYtTaDN39pS5vlMMKNPcNEQEmO99jRLtZGUKBtZCpBAOpHhfw5qEdxJa29rO32mZ3bzGlQTmA2sgZQ2D+7Gwp04PAPNcn4J8EaJcXGsfa7+41W5hnhgMsP2y3S3eASIFileV3JHmyK22QqM7SByKzLnw34yluPFbrc6rHceRcT6PHFqZjQzG8uXQlQ4U/u2hGH+XBAI+XAjuvB3jCxt0j0K4v7SGXVtRuZhFcmaQB5828uGuI1K7NxZSxyWyyOScAHoln4J0DTdMNnp2nJHEJre5RGmkI82AIISSWJ+Xyo+O+Oc5OcHQPhz4auvDS296sGoNJNdyTzWVxJDGzzPiaMeW4JQFFTaSf8AVjPIrG8ReGNd1SC9W+sdcvL2LVor1JrfVvJt57ZLpWWOGMTr5cixdyq/MpO/ODULeH/HEdq8IbU2nPniwlh1IIlpK15O4kuB5gMyGJocLh8BSu0HmgD2OivHpPDvjOKC6b7TrjtdR3hlWHUBIQ4vla3CBpkCKYN4Ox0O3jIYLj1Lw+t2mg6cupRCG9W3jE8YmaYK4UbhvbJbnuSSfU9aAMj4of8AJNPFv/YIu/8A0S9dNXM/FD/kmni3/sEXf/ol66agAooooAKxfFtwLfTYw+BG8o3HuAoMnH/fFbVcx4/w+krED8/7yXB6ALGwyfbLKMd89MZoAzdPheKDdN/r5T5kuDxuIHA9hgAfTnnJqzRRTAxDbJcXclrBfy+WkhmkjBj4JbdgfLnqepPGcfTVe3MsK2NuAHmUwxgnp8p5J9gKzrcWjQFbg+XMs83lk/K4LOx+Q9/wznpzXXeG9OmtrWK41DBv3jAcDonTKj8Rk+/sBQBs0UUUgCiiigAooooAKKKKACiiigAqtqNqLyzkg3bC2CrYzhgQQcd+QOKs0UAfPvxD8VifT9W8PXdjNBfpcCMsrgx7UcMGB4bkAY46HOe1ebSySTSvJNI8kjkszuxZmPqSeTXq3xx0C/n8V2t7YabNNDcwLGXt4mctKGIw2Bwdu0D1x7ccZa+BfFFy8ax6Jer5hABkTywPc7sY/Gkz5LMo4mtXcLNpbWTK1tpV7BeaK2l3EM+oXjK8EcDBmjbI27s8A/XgYOelfTnhbTZdI8PWFjczedcQxASyAkhnPLEZ5xknHtXG/C74eDw2f7S1by5NVZSEVeVt1I5we7HoSO3A759HoR7eW4V0IOTVr9L3t/wWFFFFM9IKKKKACiiigAooooAKKKKACiiigAooooA+efjnoSaX4rj1CAKseqIZGAH/AC0TarH8QU/HNecV7z+0EGfw7pqpZyyFbou1wq5WJQhG0ntuLDHY7fUCvKdD8E+Itcsxd6bpksls33ZHdYw/uu4jI9xxSZ8hmWFm8VJUot31Ocor2jwz8Gonsll8R3lxHct/y72rKBHz3Yg7jj0xj3611Vz8KfCs1kkEdpPA6/8ALeOdi59c7iQc/T6YosOnkuInG7sj5torc8W+Grzw9q2oWj4kitZI0Ex4EgcblwOCTtDE4GBsbsKw6R5lWjOi7TVgrt/gxI6fETTggBV1lV/YeWx/mBXEV7P8A/DY2T+Ipzyd9tbrjjHG58/UFfwahHXllKVTEx5emp7NRRRVH2wUUVDFdQSzzwxyo00BCyIDypIBGR9CKAJqKKKACvKvh3/yXb4uf9wj/wBJWr1WvKvh3/yXb4uf9wj/ANJWoA9VooooA8q+Pv8AzTj/ALHPTf8A2pXqteVfH3/mnH/Y56b/AO1K9VoA5n4X/wDJNPCX/YItP/RKV01eXadrGq6V8MvhpBocljFc6lBa2jS3lu86IgsJJiQiyIScwgfe7mr/ANs8cf8AQa8N/wDgkn/+S6APQqK5TwBrGq6qNdg1ySxludN1AWiy2du8COhtoJgSjSOQczEfe7CjxD480fQNZvtMvxc/a7TSn1ghEBEsSb9yoSRl8RscHHHOeDgA6uis2z17Sry++w2+o2b6gIxK1oJ1MyKQCCUzkcEdqifxPoKPIj65pavHP9mdTdxgrLkjyzzw2VYbevB9KANeisy28Q6NdahLYW2r6dNfQhjJbx3KNIgUlWyoORggg56EYquPFvhtrRbseININq0vkLML2PYZMZ2Bt2N2ATjrQBt0VhaR4v8AD2r2mnXGn6zYyR6iD9kUzBHmI6hUOGyO4xkd6r2vjDTr7xmvh7Tri0vJFtJ7meSC5VzA0ckSeWyjOCfMJ5Ixt6HPAB0tFFFAHM/FD/kmni3/ALBF3/6Jeumrmfih/wAk08W/9gi7/wDRL101ABRRRQAVxPieWWTUpQWBKXEEMSY6LlHYj3wST7KPSu2rzia+e+8X3UXkAxwzO28SdCqiPOMfhj/aPTAyAa9RG4j+0GBd7zBQ5jRCzYJIBwB7GmajKYNPuZgzL5cbPlRkjAzwPWt7wvFusRfETK10qkJNGI2VRnAIBPPJPX0pgHhq3miW6mkV4453VljdcHIGCx4yMgKMH+771tUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAztX0XT9YMH9pW/2hYSSsbO2w5GCGUHDAjjDAjBPqa8B8Y/DfXbDWr19M0t7nTHmZoGtiG2IxyqbM7vlBxnGOOtfR9FByYvBU8VHln+B8u6T8PvE2o6pLp501rOeFQ0r3TARoD0+ddwbOD93Pvivo/wzpv8AY/h3TdOxHutrdInMY+VnCjc34nJz3zXmGleIfE2ofEqHw/fpHPBp97LM0nkGNxGFYK7FTgLtYY453DOc17FSOfLsNRpc0qV97a+QUUUUz0wrlvE0b2+uafe6bMkd/gpPGwyJYM7iD/d+YABsE/MeDjjo7y5jtLaSeY4RBnA6k9gB3J6AVy0EWpazeEzTwJHC28kQ5aPcD+7D5AOAQeR2UnqMAG/ouotqdvLMYREqybFw+/cNoOc4x3I4z061oVHbxJBBHDEMRxqEUegAwKkoAK8q+Hf/ACXb4uf9wj/0lavVa8q+Hf8AyXb4uf8AcI/9JWoA9VooooA8q+Pv/NOP+xz03/2pXqteVfH3/mnH/Y56b/7Ur1WgDyKD/kRfg5/vW/8A6abmutqHwToul678KfCFrrmm2WpWy6XZyLDeQJMgYQKAwDAjOCRn3NXP+FceB/8AoTfDf/grg/8AiaAKfw2/5CXjb/sNJ/6QWdQePfhzb+MJ9Vmnv3tpbuwis4XSLLW7o0xMmdw3BlnZCvHyk888dboui6XoVo1roem2Wm2zOZGhs4EhQsQAWKqAM4AGfYV554r1e/0L4n3eoWQt3tl07SoLqGWNi7rNfTxDYwYBSC+eQ2cY460AbWjeA307V7OZtTWWws72fUYIRbbZvOmV1YNLu+ZP3jYUKP4ckgVmaz8KYdRhUf2iA5vb+4lDRyrHNHdyb3jcRTRscAKoJYgjOV5wMq9+J+rLMbK2j0walHJNFcRPG7GBhqcFtHuUODzDNv8Ac7SMDguk+I+tadHcNrDaYsf+nwxzQWb4jktbqOAuytMAUcyZ5ZAmOWIyQAWLL4b32qW+oW2vXiWuntqOqXFvBBCPPxcmaMO0285BjlLbdoOcbicYrZsvh/J/wk1hruq6lb3V7bSxsyQWPkxOkcE0UYCF22sDMWLZP3QABiuRs/ij4iv9H1bUbaDSkj0jTjfTo8DObgrc3ETKjJMVQFYAQcyAEnlxg10XizxJrGn/ABMstH0g2q/borSLzLpZZUj3i9ZmEayKuf3C88EjIJ6YAItP+FX2W48PyT6stwmlQQWpjMU0ayxwSmSJsJOB5gJ5Zg6kgEKuK1vB3gW48PavYXMmqxXVpp2ny6bawraGOQRvJG4Mj7yHYeXgkKuc5wO/l99401uLxUuv3Frpk08NqliZDa/JZ/6XeQvODJOioG+z4ILrneg3fL83a+EfHes+I7ie2mutC0y8WBvs1ocXEt+fLZlmhKT7TGCBlV8z7rDcOtAHqlFeE+HfiFrS2VtcXmpaZI9zY6cbjU7hJPstqzpdl/MjWTaG3wrESuzLnnGFSt7T/H/iO6xfT2VhZ2SX+m2UtlNDJ56m6it2bMm/ClGnPVOQMEA80Adl8UP+SaeLf+wRd/8Aol66avK5fEtz4n+DHjW5vntHuYbG9hc2agwcW5OEkEjiQfN94EehVSCK9UoAKKKKAIrqeO1tpriclYokMjkAsQoGTwOT+FeardXOq+IjqcguIo2uDBDE4UEQrE27IBOP3hIJz1A6ZxXpF/v+w3PlF1k8ttpTG4HBxjPGfrXlvgqRryNruaXdPvmZ0DggNI4dsAcKBgcc8luSeaAOrtYUutQhhkniiVWSUK45lIbO1efbnr1FddXM6Hb/AG65M7Bxb27/AC5XAkcEg9eoBAPHfvwRXTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADFijWV5FjQSOAGYAZbHTJ74yafRRQAUUUUAcRO95e6rexyxSNfRyMsKBdyQxk4QkglV3ABjkgn0wAK67T7G20+DyrSJY1J3Of4nbAG5j1ZsAcnnip4yjKHjKlXwwZejcdfyp1ABTI4kjaRo1CmRt7kdzgDP5AU+igAryr4d/wDJdvi5/wBwj/0lavVa8q+Hf/Jdvi5/3CP/AElagD1WiiigDyr4+/8ANOP+xz03/wBqV6rXlXx9/wCacf8AY56b/wC1K9VoA888B+J7PSvA/h3T7+w8QxXlpp1vBNH/AGDfNsdIlVhkQkHBB5BxW7/wm2lf8+niH/wn7/8A+M101FAHM/8ACbaV/wA+niH/AMJ+/wD/AIzR/wAJtpX/AD6eIf8Awn7/AP8AjNdNRQBzP/CbaV/z6eIf/Cfv/wD4zR/wm2lf8+niH/wn7/8A+M101FAHM/8ACbaV/wA+niH/AMJ+/wD/AIzR/wAJtpX/AD6eIf8Awn7/AP8AjNdNRQBzP/CbaV/z6eIf/Cfv/wD4zR/wm2lf8+niH/wn7/8A+M101FAHM/8ACbaV/wA+niH/AMJ+/wD/AIzR/wAJtpX/AD6eIf8Awn7/AP8AjNdNRQB55488T2eq+B/EWn2Fh4hlvLvTriCGP+wb5d7vEyqMmEAZJHJOK9DoooAKKKKACvFL15/D/im/S2t54LeND5EEuwoq4G75gMtnKN1yMnOTur2usrxBoGn69a+TfwqxBBWQKNykdOo5HJ4ORQBn/D66mn0BYbsp9pgkdGCKVG3cSMAnIHbnH3SO1dLXIeH/AAfc6cx+26zcXASTdF5EawYU4JU4zwTngYHSushj8qJI9zttAG5zkn3JoAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADY0WONUjVURQFVVGAAOwFOoooAKKKKACvKvh3/AMl2+Ln/AHCP/SVq9Vryr4d/8l2+Ln/cI/8ASVqAPVaKKKAOf8a+DtC8b6VFpviex+3WUUwuEj86SLEgVlByjA9GYYzjmuK/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xyiigA/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coooAP8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKKKAD/AIZ8+GH/AELP/k/df/HK6vwL8PvDHgT7d/wimmfYPtuzz/8ASJZd+zdt++zYxvbpjrRRQB1VFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Countries where people have become infected with chikungunya virus: Australia; Bangladesh; Benin; Burma (Myanmar); Burundi; Cambodia; Cameroon; Central African Republic; China; Comoros; Democratic Republic of Congo; Equatorial Guinea; France; Gabon; Guinea; India; Indonesia; Italy; Kenya; Laos; Madagascar; Malawi; Malaysia; Maldives; Mauritius; Mayotte; New Caledonia; Nigeria; Pakistan; Philippines; Republic of Congo; Reunion; Senegal; Seychelles; Singapore; South Africa; South Sudan; Sri Lanka; Taiwan; Tanzania; Thailand; Timor; Uganda; Vietnam; Yemen; Zimbabwe.",
"    <sup>",
"     &bull;",
"    </sup>",
"    <div class=\"footnotes\">",
"     * Modified from: Powers AM, Logue CH. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus J Gen Virol 2007; 88:2363.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     This list does not include countries where only imported cases have been documented.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Chikungunya fever: Geographic distribution of Chikungunya Virus. Available at:",
"     <a href=\"file://www.cdc.gov/chikungunya/map/index.html\" target=\"_blank\">",
"      file://www.cdc.gov/chikungunya/map/index.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32132=[""].join("\n");
var outline_f31_24_32132=null;
var title_f31_24_32133="Azilsartan and chlorthalidone: Patient drug information";
var content_f31_24_32133=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azilsartan and chlorthalidone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/12/12486?source=see_link\">",
"     see \"Azilsartan and chlorthalidone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13772304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      edarbyclor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13739837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13739839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13739838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3631993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to azilsartan, chlorthalidone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13739843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2956564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gout, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13739844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13739845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13739841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13739842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13739846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13739847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17137 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32133=[""].join("\n");
var outline_f31_24_32133=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13772304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739837\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739839\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739838\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739843\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739844\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739845\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739841\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739842\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739846\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739847\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/12/12486?source=related_link\">",
"      Azilsartan and chlorthalidone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_24_32134="Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease";
var content_f31_24_32134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/24/32134/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/24/32134/contributors\">",
"     Joel M Kremer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/24/32134/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/24/32134/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/24/32134/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/24/32134/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/24/32134/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects associated with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), in doses commonly used to treat rheumatic diseases (particularly rheumatoid arthritis), are not life threatening. However, some complications, particularly hepatic toxicity, can be quite serious. Fortunately, careful and appropriate patient monitoring can minimize the risk and can allow MTX to remain an important drug in the treatment of rheumatic diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEPATOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    can induce a variety of histologic changes including steatosis, stellate (Ito) cell hypertrophy, anisonucleosis (nuclei of varying sizes), and hepatic fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef54948 \" href=\"mobipreview.htm?8/28/8649\">",
"     picture 1",
"    </a>",
"    ). The mechanism by which MTX adversely affects the liver is unclear. Hepatic folate stores are depleted by MTX in the doses used in RA, and these stores can be repleted by short-term administration of oral folinic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/1\">",
"     1",
"    </a>",
"    ]. A relationship between folate depletion and hepatic toxicity has not been established. However, supplementation with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    1 mg per day or folinic acid 2.5 mg per week is associated with a reduced incidence of serum transaminase elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Thus, folate supplementation may help prevent hepatotoxicity in patients taking MTX but does not substitute for ongoing monitoring and appropriate MTX dose adjustments if transaminase elevation occurs.",
"   </p>",
"   <p>",
"    Use of MTX for neoplastic diseases has been associated with abnormalities of liver biochemical tests. The reported incidence of MTX-induced increases in serum alanine aminotransferase (ALT) is approximately 14 percent, while the incidence of increases into the abnormal range of aspartate aminotransferase (AST) is 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/4\">",
"     4",
"    </a>",
"    ]. The enzymes may rise with each course of MTX and are also higher in patients receiving daily, as opposed to intermittent, dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/5\">",
"     5",
"    </a>",
"    ]. The abnormal liver enzymes usually resolve within a month of discontinuation of the drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H25#H25\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of our understanding of the hepatotoxic potential of MTX comes from its use in nonmalignant disease, such as psoriasis and rheumatoid arthritis. MTX hepatotoxicity in patients with psoriasis appears to increase with the total cumulative dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/6\">",
"     6",
"    </a>",
"    ]. Cirrhosis and fibrosis occur more than twice as frequently in patients receiving daily MTX therapy when compared with those receiving intermittent dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early studies from the dermatology literature described severe liver disease, including cirrhosis, in patients with psoriasis who were treated with MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The authors of these studies also noted an inability of liver function testing to predict actual liver toxicity. Thus, in the past, the dermatology community recommended monitoring for liver disease by liver biopsy performed after a total cumulative dose of 1.5 g of MTX and again after each additional 1 g cumulative dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/6\">",
"     6",
"    </a>",
"    ]. Potential limitations of the studies on which the past recommendations were based included the performance of blood sampling only on the day of the liver biopsy and the lack of control for exposure to other hepatotoxins (such as alcohol and arsenic).",
"   </p>",
"   <p>",
"    Guidelines for the monitoring for hepatotoxicity in patients being treated for rheumatoid arthritis (RA) with MTX were adopted when rheumatologists began using MTX for patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/12\">",
"     12",
"    </a>",
"    ], and prospective studies were performed in which baseline and multiple liver biopsies were performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In contrast to the dermatology studies that performed blood sampling only on the day of liver biopsy, the rheumatology studies measured the serum aspartate aminotransferase (AST) and albumin concentrations at regular and frequent intervals during the period leading up to liver biopsy and between sequential biopsies. Thus, while the dermatology literature concluded that blood sampling was of little value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/6,9-11\">",
"     6,9-11",
"    </a>",
"    ], the rheumatology literature observed that elevations of AST into the abnormal range were predictive of abnormal or worsening histological grade on liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Furthermore, little deterioration was noted on serial liver biopsies when the MTX dose was adjusted for abnormalities in serum AST and albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the guidelines from the American Academy of Dermatology no longer recommend liver biopsies in all patients administered MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/16\">",
"     16",
"    </a>",
"    ]. Instead, they recommend liver biopsies based upon the presence of risk factors for hepatotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H32#H32\">",
"     \"Treatment of psoriasis\", section on 'Hepatotoxicity and liver biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from a large cohort of patients with RA (1953 patients) and psoriatic arthritis (151 patients), enrolled in the CORRONA database in the United States, showed an increased risk of transaminase elevations with a combination of MTX and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    compared with either drug used alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/17\">",
"     17",
"    </a>",
"    ]. The overall incidence of elevations in aminotransferase enzymes in patients with RA receiving MTX, leflunomide, MTX plus leflunomide, and neither was 22, 17, 31, and 14 percent, respectively. Patients with psoriatic arthritis were 2.76-fold (CI 1.84-4.15) more likely to exhibit elevations in these enzymes than patients with RA.",
"   </p>",
"   <p>",
"    Other approaches are under development for the detection of changes related to hepatic fibrosis, including noninvasive imaging techniques. As an example, ultrasound-based transient elastography has been used in preliminary studies of patients receiving MTX for inflammatory arthritis, psoriasis, and gastroenterologic disorders but has not been evaluated for its utility in monitoring patients with RA receiving MTX in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=see_link\">",
"     \"Noninvasive assessment of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of interest is the observation that MTX may have beneficial effects in certain autoimmune liver diseases such as primary biliary cirrhosis (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34105?source=see_link\">",
"     \"Overview of the treatment of primary biliary cirrhosis\"",
"    </a>",
"    ) and granulomatous hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This is not surprising as MTX has been used in a variety of autoimmune conditions from multiple sclerosis and systemic lupus erythematosus to inflammatory bowel disease. However, these investigations should not be misinterpreted as showing that MTX is not itself hepatotoxic. Rather, its salutary effects on autoimmune liver disease may outweigh its potential for hepatotoxicity, particularly in short and intermediate term studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiating MTX therapy, patients should have a careful history and physical examination with particular emphasis on alcohol intake, potential exposure to viral hepatitis (eg, illicit drug use), and any family history of liver disease. Baseline laboratory studies should include AST, ALT, serum bilirubin, serum albumin, prothrombin time, and, in patients with identified risk factors, serologic testing for hepatitis B and C virus infection. A pretreatment liver biopsy should be strongly considered in patients with a history of excessive alcohol consumption, persistently abnormal AST or ALT values, or chronic hepatitis B or C infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Guidelines in RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above observations, the American College of Rheumatology (ACR) has published guidelines for monitoring MTX-induced hepatic toxicity in patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In general agreement with these guidelines, we recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood sampling for measurement of aminotransferases and serum albumin should be obtained at four- to eight-week intervals. The 2008 ACR recommendations indicate that, in patients on a stable dose of MTX, monitoring at an interval of every 8 to 12 weeks is appropriate after three months of therapy and monitoring every 12 weeks can be performed beyond six months of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Liver biopsy should be performed if 6 of 12 tests are abnormal in any year (or 5 of 9 if testing is performed at six-week instead of monthly intervals). Abnormal aminotransferases are defined as any elevation into the abnormal range, while low serum albumin is defined as a value &le;3.4",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (&le;34",
"      <span class=\"nowrap\">",
"       g/L).",
"      </span>",
"     </li>",
"     <li>",
"      Routine monitoring biopsies after a fixed interval or specific cumulative dose of MTX are no longer recommended. A pretreatment biopsy is considered only for patients with a history of excessive prior alcohol consumption, persistently abnormal baseline AST values, or chronic hepatitis B or C infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A key feature of these suggested guidelines that is sometimes overlooked is the need to adjust the MTX dose in the event of an abnormality in AST or a decrease in serum albumin concentration. Thus, after obtaining an abnormal value, the clinician should adjust the weekly dose of MTX downward and should then repeat the blood testing after an interval of two to four weeks to ascertain that the abnormal values have returned to the normal range. This careful monitoring places a great deal of responsibility on the clinician, while making it unlikely that patients should have to undergo a liver biopsy.",
"   </p>",
"   <p>",
"    In general, more frequent monitoring than that mentioned in the guidelines should be considered when other potential hepatotoxins are first combined with MTX therapy. These may include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , retinoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and especially",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The recommendations contained in the suggested guidelines were derived from published cohorts of patients who did not use alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. These patients, when managed under the recommended guidelines, had a safe long-term outcome with respect to liver toxicity. One study, for example, prospectively evaluated 27 patients with RA who were treated with MTX; no clinically meaningful changes by light or electron microscopy were found in the 170 liver biopsies obtained over a mean of eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, alcohol has been identified as a major risk factor for liver disease in patients with psoriasis on MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, it is strongly recommended that patients on MTX therapy be counseled about strict avoidance of alcohol and that this conversation is documented on the clinic chart. Patients should also be periodically questioned about their adherence to this policy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Guidelines in other rheumatic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the predictive value of serial blood sampling and hepatic histologic outcome have been performed only in patients with RA. It is presently uncertain, because of the absence of data, if serial monitoring of aminotransferases and serum albumin can be universally applied to other groups receiving MTX, such as patients with systemic lupus erythematosus, granulomatosis with polyangiitis (Wegener&rsquo;s) and other vasculitides, juvenile idiopathic arthritis, or psoriatic arthritis.",
"   </p>",
"   <p>",
"    There is some evidence that patients with psoriasis may have an enhanced predisposition to hepatic damage, particularly if they have underlying type 2 diabetes mellitus or are overweight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/9,29\">",
"     9,29",
"    </a>",
"    ]. Other observational studies have shown no increase in abnormal liver function tests compared with patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32134/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H32#H32\">",
"     \"Treatment of psoriasis\", section on 'Hepatotoxicity and liver biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/6/23651?source=see_link\">",
"       \"Patient information: Toxic hepatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      can induce a variety of histologic changes in the liver, including steatosis, stellate (Ito) cell hypertrophy, anisonucleosis (nuclei of varying sizes), hepatic fibrosis, and cirrhosis, and its use has been associated with abnormalities of liver biochemical tests. Abnormal liver enzymes that may occur usually resolve within a month of discontinuation of the drug. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism by which MTX adversely affects the liver is unclear. Hepatic folate stores are depleted by MTX in the doses used in rheumatoid arthritis (RA), and these stores can be repleted by short-term administration of oral folinic acid. Folate supplementation may help prevent hepatotoxicity in patients taking MTX but does not substitute for ongoing monitoring and appropriate MTX dose adjustments if transaminase elevation occurs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies in RA have shown that elevations of AST into the abnormal range were predictive of abnormal or worsening histological grade on liver biopsy but that little deterioration was noted on serial liver biopsies when the MTX dose was adjusted for abnormalities in serum AST and albumin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before initiating MTX therapy, patients should have a careful history and physical examination with particular emphasis on alcohol intake, potential exposure to viral hepatitis (eg, illicit drug use), and any family history of liver disease. Baseline laboratory studies should include AST, ALT, serum bilirubin, serum albumin, prothrombin time, and, in patients with identified risk factors, serologic testing for hepatitis B and C virus infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pretreatment liver biopsy should be strongly considered in patients with a history of excessive alcohol consumption, persistently abnormal AST or ALT values, or chronic hepatitis B or C infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients being treated for RA, serum aminotransferases and albumin should be obtained at four- to eight-week intervals. The 2008 ACR recommendations indicate that, in patients on a stable dose of MTX, monitoring at an interval of every 8 to 12 weeks is appropriate after three months of therapy and monitoring every 12 weeks can be performed beyond six months of therapy. The MTX dose should be adjusted in the event of an abnormality in AST or a decrease in serum albumin concentration, and liver biopsy should be performed if 6 of 12 tests are abnormal in any year (or 5 of 9 if testing is performed at six-week instead of monthly intervals). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Guidelines in RA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is not know whether the guidelines used for RA are applicable to other conditions, but similar guidelines have been adopted for the treatment of psoriasis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Guidelines in other rheumatic diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/1\">",
"      Rodenhuis S, Kremer JM, Bertino JR. Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. Arthritis Rheum 1987; 30:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/2\">",
"      Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009; 160:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/3\">",
"      van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/4\">",
"      Berkowitz RS, Goldstein DP, Bernstein MR. Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986; 23:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/5\">",
"      King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/6\">",
"      Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate guidelines--revised. J Am Acad Dermatol 1982; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/7\">",
"      Lewis JH, Schiff E. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. The ACG Committee on FDA-related matters. American College of Gastroenterology. Am J Gastroenterol 1988; 83:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/8\">",
"      Weinstein GD. Methotrexate. Ann Intern Med 1977; 86:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/9\">",
"      Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973; 108:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/10\">",
"      Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A 1977; 85:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/11\">",
"      Zachariae H, Kragballe K, S&oslash;gaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980; 102:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/12\">",
"      Furst DE, Kremer JM. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/13\">",
"      Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989; 32:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/14\">",
"      Kremer JM, Kaye GI, Kaye NW, et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995; 38:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/15\">",
"      Kremer JM, Furst DE, Weinblatt ME, Blotner SD. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996; 23:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/16\">",
"      Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/17\">",
"      Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/18\">",
"      Barbero-Villares A, Mendoza Jim&eacute;nez-Ridruejo J, Taxonera C, et al. Evaluation of liver fibrosis by transient elastography (Fibroscan&reg;) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 2012; 47:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/19\">",
"      Barbero-Villares A, Mendoza J, Trapero-Marugan M, et al. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin (Barc) 2011; 137:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/20\">",
"      Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010; 53:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/21\">",
"      Berends MA, Snoek J, de Jong EM, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007; 27:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/22\">",
"      Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997; 126:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/23\">",
"      Knox TA, Kaplan MM, Gelfand JA, Wolff SM. Methotrexate treatment of idiopathic granulomatous hepatitis. Ann Intern Med 1995; 122:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/24\">",
"      Kremer JM, Alarc&oacute;n GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/25\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/26\">",
"      Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992; 35:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/27\">",
"      Furst DE, Erikson N, Clute L, et al. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol 1990; 17:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/28\">",
"      Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992; 35:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/29\">",
"      Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32134/abstract/30\">",
"      Amital H, Arnson Y, Chodick G, Shalev V. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 2009; 48:1107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7508 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32134=[""].join("\n");
var outline_f31_24_32134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Guidelines in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Guidelines in other rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7508|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/28/8649\" title=\"picture 1\">",
"      MTX hepatotoxicity light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=related_link\">",
"      Noninvasive assessment of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34105?source=related_link\">",
"      Overview of the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/6/23651?source=related_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_24_32135="Eptifibatide: Drug information";
var content_f31_24_32135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eptifibatide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/63/39923?source=see_link\">",
"    see \"Eptifibatide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Integrilin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Integrilin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent, Glycoprotein IIb/IIIa Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute coronary syndrome:",
"     </b>",
"     I.V.: Bolus of 180 mcg/kg (maximum: 22.6 mg) over 1-2 minutes, begun as soon as possible following diagnosis, followed by a continuous infusion of 2 mcg/kg/minute (maximum: 15 mg/hour) until hospital discharge or initiation of CABG surgery (discontinue &ge;2-4 hours before surgery), up to 72 hours (if PCI performed during initial 72 hours, maintain continuous infusion at the time of PCI and continue until hospital discharge or for up to 18-24 hours, whichever comes first [total infusion time &le;96 hours]). Concurrent aspirin and heparin therapy (target aPTT 50-70 seconds) are recommended.",
"     <b>",
"      Note:",
"     </b>",
"     If UA/NSTEMI, administration &ge;12 hours before angiography was shown not to be superior to provisional use at the time of PCI and has a higher incidence of bleeding (Giugliano, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Percutaneous coronary intervention (PCI) with or without stenting:",
"     </b>",
"     I.V.: Bolus of 180 mcg/kg (maximum: 22.6 mg) administered immediately before the initiation of PCI, followed by a continuous infusion of 2 mcg/kg/minute (maximum: 15 mg/hour). A second 180 mcg/kg bolus (maximum: 22.6 mg) should be administered 10 minutes after the first bolus. Infusion should be continued until hospital discharge or for up to 18-24 hours, whichever comes first; shorter infusion durations (ie, &lt;2 hours) may be considered for nonemergent uncomplicated PCI in patients adequately pretreated with clopidogrel (Fung, 2007). Preprocedural aspirin and heparin therapy (ACT 200-250 seconds during PCI) are recommended. Heparin infusion after PCI is discouraged. In patients who undergo CABG surgery, discontinue infusion &ge;2-4 hours prior to surgery.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No dosing adjustment for the elderly appears to be necessary; adjust carefully to renal function.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F166057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dialysis is a contraindication to use.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The Cockcroft-Gault equation using actual body weight should be used to estimate renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Acute coronary syndrome: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: 180 mcg/kg bolus (maximum: 22.6 mg) and 1 mcg/kg/minute infusion (maximum: 7.5 mg/hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percutaneous coronary intervention (PCI) with or without stenting: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: 180 mcg/kg bolus (maximum: 22.6 mg) administered immediately before the initiation of PCI and followed by a continuous infusion of 1 mcg/kg/minute (maximum: 7.5 mg/hour). Administer a second 180 mcg/kg (maximum: 22.6 mg) bolus 10 minutes after the first bolus.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Integrilin&reg;: 0.75 mg/mL (100 mL); 2 mg/mL (10 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F166036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not shake vial. Visually inspect for discoloration or particulate matter prior to administration. The bolus dose should be withdrawn from the 10 mL vial into a syringe and administered by I.V. push over 1-2 minutes. Begin continuous infusion immediately following bolus administration, administered directly from the 100 mL vial. The 100 mL vial should be spiked with a vented infusion set.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F166088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS (infusion may contain up to 60 mEq/L KCl), D",
"     <sub>",
"      5",
"     </sub>",
"     NS (infusion may contain up to 60 mEq/L KCl).",
"    </p>",
"    <p style=\"text-indent:0em;margin-right:2em;margin-top:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alteplase, amiodarone, argatroban, atropine, bivalirudin, dobutamine, heparin, lidocaine, meperidine, metoprolol, micafungin, midazolam, morphine, nitroglycerin, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Tenecteplase.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment elevation myocardial infarction [UA/NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI including angioplasty, intracoronary stenting)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9773564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To support PCI during ST-elevation myocardial infarction (administered at the time of primary PCI); elective PCI for stable ischemic heart disease (in combination with unfractionated heparin)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleeding is the major drug-related adverse effect. Access site is often primary source of bleeding complications. Incidence of bleeding is also related to heparin intensity. Patients weighing &lt;70 kg may have an increased risk of major bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Hematologic: Bleeding (major: 1% to 11%; minor: 3% to 14%; transfusion required: 2% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (up to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute profound thrombocytopenia (including immune-mediated thrombocytopenia), fatal bleeding events, GI hemorrhage, pulmonary hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to eptifibatide or any component of the product; active abnormal bleeding within the previous 30 days or a history of bleeding diathesis; history of stroke within 30 days or a history of hemorrhagic stroke; severe hypertension (systolic blood pressure &gt;200 mm Hg or diastolic blood pressure &gt;110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding 6 weeks; current or planned administration of another parenteral GP IIb/IIIa inhibitor; dependency on hemodialysis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): PT &gt;1.2 times control or INR &ge;2.0; known history of intracranial disease (eg, neoplasm, arteriovenous malformation, aneurysm); severe renal impairment ( Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); thrombocytopenia (&lt;100,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ); clinically significant liver disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: The most common complication is bleeding, including retroperitoneal, pulmonary, and spontaneous GI and/or GU bleeding; monitor closely for bleeding, especially the arterial access site for the cardiac catheterization. Patients &lt;70 kg may be at greater risk for major and minor bleeding. Use with extreme caution in patients with hemorrhagic retinopathy, previous history of GI disease, recent thrombolytic therapy, and chronic renal insufficiency. Use caution with administration of other drugs affecting hemostasis. Minimize invasive procedures, including arterial and venous punctures, I.M. injections, and nasogastric tube insertions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Use with extreme caution in patients with platelet counts &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . If platelet count decreases to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     during therapy, discontinue eptifibatide and heparin if administered concurrently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal dysfunction (estimated Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute, using Cockcroft-Gault equation); dosage adjustment required. Use is contraindicated in patients dependent upon hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sheath removal: Prior to pulling the sheath, heparin should be discontinued for 3-4 hours and ACT &lt;180 seconds or aPTT &lt;45 seconds. Use standard compression techniques after sheath removal. Monitor the site closely afterwards for further bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Discontinue &ge;2-4 hours prior to coronary artery bypass graft surgery (Hillis, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1937330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, coleus, cordyceps, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American), ginseng (Panax), ginseng (Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, same (s-adenosylmethionine), sweet clover, turmeric, and white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Integrilin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg/mL (100 mL): $514.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (10 mL): $164.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F166031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coagulation parameters, signs/symptoms of excessive bleeding. Laboratory tests at baseline and monitoring during therapy: hematocrit and hemoglobin, platelet count, serum creatinine, PT/aPTT (maintain aPTT between 50-70 seconds unless PCI is to be performed), and ACT with PCI (maintain ACT between 200-300 seconds during PCI).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Assess sheath insertion site and distal pulses of affected leg every 15 minutes for the first hour and then every 1 hour for the next 6 hours. Arterial access site care is important to prevent bleeding. Care should be taken when attempting vascular access that only the anterior wall of the femoral artery is punctured, avoiding a Seldinger (through and through) technique for obtaining sheath access. Femoral vein sheath placement should be avoided unless needed. While the vascular sheath is in place, patients should be maintained on complete bedrest with the head of the bed at a 30&deg; angle and the affected limb restrained in a straight position.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Observe patient for mental status changes, hemorrhage, assess nose and mouth mucous membranes, puncture sites for oozing, ecchymosis and hematoma formation, and examine urine, stool and emesis for presence of occult or frank blood; gentle care should be provided when removing dressings.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F166042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antigrilin (IN);",
"     </li>",
"     <li>",
"      Integrilin (AR, AT, AU, BE, BG, CH, CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, MT, MY, NL, NO, PH, PK, PL, PT, RU, SE, SG, SK, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor, the binding site for fibrinogen, von Willebrand factor, and other ligands. Inhibition of binding at this final common receptor reversibly blocks platelet aggregation and prevents thrombosis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Platelet function restored ~4 hours following discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as eptifibatide and metabolites); significant renal impairment may alter disposition of this compound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Total body: 55-58 mL/kg/hour; Renal: ~50% of total in healthy subjects",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Giugliano RP, Gibson CM, et al, &ldquo;Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(21):2720-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/10351964/pubmed\" id=\"10351964\" target=\"_blank\">",
"        10351964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brener SJ, Barr LA, Burchenal JE, et al, &ldquo;Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction,&rdquo; ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators,",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(8):734-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheema AA, Teklinski AH, Maria V, et al, &ldquo;Recurrent Acute Profound Thrombocytopenia Related to Readministration of Eptifibatide,&rdquo;",
"      <i>",
"       J Interv Cardiol",
"      </i>",
"      , 2006, 19(1):99-103.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/16483348/pubmed\" id=\"16483348\" target=\"_blank\">",
"        16483348",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coons JC, Barcelona RA, Freedy T, et al,&ldquo;Eptifibatide-Associated Acute, Profound Thrombocytopenia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(2):368-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/15644467/pubmed\" id=\"15644467\" target=\"_blank\">",
"        15644467",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fung AY, Saw J, Starovoytov A, et al, &ldquo;Abbreviated Infusion of Eptifibatide After Successful Coronary Intervention: The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) Randomized Trial,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(10):837-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/19264239/pubmed\" id=\"19264239\" target=\"_blank\">",
"        19264239",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giugliano RP, White JA, Bode C, et al, &ldquo;Early Versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(21):2176-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/19332455/pubmed\" id=\"19332455\" target=\"_blank\">",
"        19332455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamm CW, Heeschen C, Goldmann B, et al, &ldquo;Benefit of Abciximab in Patients With Refractory Unstable Angina in Relation to Serum Troponin T Levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(21):1623-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/10341274/pubmed\" id=\"10341274\" target=\"_blank\">",
"        10341274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huxtable LM, Tafreshi MJ, and Rakkar AN,&ldquo;Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa Receptor Antagonists,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2006, 97(3):426-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/16442410 /pubmed\" id=\"16442410 \" target=\"_blank\">",
"        16442410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Inhibition of Platelet Glycoprotein IIb/IIIa With Eptifibatide in Patients With Acute Coronary Syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(7):436-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/9705684/pubmed\" id=\"9705684\" target=\"_blank\">",
"        9705684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kereiakes DJ, Broderick TM, Roth EM, et al, &ldquo;Time Course, Magnitude, and Consistency of Platelet Inhibition by Abciximab, Tirofiban, or Eptifibatide in Patients With Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1999, 84(4):391-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/10468074/pubmed\" id=\"10468074\" target=\"_blank\">",
"        10468074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Califf RM, Anderson KM, et al, &ldquo;Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1997, 30(1):149-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/9207636/pubmed\" id=\"9207636\" target=\"_blank\">",
"        9207636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Califf RM, Moliterno DJ, et al, &ldquo;Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(5):319-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/10423466/pubmed\" id=\"10423466\" target=\"_blank\">",
"        10423466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Tcheng JE, Califf RM, et al, &ldquo;Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab: One-Year Outcome in the EPILOG Trial. Evaluation in PTCA to Improve Long-Term Outcome With Abciximab GP IIb/IIIa Blockade,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(15):1951-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/10208997/pubmed\" id=\"10208997\" target=\"_blank\">",
"        10208997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Llevadot J, Coulter SA, and Giugliano RP, \"A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Receptor Inhibitors,&rdquo;",
"      <i>",
"       J Thromb Thrombolysis",
"      </i>",
"      , 2000, 9(2):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/10613999/pubmed\" id=\"10613999\" target=\"_blank\">",
"        10613999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahaffey KW, Harrington RA, Simoons ML, et al, &ldquo;Stroke in Patients With Acute Coronary Syndromes: Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina. Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. The PURSUIT Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(18):2371-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/10318656/pubmed\" id=\"10318656\" target=\"_blank\">",
"        10318656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandak JS, Blankenship JC, Gardner LH, et al, &ldquo;Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1998, 31(7):1518-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/9626829/pubmed\" id=\"9626829\" target=\"_blank\">",
"        9626829",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McClure MW, Berkowitz SD, Sparapani R, et al, &ldquo;Clinical Significance of Thrombocytopenia During a Non-ST-Elevation Acute Coronary Syndrome. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(22):2892-900.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/10359733/pubmed\" id=\"10359733\" target=\"_blank\">",
"        10359733",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagge J, Jackevicius C, Dzavik V, et al, &ldquo;Acute Profound Thrombocytopenia Associated With Eptifibatide Therapy,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(3):374-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/12627937/pubmed\" id=\"12627937\" target=\"_blank\">",
"        12627937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Randomised Placebo-Controlled Trial of Effect of Eptifibatide on Complications of Percutaneous Coronary Intervention: IMPACT-II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1997, 349(9063):1422-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/9164315/pubmed\" id=\"9164315\" target=\"_blank\">",
"        9164315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rezkalla SH, Hayes JJ, Curtis BR, et al, &ldquo;Eptifibatide-Induced Acute Profound Thrombocytopenia Presenting as Refractory Hypotension,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2003, 58(1):76-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/12508202/pubmed\" id=\"12508202\" target=\"_blank\">",
"        12508202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salengro E, Mulvihill NT, and Farah B, &ldquo;Acute Profound Thrombocytopenia After Use of Eptifibatide for Coronary Stenting,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2003, 58(1):73-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/12508201/pubmed\" id=\"12508201\" target=\"_blank\">",
"        12508201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tardiff BE, Califf RM, Tcheng JE, et al, &ldquo;Clinical Outcomes After Detection of Elevated Cardiac Enzymes in Patients Undergoing Percutaneous Intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):88-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/9935014/pubmed\" id=\"9935014\" target=\"_blank\">",
"        9935014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Topol EJ, Ferguson JJ, Weisman HF, et al, &ldquo;Long-Term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Beta",
"      <sub>",
"       3",
"      </sub>",
"      Blockade With Percutaneous Coronary Intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 278(6):479-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/9256222/pubmed\" id=\"9256222\" target=\"_blank\">",
"        9256222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Merkhof LF, Zijlstra F, Olsson H, et al, &ldquo;Abciximab in the Treatment of Acute Myocardial Infarction Eligible for Primary Percutaneous Transluminal Coronary Angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(6):1528-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/10334418/pubmed\" id=\"10334418\" target=\"_blank\">",
"        10334418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright RS, Anderson JL, Adams CD, et al, \"2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2011, 57(19):1920-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/24/32135/abstract-text/21450428/pubmed\" id=\"21450428\" target=\"_blank\">",
"        21450428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8918 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32135=[""].join("\n");
var outline_f31_24_32135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166052\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166053\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166082\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166055\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166056\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166057\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822438\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166033\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166018\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166036\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166088\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166034\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9773564\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174530\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166080\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166039\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166022\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299277\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166027\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1937330\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166029\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166041\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166061\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323131\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166031\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166042\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166021\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166038\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8918|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/63/39923?source=related_link\">",
"      Eptifibatide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_24_32136="Posterior spinal fusion";
var content_f31_24_32136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Posterior spinal fusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 472px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHYAlQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APteT9qfwVHt36T4kG4bh/o8HT/v8AU3/hqvwP/wBArxJ/4Dwf/Hq+NdQGBa/9cV/maqUAfav/AA1X4I/6BXiT/wAB4P8A49WxZ/tC+Hbyyiu7bQPEklvLnY4S1Gcdes9fCVdf4D8Rto8r214jzaVM4aRE+/E399Pf1HcfhQB9nWfxt0y8uEgt/DPiNpXG5Qfsa7h7E3AFWJPjBax3DQP4U8SiVSAV/wBD7/8Abx714YgRrGOe2mWe1dS8U8R4yO4PUEdx1Fdxp99DqOrC3uG8nUEQFJsZEo2LkH3oA7+D4t288hSLwp4kZgdp+ay6/wDgTT7j4qx26M03hLxIqr1+ayP8rmuEllu47xIkVGG7/VsOW/Gk1JrxbresaGEDJ9sDvQB3a/FiFiMeEvEnOD1su/T/AJeaU/FaIMqnwl4kDN0G6y5/8ma81M+qywgqsKohAwq4O0dRmtPTr9LxIPPtrgunAcAbQc+tAHc3fxSW0RmuPCHiVFXgndZHH5XNVW+MVmrFW8K+JAR/15//ACRXFeL3eXKRuR+8KOrDGRngj1qtDHHbWhutXdkt0G1VY/PIfQd6AO8uvjLY2liby58L+I47YHG9jZDJ9APtGT+FZkn7QegRw+a/h/xII8Zz5dr/APH68h8Q6jJrdy0tx+5tYMiGAchf8W/lXHazcRQWEktwRFbIOgPP0HqxoA99uv2nvB9rMkU+j+JEkZQwHkW54PTpNVf/AIar8D/9ArxJ/wCA8H/x6vjm5u2v9UNw4C72GFB4UDgD8qoUAfav/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XxVRQB9q/8NV+B/wDoFeJP/AeD/wCPVJbftSeDLmURQ6R4kZyCQPIgHQZPWb0FfE1aXh3/AJC0f+5J/wCgNQB9h/8ADVfgf/oFeJP/AAHg/wDj1dB4C/aA8K+N/Flj4e0qw1uG9vPM8t7mGJYxsjZzkrIT0U9jzXwVXqv7Ln/JdvDP/b1/6Sy0AfWHxQ+Nfhz4ca/b6Rrllq89zPardq1nFGyBGd1AJaRTnKHt6Vx//DVfgf8A6BXiT/wHg/8Aj1eVftrf8lT0r/sCxf8Ao+er8Xwg8CWnh/wHLqH/AAmN9rHimzjmht9NmtAok8lJHGZQoUfPxlj0oA9G/wCGq/A//QK8Sf8AgPB/8eo/4ar8Ef8AQK8Sf+A8H/x6vKfFnwr8DJ8FtV8b+FbvxIZrSVIVg1J4cK/2hInDBE5wGOCrYz+VeBIMuo9TigD7Vk/ao8ExyMj6T4lDKcEfZ4OD/wB/qQftU+CD00rxL/4Dwf8Ax6vjrVIcaxep2Wd1/U0yKLMmFxhT196APs1f2ofBrnC6P4lP/bCD/wCPVJ/w034R/wCgN4k/782//wAer4/gXYpb0qa1YtvcgcD/ACaAPr2L9pfwpLIiR6J4lLOQqjybfkn/ALbU+L9pLwtKxWPRPEhI9YrYf+16+XdEtUa6tZJJOGmUAJz0I5NXLO3hRWWGaCRt5O2dSvPbkGgD6gj/AGgtAkI26B4jwTjcVtQPzM+K2R8XLYqGXwp4kZDyGVrIg/iLmvm/Tb6QWDw/ZBHlcSCNM7mz94etTWWp3VnI5003iSAbiFXamPcdKAPodfjBaNIyL4V8SF1IUjNn1P8A28Ug+MVoX2jwr4l3ZII/0Pj6/wCkcdK8EsPEuuQ3dvJrcAhhnIVWkjADg+hHQ+2a3v7en+3qIrlDE2/AaAbsbTxmgD1z/hcdl5XmHwt4kEY6sfsYA/8AJise4/aJ8N28hSXQ/EO4ddi2rj8xOa+fPEWpXF+3lG4ludyhgqsSqn0xWBKhVwrqUOOhoA+nR+0h4YyB/YXiTJ6furb/AOP0SftIeGIwS+heJQAM/wCqtv8A4/Xy/uMQz2ByeORU8+Jo08tgVbigD6Qk/ae8HxSyRvo/iQPGnmMPItzheOf9d7iq/wDw1X4H/wCgV4k/8B4P/j1fKcsfmalrJODi1k249AVArnZ7cxdCGHfHagD7O/4ar8D/APQK8Sf+A8H/AMeo/wCGq/A//QK8Sf8AgPB/8er4rwcZxSUAfav/AA1X4H/6BXiT/wAB4P8A49Tl/ao8EsjMNK8SbV6/6PB/8er4oqeE4t5x6gfzoA+zv+Gq/A//AECvEn/gPB/8er0/Q/iBpWs/DSTxxa298mkx2txdmKREE+yEuHGAxXJ8s4+b0zivzbr7V+Gn/Jm15/2BdW/9DuKANHWf2kPDGivAup6F4lgaePzIx5Vs25c4zxOfSs7/AIaq8Ef9ArxL/wCA8H/x6uL074eaR8RfHmkaTrU97b20Xh97wNZuiuXFwiAEsrDGHPb0puhfBn4e+IJt2jxeP7vSxeNYnU4nszAJFbaTt2+bszj5wmBnkjBwAdt/w1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8wfGbwpY+CPiTrHh7Spbmays/J8t7llaQ74Uc5KgDqx7DiuJoA+1k/ao8EyOqJpXiUsxwB9ng6/wDf6lb9qfwUsjI2k+JQ6kgj7PB1/wC/1fF1m/l3cLnorqf1qS5bN68oOA7lvpzQB94n44aWNCtNZHhnxK2mXYzDOq2jBuvYXGQeDwQOlZrftF+G1I3aD4lGen7q25/8j14L8G/F+nW+nXvg3xRP9n0q/bzbO7Y/LbTHsfRScHPr9as+JPCuo6PdPFNB5sf3laM5R1/voeh45xQB7kv7RXht1Zl0HxIVXGSI7XucD/lvQn7Rfht0LLoPiTaDtP7u2HP/AH/r5ugj32l8VXO3ysjGD98etSvB5tnAtqxu5yWP7tSWD5wTgUAfR9v+0L4euVzb6B4kkxjIWO1JHOOnn1oD426YYWmHhnxGYlfYzj7GQrehP2jivAdI0G9s7W+eczQXkyKuUQuwAxkbRyMj16V1EJsp9OttFTUnS5ugNyTQjb/ukZ64+YHrxQB6hL8ddIiBMnhrxKAMZ+W0PU4z/wAfHTjr0qmf2iPDgOP7B8Sf9+7X/wCP15XfLc2kaR6YRdaSkOx55CDJIoY9uyjuKrano9u9vEbfUbayuJUDmNHUCX3BPQ+1AHsX/DQXh/JB0HxCCv3gRaDb9f8ASOKn/wCF76Psjf8A4RvxKVkBKsFtCCB3/wCPjp718yXOgIkPny61bhQ+GCvuXcT0BHX3qnqRK31tFZx+XbSSARneS8gB5JHYZ7UAfTtv+0N4duJVjh0HxG7sdoAS16/9/wCqtx+0t4Tt3ZZNF8R7lOCFitm5/Cc183ll0ixSEhvOEbPIQd2GPr+BHFcbZeZLrUbhigMwJZsdAeAPyoA+vrn9pvwlawrLc6J4miRjgb7eAEn6edmqv/DVXgj/AKBXiT/wHg/+PV8h+K7y4vNWke6kEhH3W74z396yB900Afaf/DVfgf8A6BXiT/wHg/8Aj1aHh79pXwdr2v6ZpFnpviBLnULqK0iaWCEIHkcKCxEpOMkZwDXw1XV/Cf8A5Kn4N/7DVl/6PSgD9KaKKKAPAP21v+SWaV/2Gov/AERPXH/ATQdZ8Ufs3+J9D8O3Fpa3d/rDwSTXLMqrCYbfzMbVJJK5GPc812X7aIRvhfpIkYov9tRZIGf+WE/avjPyrT/n6f8A78//AF6APvTwJ8MtQ8D/ABCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXwBVzybL/n7k/78/wD16XybL/n7k/78/wD16AGXvS2/64r/AFqrWvfw2OLbF5J/qVz/AKPj1/2qpNFaD7ty5/7Zf/XoAq1raIm5mPUD2qnHHbGQB7h1Tu3lZ/TNdDpdpYCMqmpzAHk5sST/AOh0AbGha7eaEZBARJaSDMtvJyknvjsfcc17PoN7ZapqN01riW4EcRMDHDxAovI/vD3FeJS2tgYyP7SkwBj/AI8m6f8AfddLbRQxa9cvb6rLFKEi2utuylfkXnO6gD3Wx1i0guXhuFc7BhJDyW9vWkn+z3UzMJfNiHysYzhgDXKaFq9n5LN4gdpigAjuYrXBP++N3J9xXSxCy1MvLp9/bTiRfvrGRIvHpkH9KAJpLnSyFWWOWMj5VVlzuHbp1xVq7spMiWzYJbtgnLAYJrOutFmW1QC/uISCod/LYnnoASfWnnRnstkNzc3MqhgWJjYjPU96ALfiO7gsSjsEuJ1YgKDnBPQmuI1CW5vrk3N+5Z/4F6BR7DtWr4w1DSdPkBm1HbMZn+SOHzG6n0PArz3XPEcVzuW2v2hQjGRaEk/juoAfrmoWlhHmZ8yDO2Jep+teUeK7+61NzJOdsUZ+SIdEH9T710s0NpM2+TU5Wz1JsmP/ALPVDUbCyKZOpSHp/wAuDc/+P0AcVaf8fMf+9UNac9vbQasYkuHMSvw5hIP/AHzn+tVRHbZ5uHx/1y/+vQBWoq4IbPvdyf8Afn/69KILHveSf9+P/sqAKVaXh441WM/7En/oDVGILDveyf8Afj/7KtHQoNP/ALTj/wBPkHySc/Zif4G/2qAMCvVf2XP+S7eGf+3r/wBJZa83MFj2vJD/ANsP/sq9S/ZkitU+OHhhoLl5JN10Cpi24H2WbnOaAOh/bW/5KnpX/YFi/wDR89evt4Gv/Fvgn4QX9nZ6NqFro+mQy3NjqkjJHcB7aIAcRSDgjPK+leQ/tqD/AIujphx00aH/ANHz14VbQBwCVz+FAH178RPCF/4P/Zq8Y2Op3MEj3OoR3cVralmgso3u4dsERYAlVx6Dr09fkZLba6lTxuHX61NGsMeNyr5gPBA4p0kjGRS/94cCgB2s5/ti/RF5a5k+b/gRp8USxRgMRkcYFPunzr96w4xNJj0+8afKUwSRuHr70AQO7TEIp+Ue9bmj2u8NhdyxjgH+Jz0/xrO020kvblLezQs7nOcfmT7Cu5ttNjsUjjZHldT8saj7x7k+/wDKgDM0xWfWreOE4HmqeRwcEZpot1MjblJBbl484HPOR/hWohH2+1bhJEnUqYznbzzk9+KoxJeoHntJfPiBLFHxlTnrj/CgDs9GBhsZI1neWMZERiXZt9/pVXWJyltNvmc+ZhMt2HpTNLXzEXfmG4bldp2q+e3PGaz/ABLaReRI32i7U+YA0ewZBwc/1oAvaXqjx3bx3EoNtcFCeN6gKf7p4JxWpLCbfVYilkVVt5EmSVYbGxjtj2rmbTT9OYWK2TXttcgJ5gDB1m3H0PQg+nUV0wa3j1iINNNOxMgULxGMK3AXJyaAOUkmublFEYjVQPuqcAVK9mJYF+0HBPIc84P+FWIhukO5XiTH/LTAP5VdjiiUkRSPKMdWXbu+lAGA8UYDpJGqyAcjsfcVlzskOWQPgc/Suvu9OivIiYSYZwOO4PtXHask9t/rkIXOA46H2/8ArUAZltl31J253WUp4+qVUFl8oYgbCMgjvWlp0YP248YFnKCO/VajGYFyi742/gPT6igDGubEcEDa3oP5VmTQPGTuHHqK6vykmRXU8Hkg9qqz23XPPHSgDmKemfKk4OMDJ9Oav3NjySg2kDPtSWqFNN1IMOQI/wD0KgDNr7V+Gn/Jm15/2BdW/wDQ7ivi6GMSHGcV9pfDddn7HV8uc40fVxn/AIHcUARfB45+LOnf9irL/wClUNdv8OfCXifwLYL4esDot1oKXrzRXc00q3EcDuWMZiCbWbkgN5gHOcHGD8m/HK2nD+G2aF1C2G05IODvavLZEKohK4zn8eaAPUf2o/8Aku3ib/t1/wDSWKvKqKUDJwKAHRf61PqKJP8AWN9TSxAmZABzuFT/AGK4kkYJESckdRQBaOJbUAjkqK63wR8R9b8Lxx2wkGoaWDg2d0dyj/dP8P8AKuXXT75bcD7K/HfI/wAaYlhehMG1kPJORigD2yDxN4V1+K5vLP7PpF6/lmWC4YJBneOuen1ArS06W0IhTSZ9P8gOC8emOWbk/wAUmc4OfTivLPBMVrDbX66tEYuF37496zKW4Q4+6c1p+HdMjOszGJljilHyKqgeWB/ET7elAHqk2o20V3JDeySWzRArLJO42sMA4+XDOcdzx61geJdQsdOvJLq4u4vt8qGI21qgkdIyMkMw4HGO/wBafd6b5ml3C3tnA0iKIzLGMySdwSM8VyniHw/BZanE2k2lzCkiFZbeWXeVYj7xzyCRjigDY0LxBa6VZwSabaSXJhXPm3TbeDu/hHUH3q7J4y0/U0lluPD9vE6IM7pSyZ68KAMA1yDSvZ2tvBHbPM5gAYBgB1YdawbiHWryX5LWVIh92OPHX39aAOq1S60u4mtLmKHyCzs2JH3BABkBF4AB5rkzqdzdazb3clyhYyLsB/hXPAAFegWXhdIdCNze2LybY9uxsE89cZP41wl1pN/FrFsYrJVj3ggqByM5oAvtqEZjDPcQ3N+WKKGyAWOOOO+KS10+Efbb+QoxtR5rANuV5G4Cr9Kz9CttQku4l3SKgDSuTgnPPy8nqTWpqJntNAezitZIlL/cTHH455J9aAPN7yZ7i5kklxvYknHrmogPlNTT28yzMHjKvnOKelrMbaVvLOFZQT+dAFSur+E//JU/Bv8A2GrL/wBHpXLlGBxjpXU/CdSPin4NJH/MZsv/AEelAH6UUUUUAeAftrf8ks0r/sNRf+iJ6+Kq+1f21v8Aklmlf9hqL/0RPXxVQAUUUUAWbw5EH/XIf1qtU9yCBDkY/djH61EiljgUAOhjLuBjjPNddp6iNcd8ccVh2MKq+ewHX3roLJGZ8AbQOuaAJpk/cyg9cf0rdnf7HrFwWAMjpGFHcZiX/wDXWOm1mbAZ2JPAHWusutNMms3LTW0jxmOPBDAEfu17UAR6LDe3DSLZxSFEwzk8qh9c9jWy9jC0iPNqOZMYG0bWB9v8at6HI0dsLe1gEYRmLyCT1GBuB9vWh/Lhnjab7PtUEk7skYoAgfS9SinIsNeuI8Dzvsz3BZigP3gOlas93qv2zyL+W4lijYLxMWHs2K5SDxVAlzFPGjC5hLKjOnyFecZ79G6V2b6jBqSW8kYhlXamHPVcAAD3xQBy/i3cJNRDJubzHPIAI+c8iuQeM4zyVxk/jXd+LhLc3UwzDGIp5MSOcbhuPAHU1hDSldc2zk7eCH4B+npQBixwBEyOQDn3+lSXtiZIgvCrWp5IMRVQI5h8u0etVGuRJGEkwrIfmUigDhpbQy+KVWEbw1wF+buc1zxjdcZUjNd5YRI/iSzkT+K5Qn3+ashrRWiVTGD83pQBzBGKSty40raMxHq2Rms+azeJiGBA9e1AFOr2i/8AIRT/AHX/APQDVZoWHTmp9N3JeqQDu2t/6CaAKderfsuf8l28M/8Ab1/6Sy15TXqv7Ln/ACXbwz/29f8ApLLQB237ZCQv8UNP8+fyv+JNBj92Wz+/uPTpXhywWzKP9PYD2tm/xr6a/aR0+4v/AIlH7Pbw3Cpo1pvWRc9Z7rp6dDXkFz4ZspP9fbtYSnjzIW3Jn6UAcStnaAAjUm/8BH/xqe00u1ubqGNdQkkkdwqqto5LN6Dmugl8IXcEq7pFmgc/JJCu4H684H1PFbkFhZ6FGFjG65lAEkzn53U/woP4E9W4LdBxQBzmvaDb2l/duNSXLTPki1c4+Y8Zz/nFZtnplvdSFEv/AJU5Z2tX2r+tdHq6S6hrtzEjEAzOWPZFBPOP0qxJ9k02zSWe2UxltkECn5pjnkn29fWgCxZQWOi6Yssl95ST8Z+zN5svsoz0/SuQ8ReJHv3eC0vWtrMfLsijYF/djnJP6VNq0k99dyXd9OA5BxFnBAA4Ueg9hXIOCpIk+Qf3R1oA0tMjg+3WxXUnWQyr/wAsmz1+tdJoGoovmWmqXDNEwykwgbI98g9K5DT7gx3tv5Ua8SKRu5JORW34f1OB7+CCREgZmKhs/ISfX0zQB6l4fntU07et6ZYhIyrK1mx2n0OeB61U8VyQCzBa9Lhnzu+ytjcfxqh4dvvs1w1vZ3D20p3MLdlxuPpzwe9dnFpN94kZLTT57W2meEzyLOPlQKccYB65GBQBw+jm6uSJ4reSe1tSMtHauu3Pqc8/0rq7uYRalaRfvEdwxVBaHzHdlbHese+0rUtD1+50y8lSa4iVXZo5SYypAPBOOxPGKnivrew8R6BqFwkhS2f5scjYFbLHvkD+VAF/wx4IvdZ8Of2jBqSWMpLpHHLbMSCpwd+eetcLql3qukalc2Gp6oILq1lKPF9lLHI7j/ZIIIPcGvpPyrdp5prWUtFOFmXYf3cgZfvr9RjNeJ/tCRSR+INEuLGPNzPYskjquS218Ln3A/SgCjpOvWd3EYr65Czr0ljtXXI9xnFaV3YrNEbiK6S4hcfPtt2ckf3sZ6eteT276pBdJIrHcD0ODn1FdHo/ieWyumt9QhlijkOS0YKsh/vAf4daALbaVbwPfTWd8dhtJfkNs5wMr055FZ0MVuyZGobQeoNq5/rXdWgg1W2nmhaMzvbyDzoR8svK5OOzDuPxrnNT01rKVXCr5Uh7dN3sfQ0AYJitklI/tHHPa0f/ABp+LQrhtUDcdfsj8frW5pumwX1td74282L590eNwTuR64PUelZ17pTRruZBOn/PWHnH1HUfjQBnNa2jZxqgI97OT/GohY2X9nalnUiSRED/AKI4/j+tK8SI5IU5/wBk80zj7BqQ5ORDwwwf9ZQBU0/S7OR/l1HBz3tXNfXngNBF+yJqkYbcF0rWFBxjOJLnt2r5W0FICRuJX5u4r6t8GAD9k3WQDkDTNZH/AJFuaAPm743qqt4Y2gDOnnp/10avMm+6tem/G45/4Rj/AK8D/wChmvMm+6v40ANor1DwDplhdfBX4n31zZWs17Z/2b9muJIlaSDdOwbYxGVyODjqK8voAfFzKg9xRIP3jD3NLB/ro/8AeH86HBMzAddxoAfIAFUYA45OOa27DZdRotoqbkGDHgbvqPWsVk3YA69OTV220xmu4oiZWdmAAiXnJ9DQB28Gh295oNw08Qgu1KAuqkFl3jkjp+NSeHfB1nNq9ssl3PKkjH93HGF3oOT83pjvU8TrbWV5ZG+vpreFYwxuE3LneOARhmH6VHZJeaXpjarp1xHLcEkNGoKskeeqj0J470Abus6hv0meO2aNEwzQnceWH3cg88A4Ge/SvNNT1J0tjb2283NwQ8shOX57Z9TW7r2qx3lkzxoIUdxJIgPzE9wa57RIy97HcyBQA+7JoA7LRfD6RadZvdr8yxD5R1J3N1NddZpbxKgWFRGHIARRnjoaouq/ZrZJZCf3IBHTPzNzWjotjc6u6rDIka/xO3IAzg8DnPpQBLp2qvqmsJpzzRxWzfvGQgM0gGcgDpyeT3xVrUdO0q71OFGhgFwimR5LYBoyCcYI7fnmuY8QeE/P1O1NnNJaaes5ge7kc7E4+XD+pPB+tdDG1tBqC6ckZs7hYgNpHyygYxsPfk5JoA5U6FozqTZNLHIcgXCxfIT7+hrnPF+j2kMFvGl4xxkktHgn3+ldZDKdLSezubUmFpBHMezgc5B/vDNV/iTYQX3he2vrSRWeFGw/QumRnPofagDx1wASAQR609CPJkB65H9ajoHQ0AJXV/Cf/kqfg3/sNWX/AKPSuUrq/hP/AMlT8G/9hqy/9HpQB+lNFFFAHgH7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18WKrMcKCT7UANpatW1oz5LcADpU626gYXp60AS6lb5+wBQObRGx68mljh8hNzKoHU5HSr+oxA/2b0H+gRHP4tVR5pG2orZTOBkZzQBZs5MJvkRMHnpWlDKcA4AyMnNU1WNio2AFTzjjdWxptl9qukiXIRjuc/3VHU/0oAt2ts9rGzk/M6bWGPu5GQAf5mt/UoA+rSMbqCMkRrhmIz+7XpUVxAs1s0iqxTJGFHLN2A+g4q1rUPl6huNlGFwiuzgkg+WuQfSgDa8LQ3EAzNDbT28gxJI7j5cHgevArRvolMwFlbWkigthvLALDH1rJ8Mwfv8AajwNIB80Lk8D/ePFdNqVnciG2MNqIpg5DCRgoYEcc9/qKAOZ0eWSBrl7/ebVCimKMBOWPXOPQfia6nU7CMuI7GOz3QyCMuwVHOMH8SciuR0yDV4tRezs5LG2lkZlH2lt4z6cfmD2roLGH+z9NWLU7oTzec3mRQwsGZsjO5m6Z9fyoAy9W09xrNyJz96dyW/hUbj37/SlitI408uFmLZ3BdvX3PoK1tSjub68fzSltGJnEUFsgDNhjzzSSTQWSeT9utLUscsZpd0h9qAMfUtIln2TQws869fLP3x6H/GuU1BI1y8Ue2UZ3K6kE+x969CsLm3vmH2S9tZJSeAsuA5/Edfaqmv2sd0jve2pWRfvkjGR6gjv/OgDzXSY1k1yxIVB+/TGPrVGCLamJQxXP3h2/CuoGhSRatZXVkTLB5yEg8MOeo9RWLbTJgbx84PHPWgClLbBj8hyAeq9CagmtSU6d/StKSFV3tFw2e3INMjlVozuHyE4J6igDnptPVmO07CD6Y/Sk0e0eLWYQ2PuTAY/65PXRvCHXcG8xM455xUen2oXV7cjkFZf/RT0AefyIAqHHUD2r1n9mS18r43eF5QxIJuRgj/p1mrgrq1QxxgKM8V6r+zxY/Zvi/4TcNlTJcDHv9knoA679qSWWH4oW8kEjxOujWxDoxBH7+59K4bR9V1C5tjLq6wNp3T7Zc/I3/Accufp+denftHz2dp8QJrm4s0u7pNHshbrL/qlJnu8sw/ixgYFeHXs91f3IuL2Z55OnPQD0A6AewoA9CstStorOQeGsyKxzM9xjzW/3V6L/Oufv9IW8nM9i5FxI2XhcnLNnsfWsW03IyyQs0br0ZTzXX6BdG8Ytcxk3H3I3QcE9yR2+v1oAptpwh1C6ikVl/etJO+OWBYgKv16D6k1wviXUHn1hmjKkxnZuBwqAdlPYD1716z42vU0uyFtujkedpJGd/4BkjcD2wMge5JrxnUoNOupVjtJJ7OMkYSRd4b345/CgDJub0CXbA+98Eedjp7KO31rKYYYjOfeugk8N3JBaG5tJCTgZfY35Gqj6Lfo2Rb7xjBYSKw+uQaAKOnozXsGwc+YuPzpYrSWaYpHgvk4wetWbS3NvqNsJpYgRIuQrbiOR6cUtrdW9tLu/fO2eSML3oA3LO5vRNZXUzBhA2xivJ6c5/CvoL4YaDf6bC2q6qYoWvLcLFbDPmKpYMHfsMgdOvrXhVjqFpdWtxFbsUuc7hG/y7xjnHYkY6elfS3hzWrLxHpEN9psyORGizR5+eFwACrDtz0PQigDzH4ueE9Yn1vV/EcbW82mARERrKRKMKFI2+3WuT0LSpBNbTXRbBSTai4YsQjdfQmvV/id4gsbbRb3SLd2l1KZwkgUHbFxyWbpnB+6PWvMNGnCyWyLwu6QBh/uNQB03wb1W5TVLjSXml/s9bXzbeGU5KEMM4PXGG6dBVH41w29uksklxskW/DoN3O10yce3Fdf8K9PjHhn+1LlFOozXUsSSNyQoUKE+nXiofidolpf+C/Ed1cwxtfxRJcCQj5k2EBcDtkE/WgD5xku7Zt/ySDJznOT9R6VtW1zHPsSOVJeAPIm4b8CetZ1lpZklUfZLqQgZYZ2gY+oqefQ7liJLSNpUOcpIQGH+NAG54cvJtL1G+exzGREzS20hIUkFcfQ88GvRrf7HreltNGjfZZfkni4D28n+eQehrybSVu1a5jvCmBbsoZnBkQfL09foa9C8EPBY3Ss1y11FcIV3KNqNg9COv4dRQBBb2l9pOrRfZd0lzEQ0bxrkSr64/MEfUV0z+G7bUGa5jnXSbzrJa/eBzzlCPuj2OcV0N7bb7QJEVhtyMxuvGw+hPp/+uufa5s7SMOQXuYThtvUYPtQBWk0Cyh/11lcTseQ8j7lb3GOKemlhbO7W102NCfKAxF1+f6U2TxXfElI2jsQScssYYP7kHgfUVHJLqd5aXRa/uUkYRlCJv3b/P2P8JoA09F025OM2TAZ5JSvVdDXb+zF4mXaFxZ66No7fv7rivF9DuNSikKPdXPmocFJTkg+mDXtGhlm/Zi8TM/3jZ66T9fOuqAPl/40nP8AwjX/AF4n/wBDNebN0FelfGPyiPDvM3FkQNyjkbz6GvNm24G0n8aAPYvhJp17q3wV+K1lpVnc3t7L/Znl29tE0kj4nYnCqCTgAn6CvOdW8GeKNHsXvdX8N61YWaEB57qwlijUk4GWZQBkkCq+h+JNc8Pif+wda1PTBPt837FdSQ+ZjON20jOMnGfU1Z1Xxn4o1iyey1jxJrd9ZOQXgub6WWNsHIyrMQcEA0AYlqM3MQ9XH86ey/6TL7Mam01YG1C1VjLgyqOAPUe9XmtbSS/uEja8LCRs4RB3P+1QBQW2ec4Tov4/lXQ+G9NCPcXdw18kdsvBt5PLYyNwqjg+5PsKpDS0LDa15gHnain+TV0tjpVpDbqscurFpEWSUoFKjJO3Izkk/wAqALOkWV3etOjXU0UjPFgzKdy/OMEt0x/Kl1PVpTq76bqCyQrGMRqWDKSMchgAe2as20dzpWjajfG41E7zGy7Sn7vEn93PHFc9qOo2eoWeVmuHadlDHy0DBh14zx+HFAGNrtz501xKoy1xJx7gd/xqbw/KY4BLLgqjFRx27msu9ltpLvO+fYnyj5V4A/GtqFbJh5du1yqhQwXy1I5/GgDure+ikt7SJ5lDeUNsh+6fmbBJ7GtfSr1tNvAQscbAmZHkOFQfxZx19hXnFy6af9heOS6QtACPkUqw3NwecGtnSdXs7q3aNnuPkOWjKqTF/tLk8r6igD0m/wBWme2ku4lM1pcLsVJFCmdv9hey1n6HfaZp1vPb3Vlb3nn7I5bOeXYYZAeGiflgcHkdDWAmrrbSPHc3U6s3In8tX+T0TngfSok+wz39o4WWMs6mOPapPX7xOaAKMl9qWjWosbSBblln3yM2G2DkqVz3weT+lXdI+IPh+QT2Ws6b5Nts3QzIpZllVTnI7qxAXHbOa0tD0OQxPLcXcyWrfMWukGCAQc7c8+1c38SfEPhqSwOj6LpcSTCXzJ7zYGcsPQ54J7gfSgDzA8k0o+6ae/k4OwyZ9wKQbdjct2oAjrq/hP8A8lT8G/8AYasv/R6Vy3y/7VdV8J9v/C0/BuM/8hmy/wDR6UAfpRRRRQB4P+2QsL/DbR1uvNMJ1qPd5WN3/HvcYxnjrXyOkOkbMKurfh5Qr7D/AGsraC88C6FBdvLHC+tJuaJcsP8ARrgjA+uK+ZU8L6Q65h1i7Q5/5a2hYA/hQBzscOlbgdusYPHBhp+NIGB/xOB2wDDXQP4KvpyRpmpade+kSyGJ/wAmrCvtJvNLm8u/t5raUdNy4B+h6GgCbWf7J26dj+1MfYYsY8rp82Kzo/7M3BgNVOO/7qtK6sPOGnbhlfsEIPOMctUtj4dku2Gw/uckCQ9PegCtbrpjyK2NUyOSf3Vdv4Z0mzmtyy/2nEjr5k0rGL5YxyF+p6/lXNaPoU13qi2a48skBpByAvfFdz4n1W38O6E8qIrO/wAlrAT94DrI3t296AKeu6xpOmW4NzNqFupT9zbxiIyN7j0HuetU38eacutS+dPrCwSbC4kjikT7i9QOa8umku9Uuri4ncyzykmSVzwP89hXRDRIbrUZEP2kqAgM0S7sHYvUelAHp9hd6OLiF4ReFbg4UxNFskB9Pp6V1shtRpiWqNqU0SuGBIj+Q9No9q8i0fTLy3tw0TrNEJM7Cu3BH8QHbOK9P06e1v5Y0N7dwicYVnxtz3QsOn1xQBhXEmnWGv8Ant/aW3eSSRHwCOefoTXT+HdXsLy6k/st9Ru2SJYQ4gTDBejc8AgdzXPeJ9It7e4WWS3mkkA2sszblVgcdB1rb0W+lurS3afJeDKxnGFKk52HHG0jI9iBQBz/AI01OMahPa28moJmZ1YRNGWYljnLdfwrjzb2SXKLcf2izY3eUvllm+pr0DW9LRNd1CK3gZJZGfaoIyVJJZyf4QPU155fwOsssFhKqwEkNcbtzS//AFqAHSarp9jLnzL6GVSCqRiMkY7V1ej+ObB0ha4u7+MMcMZ44yB7/SuINjb21ujBFmuGOA0mAFOOcCn6ZcuhurdjbbHAdUIBQHuOaAPV4rPSpdTspo1uLUTOrRSRMjQTc9Bz8prkNX8P2sYaYxaiCOTtEZDf4NVLRL2WyvLY2kflxNMu/wAht8TAkZDJ0Fd54dvoNctY47OQC/Rflgc5MoA6KT976HmgDzoW2msRhdRBZgNwMWOaTU/D8Onl3H9qPGhwxTyjs9Mj07g9K63X/D4jEl7p6FYA2ZoMfNA394D+6T27fStLQbP+37UW0xe0uIFxBqHSLH/PNz6dwe3TmgDytYbFTmOXU8n08rn9at6U9k2pwAjVGcLIACsZP+rb0r1SbwPZ2iiTUbNtTdsnzbcBY/zXk/jWppGhtBJF/Z+mQWkBDAuI+QdjfxE0AeFJpPnojLYa1jjkxxj+Zr1L4NaV9i+JfhCXyL2LN1Ov7/Zg5srg/wAPfitWWJIAqXurWML9SDIGI/Kuj8K/ZT458FG01CO6/wBPmBVQeP8AQbrnmgDl/wBp1N/xMjyTgaPanHv591XlSxA52rnHtivXv2jxCfiaPPMwxo1rjywv/Pe69TXmsEFrglTeHPfan+NAGXDCyznYOM4wvVvau90a2TSdEklnxvXPmMem4/wj6VX8PaXbk/aUF0zB/Ljyq8ue457f1qr4ku7e6ujp6S3X2O1chmjCYkk6MBzzjp+dAHCePNQurnWJJIZGS3Mrq245DsG4yPp0HasS0v4hIoa3Ak3giSLnHrwa6jxVFYSyXnnNdwwxzMwcqmM5PTnk1wt5dWhzEhu40HXKLub68/pQBu3V/YhWjjnSWX721jtXPuf6CsK9W6uTg/NHjIWIfL+X+NVN1kMDfdYHT5F/xpY/so3eTJeKQM8BR/WgCGxU/wBoW6kc+Yo/Wmom6ZQe74/Wr+nNZvqNqZHu2YSp/CvIyPetDRha/a5DbJdEqfvGOPj8SaAMyOKSW6Ijhd3dwEUKckk4GK+kvgz4S1jwsdYk1uK3RbqGBIfKmDlsEk5HbGcc15lo1tZ2uoRX0r3LvC6ylSYstjrgA179ompaZrMMk+kXouREqRyJtKsnHBIPrQB5n8S9B1GDVr2/eJJLS/uWaF0fO08YDf3TgHjvXK6Tby/acXIWLZucBW3E/IQa911660RLUWOvywtHOwbymBJG3oxxyuOxrmR4W8J3UvmaVqzQOwZdgmVgdwI6Nz3zQBj/AA016K2sLbRrqKQwzXIaGVTko7How9Ce46d6k+Nmtto+hpp0ER8zVB++myABGjD5R7k4/CsnUfDreFZNMvDe/arOK8iH7ooGB3DsTzn2q3+0ItvLBo0snmHZPKmUUHqoODn6UAeQNqF0saOCELkk/N1A6ZqeC/tpXRbmL7O4OBJFkoT/ALS9fxFUNy3cscIa6AC8DykCqPzqC5gikVgsl6zDjaAmP0NAG4YYfMvJJpEXNvIBIhGOq9PWmaNqzabejYnnRMCXBOFf3B7Guf0t7WMXa7ror5DhlKrxyPeug0i2spLEyJ9rljl4YFEyvoDzx9aAPWvDGqJqtgILuXzLeRcBhxgeuPVfSqupWDWpfzVxIoCPjo4/hcfyrjtHu4tEuEcG9NvMdp+VOCO/Xhh+or1oWsGqadbuDI4li2RuAuCO3f6flQB55JAWHKHkdfWrmhQvDY37rsZMxAxOMqfm64/rWm0Nq0ZBF2CQQRtTg9+9WNFFrEt4jfadj+XkFVH8X1oA6DStCXULOG5XEc6jgn5io7Ke5Hp3rtdKQxfs0+Ko2+8trryn6ie6rm9CksUiJaaeOQnChlXk9OueK6ix/wCTcPF3X/j31/r/ANfF1QB8p/GHkeHD/wBOTf8AoZrzo9BXofxdOV8O/wDXk3/oZrz09BQA2iitDSbBr25VApIPYd6AJdAsprjULVo0LYmj6DtuHNal7pdx9rvCYjgTyck4H3jXceG/Dj2qwvLCUZZUAAYZ+8Dzz+latzpN20lwVkSGMSuclunzHsBQB5np2hy3TFC0uGyAEbaucdyev+Fbz2V1PYQW0Ny09w5BRtu1mAGMqTwB2HGe9dQuiahGhuBdmeExMrebGFZASOF9yKx9Re+0ma9unaWC33iMAp5inpjLdsj0oAyX1aZrPUbPUJbkT5iVXm+9kSDK7h2/SuSvbgtf3s4UKfuqFGADjFb2pXcdxZai8PlyROke1Qdx3b+TntXO2um6hKS0drKQOTuGP50AUpE2qhwRkZ5qdbllRdrbTjafpWknh/ULht0piT/efOB+FLL4ekgDGWYELz8q0AR318rWemx/MTHEd3PH3mxVKS5ZJo5oJdrryCOoqe6tYwlt85IMQP8A48w6Cov7PmYZit7l/pGaAOm0bWYr6H7JdYic/dI/hPt7H0ro7Hy9ASK/uEE87XKRW4kzsU92weuPSvMjY3Scm2uFI6fIa6TStedtPj03Vo3YxzrNbTshZkI4KkdwR+WKAG+J/F2p6rGiPcukTZyqHbv7ZP8ASuTqW5k82XIJIAwM9ahoAKcPutTaUfdNACV1fwn/AOSp+Df+w1Zf+j0rlK6v4T/8lT8G/wDYasv/AEelAH6U0UUUAeJftZXE9p4F0Ke0KiZNaTbuTeP+Pa4B4+ma+brLxdqEJH2m0sZ174hMbfmK+nf2m7K41Hwt4dtbNN88msrtXcF6WtyTyfYGvCT4Xurd8X09vC3XaJVP60AV4PE3h/UAE1O1ksZDwJMb0/EjkVsBGNmMCDWNGbqoYOUHqD1Fc1PpRF0YEMMsg4+T5uv4V0OhaPDocq3l/frYynkWsC5kce4PAB9TigChdeC59WubWXw+GktFs4t8ZOHRctwCeP8ACnXnk2dudP08AzN+7d8EY/2Fzzj1PeuxvvEsN+LW1UNp0ZhjdFQ4Unn7zDHP6U+3shdyNcatax3ODsilQ7XYnqQR1/8Ar0AczZWttpNo1xcn91ApaVhwXY8BV9z0Htk15x4ha71s3l7dnYjMrMR0VVPCL7AV6t4w0m0muLawg1J7eC3JaRJoyyySHjG5fQcdPWuF1qwuEj2rNp1xFghI0l2eZ26EfdFAHntzcLFb7UzFDyEUD5nPrTdX1K6a/YRzSQIAmEjYgD5FH40ajo+opJK08O4r1cSKRj8+lWrvQbufUJN5SFPkXLHJPyA8AdaANLwl4suLd2ttRmkngY7lZuWjb1B9COCK9D8N69HJdS2kphurZ182DeuMMOwx14rzq18NxnbLBI80i5b5uN+OoGO+O1ej6Ro1stjbOCUQktHIny44ztoA6nX5Wv8ATWuYZEkuFxlEH3s9K56Ea1uiglum023k2hi3BYBs49etdr4Yc3FvGHs7cxSM0EzwqFZAeA2R+FYfiGxlt7iEsWYxyeXubOW5yM/rQBp6lbLLa39r8tokkjZYnmYElTubvz8w7V57rDR2ulstvIokc7I0ROXI4OPTJ716RbOl1Y6jbSAsIZpJYtgyfvHcv48GsK98NxtFdXNwH81cDyYwHKLjBb3OaAPIhZXN+fNuma3j6FUHJHqCauWej2sfmMIXuXUY3SOcc88AV1d5odtCjXWoX08gXlsKFYjsuPXHb0rMWZJEAs7EJADkPK3mHGMDPQCgDOtLa1jv7XyYp7GfzFGY3ODz6HrV/wAOrqcjLK8DCNWDC+iHllT6lf4vqOa0tKuNSjvIPLEKxFlAjKKRjPbPNVbbV4fNU3W6yuFHVmJiPbv938cigD2/RJrXV7OC4vJYLm9KlTcRjEbkcc+v48iqHiCz+zESXjiK1Q58peFX3A9PX0ri/D3iQWDTG2hBYurPzmN+MZHqfevQYZodc0xJeJmjOPn5+qH0OOnqKAMBfFElohTRYFEZP3pcnYf9nuKy4NSfVdSi+33Lyvh/luGIP3G6MOKXUtPfTrs2yHfBN88Dkdu4+oPBqktmEvIicZ2uenH3GoAZJoDnyzawsrkBvJfGWH+w3Rvp1rq/hzEF8feDmC7WF/OpGMY/0K64PvT/AA1bvCsOyXdZKis0TjKHp0B6H3FdpHFa/wDCc+Cp4VXzX1KX59u1iv2C76+vNAHC/tExeb8TsYzjRrT/ANH3VefpB8ixxjk+3Br0z49xmT4lygZyNGs//R93XF6LAZNVtIypI81M+/NAG7JH/ZWkyyISv2dfs0RHGZSMu/4f4V5jq9xDawCabcsSNshResh9B7epr1jxhHAuhmOVtkMLmQuOMknBH1Y8e34V4JrUtze3zSXI8lMhFH8CKD91fX6/jQBmeKL+TUb65eRydkjBYlGBH83Yf1rHW1eXYJyI8jAPVjnpxW3qMTLe3n2XaoWZt8p6Dk4yf6VlXF7bKVMMReXjLHhfwFAFcw/Z3yygY45OSfpTJXiUDjzHP3j3/Ki5uRPMzTbihJwO61WYjd8n3eg9aALFhK6XkPlfKTIvI69au6Na/aJnM8RaNs/Oe2OtV9Esp7rUbYQxlh5qcnp1Fel6XolrbW1v8/3M5ZOQWPU88UAc3o0Qk2bYyZiwSNAOTk4Fe+/Cnw/qugprB1qzW1E7Q+VhlYOF3ZIwfcV5foy2emeIbO8Cl44Jw8jZLnHQn8M5r37TL2x1Pzp9Lvob1F2q3lNnYccZz0zQB5p4g0a+sfEN3dX9ui2t7evLDOjhlYE8BvRsdjWTrNskuspsQMilwhVcdUP5165r02kwWqWuuvEI533JG2Scj+LjkAetc/eaL4b1GSOW21YRSqpUfvgR90jo3NAHjV1bJa/Z5Js/aEdDsBzjBB5r0T42t/xTNrKDhvte5WA6ZQ81zHivwfPpVjNe2mq215AcKwDASHPfGcHHtXYfFOMf8IXbzN8+yW3bK98qaAPn2bUYlVFAklbbhtrEfrUcXlyIq2kr7wd5ifAc/Qjg02/iDOxhUBZCcFR0PpVCW2a3gSR0JJOAwPFAGrBZmdbqcgLIYHOzoWwRzik0y6ltr1ZUfbIPlMbA/MPQj0qTTb1riO7e5O+7Fq48wnhlyv3vcetSBftoUbTvx/rejf8A6qAOktpYrwxSwlntvuMrdUPcH+h7ivVPhtKz2V3prPuSMia3YehPK/1rxfThNpkwfaHjb5SoPyyr3HtjtXrHw+lSGQzo7G2l2oknoc559x3oA2detvJ1KR0UeVPlsdNr/wAQ/HrWUUK212ykBgYyD/wKu08RW4IuM8FVSYcenXH4fyrAmtwtpdlMlT5f4fNQBLobCdA7H6g9vau90gAfsz+KQOQLXXf/AEfdVwOhQ5JHq3NegaaNv7Nniweltrw/8j3VAHyb8VX3roGe1mf/AEM1w8kZWCF+z5/Q113xDu3ll0pBsJS2zxGv94+1Yk88psdPCrDuIkzmJf730oAoWds07gAZya9F8J6WI2QRjaQvLkc59qZ4N0ydwk86RBWOAvkJnH5V6dp1pFCqghVbHJMCj+lAEWnwSebbxhRIEZT93nryc+tb9tZ72kzZjh2JYsDjnqBUlmoLoFkT746qPX6Vq+Vsjfbgvk5BxzzQBHPZCeOOOJ/JfoSUDYHpzxWZqGgW17E8F/pcsobpMg3nA6Fh0PT0rdtWYHlRtHPHar0LncCn3u/oaAPI9S8C30CXMOnacyRSCNgwIRCQ/UZ6cVWfwdqssSwSm3g7mQyeZx6cV7grLtbzFB3YJXA5qlLZuzboxkE5IIGRQB5bYfDeGQ7rrUJ3x95YUCD86t3HgjR41H+hecRzmWQsTXpC2siIAoGc5OFFV3tX8ws4O0cnEY/woA8Y1n7Fp1yLSCxMk8abSEUKqfM3BP8AhWS93dg4k01CB2Vz/hXoksC3O6eVU82Tlcxjgbmz29MUk1ko5HlYAGfkUf0oA8xvLoBCzafOpHXDjFZkdzNLf26paqoMij942e/tXp15BGqnLRYPBwi/4VjWyBdQiXdESsoH+rTpn6UAeU3drPN/rY4Iwe6rj9azrqxlgYgjI6j6V6xPErA7nhHX/lkn+FYupWz+UWjeJgD2iTP8qAPNyCOopQuVJ9K6mVJN2CIsf9cU/wAKie1uGs7gBIvvR4PlIOu72oA5mur+E/8AyVPwb/2GbP8A9HpWY2l3O0ZCg47KK3vhbbSxfFHwjvCgLrNlnj/p4SgD9HqKKKAPNfjhC09p4UijKh21g7S4yM/YrvGa4FNFtrxi2qRTokILzO/7qOJB1YuecfSu3+Pkhi03wowDsRrQACNtJP2O6714/wCN/ELT26aOq3EtvGweXNyfnfHC9OQP5/SgDP17xLaRTSp4Xs47O3PyLdOuZGUcZGeV+vWuRhkfzHPm7y/32bksfXmrEjW7EbrOX/wJP/xNTwW9qcH7FKcf9PJ/+JoAtpE93Np0Ck7pLSMeuB82TXe6P5lhbSGAhbeACOKN+VEh7n6AFjisbRIbdr60ENm/mGwjx/pJ5BJH92tPx7ewaN4bjtRGxaRy0hExG1SMFs7e/QD2oA4TxX4osmdZpopI40bZGUOdx9u/Pc9q5ZJP7QufMt5opGY4Yk7dnpgdgPSs3VpIb6VZJrKVYx8scZuj0/756nvT45tPFpvurJ4woxk3Jz7Y+XvQBHqemNaDcweSUZBYjj/PvTNdu4YtUnSV3kkCptRG6ZjXOT0H4c1lajrUT71gt7mGLoy/a2y314/Sl1e8tpNQZH06RyETlbjH8C9TtoAll1a+WKLyJFtwo4VOSPxNbeg+IdXtFWKO6a5jYANDMvmKcdx3BHqKwIRp0yxBraTd08v7UQ3X/dr1DwdbWgssWmktGx+8/nktkerbaAE8O6lqKXvni2nVX4kjBIXafSvSZrOfUbeMeWsBmADCcgBmBHT17Gs6zWDzlV7V1lZcMpusHHqOOTWxLf29gltDdWxfex4a4PQ45BxQBk6LBBYeIr23bzkeaSVHZsnkscH047U+Wb7MzrFIBcr8gJ4yR1rqdRsrbUJZLuO2Lbi4Ledg5XOO1cRrcF1JBb3MFlK1zIu2Qi44XA4b7vp/WgClq2mQXc/myOsV3IS0hLnHTk7f8Ko22kwW3nW05zIx/dwqvzOMfeJP8utW9PubK1uikMDSG4j8uSZpyfrj5expPEt9bw3AkEJlubRdw/0grk56Z20AY0s08TWiQWwAeRSWPzMTurgrki8IS6k2upwspHTPYipZtSe/1uB3hvA6yglBOV2c9AAOMVUt9YRmWC8smueeW8/Eie+dvP40AaOiz3WjKqTIDBK/3WOUYDjKnsf8mvR/DeutYT291ZM0kTECSJuuP7rDse4P5Vx8E1hKkccdq9xa7AA3nnCgdQRt4PrVmDy7PUllsrWTcowYnuThx3H3aAPcNU0+31CxjkhbdaTj7Rby45jOORXNQ2QW7Ecq4kXerf8AfDdK2/hrqtteaXLZCJ444ZceXJIWZN3ODx6/zq9f2EcF6jtbsTCGTcZeq7Tg9O3SgDB8OXZgsWtpQP3ZBXP92up0++N3438EIIYo449Rl2FOuPsF11rkHWJdjpavuHfzz+vFdH4flR/GngkLEUP9ozHl8/8ALhde1AFH42Rh/iRdZxxo1l1/673dc74Zs9rXF2Rjy12pxzub/wCtXU/GL/kpd4DnB0ayHT/pvd1DoFp/otvGADunLE+m3FAHI+PpvtN5DYu+yG1TdKBx5kpHIHrjp+deca1JDHCst8gS1YgRQp96Qg/w+iju1dj49uoTeXV1Ou+FHMcUOf8AWv6fTuT+HevKb2W81G6eWfbJyN0p+VU/2V9gO1AGX4nu5bm+uvljW3jmfbCBgD5jz7n61kw20snzRw7QO7HH4102seVZXUzwxpJLLK+1254Denasi4kmmZvNfBUYGMYx6GgCq62ccmZTJO+fmVOFP41G7qJCsMeCThRjp9TTGIZxHDHlzxuBz+XpWnZ6TPlR5eVcctnGR7HtQB0HgRYItQt4ZBI8nmK2yLnPI5J7fSusuZ5IYybWK3gUEr84L5+meKzPCWn/AGW+t3tArF5FBwPu8jIzWpf2NwbiOBZQMnLCP5iAT3oAwmk1C5v0tUEsss5Aiij+XcScAACvafgzoWp6HaawdZsLizM88JiE3JZVDZxyc4z+tcLoJtLXxTp885VI0yplf+DIwG9h7+9e4afPb3guZrO8gu4tyj90+8RnHQ+lAHk3izw/qdhqtze3ihrO7uXMbxyb1GWJVW9DjpVO9tlMcT43K4YNxgg7GOK9k1a2sriwNjqcqRC5OEDSBGYg5yufSuR1zwTdiEnT51uowSwR/lf7rDg9D1FAHknhbw9da3qb2GniISCJpi8hwiKBjr15PFex69oU+r+GY9KV7dJisIYuxKZQcrx6+tcT4I1O08L63cx6rbTWUbQ+VI7KWdGHIJHofavRn1HTrbR49ReeT+z9iyCVULEhj8vHXNAHgV9oE0d+8TqgXzfKI7KeQVA+orjdSEJusSSo67doUcHrz9K9P8cOmoT6reWLNbC5Yz+WHBaM4xk+hPXA6ZryCKUSxBZ40DPwsh6E+/v70AEUQjlvduVRrdmXPpkVe0i7RX/eFQgBwSas29tbNHexPFIky28jhmbIVcrjHrWeu+BvLkjV5c5VwAQB7CgDtLOB7mNI44wLYfKS/T3x7/Su18LldKZLZyzafKeJCfuv/ePofX1H0rhfDupyxMi3ZPlEY39Ntd3b3sWwxxjzkkxkjlf94GgD1VYvtljbk8ugaF/cdP61zUcLLaXCMc7dik/Rq2/BLOdCijdvMaCUqr/30wMH8OlQXFsIZ71RnaSrL7jdxQBU0GHy3AIPJ/8A1V2Nl/ybh4v/AOvfX/8A0ouq5/SE2A+vfng10Nn/AMm4+L8dPs+v/wDpRdUAfKPjnSfs2g+HJypE97C0rHuF3naPyrL0LSHvm04FSIkEhJPs9eqfFXTvtFj4dES4RbcxoMdBuql4c0lN2m28asy7ZF4HLEycfrQB0nh/R0hs4nbCnqBjPHv710FvYh3GMsew/rWxZ+G5Ibsi9lR7UR4XyJCDu/8Arc/WnQ26xRlVZ1Xd3+8fTNAEen2qxEkxoQOjEd6S8u4YztdgzZxwOBUzTLFMFBB5AwP8ary2fmSu4AKtkbu496AFhn819qn3OKuwOT1GCDk5qh5EcKYRduBkn096l0+4MrbidyA4U9zQBroBznHSlUsGJ702BgVJ5+lSgZGMfWgB5IJGce9IB12swyO9IF9O9OGV70AZxSaAheGUDg4z3NRyO2ckRtnsYxxWtJtIGQCPeoHWE+ufagDEuGiYHdaWzZ9Ywc1zWpPDb38AOnWQ3sBv8kZ/Cu1uIrTb8xkH0rG1TT9OuY1LzzK0bhlO3P4UAccbqJgcWFj9BCKoXUtmx2yaZZnH+zjNazWWjNgpq0y+xhqrPpGlO3OuAfWOgDDeHR5wwm0iAf7jEVQk0jQpYpxH9rtQSmdr78HnHBrpR4dsGP7vW0bt2B/Wmv4WgZHVNTD7ipyNp6Z9KAOPk8NW7DNtrUOeyzxFT+lT+CvD13Z+PvDN209nPCmsWG4xS5PN1GOn1NdI/g6RhiO8zjpuTr+tS6F4ZvNO8U+HrqRomiTWNPyRkHm7iH9aAPsmiiigDyr9oR/L0fws2cY1sf8ApJc1896i4kvbh2BUmRuPX0Ne/wD7RrbdA8MnGca0P/SS5rxC+sDJIsyjk+lAGfZ2fmtufj+dav2cfKqgHjqB2p9rAygAAYOMmtfR7J72/WAYCsfmbHRR945+lAG14ds47UW97JwrWSKSey88D3J4rmfGca6lcTLcOUjdsgjn5x0OPRegH1ruPFEkVjokHlhVmnjUQKP4FXIDfh296841vVkghSPYJdRZf3cHXj++fb+f0oA868QRxaUxN781wWykS/x/T0HvXI3jS3cnmuQ+eMLwsf8An9a7PVrD7US2ozfaLuQ7gn9Mj/8AVXOT27WbBZWUluBCpwwP8qAMo20SxnzGaV9vGBhR6fWtLWUiW+lDTptxGCijn7i9BWVc3EsoP3I1Axt7ge1S6gpl1CUgkH5Tuk4/gGOaAJYbiUzxLbwhXRtqyFdzcHP0FeiKL3bDNcfaQ78uHchQPXjiuZ+H2hG+1VbiWQ+UjAgL0f1r2v7Cm1p4bby41XH7w4z6HLcUAc9ptrc3jfuLVyDjazjaBj3NbUthObiK3mmkZEcDHOFPfGapprKwK6veI7HgpG5dh+PQH0xW3ZarZ3SCRPPlUMMsFwAe3XvQB0TTLZ2s0ZeZikrswHYbjg8c8etNuLgTQ+TcxpHZ+SrhFYAqSTwMe/r61h6tquy9uwFdQrvjrnhj371m6ZAz2UkkMzC3mjZtgHdecZ/OgDK1GRYJ5Vi2CT5mCMMFBj19aqT2c12zwxRlpJQCXfoDjnNaM2kpe6e5QTNfk/KvRNo61oiGZZgY135h8tvLHOcdzQBwn9lKut2Mb5N8sgDbSCpGeprIvNGCLvuBlHOZHP3lI/hHvXqkUCQXdlHMI/MO3c+35lOc4z1J968x1zV7PUtUuI51NnKjkLEGzG59Se2euKAMiOR9KmMrZkgnBKDPMg9x/OtnS71btyGCgk8Yz61VmtRcSNb3bD5iMDbt2Ad1PT8KpC2n05md3yhbAmU4U/4H2oA9c8DXcsWoy3KlRIIRk9nAb7p/WvYNsV8kMqA+VcxlST/AdpHNeI+A7qMo0V4UilucbN3QgdMnsT1r1zwjOWnlsJTtIQOv+y3I/kaAOea1ZFKOMNG21gexrW0KMJ408FY6/wBpTfT/AI8LqrOv2pF15+zaw2rIMevQ+/OaTTE2+NfBJ/6iUwJ/7cLqgCj8WGj/AOFqzxyIzbtGsiMNjkT3ftUui4XT42VGDszOMtnHoen41H8WYzJ8UrnbncNGssfjcXdLfHyrG8Eb7FKrbq3p6n8qAPKvGcUF7eTTiGX7FESi7ZQMnOSR8vc8k1xGpGyEUbvbSrAvCKsw5Gew28/WvQ/EVzDbw+YwC26fJDF/ePf8PU15ZqKzX147IGeaQgBFO0YH8gPSgDM8Q38JvLgCydYvOcDEuCefXbVLT7FtYkAgsZ2QHBYS/oPlrcbSFvNamS7czJG7FlXhRyTj3rs9LtFjtuI0jgUgKqLhQfYd6AMTSPCtrbxgzJJFkcgTBi31O3A+lbFnpenZLNZTO6jrLMTjnoBtxWlJDEiFHuEfIzkAj9Kr3N6sZXyCzsBgbhwB70AXLAWcVzAWhmUiVcRiXJ4PXG2q0N1ZxNJKLKRg77WLTgkDPstJp9nMZLVoQ7KZFZmbjPI9adBaQxxOtxKCQ+7ZH6fWgClNdRTzzv8AZmRD0VJcHGf92vUvgjHH9h1UxxNGGvIQQz7s/J9BXKeFtMsrvxHBA8atFku0bj/WY6A+o9q9e0qztNPSeHTrKGzj80FliXG9sdTQB5P+5vNVvVmimkcXEoAM2Tt3nsRwK2Lf7Vp8fmWr3MKKpICz5X7pxkEY613eraMmsQRNkR3URykojBIGeVPqDWbceGrwjassDx7CpGGXPBx/OgDxTW9cN/qUjag09xqAAjLBsADHAGFx3PPvXo6+X/wqy3dYJGVLONgm/nhh3x+tZ9p4Hml8VWsWsQyRWRgO/wAl8eay/dG4dPf2rt4dJ046MNLWGQ6eE8ry2kO4gH169aAPFBeh533aTKkcinJ8wEDPGenvXmt0IYmltZLV0cOR5bTAdDjI+WvdvFnhzTtOure30u5uJrqTfutGYPtGMjJ984wa8k8XWoTW7pm3bGYptY8owABI9s0AYuk3MNu13HPbybBA/wAwmyV6cZ29PatK3SzmEiJFvYnIX7QAoPqPl4NZy2sjT3kM24Sm3crj7r8jvUcZEBiSGJIxt2sSf4hyQT60AazWccbCXy5biJT82LgYQ+/y/rXR+HNSs7cpA8M5ty3BWYMyZ7qNvT2qlpMU00X71RGB8y7cDnv/AJNbenaRHGyyWSok+M7c8kf7PpQB7R4TRLe3tINpCsCQ3mBhlueuOR71Y1BFS0lkaJw6sEI3c/ez6Vy/g7U/9HSzmGx0P7pT/C3dD7H+ddrraA2E7DGSYyxx15oAztNMQx+7cc9N+f6VsWn/ACbl4w/64a/1/wCvi6rC07qV7g/nW5Zf8m4eLv8Ar31//wBKLqgDz7xvYl9G0dhtLCNgAWAwCevWs/QYprOXT5LcJ5qb3BYgjhu/PSt7x0M6dpw4+QdfxqbwlovnW1reSiI24eRGjJIJAOR+GaAOpmm8u0jnmRY2dQWRTwGNUbiUyWkjy4yuNpHB3elaUyrOwDqjrnowzVG6jtBGUlkfaCSVSgDCtoWluY342BhkKRxzWswyCDjGTxmhJtPjKskcjZIGcgVXury3Xc0SopUnJJJJoAbqMYaIwqwDSDqWHyj6Uum2nkRkyMGJ9CMCskyrLdeYsqMSMEelb1k4+zrkAsDjJGKAL0KkDpweas7SeeKqWyHcxJORyfarSEdvTvQAqg8nsKCO2KlC/MBnP40hUD6UARkHNROnpVh14AHamZ56AUAUZoN3JxVGazL8ccnArWnLhcpj8qqNJNuX5wPm9KAPJrywmtrp042knA3DHv3qvJaz4IGzB6fOP8a1PiBPfWN0LiJo/LPzj5Bx2b+hrkn8R3yqcmAjHB8ugC49nIf4UPp86/402OyfyJ/9WAWTpIvv71R/4SO8X7yW7f8AAalj8QObeZnt7c4KcYxnrQBYW3uoxgS4I9JwP61oeG5bs+LPDqS3EjR/2xp+5TKGz/pcXbNY3/CSKVy1jD8o52ntWh4U1iC78YeHIltTG7axp+G47XcRoA+3KKKKAPJ/2iozLoXhlB31kf8ApJdV5rZ2omtBEytvHHTk16Z+0LMtvo3heWQEoutDIH/XpdVxFptDiWPBWQcYPWgDENoISQT8w6e3tXX+BdKWYTSMo2vIkIJHUfeOP0/Ksq7g3ypjkHnH+eldv4btxbWsVtwsqN5rn0yOT+HSgDgPHt+v2wT7AZ5IlS2hY4CKuRub/ZHf1PFeU3sTSTzOkqyOx3XFzKcfiT/CPQV6h46MF9ezSzKscSwI8rt/yzQE4APcn07k15DrKDURsh32mlIfkQ/emPq3qf0FAGPf6nIr/Z9PkE8pXDTlSH/D0H1rGgtlmYG8n25bACfM2c/3jxWzLaeVaEMskMG7rH/EPcmsSW9iiQizQ5PAY8n6mgCSbT4rVZC7xo2CQern8e3ao9bjWbWpI4syTNsGAOVGxcmqiw3d1vijUqrDcxkOAB7dxXead4Utv7Qla6aVyNm5lYICNi8DuaANrwUoW2QWSbZIkyTjLjnp+feunvYdQ8wSyJ5u/BDXMmDjucd8U7QP9Dkghgt44bcnBYDGR7t3q5qM1jqGoIiPLIkQ2kxjAJ9ifegDPbwt5rxzyXAWCXOI0U8nvjNaumWEGm4Up8kjhMNyQ39769qTW3vLfylMKLHjMXmSFiPwFZFydTkRS1wYiWBIGAD05HegDqdUsFN9cFbbzCZHOSp4+Y9KrQSQ20UP2nZDFFLtaMg52tkZAHoeefSqV1Bdsrzm6lcGZwwLEBcMakj0qVrcTMzSIoDOjdDg5x/9egCSfUPLmCIXeR48goQBzx+RxVODVA0ckAjljVtuVBztYfz71N4i1G3t7m0thaH5BuOxeqkZx9abo1wl8XKaRMbZcAyvIFOB6igBt5cRDUrXYJHmaRcMPuY3Z/CvG/Gtk2n6/cRvCEWRRKoIz8p6H3r3afT7+a8tri1a3itxImFUZwueNxPU1x/xK0F30WyvL2VZXgkaMPCDgIeQDj0OaAPMNJvLuGIqUaey6EFuU75Q9jXZWMUOIyNtxuxtLjhR6Mv9761xs4nh2MzZhB/d7Bgg+pqzYXSWExkDs7ufnTrmgD0a2tESN3QYzn5Gb73uPX6V2Pwy1hp9V8q5LGR4ZFjc8EALwrflwe3SvMtN1I3yo82NqHjBxtHbA9a7/wACxpNqM0jHayxMiuTktuU8H6AUAev3kJu7SJip3PHsb3/+vWJYAjxj4JDfeGqTA/8AgBd1c8L373Fu1lOcXMESyqSeWTOM++KW5iEXxB8GkDCyanK4H1sLugDM+Iq7vi3L/wBgqw/9KLus7X1J0dIicfaJHdiegAPU/QCtP4irv+KtyAcN/ZOngf8AgRd1h/EN2GiCOLAeaV7cN/dU8k/kMfjQB47rV5/ad+wDGO1QbI2I5VO2R3J61UnRFVbawXAkYLuH3mHck1q3kSNmOPasMaElm4J9SazNGjae4DQxf6OTsjBBBbn/ACcUAa62UMM07Rj955rDcehOT0/xpN8z/Lyf7q9z9BXVDS4WmmkvC6x+Y3yKeTz69qnS3jAH2cRxx4znbyB9TQBzX9nuNqXKiFFHzc5Y+1TW2ll2EiRYQn/WHncRWlK0EEhllw7D5snqazZtTeVnEbPz0BOAv0FADri4SO9tgXZn3qNvXv6VhfbmV8W0MasCTJJJyQP5VLZqx1GEsS7eYpbnOTkVFb2L3M+SNsRztzxu56e9AF+K4vra7gura5dbpDlGGOD7DoR7V658M9Tvda0u7fVLlrmSK6WJSQAVG0EjgeprzTR9IOs6jbWkMixHaS0jjIUDvj16CvXPBuijw9Yzwi6W5eSfzmcJtC/KBjH4UAclca1e60EE7xwQpIwVbcEZIYqCxz7dK0rZrqIgC+m24OcuePlPrWhL4WhgjU6SHXexaSOWTI5Ocgnpz2qRtFvTuUiLaRj7+exoA8/1PxHqWmz22oCdrloGZFWQ7kYMMEkDpXX2Wt3Nx4MTWvJtjctAZmXaQhYNgZAOcVh674J1a6s0iiW0O1t2N+3p2zWlYRPafDErIGWSK1cEDkghyOPXmgDzfVJZby+vJ3uS88jMzyoCpDkdh2AwBXnEWoLeiR7hmFx5uBI2Tg+47j1r1B7CaG4eO9W4t/PQP/pEWDg9/pmvIri3Md1dW8pETxu232cMf0NAG/dWpuxcLKAm21bZKn3WB296zE0G5Eh2xiTn5x/EQe4FaekXfmw3NtJjJt5PLf8A75yPpVtLn7GkIZ3bYeJB97JPT6elAGbp3m2c3zFzCpKgZIINdnpepW6AGMh3PJQdQff0rn7uJ5gbq0kwkvDx9A5+vY0y0VIDvhRoWzh42H3T/nvQB6DaO17Ktw37p1xsbPp0Df0NevTK1xpLGUYklijDf7//AOuvH/CMy391HG4CbSGdRxhfX8a9kiLS6awx86svGe2aAOYs2dGAcZ5IwO1dBYHP7N/i4/8ATvr/AP6UXVZksOLidQOBIQK0tPz/AMM3eLc9fs2vf+j7qgDlfFUJuE06LOEX5nbHQZ4rU8OXe6JLIQokcMbOhGd2NxAz79ap6+CYbQAZYtwP61J4eHkyajKx3bWxn0UZPH4UAbnzyW+6OMgkj5XOwgVgXFrBczPEj3VrcocbZYyyZ9j3B9RW5BewyadLdgSiOIFmUgFsDnp9DXLaz4n1E3H/ABLXXyCRiMqCwX6+vegCO+0+7tBFI0WQGGZUHHUdfT8awb+6kAKKRuZyCCSCDnsasSa/qM86pdXEjwlwGRSFzz3/AMKptcwy3myUbk3Nk9COTQBp6VuuJFIUmRhtfb29/pXTxWzLEu3JG7OaytGgEEibHGOOCOo+tb1/mzsy0JyZPlHc80ASwSv5MjDGAQMj61NFeR7BuOGqkiSCynjZvlCr0Xvmq6OxfYVYHHGB2oA2fPUcod3pip4JhIQWAB7ZrGQlCMDvxU8dwV4HT35FAGw6DqaiZMenFMhvArqr/dYdauMvHy8+hoAqOAOvSq8sQJDKOM1ckXjp0qDJB557UAcd4r0tdR0+SEoDIoJTPQn0/HpXg1+slhcy2sgOUO5Ce6/5/lX0xfRrgkZwea8q+JXh1buFr23wsqHc5x90/wB76HuPxoA83eVH2YPOO3cVYg4s5/8Aej/9mrAacxSSRTDy5Y2xjPr/AEq9a3ifZJ/mJAaPp/wKgDSTAPIGMYNafgbA8f8AhkKRj+2bD8/tUdc7JfDbhVbJ9eK0vh7dNL8RvCqkjnWLEEAf9PMdAH6C0UUUAeR/tJHb4d8NEosmNaX5Wzg/6Jc+lcD4cvU+W0mtYVj5KHcxAP516B+0au/QPDK+utD/ANJLmvNNOTdDz95T+VAHa6bDHNeRxNbxcyIqnLfn1ra1SZ7XTJJY4l8+4conLfd/Puay/DLGd7NmwJBJ8/vwea1vE8TT6KywsIpixVH7KpHzH246H1NAHkHi2/N3NFE1tbTWUMaHqw82TnLZz90cgVx+r6lZxwl7myt1kZR5cW9gSOxJ3cD9a63xWqafb2rmJDI1ukdvbkZzjPOPQH8zXES2TI7S3uJdQdtxBQMI/r7/AKCgDG1N/tpM95aW8EYGFXc4JGOMLu4HvUGlaRLet/ommQQIf+WuZCzD1HzdPet60sWubhri/CmCPOyDoDjufQV2OnrNdIhijCAAJuK7Vz6A96AMCy8P6fYWwF7aQM2C2wbyW92O6ujuWt5NQl8vS4nACYALk/cX/awPxq2LGFIZpLoRXD9RkYVfb3q5ftL9plTcscZC7UT5f4VzmgCG3hWWOM3cFqiNyqq0jbTnofmq7YWNk7TxLYRuQMx4d/mx7A1VW6jtYYgGLEZKjaAPzqgusXZkWWN/s8EYP+r4yPrQB1s0TwQAtaQQoOm524H4tWRcyWivFm3tW+YEqCx2/jupssU89qskStMrgMS/T8M81D/ZsrJvO1VVgSqJ/WgDp9OubOT7Yq2ikJcP91GYdT6tVmWOC6tGTEIbH8SOMH6g9KxtIt3N/exGVlR7g4wTkck9K677OrrIFRCFXhcYBoA8v13yU1CbdbxNIjCLK7yzHp6/Wo4LmOEJ9ntFLKcuCz8enf8AStz4hW8VtrUc7xyESqCwCnBYAc8e1Ymm38CTvst5Y5nHK44+uDQBtR3CQ3No6WkS/aCjNES5Ix+PUVkeKdWsFsbPTRCsRPzlptwjYnIA65H1rpEvbW6NhBNI63TFWjcIAGIP3f8A69eW/FGAtd2ckyFZPLAdw2QACeTQBk6uEgUqbCDy5M7gWfpng53dKy5LKGG1WWLToZFMm1o1kbevGf73NWkvXsoYYb53eKQNsMYBz6cmpEsrZ4kkVpChBO1V+4fX60AQaZLHJPvSztwBk8s4xj23V6r4C1aFrmGIWkMbYbILMScqc9+a4OC0E0ayrIqTSYGTwPow9/WtDTdS+y30NsiBZQJCTjBHyN37igD1/wAK6kp8TQxtBGoEbR7gWJXgkjk9Paut1IbfGvgdSqgjU5SCPT7Bd/8A1q8g+Gl79o1WFJifNETMHz98ngfjzXr922/xT4BY53DU5VJP/Xhd0AZPjv8A5KzekjhNEs3/ACmvKyvE8IuNPt4GBzKu48cgmtzxigf4r6kpTcP7Css89P395XO+N71bNMGJS0g2R/MwwMfMfy4HvQB5DrEbT3LadbAvHu2s68GTHp7Vs6XbxafGkcKB5yMFs/dHoPQe/erEVkkTgGzjLsuTtdyRk/dHPela/W3uHWO3habPzusjYB7gHNAF3UnWzkuDOwZmclYwenPU+lUnvfPUBuGOCyDgf/XqK9u1nvp/9FDjzScKXPf2Pen/ANn3U2GOlMiNzglxgfTNAGdfTea4WNgvGAB2FOhs3ZCwVUCDDE84z0471uRaXPEjSppsYycAs7En9ageyulDb9OQj+ICR8/TrQBmWVvDBeQbVLHzRgt9RUBuYo5HR3LuAeFHCj1zTprwpfwrJYiJt643M478d6zFuoER2a1hGc4G9/8AGgDc8N68dL1cXksO62Csrxx4BIPue+QK9h8H6vZ69pct5YRTxJ57K6zYzuABPTt0rwNLiJ40DWiLk8qHck/rXsfwkQJ4QlKRCMm5n+VWLZ+UevegC5ceJormzj/sdpsuNxklj2hR6AH1qC21K9mKmS7b5s9OMcGsnw8FFjCnkIvyhMEtke3J4rct4Ih5TLa5chgQCc9DQBS0vT31O/WO8vLmW3ALuPMI3j+79M11Fvb29tDHDbRKkUYwqjkLzWPZySWcvmrCqy7cFW3DitppGjsxO8atJtBIHTJ/pQByfiG0Opa7Ol7LH5MQEcaMSMLwx/E15vq3hS0nuLqWWBS80hk355UH0r1XUAJIZ3ljVpGyd2T1NYtmiTBIZbdFdQcMWb8utAHmE3gqBFfyPNRhbPg59x2qG48H3Ybzre4SQFQrLKuN3tx/OvX1s4pfO3WqYaFuC7e2R1qKTTY2hQC2XEZ4Jdsr+vNAHiwtLnTN6XVtIIm455Trzkj2rSt7eKZVVdz2zqFEi8tEfQ+o9vyr1ZtIimjO62iLYwVZmO4fnWJP4YWIyT2FpGsuMtBvYB/UDnrQBjeH7WWwuIyrKVzkSp91z2z6fSvX9BuhdwzGMjMaqGA7HNec2F3GkO6G0jy3yNGzNkeu7JruvB8aW6yyRxgK7KjfMSRzz17UATXcW3UJ8dHfcMdqkshj9nDxePS31/8A9KLqrc6AvIzRjKSEZBPc4qtbf8m6+MeMfudf/wDSi7oA5/Wti28G7ftAyWBHAo0W4SbTb+RNwA3DJxkgCqvinc/h9ME8EbvpR4Vt7mTR75GglV5N2zcpXdkHGM0AdDpVhDaw3KoZJFuG3OJTkEkYwPbFZeqaZosF0kk8wtHdcrEnCntuAxxWhoPnoVS6EpCRhTu6Aj/OK53WfDOoXE6zNItyWYjcHO5BnjOeCMHHFAFS/tvDpkUi4vXnJG1o8cnP5GucRI/t0irFKWLkbsrnOfX0rQvtK1DS3hD+Wys4/wBX8xHI6jtUVtfyrfxh4VYrIwYFevPGaAOotdtpp4nkD7MbW3OuRWhbXdtf3UQfzk2DcqnHJPQfXisO9EV4vmxDdHFwyE9Tirgkimu44tzRyZCxMTjAAGQfWgDfhmhkilKF2UYz0yOaUrGXyXkZT3JXNV4LU20TtExkI278DHesvUg8lz8hYADgdBQBv/6MBuw+T34xQohJwQ/5AVzayNH/AAsvuae9yzIDHuRvUnP5UAdFNHCAhCyA7fUe9WbWVSgVd5IGOSK5pprg+Tumf7nHPuactw8Q+aVwV5Dg9/egDq3AC55xiqcwVXz83Wo7G6W5gBDDJ4bnoaragjAqoZ8E5GDQA1mjbcG37T34rntYgjAbKy5HoV5H41BPJNG5DSMc9yeKju4FvbQq4YuvzKdx/EUAeR/EHw3Zxh7y3WdApJKqyfu8+3Ur7dq4CC7s4bedJDd7iyfdZD0z7V7fqGnRMXzENw65HavOfEvhJDBcz6ZH+8BQvCBj+9nZ/hQBzB1Owxwb/wDEx/4Vt/DK6hk+KPhEQm4+fWbIYcrj/j4Q9hXESoY2IPY4rqPhP/yVPwb/ANhqy/8AR6UAfpTRRRQB5R+0QM6L4X/7DQ/9JLmvOdMi+YgfdxzXo/7Qv/IG8L9f+Q0On/XpdVw2mQlDg5A20AdXoEXksXXICQ9/etfWgsiW9vu24XfIf7o6nP4VS0hMxOrfxKgx143U3xWT/pIVihkcxHH/ADzHJH48D86AOC8QWkV5dJfyALG1uiwI2T5aDPP49fxrgdRtXF9Fa2weS4l+YqVywXt+PoK9D8R6iLS1gyivdTwosUXGO/P0H86r+E9LWGJrlj5l1OSzysMnHoKAMrS/DSW8EZuGWS4POHPyofX3PvWx9il+VAUf/ppnj8BV/U2hSM4jV8NjzD2P9T+lZEIupQWAKRAcuTjP+fagBt1bv5LxoY41jBJZj1J75qSV4TrBiWGS5LbQSO3yLUN1HFFBL50xlkZexwo56VYubhbe6mmHJIUKo6Z2CgDNvYDckmVvKiUnCL8xbnqe34VJZWccUyiOAyFcfOxyufX0pkt6sM4bG/byOMZ+tUd9xfThJJCIgclU4Cj0xQB197qMEFq0ck8bSIcbIBvwO9V7DV4Z4sRxOzbsdQvGe4rnwlwJpjbx7NnRsdaWKDdl3JJZhnaMbTQB6FpNx5k92GgAHnMoOeeprXiVjcxrCMlzk5PQDpWb4atMQXLyEszzvsGegz61sbClwkuzIHGfTigDjPiaJWt0uEdlKS9d2K5rw86Pdw+eWaaRtqgrkf8A6q73xWtve6fLDIhcB1249j1+lcvBok8V1FNGElSMgqC2CoHUYoAR7S0n8QWYS3ktjC23Ab5WHPPNcJ8R7VTqFnNBIwNzbneG5JIO0/UnFejMgg1Symfc8qYDKoyMdc/SvN/Et7FrNzcSQs8cEKiKNWPzIR6/iTzQByaW8a2U8U8LGKNwWAPK8clR9a0LARWcaXUEX2iEnPmN0A96YzIIkmDK244ljzg4GOQKrXUU0MqKFK2zYcKMjafWgDVl1G2v3K2EZtW53KOSw/w71Nolu/2yHzFLxLvOe6/I3Q+9ZMZQxhlZEuYySWXqAP6Vt+G2N3fRNc8phwX3YZvkbgUAbvgyN7RBcOoZZ2VRIOAqjoD6ZP8AKvYtPu/tfiTwZuOXi1mWMk9Wxp13zXmWiSfYIt020LtBx/DIO2R37cj1rufC0e3XfArqflk1adypOSpNhdfpQBt+LAP+FqaoSMn+w7FR+M95/hXGeM1EmsbpmzBDEoXHdgOf1zXY+LmK/Fi+9BpFgx+gmvTXN63ZvcpwhZoWLuT/ABZ7fyoA4lGubuRre2X/AEpx/rCcCND3P+0R+lb2jeE7aJP3489v4mYcZ9hWpoukpDESVIdjlj3P/wBet5NsYUYGO2KAKgtI7dnEMaplicge9I8ShhxjPrVy4IEj9M7jVS8kWGMvxu7EigCreMkK7mbao6Cufv8AVYIgQqNIxPBDdqg1W6aWX55GdiflUc/pWHMBg+eR/uDqfqaANOy1GG7u4YpIXC71y2cgc96ik0SynPnRQxsd3MqHaqiqC3UUMsWfl/eKEQfUVSt9RuFmBXOzPKDoR6Y70AbvhPStNvvFCwyxC4hjUyFX+6xzj6kDrXrmnxww2oitbdbeGMsFjVQoHqeK8gjlkjmhvNNla2nRW+deSM9RzXpvhi+u5/BKX95N512Ipn81lHO0nbkD6UAaV49jDLFPdRI0z8KdmScD/PNRtqZ6QQALzyT6D2rnIZ7m+K3N44lk2gY2hQB7DsM1ftXJk+bOME8jrwetACSyyTu01wcuRgccAegrXvVxpoA9FGKz0wQB2961dQX/AEVVGM7h1oA524RpkaPPIyeTgnjpWbHCd6oBwOfxrZcoshXkZPX0NPWEd1BPY/1oAqWsRO8cklG56elW0gyMcdKliTBcd9pqWPGAaAIvsysqnofXrioLq334CfLJ61oqAcY4FDKHAzjHTHSgDjNW0VXZrqEKLnHzgDiT6+9begsbe0ZJBh41G4Hvk1pvaAtuPQDpVO9jUQsqcN8vbqM9KANmVcq744aNWrPg4/Z28Zf9cfEH/pRd1oxkNYQtz/qxWfB/ybt4y/64+IP/AEou6AOP8RyBNHiydoByPf2rc0bXbPVWhigkmafy9zI6EBcEAgHvzXE/Ee5+zDR0yNkkbjGeCeOar+A5bmXW7GWCKWWEpLHK6qSseT3PQdqAO/sNcgubnyCkqSeaYguOFwcZY/4VJr2qnTYSiACYgMpbBB/D9M1QXSrj+27idFjWJ/mV93Q8dR9a2b7TrS/kV7mPc6rtDZIxnmgDj28Tam0qqv2diSOI4s8Z9c1iapqFzezrNeRxbYXIUxrhsZ68c13E2n6Xb4jnvo45gRjLKCOfSuY12y0za5s9TMlzu3FVUYJJ7n2oAraPcCK+igtyZY5G3FyuSta1qZftTRSwCOMsSN3zAfQ9awPD0z2epOkyo8pBy2eQMdamHiJZNXCHiKMbQ0hoA7KO6SOOZFwQm0YP1qYTQykFFOVHTP8AKsM3cN5HKoKPKduCWGSN3Qn19KgindJDsmKyLwwJ/SgDoyqzYMLDB5Kt1o8pQx8yNCOmMVhieb7+3I6EKelPM18T+63suM4brQBp3j2kfleYwVtvG3sMnrWdcXNqScXCBugB60yX7YFjZrf+EdMeprNvCswKTRmI5B2kdaAJLPVo7HUlZpFFvJ8r/MOf8CK6ySZZ4yFdGdSGGCOf8ivMLzTshtqpx0zjBrpPC83m6fbmXie2kEL+69VOfpkfhQBLdvFNCWRlJ6jntVS1u1IAI+bt/hUGp2EUeoywoAFYbwAeCDzWDJa+XcHHy46fNQBu6hCm9twGDyCO1c9fW6ATMzoAduG3Y6Z61eltFltRvckjjO6s82cEUcvmlGUlMgnPrQB534x0qwug88c0MN4BlueJB/tY7+9YnwpUr8VfBwIII1qz4P8A13SvSr3S7OQFofL+nrWB4V02K3+KvhNuBLHrNiQQQd2bhB/WgD79ooooA8r/AGg8HSPC2f8AoNj/ANJLquMtV+QYOMr6c9a7T9oHP9k+Ftqqx/tocMu4f8ed12rjrKRvLVvKgHOCREvWgDrtE/4+QcYUxNx74zUXi9G8y0JOyMxb5G/u/wB4n8BU2lsxlwqRDCHbhBz0707xjmS2aJY42847DuTI8tcFh+JwKAPMr6L+0byG4EW3zYEwpH3I+QFHuf61alvfK3WlqFAXHmlWwPdQeyjv6mrUy3d1cQRafb24maBMyNEMQryCT7noB9TXS6P4dtrJFJht5ZBhjI8K4J+lAHOwgzJGkduZ2/2hhR/uipLmwu1QeWoVyMszHOD6fSu0KKgbEcBAOMeWOKqyuTjbDBj3QUAcFJoVzKrBpEGQSW2nbTNS0q7TUJXhWOTIVQDx/CBmu9cSeSQywjjklB09KLhFW5ciGEyYGCYx6DpQB5XPYTxNi5jMJ7yP0P0qzplvFG7zFM7VwJXPyj2ru7srIzI0NvJ1yWiGF+tcprWnea4eFIFxyFMI2D14NAGNc6harwJGkkckfuxkD6E1Npb2xwGju0zg7mI5IPcVnXUEtvKXaG1kXqn+jqM571s+H1ubm/gWSGzKBgTiECgD0TSjHCHEJLfO2F75ySTWrcsyW+VJJc5/z7UiSJE7qkUe/JG7yx69qmuHVlQEIMDH3AaAMf7KJWJljBY8E5p8OmqkhfYGU9SBgr6VfjLBlOyP8FHFSl2YsuEAxjhRQBk3AiVWY43sAoOOR7GvNk0eS2mW4ESEupwBzkk85r1eaLzIwAkTFSuCUHPNc+iNHI6eRDnkEeWPSgDmpfDem3cK7rOEjHzBgM+5zWXfeBLYWZ8nzoyp8sMp3AJ7A5BFd5BGVUMYoOeCojGK0kgAABSJlPYRjAoA8EvvA2q2QLwmO5hQfK0QwxH07/SpdFWJ9QjKgI5V1IC4w2xucV7p9kCHKpBtI/uCsDWPDcN1cJcWsFrHcgON4hBI+Qj8RQB5rZXTEJbT58pcbTwSx9vb+detaLEIfE3gOIYxHqEijA6/6Bd5NeZW9nPaahDaajZWoIxtcQDa3pg/XtXonh24dvF3giGUR7hqczAogXpYXQP86ANrxaA3xX1Hd0GiWR/8jXtVWIkEaBRu6sD3J6fpVrxdgfFTUzxk6LYKM+895WVbSfv3lPdiMe2aAL20RoBGBtP6e9VZZQOnIP61O82cqCOR83+FQeVhgVH4CgBznEsnII3Hj05rL1eT7QhTOyMDn1Nas3yu+QM7jx171m3UbytgcknIwOfrQBzU8MYXEOVyufc//qrHuY4RySSwOMHgn6V0d5azOwVAUAPOO1UJ9HuJZSxHuMd/WgDnvIijvLbnMjOp+Y8AZ7VURGyCoCAkjce1dTb6FN9pieVRtEgwQOvP8qz00qRLgPKD5SBnO7+goAk0K1ed/s1vDJLcSEBEU9T3+n1r1rTNNktfCyaWzxib7O0RZeVDMST9RziuG+HV3bR6xdSTYtg0HyPKwA4PP6YNelxAGNXEilCobeTxj1+mKAOfsdDvVf8AeeTGBxt3bs/lVfY1tqH2aRlZlByUOQcg8U/UNZe6vWW1lf7ICFUKdob1P0NUx+7uo9itltzEn6GgDVtl8xUyOcjof1rR1l9kce3qWI/Ss3TFDNGFYHLLV7Xss9ugPHzE5oAyXG4knvUkDlTtP3c9PSpDEMZBI9u1MCkMevHagC5HyDzyVPNN2cgimQcBgR/Ce/WphkigBAwIxn8qmUBiCcUwJjGOtBOCSM8UAWCQFz2NUbyLzo5CMgkqAc89alD8fjUyAsrZzgY/A5oAlj5sVB+8ABx3INZ0P/Ju/jP/AK4+IP8A0ou60Y8eWV7ZP6is2D/k3bxl/wBcfEH/AKUXdAHn3xLd4dI0h9xyXIyAMj6ZFUfCXiqHRLWS21Ka5miLPJGLaMEsc4KsOB6HNSfGmcW/g/TyD+8lYqrf3R3/AKV5xYXwmtdPlXD7opDgc/MHxQB7zq+rzwWNleWCoYp/nJfksCuQvH+cir2mX0t/o8lwpUXSbh8q4APUcfSuU8JTHXPBctiW8y8tGwuTz/eX+orq9CtPslkv7uRZnAMods4YdgOmKAMJPMe4D3MTB3IOHUDdk8ZJFYWoW12PPuJJJY03HaFiwnXjJxXoGpahb6fAsl2dzbgqLjLZP8q43W/Et7qEb20CCGJsq6A5ZsHpk9jQBzA1C6W6jkAKLIhG7CkfUHFMudRa9RJopwskfLhkX5sfhVqC9htEKMgeZgfl6qq9DmsuDRJbiVTEDD8xIZf4h9KANuz1ZprWVLa6EkwCAoIwDkt245rpvDttqV3K322URKoHVVLt+lcrZ6O9nJcNaoXZdmWAyT81dxol/L5Si6gf5QNrqn6GgDdhtoogAq5YcbmAJ/lUpU5ADf8AjoqNZSTkk/jxT92ccZoAJlfagDfw9wPes68SQqd5z2GVHH6Vpu+VXpjGKhcAg4H40Acpe283zeW5GeQQq/4VHokk0eoNBK4AlGBhVGSOQeldFPbqwJUYbqayp7bZcxTbfmSQMCKAK+qmVVgug5+T92+FHI7dqzLiJyRJ5menG1cfyrpZ41ktJFHKkbhisOVMLyuKAKbef5bASHgdlGP5VQunuTHIN5z8vVV9/atSJ8sBtz9DUV4nlCRZMnBXGfxxQBgy/aVgZvNIkzgDYv8AhWbo0103jHw3HcuGH9safj5FB/4+4u4Ga25GZM4J/EdaoWKRnxh4dcfeGsafj2/0uKgD7CooooA8w+PEZlsPCaDvrX/tndVxdqCGCBSYyccnP413vxnhFxH4QiPRtaPfH/LldmsO30qONlxuyOmTnigDR0YYmKjjETZx24p2uIZrqBAxCtCCWH8C9WP4nAqaxtfJdyueE/vZzk1qXFqkpcHOQQo91Hb86AMeysYoUV/L2l414A7c4HvUs2QcLwcY+lXp4hHtCk5KAYB6VGLZdgz/ADoAzihYcj8O1NZVTvluma1Ht0wAOn1qo9qM4Gcf71AFGVlVHdwMAfWuZ1zXZobuSKHaqADqM/wjr711Wo26iycKMnHZq5a+0qBr2aWc7nIG1dxwDgUAc8moX87s/wBokRQOMAYx9K2dOuUu43WQb5FHJY54rO1GC0gZUkfDY+6r5OaLC4gtb2PZEfLbAJaTkDuaAHanaorvsiyCMfKKt+CLZU1OeVxkRgYXqNx6f1q+IvPkaIRxsM9nIwMcYrotN0aCxgkZ/lllILDOSABwKALt1tIMhXJ8wr1681FuDsOpz07EVZkt924Ln5XIGD0Hc1DBbxlvlbg+hoAIwA2R68ipZHCo5GSPy5qw9um3nr9etVJLdiuwHj+dAEEE6yTBANnzAgk8N/hTTaBudp3DvjrVqGzUsvqDwQasxxBuvUd80AZq20YXhehyT1qaNAowwIx61eNqCAcc+1Na1B69B70AUvLB4OQM880RxfvV7kg9PTB7VdW12nBHHqT1qaK2COGwT159KAOe1HSYLy1CSop3cn1z9e31rF0u2ntviN4NWQs0S6hMqsfaxuuvvXcTWqlFGOvvWTc2wh8X+B2AI/4mso69vsF3QBT8bMV+KGplQpI0WxPIz/y2vazZJBAmQsR4x93vV7xwcfFXUOf+YJZcZ/6bXlZl6oZFRhjjJ9c0ANSdzJ8qREt1+WtCOcAZCxEjA+5zVGCIxx4kJDEc+1NZzvBJwfSgDRuJQZWykRwx52+9VWnIGAkRH+5imSzjzZV6cn+dVp24JJAHTOM/gKAJHmVnwY4GOeuzpUqDKgusAB6DZ+tRwxKmHcAk8gk/zouJgvIwW7UAI9wEljBSIlmGBsxjmuXvNQM1zIsaQFYyRnyh+QqxeXjfbI4omJYuokcdevQVlqix7gAMA9vWgAlbNuzGC1PBPMIr0/XsQ+F441RQCtvHsxkYOMjH4dK87isZ790trKIvLLwqg9u7H0A9a9S1uykv7OK3geNdsqMWfoAoxn+VAHHHdGRlbf0H7vrVmJ2Nyg8qE8HlV9jVnXrGG0nghExlZ/mcNxt9D+PpVeBP9JDNnaQ38jQBc0GdjqEC7EAOWOEwRgVoa7cbLlIwqHCZ5XPem6JaSJNFNKhERRtrf3iRWb4gn2a7Ir8xhFXPocf/AF6ALUNxuBEix59QtTH5hnZH9dtZyk545B6d+KtW0u1iT0z+IoAsoT8/ypu2n+GpY3HGFUe2OlCKGDdxtOD0qPBUY6e9AE4cEZwvHtTWYMoyFzj06UwHnPOfrS8Hgd6AGgleNsf/AHzViGQKjKQo6HpTAoIwevfmo5eFcZPb+dAFqJ8+YcAc+lZ9vz+zr4yOMfufEH/pRd1dsTmNjz1qlbDH7OvjEf8ATHX/AP0ou6APO/i28Evh3TraYK8MillPQqfUHtXjXh2F1QWpJ8yISOik4JQvhv1wa9M+LJk/srRFV4jG4IIaQDPPavNLu5awvNK1TfbsqeZHKPNXDIX2/p/SgD3jwZ4g0yDw7Y21zcW9ncxkW7QKnzO/9847EEHJ9609du7qHVUjVnihjQSIN3EhDc5/livItPiMLP8APET3xKvIPSvV7Rz4h8NW1xJse8smG8K+d4HB/wC+l/UUAamu2j6nb2s9jy5YHGQBg8859Oa5keH766M0H2UxuzEvMx2r16e4+ldpZyW5VIrZotm3ciRnovrWVr9zM7GGJ2RQOQW27jQBz0/hrT9PgYXN881wB8scKjG7tk9hV3R9GlJElyvB/g6Zp2nWfmSrnA2Hc67gc+ldTbg99q/jQA22tYI4n2gKvHGPep0aOMDy1GBS3kQaE7MLnHOfessGRCAdv13UAaomhdsOMZ7npStCByMEH06H3rMJYnBKkn/aHFT2s7xEDcjLjkbhQBYmiYBfTH9aqSErk5IrSLCREZSpGOmelVp4A3Tb+YoAoPcY4bn3pMq4HHGeo70k8DDoy+3zColDLIMOgORkbqAGRMDGFBPy+tZ16AJtvy8jvxV+NCCRvjA/3hVe9txKm7dGGHTLigDOQLGvG3PXPXFV9aA+yCffkEqp4781YC5JBaIEf7Qp5to7u1ntmkiCyAAMHHDc4NAHMs0LjDs/HcdPpWbphH/CYeHwucDWdP8A/SuKllDQSyQ3Dwxyxthv3o603SBH/wAJV4d2vAzf2xp/CyAn/j7i7UAfY1FFFAHn3xddI5PBzSuiINaOWc4A/wBBu6qW1zYs6Zv7bgc/NR8cgTaeEgDg/wBt9f8Atzuq5GyA84BcHk85oA9DtJbJmOby32nB+96GrvnWofIu7cHGTyea5HTlG9lzklD0+oq9cr++AUgbjj8BQBuSNaswc3UByo71G0tpn/j7g4PQms5toRNpwNo4/OqUihmyrAZ6igDXM9qOtzDnqTuNML2zgn7TDj8eaykjAHTGentRKyom0tgdaALWpXFpHYSBLuEYGCcmuQ1zUrdJ5kiuIF+78xJyflHStW4CzQujkbSCMZ6Vga7awqZCgGflBJ6/dFAHPP5E1wzi5gbHO7JJ9u9WdLa3jZppbq3JB2AMT/jVSSMM7LGq5K54/wAaktIEVoFWRGJb5iKAO+0xLeYQlbiCM4DFuc/hWxLNbBgWuoyB7nBNY2nIbVleQAMw2quecevtTJrhJZxEpCgnAwaAOie7tUaRBdxAknPJ6Zp9tcWJIxdQc9ua5y8ZDOwHUMfmH6U2TdbQMRtIznigDrWms1Qg3cO49Cc8UitZAY+1xE55PNcl/aQmWNg/zr1HQ8VatZyRiRgw6n1FAHTxPZh1P2qH7w7nmk820HH2qHI5GM1mQqGKn5cjHIphXGQCMDqKAN1Lm0PS4Q54xg07zrTvOjY9Aaw41znk8DmpwMA84+lAGoJ7RWGbhCe3Bp63FmGBE69D2NY4AwQOh9+tKF2up7c/hxQBoNcWe3/j4TPqAazNVlgk8U+BvJkDN/a8pwAen9n3lRFQVI/Wqs4x4w8ED/qKS/8ApBd0AV/GUAn+KmpgnH/EjsV/Oe8FZtvCJbqRCW4Pf0HatnxSUX4paoXlijxo2nnMkipx9ovM9TWfGtqk0zi9sPmYgH7XHnHX1oAbcQbl4LAjoeKpi1y/zsTz2xWkz2znm9sRjt9qj6/nUTNar/y92J9vtUf+NAFee3T7RIAWyWP86EsQq5JbzB+lTk2onZzeWJLMet1Hxz9aJZ7faSbyx57fak/xoAiaBRuG5mx6YrI1FXcmOGR93dwBx7VdnnjlBVbqyVMf8/SZP68VDGIsDddWPHpcpj6daAM230lRcQne20MrdBnrSpoKSNksVAJIFbUCW4kjc3VjlWBwLpPX60rSwINqXNkcnn/SU4/WgDS8G2qQ2d26485nCHpkKPur9K6JAE3O52xoNzMegFcNp0cDa3aSG8tAonUs32pOg/Gun117e48hF1GzEYJd1W6jAY5GM80AYM1m1xLJKdw3Oz8kZ5Pelhs5PtSNIxZUBwMDpg1o5tRICLyy6Y/4+o+n51K8lmJCzX2nom3ljdIMcdevrQBrW0X2ezt4mbdhB1rn/EulI0y3UZYefkOv+0PT2xWzBqumSwx51TTlZVVWBuo+uPrWbq2raVOtvGmp6ecMXJ+0px255oAyLSA2/wApJMY7Dt9K0kt125RiR61Xa604tkalpv8A4Fp/jSLf2EbErqencnODdJg/rQBpW8ewsMkjacU/ygSMHj2qnDqWmsG/4mWnA7TwbpP8asRahpq9dT07/wAC0/xoAlEABGOlKYQPUU5b/TCD/wATTTf/AAKj/wAaRtQ00LganpuO3+lp/jQA7ZxjJpDADFJknPHJ9c1EL/TgSf7V078btP8AGlXUdO2sP7T03HB/4+09frQBJaRbRt5zg5PvVCH/AJN38Z/9cfEH/pRd1aTUNNWVP+Jrp+Cef9KTj9aqW7K/7O3jJo2V0MPiAqynII+0XfIPcUAeL/GNt3hzQgpxIAxQjsQa8yllt9S0tYHX5Xjkd0/iilD5yPYjP+RXp3xrgjj8P6A+2TID9z6ivG7jFudOuLYkMyy7upDDf0NAHf8AhqC4utKsmQl2X9yWXrgdyPoK9H8MaoujalEZH/0VwsMgA52k8N+B5/OuN+DdxaXTahYzbkLgPECSdpPBx+OK7yTS4F1m3t5EbEfyMGJPzEZP9KAOquLcaZfrPEFETvkbehz1H9RU+p6Z9quEmjkCArg5BO70rS0y2ja1jtHyxhAMZfngf4fyq2tqJJGjDHzFGTxxQBgafpskS/PsQnk85rTjiiU8lnb2qafT2Zjyd31qW3s9oAOcA0AMI3owChVwCB1qjPA2SAM49q21tiQeMUG2wMAEDFAHMtbSeh+uMVGbdyMbWGOma6gRYwDmmtbqexH4UAYCiVDHhui/1NSSSNtyRjitWa2UBSQenaoHt0bGNxz2xQBkswYHNQsitIn1Fa0llGQSFIPpUKQIjgMrdRxQBz7qyGTPPFRi4EiHjJBAPtWvNbx4bKtish7eK3dxtf5vmoAz7pSsu9VABOCTSRyquckA5X+tXZ44ZYjgOPfBNZ0SRDzFdHyGXsc96AMnxdpQ1FPtFsQl8g47CQf3T7+hrh/CV8JPHfhu3lVkmXWrBShGCCLqLINemy+SyshVtp5zg1y8mlWsvj7wtqEZMV3BrNgJDt4nQ3UYGf8AaGRz6ZoA+wqKKKAPNfjczJbeEWUkEa11H/XldVzdnPN5pAeTp9410fxxAa08JBun9tc/+AV1XMWzkT8dCB9MUAdFpszicMzsemfpWg8jbjhiCBjjj3rEsZtjP2yuR7VfllKtL6rgfiQKAHS3btJHh3A2DOO/WrMcjBQdzA1VVMLG5GMxgY/Oh5cJ14HT3oAtPKQD8xrPuLljk7n9u+KGmJHzAA+maqPKZGK9AOST3oAeLlwhPmPyM4qG+WVp3zKwUhRj3wKUfKrAYAXgk1i6/q7G6kt7Igtxvkx04HA96AIdVu2hwguGQ/3gf6Va0WfaGw8jt1DPjoO4Fc60eZA0mWYHOW5zW5pto0kKMgZdw3FsdPQUAdFNd/LuR5GL87s/yrMluJ0nLrI/BHB71JbRzR2e1iGJPA6EU6OMC2keUcjA9+vAoAfHPcXGoNgkIrkYz6VLfXcn2QsrFF3fKc81GriOZ2bhN53Z+vOPWotSkieOOKOQBc7gwP3s0AZUd3ceYSrtgZ4JHrWvaXErqSJGyOCM1lGIKu5VAB5+lLFI8cgdcgj070AdZY3MgdAzMVJHOat7mYEhs49O9Ymm3Kysg+65YHaT1+lX4ZsNhjwfU9KALaM2TyRT2kYcc+tRhg/JOcdD70hOTj8qAJFds8k5NSxsxYc+o/SqakjbzViJ+cHjg/yoAQ5UdTgGs66ct4w8Dgk/8hWX/wBILurckmMY4GKzXJHjPwQp/wCgpMR9PsF3QB5h+0uIz8VYfNVGH9iW/wB4A/8ALe49a8zktrdIy/lQ8c/dHQ13/wC1TLLF8VLMwyOmdHtw23/rvc154015/Z9szSS7nwrfKOwzQACCDGRFD9dopwgtT8zJCFH+yKrj7aDtMk5OcDI61qQwXCBR+8yR3AoApTR2/mMqww8EgllGKjW2hbkxxH1+UVpyRXDXkqgPhWORgVYEF1/dc47YFAGN9lgAH7uLr6CpksYBg+VDyP7orZW0ugAdjcj2pHgulwAr+vQUAZKWsBkUGGH7wydo5pDawKvMcR9go5rXt7e6MqfK+SwHIHrSG3uwxAVzjr0oAr6RpSzTiYQRCGM8kqPmOOg9a1Rptsjb5YIgiDklRgVtaJZyXNhbxIA0wDEpxu4PJxUms2M9pZMDC4lk+RFxz7mgDjBawMzFIYgMkgbR0qxbWcBlgHlRgZwSFHSrsdtdsMBXxnOcDI9qt2NpeS3MStHJhn29qAIo9PSMkLGhGSRkCsRYFDFZI1Vl4ZWABFd7JptwHP8Ao7gduO1Y2u2s6X0SrG4byhuAA98fpQBzKLCGAXyyfTAqQwxn+FfyFX0tJ0bPlSA+uKeYbxW/1b/kOaAM1YUO4bU4U9hQEUcgIPqBWxHb3TK+Y5PuH86ha2uwCdkmPXAoAzlaNAN0Sc9MYqQmAjkL/wB8irJgucE7JPrgcUxUumyux8/QUAUy9uGxhSc9lpHngWORhGCF29cDvV/7NdYJ2vn14qnMLry7gAPkbBgY67qAI4h5sTsBGuBxgAnJ9/pXunhMAfsp66B0Gna1j/v7c14xpwuWtmADN5bbST3JzXs3hLI/ZS13dnd/Z2tZz6+bc0AeWfHbVLSLSNFt7nSHHyvs2Xp+Xkdfl5zXiz6ppxjtEbTbjaofA+2erf7vtXdfE3XbLVvC2gR3Echv7aN0dfOwSobAbO3mvMbh7TybUiGbO1s/vR/eP+zQB23gvxJp+i+IIHk02YRSHyyWvDgBuMn5a96n16NpIZzom6ZQrH/TCc44yPl56c18wWM1jOhR4pA4XjMo5Ht8te2+BtWi1HQLfzQ5EAKgl8suOCDx0oA9E0/x4pdCuhoGQ8H7Sev/AHzWz/wne9RPFokW5ThgLg547HiuO0+3tXZiqnJYDIbP64pbRWTUHSGJ5N7Heobtn734UAdq3jOSco8ekWxDYAPnt09+Klh8V3DOQdItxjqfPb/CsOK1jUYVcDJqZtkWcAkr1OeKAOjj8RyMvOnw/RZW/wAKc/iXHH2C3DeglauZhuRLuDlgMD5QcDrVgRKVBQde+aANh/EWSMWEWe371v8ACo28Rsrc6fEPpK3+FZyKqZyCffNMlWPcDhyCcHnpQBoy+ITtX/QYsEZ/1p9/aqz+ICGyLKPOc/61v8KrTQqNpCNyo78dTUZhiYfMjce9AF1/ERA+axjHv5jf4VG2uszLmxhJyP8Alo3FUXgRFBMbMOf4j/hTEjjDLmJtpPZjx+lAEN34hZAT9ghIH/TVv8KwtU8SAxHfp0Xy+kzZx+Vac8VupIEbbT0y3T9Kx723gZT+4Yk8ffP+FAGE3igBh5UMaYPAFyw/mKjvPE86xSP9ihkOVz+/JyOfQVlXtnAtxJGbd8KeCZDz+lUpLK1eCZfszjJX/lqR6+1AFy48XXODt06JfpK/+FU/D2rTXvxA8LJNCybtZsCP35Kr/pMfRcYrmL6BIZWj8m4GOmLhv8Km8Bxw/wDCyvCjLDIHGs2PzNMWx/pEfYigD9BKKKKAPM/jmQLLwmTx/wATr/2yuq42KUkKxIG4cCun/aIufseieF5yAQutDg9ObS6H9a4Cw1GK5jHO09dp/wA80Adbp8qtcgA5/dlR7c1f1GVlvItmcvg/Xt/Suc064UXsHzcM4U8+1bVw/mXETnJCRhv8/nQBstJiOMKRjyx7VReXc25Bx6Gq810N0MZ4DRqevTrQXDE4+70xjrQBIhLg5O1MjPrVW8uliibediKMtzgD3zTNS1GK1VfNcl+oReprjdWvJ9RlAfCwA8RA8Z9T60AaGoau92jxWpZLcj5mHBb6VHNAPtRAGOF4Pf5RVS3XywwK5GO9at1Kn2p14HC9R/sigCGKzllfYoGc4B68/Su6tLcW1olpH0ijVXOfvEda5/RjGJPNfZlcdTitx5k2ExbvnOTk5oAqOPMYhe56Zz+VSPkWTr6uo68E5qhLE0k25WdfL+bOemOauQP5skSY/dq+cKfWgCvrNkWWaVQQyEnAPbucVzjylpPlJ25+XHY11OqXTRea3JM0rRHPZO/6cVygjEEyIp3RAnafbtxQBsW0qzpsdAr/AKN/n0pssRiOMfL25/Sq6DBz/Krkbh2w+OeAW7//AF6AEtQfPi5ON4P61Zi1CSMYn+ZQeHHUf40lvH/pEZTI2sM/nVWReemMfyoA6Kzu0lQ7XBPQYqyTkccf0rjmZopFeIsjDjKmtC11aUgiQAkcEDg0AbYmxwcDFKJyHULjv/I1g3WrxxkkiTI7YzmqS+ILfz1AMmSG/h/2TQB0KT/LkYPrTQS3jLwSx6f2rLj/AMALuuKn8Tcj7PDIfXcdoxWv4ev57zxz4K80IsY1CYqFH/Tjdd/xoA4T9q3/AJKXD/2Bbb/0fc1xMcgl0i3mABClWI9ivNdj+1k4T4oWo9dFg/8AR9xXBeHpd+mbDyYxjH0PP6GgDdso0nnXBGF+bPp6VoSyLFjeADxWXpKm388A5TICn1TrSeabm5DOchSFHsKANhYwL+fKjBkbJH1rZt4AEEhC4PHPFZ8aq11cMfurIxx+JqncXxUNJLJtUds/oBQB0ZhXqB+VMFuGOWA3Z5rD0rWQJQJ43ETdTkH8a6RCrrmNkZSMgg5yKAIo7dRMnQ5cfhzUEduhjDEHJJJq9Cf9JjBHO4Hp05qJpMZCjHHBxQBVs7VJJZC0bKykYwME5rcttN8mQu8jsduDnk9fek8N2xN5JPMmI0j3bTz83atu8DND5w2gkc/yoAyPsyC4ULnGQfu1YtLNVmIUgSAttx2ODioXdWcGJgWABYDr9a1rWM/2ocj5QC/5rQBUXUEtbAretLJdNkq6oCCT0HtWPPEbl3nuCGmblj2z9PSt3U447m0t4ZcKz5IPoR0NYoLwgK0bHHBA5oAZHaqVGQSMVKbVOmM9ulWIGIU7lK+3tTyARx1oAqxW4Bk+Vf8AVk8fhURgQnJ4NaCLxLn/AJ5HOB9KrOCPWgChPaYTKqPpVNoQq7h19q1Wftnp+FUL1TsLLwBycUAV3YYwOp4Jx+lZl6nlW1zMwwSEVRj/AGutTxyKkrFxxjior9xNb3CZOTsz7fNQBFou1LPaBkBwx9yAa9Y8Nf8AJrPiHjH+ga3x/wBtrqvHbKbZbiLjcxKnHbnn/CvYvDX/ACa14i/68dc/9HXVAHyl8SwYpdIcDBML/iN1cjcgC2s2APKt/wChmu2+LKbE0I+sMn/odeflmIUEnC8D2oAvIGUq8RwR3r0n4S6uqajLZScLMpZeejgfMPxHP4V5rayBkKtV3TbuXTNQgu4chonVgPp2/HkUAfSdgxtrzyS2Azjb6ZzV+S5a1vRcRjgseM8HnlTWLp11FqVjZXcB3RsUOc9VJGPxHSrtvdfvZ4LgAhmbDHoeehoA6iy1GO7naJF8sHlCTyfUVpSxmUKUXJ+6RXKadbOdSgSGUKpbd8/UY5rs4gWbpQBRt7CRtwWMgg4JbjvWvb2G0Ylkz/u8UiXChpET7ycEnpn0rMvbuV5Cu8MF/h6A0AbLSW0SssADOR1xn8aoGAHGcemaYs6iMOvJPIX0pyM0vzSgqM/d/wAaAG7wu1eo29cdetRvn7wXA71auIwyIq8Dbx9c1FHIQAOM0AQqxYEMhX+tRlCJBjGcirMjArlfyHaoAytIvzAkEZA7UAY12GRiByuc1QmUyAhSMDr/AErVmAdiQQcehrMuI8bthIzxnrigDnNUtMEEA/N1rGuIvLhlOTgsv9a6G7EgyGYkDOR1rIuwDby9xlf60Act4ggDIky9uDzVLwUv/FxvCp/6jNjj/wACY607lxJFLC/XtVHwYMfEPwv041mx/wDSmOgD71ooooA8N/a8mnt/h9oktoCZl1qPbhd3/LvcZ4+lfPuh+K7xFWO7064yBjdFG3P4EV77+2MSvw30YqzKf7aj5U4P/Hvcd6+UbKeVZB/pE57f61v8aAPatG8SQtdW8jx3UeGDENbuP6V31vq9uYzKzyFRgMRC+duPpXglhcSBonWadvmH/LVun516TZeYPD8AeWXzJh5H+sPXJIPX2H50AbcutMZ4wttdvmFckREDBJx1qz/at/OgRIJYF+7xGxJH1xWE8crRWjeZLvFsp/1h9Tx161JBLJI+wSzYHHEhoAviGeVmPlTnPVmRjT2tXC48iUc84jb/AAqSAyKRmWU9vvn/ABp80jkqqzSZ6/6w5oARLSUxtiGU5zwEIqxPBKLqTMUxPH8B/uinwGTaxLy9OPnNPv2l+2OEaY8LwGP90UASafprSkSbXDdQCpH41sWdpNHHIsiE7jgYBqfQI2t9KiEzs00hZSd5OOeP50l5L5U+xpGBB7uefagCvHBPHMSYpdoBzweeOlVreR4YA6W8zS5AChCMk+tXLeYvM/7x9rIWHzHHSlsmLR+ZLM4QuFGWPJoAwdV1I3VxJHPDcApIQCsZPAJqqF34JSXOcgmNqPEMZh1aSRJZCjOythzjdn9KqiQlFxLIOwIc/wCNAGmvmqfkilbj+4RipJRI2AIG2j/ZNVoGcAgSyHHq5/Op5HZgMSSE4/vmgDUsDIzRhkfdvHOw8/Wop4HOWCOD3BQ4xUNnK/mxne4O4dWPrUqzM/G9+f8AaNAFV43Of3cnv8hqk5ljlykcuTnIKHBFXrgvhnjZie+GOT9KyJ5JOvmSE/755oAtTLI4yI5SOudhrOe1lF4myCYghifkOB8p9qWO6kDMpkk+boQ561aR2MyZeTJVs/OR/CaAOfMEqRAeRNvONx8tuf0rc8ETSN8Q/B0bpIEF/OVLKR/y43WetcvqF3Iq7fOl3Dqd5/xre+Hjt/wsbwejuzN9unJDOTt/0G5wKAOZ/a4JHxTsew/saAH/AL/3FedeH5TDMSP94D19R+Vei/tchm+KNkFVmH9iwZ2jP/Le4ry+waTbGyxS7gcj5DQB3Coo0ptnpuiOeoJ6VmWLFXVTnOcc1cs5G/sYRlJAPlYfIcg85FVIRN5obypDgjqh5oA6syFbidcgDzGwSfesK9hklmMZUgkZQnp781Brd3Kt9cjy5MCQgfKcdadb6jNIpURt5gGQGU4Ye3oaAMYyzCYFgwkzwB2HtXQadfO1ouwsHibnHUe9VFtvMuCsSOsZ6MyEj3q7PpbrbpLC3ygBTsBzQB2Ohym5EbuRvDrj6ZqZwpYEMM/XGKxvDruJ4omikKllAG08YPrWiwbfhlkIHfYcc0Ab+jSJCpYyId2cjd196v3E8T24CjMa8YNcxptncXlyFj3RRkkZK9RW7DYtAz7izKx28gnpQBBZRwPOeVDOpC89TV/TJi11xyGY5X8DVVYFS5VBkc5zsPrV+GxaO/xkqCSy4U9CpoAoatdojLFjiHCrtXOB9agEiSHIyMjOKj1XTDbwLcR+c6Zw6kE4z3qK3ZyvzI5PT7p/woAuqFKjDc+3emBsYOOQKRN3TY+P900jK2CQjf8AfJoAmjYETY/55t/SqkxPemrJIjykI+PJbop9qY7sVzsfPpsNAEUh2nPTB5qrdyjytuOT1GO1LJJJk4jkY5/uGs67Z8k7JSe+ENAGdeylNwBBPrjtVGyuN0d3vyWIT/0Knaiz4IEUpz/sN/hWdbmZIrx1hlHEZA2H+99KALVlJ/pRLNycZr27w0c/ss+IT/04a3/6Ouq8DsxKd7+VMWJ/55t/hXvPhT/k1TXcgg/2frfB/wCutzQB8xfF8q0Xh/aRnyZc/wDfdec16d8ZZpjB4f3zSNmGXO5ic/OK8xJJ6nNAEkEhicMAD9a0Y3guIzglG7qTx+FZsU0kRzE7IfY4q1Dqd4jf8fUwH++aAPUPhB4gEUx0e7kBXeHiz3GRkfh1r0WVwJplJG8SEgg+5rwHTtVvYdRs7iC7cypMjKd54O4cH2r2rR9eOuaS17A7LNDM0VxHu5Q5J59vQ0AdNa3W0RSK3zoQQfTFdKusOYZZWRZo5RtVUO0RnvnvXGWU8okSTz2aN+nNbOnXUqzkGXcjHBXd1+nvQBsaE7kvGOYyAfbr1+tX7m3QyGReN3Q+/pWbFeyWaTNHIxU7cMemCen1q9p+otcXCK7BQxAJBNAE1kvl5Z2zkdBVtlySB36UamrwBpVcOAfuA9qi0+/ab9223f2IPX2OaALRUhV9NtQXMW0bzhT6etWZbsAoqMScdvrTHWUndLIV78cmgDF1C58n5c44z9ayIrxUuVkYtyccVvawwIMIYggBlJ7eorHMU0rRssjbNwHBoAwhqGWbAIPOOaLWQtKct1P3c/eqKUXCXcgVn4OBk9cdxU8Fyxx87BhwfUe9ACXuwFhjocdKwNSVVjn2cZK8Z69a6KS5eXcI2faowCTyT3zWZeNKYJgZD1XofrQBxd3tVAxx7mqnhNQnxJ8NKCMf21Ykc54NzHW1fvOYnHmNkD171neGJJX8e+FCzsQdZsQ2T1/0mOgD7pooooA8F/bMDH4Z6QEGW/tqLH/fievk/TbQtKhncnnoK+s/2xv+Sb6N2/4nUX/pPcV8tabkzRAYHIzQB18EQW0ZEUAAYGK7y3/eafaRA5JO4ezKorh4TlcAnpxXVW84jtYiG5yHX645oA2Jpd5gI6NAjAntyc/jTbb5JdyHgnIFVnlBFtj7r26Mp9Dk0RSjeMHnuM96AN6KbIUMuDj1p6PvlUH9azYZgAASPSm3d26DCfKNv3umRQB1KSReXt3KGA6FqdcnN+5WRQTtwM9BtFecy30oSQbskZxitSLUbhtRkjLEjaDk/wAPyDmgD1K0UJbwJvJKHIyRg+9UNStPOcOXBl5A5rltPub6S2E0MTlWO0Mp4PPv/SugmE0xiYg7hwx4oAluIJLOwhELhndPLzjpk5IqW3YGKDMixxwuWcOOT9Pxqi7XBtJMpkI6sMHqOhH8qoX11fSwLHDE+1jhvl5OO2aAKt7ctLd3sLodplYkN1J3HGPpUaIQu3kcVj3MhbVLlsMpLkcnkYNW0mlXGHJB9TQBqRPhSPaplcFc9O3NUVmDLn26+lSBsgjJP6CgDUtH+eP2dfqeajMmx2IJBJqCybFxGDn74x7c1DJLknHAB70AX/PHOevQg/1rMvOASBwT6/pTRPh+T+Ipk7h0YBqAKEsu3JHXjvUlpe7pkXHOG5/4CaoXLZJHbpzVWGfy72PnjD/+gGgCDVWWKKObAZiAAPQ9jXR/DU4+Ifg5SCW+2zlm9D9iueP8a44zfaiRn5FXG7HH1rqPhhOG+Jng+FQMLeXBOPX7FcUAZP7W7SL8ULTy5JE/4ksHCMRn9/celeT6fc3BhGbicjP/AD1b/GvV/wBrn/kp9n6/2LBj/v8A3FeSWXy7TgY/rQB0VtezpFsFxMSev7xun51cguphgi4nKk/89G/xrOsQud7gEkcew7Ve8sq464yDQBY1lLm4ubgx3EwPmNlfMb1PvWF9n1SJGZpbgr1/1zZx+ddDckm8nRW2sZmGfxrBnurr7U4H72IHbgHj6UAbSXswsctLcZ7ESNzx9eKS2urwwmWN59j/AMDStkj25qK0tUZGElxIijHy5zg1tw26OoAyQAOg7fSgDS8LyuJ4Ha4mJLgY8xjjnoea1C8zKcTS55/5aH/GszSIPs11b+XwhkXPHv1qZLrnaeDnGeufegDqPCTyItxJJK8hUqEy54BPP4VuXjg2qyrI4BycByO9cn4euoQlyZ3IQ/u1CjJPOeK6IyLc26LASI14255/GgCgmojz4k/ffNkMxY4z6V0kMm+eCRZG2iI8Fj6E1hWUSxykCNipOGzzgeta1pujvAvRVJHIzng0AV72bfahWkYru+chyPlIrnIS6Bl86YkZH+sP+NXtWvklVoki2RowKlTjJH9DWM0zeYzIMZ5wecUAaLzzIB+9kI/3zVae8fbkTSAg8jcaiNwSMFsnFZ9zIS+WOcDmgC8l4+yc+dJjyW53n296y4tWXd5f2mQseF+dutVCWkiuVXPELk89uKyLuDy0B53t0wc0AdC1zMcfvpie/wC8PP61UubmTYcTy+v+sb/Gs2xvnOIbnh/4Wz1+tF/cfuGweSO1AFSS4meUkTzcnAxK3+NKWmS0vQ00+SI/+Wjf3vrTLQ4bOAMDjNExLWN6QP8Anl/6HQBX06eVgB9on6n/AJaN/jXvnhTP/DKmvZJJ/s/W+Sck/vbmvAdKXIP1r3/wr/yarr3/AGD9b/8ARtzQB80fGgYt/Dv/AFxm/wDQxXmNeofGof6N4cP/AEym/wDQxXl9ABS0lFAFzTJSt9bDt5qH/wAeFdX4L1xtK8XSEvmzu5GguAR0VmO1j9Dg5rjIH8uZH/usG/I1MLplaYpj95nr70AfRUDSxyPaTgb0JYAHPStLTrwSyBEGV75/hrgNA12XUdJ0y9kLNOEMEpXqWQYBP1GDXV6HMdzOw/1uSPQetAHZwKXW4CEsuFznuM9atWwCuqxBgcjAPY1U0tsRS8c4X+dakEgQhwi7+woA3ZY1aPDgMUOTk96pvYHzQyHCsecj+VEWoCQDzkIY8ZHetVgBaIpkAIGSWoAYziNU24Hy9hUUjZA6/hxTYriKR1j2sTtyCeO9WBHlcnj3NAGZqVt56Bx95OuPSqEDyI6wzfdLDBxjNdA7RbSGbPsBms+ZGfhWJ+YY45oA5nULQterlCrYOeP5U02KFH8xPmPcHkVoSEqpecMpU8D1qGVw44DAkZGehoAz72ItAscQSJsZY9qxrp1Ebxs6mUFQcdO/etmaZcAAHnORjis6+VGjdgo3HHzAc96AOWvF5J96z/DCbfHnhwemtWBH/gVHWxcw4yCDg1Q0KPZ488NEf9Biw5/7eoqAPtmiiigDwj9sX/knGjYP/Mai/wDSeevljTMfaFwflHOa+qP2xEeT4c6Msal2OtR4Ud/9HuK+X9JsLwsWa1kPpgj/ABoA6q3lyg7ZFaMUjNaY3HchyPpWVb2t75QBtpAcY6r/AI1tQWl2YTm2kJHGMrz+tAFs3beVbIM8W8Zx6HJqzC5DLICc9TVSWyvI3tj9nkI+zID09/ep7a3ukYA28u0Ansf60Aa8NwhK4AHr/wDWp91tniDRsNx6oeDVNYLoruFvJ16cf41cW3uf3eLaTIHXjigDFurO8iDSJbs6kEAgZxxWnbpMl1LJOrEsUUKR2KrmtNo7hEYLA3C9ARzx061LNFcnU3b7NJgKCBx12j3oA7+GBYIIII9q+SvCqBggd/1zVC4uVhDJNJtHbJqxbpd+akzRsqmJSw4O4lecD1rI1DT7qedHMLls+oAAoA1NPuEls7popCY/LJzn+VLH8qQiV2y3bP6+9UV05rKBRbo/lsDkFuc+n9atTW88tpG7loQoCujnrzxj+VAHGeKYPJ1yWWFf3crsPo4OCfx61UiHAwp9OtafiRbmXULnMWQsx2YYAEevWqccU3aCRifb9KAHo2OD2PJp3mY5H1qvKlwG4tpPxx/jUTfaguGgfafTFAF6yvFF7AGGEZ1U57HPBp11JjjIB69eRWO0zJdQo0UjNvXpjjmpInuLiEARPnJ9OfrQBae4AztOM9D61X+17AytyP5Uz7Pcf88JDg+1VpoLkKf3En5d6AIp5wWzwKzTPvvokDDkOfp8rU+8iuAh/wBHkzjjpVKwsbt75GeCQEh8+n3G96AKsF4kdpMgJ4xz6+1dT8IJjL8VvCeRgG6uD/5J3FcbdWNykAVbaTOPb/Gux+DsFxF8U/CJmhdAbm45Pr9juKAGftbqT8T7Q9ho1v8A+j7ivJbcHATofWvXf2shn4nW3/YGt/8A0fcV5FaruwQT/wDWoA2rZ8IAAelaTEeSrY6EYrGOU+ccA8H61fMxZFTHIwx570AW55MX9zzn9638zWLfWjQXJk5Csd2R2NaswLX90PWRh+tWUIUhWYZHIBoAradBLLGJOibsEn0rro0ATCY4HYdayoCXCgnuB7Cte3wo2E5z0x70AOgY+db+gkXofeqSuzOCM8GtK0gZrmLjA8xcc9RmqsMe2TB4yaANHQbn/SfIWJSQcl2Nb0d3cwMzxldrNkAD7o9M96yvCiJHPeXEmzKgKm5c556117XEUtmzIwUKMEAY57UAYgurxnBRZAc56H1/lWxK135tnKhZfNQ7lIPDAHn+VZltqM73agDKhsHLdq6COZvtsUMzhfLY7ST14NAGFc29xMjhlOGXO4J0PesHJRihAyOPxrs5LuIyiIlsKeSDzXDatKkMsjRkyc5UY+7zQAjSMBlScCqlwwALFgB71DPeSiIkBVzyMCo5Ypb+FCoXI4bnp70AMW6hje4VGI/cOSxHuKY23ydwKk46/wCFP/s1QZ0CYUQPznJPSqjsLCBo8eYOvPb2oAa5LIAyhj79fpWXdKQSMk7RyKvR3KySRg5CHjOc4qK7GMnHNAEFtzETnHPNOP8Ax4XpJz/q/wD0OktlKxyggdc5pFGbK9U8n93/AOhUAR6WNsqeh4Fe+eFhj9lbXx/1D9b/APR1zXhGloDtB9a948Mgj9ljxAD1+wa3/wCjrqgD5t+Nif6H4cYyQtiOYDYxOfmHqBXlh6CvVvjkMWvhn/rlP/6GteUUAFFFFABSjrSUUAel/CstNp+rWokhAhaO5DFjxztbt9K9Gso2XYnnQblO4fMf8K8x+CP7zxTdWxPFxZSJj1PBH8q9btlHmwOR04PbtQB0mm48iRxLFtIXoT/e+laUMTOQS8ePTJ/wrK0oYgmU9ivX/eratF+QDv70AWreIsQA0fXA5rYmhSSHYWXj3NZUblMGMDd2HatGC48wgSDDHrigCCa3aOaNoyBgDafQ+lWmty4/eXHPv61YmUoVIwFAxyetRlScEZ570AReREP4yx+uKgKBJ12sgBPAzVrB+lQuoMqfWgCpLCrjLFDnrmqdxAG4BQY6c1dcYJ5OKgmUyW5AONwxQBiXVsFD7TGx+veuevopYYZXaaI4IGx8j19q6eSJ4ozgbv72Kyr+Fp4XEyggYIPQ9+KAOPuZsHDSQAt0Jcj+lVtEjx418OOXjP8AxOdP4BJ/5eovan6rZBXZ2VsDov8AntTPDTO3ivw8Jo9rprOnhSDnj7XFQB9pUUUUAeDftkqG+GujgjP/ABOouP8AthPXzBpdsixqAi5+lfUv7XwDfD3RAeR/bUf/AKT3FfM1kvlquQBQBoQwxsq4Rcj2rTt1TytuxQTz0/SqdmhKMc8mrEbYY88Hpj0oA0rhVK2vyKT9lj5x9aSGOLnKjJPpTLlxi064+zx/h1qOKUs4CY5PU0AaQ2GRIwFxkDpWphDklAGbHasK0kZr5V4O0ZrYjJJyTkCgBbgxRxOzKoUcdOpq1cqr6mwOAPkJJ4zhVqjN+8yCNygd6s6rlbi4B4J2cf8AABQB19ncRrIs8l7Hl325X5s+1ac9zp0iRkyMxGfm24/OoNL0lxbxKojQeUuRxk+tQXGlQWrH7VdhRjI2r1zQBpRXGnXFg+3fmD97sx1HQ/of0rPvJ7S+jCCZwFkGcpwa0NJjsY4HnEjssitGSV7kYxj/AD1qKw0y3a1LuZPvZGSM0Acdr9ukepyA4Zt7HcFxnnpTFjUIpAUfhXR+MLFRC00IOFlKHDZznPaucgBKLuUn2oAV0jkz8gPcH3qncRKRuIGQQcY61o7PmOQBjjFNu4yYiVOOuBQBxVzEY9ViR1x+9U9PemaDeLDeiNgPLkOCCK3JrZbiWAgZkR1574zXKtEIrzY0iBs5HPfPrQB27quOFXA9BVK4K88CpLGUyWq+YRuHykiquoyeXGWAH4+tAGTMFmuNgA2r3xVi1VRfRgIAFV+3fY1RxLsUt/E3PNTWIH2uM89H/H5GoA566RWhJ2rkD0rufgsir8VvCJVQP9IuOg/6c564q7X9ySMZruvgzj/haPg9gOtxcfh/odxQBY/asgln+JkAhjZ8aNbZ29v39zXldjZXa4/0aTceoxXqn7VkYf4nW5IzjRrft/03ua8jt1RPmZR7ZFAG2bO4JEa28mxfmPHU1NFYXJcfuJDz6VQtrRiE3Dbnn61fhsUBHGeR+BoAu3FlcC8uc28hy79vrWXa2+oeVGGt5CcZ5FbT26i+nOxeJWyMe5qMwIsrAQOU6Db6+lAFvTLW8dUBt5OO5HSt+0s7naN0Eh56gVnxaaJGjWJQHAA4Hf3q7Z2zQQPviIJ4WgDVtbKcTw4gcHzAW496rvazYbzLWQkHsO9WNPhWW4gCqAQwP61SvLfyy7DBx7f0oAt6TbsbgoBNuZCNuzAP410yRNLY4W1kikONxHJbHeuX8I6ckk5uipdlzHGp9+pNdi1mkQZUUBWwdoHSgDJ+wTo42xEDHzMV61tfY5JFt5WjJZCY2x1K7TtP9Ky5ZLOFsyyEMO23OK17aa0VVRJkLSfMB3I2nmgDNmDlocWT5IIaQdcgccd64DUp5QzBLO43Z+YOOh9K9Ejit9uElTeRkAg/zrifEdlC+sSSsqhmON6jAJHqP60ARWenXTqplhJXP3NlWksJoOY7ZwACMAduxq1Y2iNaQHAJwcn6VJPbjAIUYJ9O1AEJtJvKnJhk4hbt34rHvNMmlXDQTEHrha2FVCtxtBz5L8dj0rIYCQBduHxggnoaAKh014lIW1lC54G3+VU7y0uGIP2WQY4zt61trZGWHLo28fgMf1rPubGNt21Pu449KAMyO2ukbIt5CP8AdoksbgW926W8nPl/Lj/aqV7JA5+SmtZKLS72g/8ALPj/AIFQAulWVywXFvKBn+7Xtvh5Sv7LviNWBVhZa4CD2/fXVeHaTAY8Er8pNe4+HeP2XfEfGP8AQdc/9HXVAHzd8cxi18NcY/dz/wDoS15PXrXx1/48/DPp5c//AKEteS0AFFFFABRRRQB3nwTbb4/swP4kcfpXtRXbMUAIUOR+Wa8b+BEIl+IlqT0jglkP4LXs27fMT3LFsUAa+nHAlJHZf/Qq2bcEnCnAIrH08YEo5GNo/WtiDqD1+tAF+IbeOvqTWlaQbT5hxxyPSsyEFsbcCtK2YjKv09TQBPOnm9OcAYFIhEeA5IPpUrxjYp9evHSpMBkUDnFADCyMpznPtUMiBlXZu3A55FTFFJPykUbFyvJycUAY5XErAnrzTJc/MMZ4q7JHl89frVSdGjyW5X1oAz5eAQ2cNVC4iZo5BjPTFXbqUBiAuaqsxKE+4oA5PV9sU7JjkJ8zYzWPo8ZPi3w9MB8p1jT/AJh3/wBLirqdWgWblhznJrGsLdE8R+Hig6azpx69P9LioA+uaKKKAPDv2uhn4f6IP+o1H/6T3FfMlt/rFUHpgk19N/tcnHgDRM8/8TqP/wBJ7ivmS0ByuTz1P1oA14m+RVB5c4z6VZZRkEdulZ0MoMob0+7/AFq7FIBtJ/KgC7dLmO3yf+XdOv40looPXjAx0zmlujlbYZxm3TqfrTbRwC+Mc9OO1AF+B9kh/EcVoW5JUDpngis6ADfuIyf5VrWiAKpPIzgEUAWhEht2YehGAasajGrXxULwCrE4z0UHFVbhCEOxsDBHHtVm7mlS+kIdcfL1UH+AUAdhYXt1e+WbVBvKAlVHDEYzTtdjea9+6C3ALdh7Csfw+t3e2kcxYosMhwVO3eB/9et+bMrHO4t1wOeaAIdOEc1lLY24HmElg5GAzjse/NFh509uYZpNqBhhscg+n86saaksczHZhgc8Djr296l1K2Iu3kjVgPM3dPXk/rQBga+Gk8xUljdFuH5V+M9s+9c/5qQO43BsnPFdBr+jyzJcNAigiVpQh6kjOfzFc5CqM6Oi9R0oAuxu0oUkAUSqvllWA3Gn26qyEjtjHNSsB3GaAMQxFbtHTjLL7965LUbJJgpAJIbII6jnpXbyD/So1HHzrzmuaYA78HGDwT2oAWwmjjmeKNyWfqD6/So7zdKxDAcHoO1U7a2e2uBL/CrZLetXbiVXnfauQeefegBpj/crg/dHzZ70mnlTdqDwQHx/3wab5jgnarY6YotyftaMFKna3/oDUAZVyn7rgc12vwbTb8UfCOOn2mf8P9DuK42R1kiGeG967j4QgD4neEB3F1Pn/wAArigCT9qcM3xOgVFLMdGt+np59zXl9nbgbCxDuBkccCvWP2mxn4mpycf2LbDj/rvc15lbhdq4JJx9KALkSnKk8tV2EDcPr6VSiJPQg+uKtW7HKDA+Y9fagDSlhJv7jbkjzGz+dXrOzGQF3E+nYVEU/wBIuj6SN0Ge9bGnp8vfdjkfyoAsaZAI9zFTuPUk9q054leBVdcEc+4/GmWFt0JJ55xVzy22lWIwRjNAGXprIt8gcYy4A596fPAsg5GVJ6jpViOzLTwPtwRIM1W5yABjB/l3oAvwptijRDsRP7vWtISeZHIQpVgDhjzwOMmsfT9zzYGOeW3dgK6ESpIoiEYjTjPvQBz7adbo67kZxwSSc8VeWxie7h+znaVBxjrjaelWZntDKmGIwfT+dSwx2iXEINyrOhbGDyMg/wCcUANgNv5QDjcw4J/u/wCFVdQsbe7iLSxhiSGy3XPrWpaOsEYaFQyE87jn8ap3295GYRbABhdvH4UAYcVqLQsA5K55B7elNuJSCnrznPSp2mjZSAwz0PrwaoMrySyBARk55PAHagCOZzvnKgn9w3bjqKbZ2Kt+8kj6cjHFaNhaEmcspx5TAbu/TmrUceTtHGOMCgDKcRhCDGRzwB1rKmRZ2JztI6k/xGtTWo9ibYyykDJA5J/H8K5va8bK6sMLjchPOPSgBHUKzckEeopjKPsd2crj93/6FU98uZCQRg9Oar9bW8AwRiP/ANCoAk0aLO0Fc/TmvW9DGP2YvEwHaz10f+R7qvKdCzvXAPPrXq+i8/syeJ/+vTXf/R91QB83/HAoun+HAYApKz7T5jNgbl45ryViD0GK9Y+OZzY+Gv8Acn/9CWvJaACiiigBaB1pKWgD0z4Csh8YXZEYDrp1wQ28jHAr1yILmP8Ac8kf89Gryn4BwFdW1q9I/dw2Jiz/ALTsMD9DXrNvgMmSM46+9AGtYFd8y+V2X/lofWteFlJ2+Xgk/wB41jafgvOM84Xj1+auhsotuT1OMUAXrcIq42D/AL6NX7byz823J7c1QSr1sOfm4UUATSSHcoC9vWp1Kg5xj2JqMBWOT+HFLtIPX5fSgB8g9FH51ERl8gfmalyGHPBFUZ5cyBM8ZyTQAyd9hwE5P+1Va5w0R+UdPU06GXzdyOeB71FLuXODkUAYep2pJEkSEOByu81WgmLQuWTuvJY1syHJ5xxxWLrtvJIrNHtGMZGcetAFC/lQ9Ygc8EFjWXAE/wCEg0DCAE6zpxB3E/8AL3DVh3MsRWXG8DoDzVa0J/t7QA3Uazp2D6j7ZDQB9Y0UUUAeI/taIZPAmhKCoJ1pPvEAf8e1x3NfNVvZTsSqGEk8f65eP1r6Y/avjEvgfQUbODrSdP8Ar2uK+d7a0SPAwoHYDqaAJbXSHyrM0JweT5y/41qW+kc9YfqZl/xpkCKY/lGMVbgVdvT689KALr6WWNsu23P+joP9avv70+PRkYFf9HyPSZcj9akiVMQMxC4t05PbrVi1iiAaWN9+RggDkGgDOOkTRPy1u6g4/wBav+Na9taOEVQYC2McTL/jV20szLFyoLdc9RVWe3+z5YZKLz9KALI0p3jLeZBgDp5y/wCNO1PSLl70pbmFt5UAGVQfuj3oWcSQFQvy49f5VrMyJqDMBjaF5PQfKKANfS4fsttHaxiM+Wu3h1P9ar63ez20aiNgsjN081FwMVFHO7MAuzc3GV44q9PFEyxi6gVpGB+92HYUAc3Yavew3jyTTBo2Ughp14PYirFlr17cXKxyfZ97EYfzlJP1564rYNhZrbuGiXYxxjHGKqJbW4lEsESMAQMjtnsaALs6XbvMXkyhZsAyr6niuPvbGeK8IPkqpO7d5qgHPpXeyQXEk0ksWCm4/KDyOa5+9gS5kJY5KqFIIxn3oAzbS0mMeS0XHpKtPngk2E74Cw/6arV1Y1jjBAA2jnj0rLupMsxO0d8CgCrJbyG+hYSW/wB9SB5y561njT3dz5bW+T281aCu/UIApyQ65/OtrTIF+ygsn7wdSfrwaAMaTSzDCTJ5Wf8ArqoPv3rIi8xJpA5ttueD5ikj9a6nXod0QAPynjg/yrkbq1CF9m7BGTzyTQBqG1LgMskO08581f8AGlgsSbpMvAeHxiVT/AahhAFlbE9Cg5796WBs3MZIGcP0/wB00AY91pnygiS2B9PPHNdj8KrQ2/xL8HnfGR9rnGFlDn/jyufSuQmb5B6nkYFdp8LQP+Fj+Dz3N5Px6f6Fc0AL+0uAfiYuf+gNa/8Ao+5ry6IbkHp0+terftIxNL8TQFAIGjWucuF/5b3Xqa8vS1nKZAj56/vE/wAaAFiYKCB93FWraXDL26ZqBLWYr0Qf9tF/xqzb2kpcACPqMfvU/wAaANuW6jtbp/N/5aSseD0Ga6HSnEyl1GAOM9a5u506Rr55DGjgMwAMi4HP1610mlQGOE+WqqrLgqJV4/WgDorNV2joBjHPJ96uLHlsnhT+dUbG3lccqowOocf41swQu0e1to4wMMDj9aAIIEQyx5OfnHWsqaFHVmRgGHG0nrWpZ27i9ywTIYYBcev1qs1sPMfCquGJB3jB/WgCpp5WC7YONp2ZII/z71oyyh4vLiyd4ySKqySSEBGZMY/56Ln+dXtMlKsA21lP3RvU8fnQBRUKEICsPwqS3VTKg8tRgt/I1eulgkUjCZHP3wP61QSFpZ0wyAruzh15+U9s0ALZsY54lwdpGCAf6VoSB3V1CEqe/pVCwjMIDfK2F7uM/wA60WmaWHCqBxwNy/40AYlxpbiRwzRhCc7gefyproiJsVcAdz1b6+9abrK75bHPT5l/xqlNFIQeUIPH+sX/ABoAs6emYnIxjyj2pphKtz64z9a0LC3dAwJX/VnA3jjpSXET7flKZIx94Y/nQBgawseVZ9xwOw5Nc1c29tLgjepPA4zmuv1GyuXRN23eFwRuAyfzrBuLJ4izPsLdOZFzn0HNAHM6hJtuIlhzsThufvUmB9mu/TMfX/erSn04qwk8uIEesq8frVb7HK1vdn92R8mf3q/3vrQAuiLgrzweter6N/ybL4o/69Nd/wDR91XmeiWkmVJ8o/8AbVf8a9N0kbf2aPFI9LXXhwf+m91QB81fHL/jx8Nn/Zn/APQlryavWvjerHTvDjeVIqgTj5kIx8y+teTYoASiiigAoorS8P6XNq+sWdlEjnz5VQkA8DPJ/AZoA9n+GFgdJ8FQF/lm1KX7S2e0Y4QfjyfxrsLbkBifu57etZXn5kYQwyiGLbFEoQ4CKMAdPSrqzusJHlS5Y/3T0oA6Lw/HvnnbsFU+3WujQbCKwPDm6O2mcowY7Rjaema3oj5hBUMc9ODQBdtAJZAB0I59quyHB8tR9aihUW8JwDuc4NSoCXHBPr7UATRjhQTwBiptuFJxjPrSAbMDBzjpinPk4JBoAhMg3YHX19aoXPEwPqannJV+AfypoTzCNynBIPSgCC1QNJnpnqRSzxKFOB3qzbQtHk4PT0pJCzc7aAMa4iwSRwfSsu7haeJ85U5Ht61vyoTng5+lZWoqyowAIbIHAPvQBwmq2z2Vz8qs2eQVpbfafEfh0r/0GNO7/wDT3FWvfxSTMQ5ZCBndg54rKiYDxL4fURuC2s6cSWH/AE9xUAfWNFFFAHi/7VGf+EN8P4/6DSf+k1xXz3G4Vj6eor6F/anGfBvh/nH/ABOk/wDSW5r51UELn8xigC5BIfuf3sg45FW4ZMADqKy49wxjjnNX4wWcHorc/Q+lAG1LJttYjnH+jx5/M1e0ZQd3IIY/5NZzReYkMZcr/o8eD784rZ0i2MKxbwSV5IPegDpLaINDwpIHXHem3NkbnCKABjrV2xVfLAwGGcE561ZlX7MpJB2nGCDmgDmzZNDIVRSxAx+nWp9SUrdS7T/d/wDQR271pXU8YV3iXOBg5HWqWqqTcu8Z+U7cgDBB2jmgCTTLi5t286JQRnHzcg/h61tR3O1GnuCBK2fvdhn+dYlncuIEb7OwUEhTglgB3NTXDzTeW5jfavygEcfWgDYgurWUNGXWM7g3IwMD3qO2ms2uHEKrgHuCKypHcccA+1NRnEiHdliRnrQBu3scjGdY9w3M3OeRzzXPais1moMjGZWHH+zWzaTt59ykjEDzWwT9TRd2JukCSusa84JGSf8A61AHOvd5gOQAMbSQc5FUbiJpOXYqrfdz1x/hWw+mLbOWkn80jkKo4HufX6VXKbrlVOeTk/40AZ1hZmK7i3Kd3mL1+taWkwncygnoRgVqw2wcxFhyGUYH1pmmQhZJGw2f5HvQBkXab4pYsEcZB9K5C6tp5WPlRDA6jOK6rXXK3bRhvlI+b0NY27Mqwuo2HOMcGgDMWOeBEhkEZhAx97oaIPluowRwA3/oJq5coSedoOBVSHJvE5zgMP8Axw0AZbZaPpiu4+F4/wCLi+Djxn7ZNx/25XNcUEyoyOc813PwzUj4h+DicY+2zj/ySuaAF/aQj8z4m8YyNGtev/Xe6ry+OLcmAq8e1ep/tFOqfFFQ/wB06Na5/wC/91Xn32Up3+8KAKAhyMFQKt2sQLD5QRxUhjOemPb0qzbRqXUjPBHQf5/OgDTWNTczqwGBI3JHTmtjT4wIxlQRnjHP4VQRR9ouQccyH8s1q211b28yxOrkEHc4xhfWgDodPVfKwBzx0Fa0K7Q3AOxc5/CsqymjdUWM9P4e+K2Ldhk7gfun8sUAULJQxEjDq4574zVWVBtkwpLE5I9TU+liQzGOfn5wyEdxmnSRFjj+uaAOfaBkkLsOmfbFbWmLGLZsLhyh+ZuSaZHaKodpyqRn17+o96es0G8ptbB4yV4xQBXLq+S0ZPG0/X0qvayIl3HsJIG7jGf4TxWhfxFZQkYUqOQAPamxHNxGHA6nHHfaaAIIJEa23SLsUeo5+lRHV0TIeIbT029arzXalliPCngjGRWEb2OOZgyGRS2eO1AHaW5jufmjyR0OaDAoCgpuOevr3qlodxbzrA0bFXUEbG4yPQetdCwUr8o6jrigAgUbZWA/5Zk5/KopjiFHbAw/TFPjLQq7L8yGM8E9+KdPDsSMMMkYP40AQTxhkK84zkH0rn9StFw3PBOfxroGjdSw35VjgDtWTqMUjq4Jwu3ofXsaAOYmhJkORnvxx39Kp+UBb3QAwT5eCP8AerXmjJc8g4HHPf61VWHdBc4yf9Xn/vqgB/h+AZGQOe3+Fei6YMfs1+KwO1tr3/o+6rjfDluX2EDqcYHrXbWa7f2cfF6+kGvj/wAmLqgD5l+NpZdM8ODzJGBE+dzk55X1NeTkk1618cP+QV4b5/57/wA1rySgAooooAUDJxXovwl0qZ7u51SWR44IImSPBI3OeMj6DNcDp8P2i+t4QM+ZIqfmQK9p8FqLPRZ4GG0LKY1PYgE0AdHZW3ysfNuCTjrK3+NaVpAZLlF8yTaG5y5NQWhG0HIIyOa2tJiwrs3DN3NAG1p0BEUiqzjIHVjxzWzYQGJldnbHYZNU9PjdzwDtO0M2OMZ5rUX55n2Z2LxQBYCGWUMWPHYHtVpR5eCRlj0561Bv8lFXHznnFKZNyklgvck9qAFmnKYyfmI5z2qKPUCCElzt/vZqhdyNMylB8mOPz60i2jujHadvbnp70AaMwZmyAxQ9wafaoQeWYnOR1qawgaOJTIeQuMVYCgkUAQscrgEj8aqzZGcMT+NXGznmoXjyMcZoAzJWI6k8e9ZV+xCt8x5I7mtuVOprI1QDBCdRjP60ActrzSpGssMrrg4YZOMVgWLMfFHh8h2ZDrOnnlj0+1xVvaispZlVNy9z3J/wrEswi+JvD6qMEazp3/pXFQB9c0UUUAeNftSLv8H+H1xnOsr/AOktzXz0kbBRwTmvo79pIK3h3w0HKhTrSg7un/Hpc14XLpnl5Hm24GMjlun5UAZUUR3r8uXHatBItijdyW5Kg9KlhtUDA/aLfI6HLf4VbitF73EBLHnljn9KAJ7ZSZrXk/8AHumOnUZratIZ2UDzyUzwSOn1qulsqG2JubbHkIOre/tW9YxKsWEmhGBydx59+lAF+xjKxRdNuc9fSteVFltHDgNjJ5FZunRlY4w0sPGSSGP+FXr0smnSlZocAjLZPT8qAMe4idbFpQQOuRViaRBO5kAOQuPf5RTriMNZBHkhGUPGTyPyqpqEI+0sPPhLEKRkngbR7UALPe8FlycA4Gf5VcsLuK4sgkyjC4zk596wWhG4K11CI92Orf4VtW8cKxL5ckJY8E7j8x9elAD5YFMgIYMh7DrVdLZxIu5jjcOgxUsrxwgt58O8gFV3H8OccU21uQ7hpbiDaxwCGJz9OKALczW9g80knLs54z7mstdZE8rI+Q46DgY/xq3qkcbeYXlhzvY/MTjGfpXHXLg6i8Ud1AXZsZBbj9KANy7ulMALFiM8KDnOPWmWRWW4RkO5cEn/AArNVI/OWH7YjuFO7knnP0rQ01VWVts0IyMYycAflQB0MLKZothO0kds0QxBJWXHXgcd81Ja26r5bCWMncO5A6/SiUEyoY5YiRyTuPH6UAY2p2MUssjuhLZ5boRWFNaxxPvjDbhkct0rsLqIHeZJI+eByR+fFYGoW6jP76HBPdjz+lAHLzgkt2qvaKRdJnuGP/jprXu7YAOTNACBxkn/AAqGys1N4jCe3OA3GTz8p9qAMlIsoqKPmPX2rv8AwJbC28a+Ccj95JfTMSew+w3WB/X8q5mysVOwtcQHd7np+Vdp4ek2fEPwZbB42b7fPJJjrn7DchR06AfzoA5r9pQZ+J8f/YGtf/R91XH6cwe1QPk4XBzXV/tNTeV8T4yRkf2NbE+37+5ritGuo5iPLcEgYIHBFAGh9nAP97t9alghw6kg9en41Oh3HaRyD/OrSw8qqA5BAINAEhUi9uM9d7Hj0z0rWFusLRvsGx+cH+RqqsTPfSkLvUOQfUcnitpIw9sm4Er1C9CD7igBlrGYLlHiJ5zjt9a3w7CDeuASOOaz9Ot2ml25xjgH2qPWtcgs7p7WCOS4kiO12ztRT6Z6k0AXoJF+2wKAMsQc/jU29cncc+3rXOQaqsuqQyKhTgLtznnNT2N+0gBOBnIz1oA0p1FzIV38gY9hj+VJbQmNzvVTxnPWsm/vzGqbH3A88cfpUFvqm64AJAHXJOKAOmh/eiQNnIXAJrOSOcz5PDqGUD1ODUt3qPl5kxyBgY4B96y/7XMlysce0E7skdjtNAFfUI4IChkc+aRkiPnJ+tc3etGz7xG6rnIPXH4dquHUZAksbrudk+XqMEd6y4vOuiCpdx0IXt9R6UAa+mCWFlickM3zDnn2rt9Gmd1KSsTj+I1zOiWi2cameR5xnOwnOPzratZYw2IkbODzzz+NAHQn73lkfJ5TNn06VCCGcMx46mqomGS7EbhEwIz24xUMOpWkkrRTSeU5P3h93PbPpQBffONxJIPUdqz7xienOeue/wD9ateeLZb7jt246g9ayJtkpOAMDrnp0oA527GXIHA9hwabFFm2uB1YhDk9huq3cx75SwwNuDtHb3p6rts7kthThST/AMCoA0PDsIXYTzjmuhtW3/s5+MG9YNfP/kxdVy2nXYt7CaeQZCAL15LE8AV0ekO0n7M/il2xua010nHr591QB82/HA50jw0f+u/81rySvWfjL5b6J4cPn7iPPA/dMM8r3NeTsAAMHP4UANooqaOOJhl5gh9NpNAHTeAtP8+/juXXKrNGi/XcM161bWyrZ3K463D8fia5PwTYwQWunILoZLpISYX5ywPpXdWyR77pPtC8yu3+qb+8aAIoIpI3xC5A4zzmut0uV4wEdc981jWcERY/vl4x/wAs2/wrpLeGMqP3g6DJ2GgDe0243W0+7jG1V9a07F1gtGkkBBHY/wARrNsFUowDA4UY+Q9c9atXmxUCtINqDHCnrQBBcTSKhcHLHk8U3T2kmtXGCdwOd1T2eGj5lBYf7JqR2VWHzj8FI5oArpaoHh2KynaM4Pua3Ld90ZUhdw4qi8qrsBcD5QeFPqasWWGkJDjAH900AXzkKFxwKE96aWyfvYH0p4A7E8e1AER4pjHHPT0qYpwQCKidRtJz068UAVLpc/MKw71A2/1yK3ZMH5cjHbisC9YbZCHx8wGdp4oAw78iON8ZyRXJ2j7vFfh0DkDWdPBI6D/S4q6vUYgY/nkyvTG01ytsgTxfoIWVWH9s6dxtIP8Ax9xUAfXdFFFAHjf7UIB8JeHQf+g2n/pLc15HaEXNigcjzo+Mnuter/tVsyeC9AZPvDWkx/4DXFeK+HdRSeVYm+SYjgf3vpQBe8gJMHxtX+ImrKRkngdfyqyQpyrgqc9wOf8A61J9n+bJ5B9P6UASgYFuAQSYY8Ed+ua6KxbICgEEgdug+lYaxFpoNpCnyEGM/Wt+12q6jHBGCD1H+TQBoJhSq9MDsal1BsaTciU8KVP+ApIIyblMjGeAOhp2tDNq9uFJzg8eooAxjdtcacy4PmRZVvbuKnuWPmOwAJfb16Z2isrTyWWZZBgKpDhuuMcVcuLn7PPLtAz8vH/ARz7GgBLyGCJofOZvNH/LNME49yen860LB7eaZRyNi7lXPU+lc3I7O428jrluD+da1i0W0SLIu/G3rwPrQBpXECXQdmBXb0C84HqarbIreZQCNvC4I5NOjuNgUJ8pOepwCfTFc/qF4yzBxnaz7Qe46UAbet3NtKt35jlGjcgZOM88CuVe6tdiSW9rulzgk5+YfhU+sOrwT+ZnJuHA56YNV7MpHblbhkxjIcHgH6+tAGhq15D5SBY1jmbkqB0Hse9XdIhfyxtXcAMq3qO9cpq8jSXMbEHZwFI/T+tdL4bv18tLZnBkU7TQB1EEqvLBCgIKsC4PYZ6VVlu5Reny1yo5YYqazcS3/mp/CfLHt7mo4kLs27hScHPpQBZkIeLJXGecE9K5/UVUhuACenoa6OSMJDhQQMYHasW6UlJGZhtIOT7/ANKAOXnRg4XO7Bxk+9WNPth9pj45AbOB/smp2gIl38En1/iFaMKiERscruDHjqflNAFK2QKyMRkgZOfb+tSeBL1rv4s+FdpBjF7cEkfxN9iuf0HSszUrtrPR7iccStiGP/ePU/gM/lT/AIUAL8SPBw/6e5//AEiuaAE/ahQv8TIwJYY8aLbf6xiM/v7n2NeU2ySQsssV3axyL0YSE59vu16z+06u74nRjGf+JLbf+j7mvK7eLIGB9aAO10iZb21EomtxLHxKoc4B7EcdDW7ZwB9uJrfd0A3n9eK4jSZ/7Puo5wMxEbZl/vJ3/wAR9K7y2jMc4ZDuU4YNjqD0NAFuS2zdSIZYAm8kgOeefp61q2q/IAJYC2Ohc9fyqtcRfv5CP75Y+3NTwtsIZevuKANPS1Mc4AkhLhskBj0/KuAkExu53kuLdmMjZBc+p9q7y1AE+6PAcNzg9TXG6tE1tq90gyF371OOx5oAfbW7G4hdp7bdvUthz6/SqN5MyQlEubdTnGRIef0rUslAkgJyR5g49ATWFdG3+0hEDEbjlweCf8KAJJZ3W12C4tt2M58w8D8qpQK08olmvLd1U8fP8v06VPHNAssqoiyAHPzf0qG4uVWSNZV2xsv8I6UAdnEyXljGxkgCsCCEf/63SufGnSx6ssn2iExNuIG8jjYeOlUrW8ltWCx5MW7jJ59zWxYT77yPPzBwxBJ6jacGgDMmz9lUiaBpF+Uo0nBGOucUmlsI5d4mtSOhXzD/AIVtfZIdQhQTp0AGBwc+tPjsLWzkcpb5cjlnPJoAsaSjukk00luDK3y4ckEd+1abxKq/LLAB/vHn9KzoYtvTcBnk1J56Pw52fMNueMUAX1jZlkBkt2PlN/EeOntWHNBLDITHPbmNs7lL4x+OK2UwUlPcQtnn3FY0zbS5wcNxz29qAOs0yV20W3JmiJ2FWO7gkcelQm32Qn5ouT0DdP0qxYWv2fTII2G3avTvk8n+dNlHzZ/hHFAGYbNpHOJIcA5bDnA9e1R3cRkinWKSBQAgBLH+99K04YwY5P8AaIX3xTJLeKC2up5jtt40Dtn0B6f0/GgDnrxCptrNZbcBB5rjf3PC9vTn8a7PRxj9mbxSMg4tNdGR0P7+6rhdPL3Uz3M2PNmbew9PQfgMV3mljH7NXisD/n117/0fdUAfNHxoULoXhgD/AKb/AM0ryk9BXrXxtAGg+F+ef9I/mleSsPlWgBtORSzqo6k4ptWdPjL31spHDSqP1FAHs+ixiNrVBjCtEOPqK6K3IW6m9fMf/wBCNZem2JFzEQDgSJj6ZFb0enMZZsjrI+P++jQBetAFG4D35rorQgkH1FZltpxAxjPy9q3LKzJiBYGgDU0lwgYqCxwuAPrT3Qq5Z+VYnjOcUy1tiscgHy8Dp9atLCXBJGDjmgCsFVXyMk54NSEh175xVgW24Y5Bz19aabcA7sZYDigBEXcseRgbf6mr9lH5cZOAcmq8UJJQAY+Xp6c1pxR4iHpQAiZJ71KODjrSBMY68U5R3PWgBOnXt3qOQgDOMdqmI5yetRSgbeeSfagDOuV2sGxwfSsy/T5HYDhjnGehraZS2Qwzn+dULmLGRjg/rQByN/wCuCDjrXKJFt8XeHHyTnWdP5Pr9rirvdU09njJhz7giuQezkj8R+HpHB+XWdO/9K4hQB9VUUUUAeLftVkDwVoGen9tJ/6TXFfOByMFCQ6kMGBwR9K+jf2ruPBGg/8AYaT/ANJrivm1N5Y9+e9AHfaJfC/s/Mb5buDCzBR94Ho/+e9b9lGs5LRbd3cdq880a7fT7yK62lo87ZEH8aHqP6j3r0GJAro9uweN0EiMvRlPI/z60AXFhQPbgcyeUoH61qKm+1UrwQCMdCR71SnjL/Z5yAA0Kgjoe+TWhZMcPu27QvegDR0H9/JiRkQZ/EVhal4isJL51gkkO2TaC8ZAODjr6cVqWDeRd7lx5eeg6jPevO7q1e31O7gl4ZZm/I8/1oA1ZrqJ7nUZlbZ5jfKCc7uO1QajPmeUuGUArkf8BHSqaqeqIGPTJ+lXNWi3ST/IW+6OP90UAIl75kOyIIIRzyNxz6020lknnS3kk2x/3lwCBVOzCxCRN2Sv97jAq9ZSwvMYY3XzGQ7X9D2/OgDTEkdyFTdIhiI2kgkj/Gorq2eTUYrlSY8cDPpnrj3qVUe3hBkJwARxT7K/juJo0A2O2NobkYHb60AVdajijMpYli0rhYiMc56iuctbaWaZ5YXZCrD73KN7YNdfqkaNJOJUDATMdzcbeaoxwRNIDCyCHnOOMn6UAV47c3NvMsqosjA7CeCD7egqhp1lPbX2FTITr2x+NbUtg83lt5wTYAxGOQfaq19ewfKqzI0ynHB70Aa+j3ksV00ZOT5gIPfrU9jrVrDNsvpEC5xvGfkPrx1rD0e5+0XADDDhgMj61XvIkRXxhc84oA9H1Hy1tQ0Ukcg4I9waxnjbyS5ADN6Dt/jVy1jcaTZJJkOsKBge5x/9cU24QhWQE4XgDNAGNDDuuCSf3cYy7H7xGelJI73V6jMSiYIGBwPlPNXYIiEmxgAkZHt3FPEKwBrqUZhgRmb1IAPH9KAOD8XsDLbWyDCxJvZf9pun5AD861vhYu34keD+v/H5P/6RXNc7dF7rzJ5jmWVzI3sfT8OldP8ADNQPiT4P/wCvyf8A9IrmgBn7TIz8TU/7A1tz/wBt7mvMLNTkE9vevUv2lBn4mrjr/Y1rj/v/AHVebWERbn0yaALUKZRuldt4JuluIRaSsBNCuUz/ABJ/9auTiTYhbg8d61NFJs7i2uDuyB/D1Gf89KAPQZkZpJAM43Nj35pYLVguGHQcc8k0JfRyF/IAyHYb26delTxCRAWMhUnoFFAEsEbIQSB744Pr2rG8W2bTRxXsanMXySD/AGSeG/A8fjW/A5AxId+O2Np/+vUkyBkZiC0bAhlI4x6GgDhLSQCSIHgBl/n/ACqrDHm4MmxOfl554/8A11p3NiLHUYkBLQPIGic9xn7p9xWROZEyjcY6AdSKAKqWiNdOsUnlgnALD9DVldAnLp5jR7VPGD1qtKcn94TjqBUv2qWFQEkYhfU8UAaH9hvvLF0xjGMn860LC0jgnjUL8yhgPf5TWTa3M94CmXBXpg1q2RnF1GCOAGz/AN8mgCaylPCSAKcjBxnPtTpQwcEtvTnk8cVVwdqGXIOMjn+VOjuWdyEyUHdsg/SgCxbsyqWHzKeme9V5JN0jKIyN3VyvAqa5mMMa/NtJPb1qss5mwkxJccswHGfegDRtn3pIuST5LLnHXp+dO0+x+06ikcq5ij/eSfh0pbNcq4wS5iIUeuSK3tPtlt0EIwZTy7f7Xp+FAFlQXclh16DpzSPbjHzlQehxU7cJtUcY5bFQFF6kE+uTQBGsOFIBGc9B1rN8TnfoU8IHO5Cfpuq9IMMfLBGO4rD1ae4mhuY5X/d/L/6F0oAo6InyLnkgc12WnDH7Nniwf9O2vf8Ao+6rktCUEYPO2uu0/wD5Nu8W/wDXvr3/AKPuqAPmz4ywTXWjeHTBGziIThtozgkr/hXls9rKtrbP5b/Pvx8vo2DX0la3gihAFnbkDoCXP9afeagFsbNxYWZP70H5T/f+tAHznoWj3Oq3TRwRM2zBbjpk4rs9P8G3kc9rL9mfCyqx+X/ar2TwRqQlutRCWdrEVVDlFOT1rsBev5ZBji4GehoA5210CSO6XKHCuPbvWvHpJErZXqxOfxrcE5chuOQDUu8gAEUAU4NPK7cr24rTtrLC9DToX6ZrQibkc5/CgCOC0G05B5AqVLbB6DFWUbj2pwPP9KAIBB3oNtnII/Gran19KXIz/jQBUNt0IB49KlWLoOgqfPSkPTmgCIxkd6AnIzxUuf50hwM0AQYpjqCB61Oee5qM0AQNHjOKgmTIPXOauGoZOCR1oAznj3Ajr7+lc5rtl5d1o02ORrWmc/8Ab7DXWvgE+9ZHiTH2fSsY/wCQ1pf/AKXQUAezUUUUAeLftVBW8F6AHcop1pMsF3Y/0a47V88Q29uW/wCPtvb/AEdv8a+h/wBqoE+C9Awf+Y0n/pNcV8+2yYIJ+vFAF+2t4DtUXRwvP+oP+Ndn4KlhnjOmPc7pFJeAmIjjqy9fXkfjXIQALtJ46Vr6IDHe20wOGEuQScDPbmgD0OaKMPGhmwViUf6o+/vSwooKqs7Bj0Pkn/GrIeMpE85VHaNTjjk88VJBKM7lgJB45OM/SgB6RJvOZSM4xiI4Fc34v01DJHqUcpCrhJsRE45wG69O1dXEyAMGDKBwO4pJUA3K6loscjHDD0oA86It1hkL3JHv5B/xov7cSX88guZGztI2wtj7o9+av+I9MFokslupa1lBAx1jP90+3oaos2zUHLHCjbz/AMBFAEIt/Nj/AHV4VZAWwbcgntnrzT4bOOMwTxXGHDcL9nOCc9cZrQup4xCWfuMeuB71XsbzfcCNYt8QHysf4e2aAE1nVLWTzLaa5cR5+YiEj9c1S0u3j81fJ1BywcHLQH/HpT9ZhhuJFjaNcIcbjzuHY/WpreOLMKJldjAcryT2oA3NQtoJ2nZ7jP3gR5ZOOTnHPNZdjFCkZJuCQOMeS3A/OrM4njubhTGApZm3Zzu5PFVrSSV5PmgCY45zk0AS3sK30aqt0VTGceSf15qp/ZMWEDzrhThmWI5B7HrWmgUMRyCD90DvVlkRjgKM9emM0AUdPsIba8RxcDBYD/VHnnr1qXT9MS9v44/NzChEsp8oj5Qemfep0UzX0EeNzlwFA+tdBptr9kj8mMq7sQZGA6sewoAsyKjtkyYI7bD07U1rRSCfMIB5+4elWDuXKoFY9SxPT6VXlyRlmLd/SgCD7IoQ7Zh1/wCeZ4qhrSr/AGabczYLNk4jPICmrUu9WZoXZe/rWNqF3O0whlO4HdubA5+U8UAcb5cHlKDdHI/6YN/jXR/DpI1+JHg4pN5h+2z8eUV/5crn1rnplAB9R0rovh4MfEbwcf8Ap9n/APSK5oAg/aVYL8S+f+gLa/8Ao+6rzrTs+WAQQMV6j+0JYre/EuU+cI5ItEtXClC28efdZxjvXmMBgijw1ztIHeB+aALysHKoMkY5+ta0J+SNQOcqB+dZVgkBO43Yz2/cNXV6NpSy7J5Jv3SkEAwsMn/CgDc0qP8Af3EbLwXYr9c81srGyxtgZx6VBDbxpeM3mkZZv+WZrSATAJkG7OOEPFAEarkD5eo5xVoZELSHnaRkHuOhqukaNKMS8dCNhq/bhCXXzDhlIxtNAHOXcCtdrBKCYmkDA/3WB4NcvcwMkjwzACVBjP8AeHqPau5vLZHkiYyj5XVuYzWdd2VtfW6x/aBHLGTsk8s8ex9qAOGuYW2hiCcHApbayeWT96doP6VuXmntbPsuJ/L5yB5LYb6GnxwQp/y8g8f88moAis7WKJf3eVVOQRVizmR9QQHcSMjJPqppkqwrgpdYx6wtRZeR/aEQNyMlTkeUw7GgCaMK8YbbjA6Y6U0w7SPLJPrzzTo1TgG6VkPOPKbpVlBbgA/aFUDplGFAFR4BNF5ch4HYj/PNNggdF/eS5UcdP0q+8UUrBY5izHssTGtLT9IigdZLuUHHIQoevvQA3SrQwQvPIP3rRnYP7q8Vs2sW6MYzhiFzjmotscsrfveqHjYfUVfgRRCx8wcZ/hPpQBBIMDtgc8GmqMjPc9BUsgTp5mA3opoGCvyycZ7IevrQBTuoiqPgjcM4+tYF3GVguiwzkL/6FXS3KqVOZevHCGs2e3iaKYGTC4UkeWfWgDC0cbJUUfxdK6ywOf2b/Fx/6d9f/wDSi6rmYrZYHCSXA4OQ3lNg10un/wDJt3i3nP8Ao+vc+v7+6oA80jtQFzgfSoL6LFhap7S/+h1pspC4Gaz9RB+zWRwePM4H+/QA7wDGF1O/TjJiBH/fVdyYgRwK4fwWfK8QupPDxMnHr1r0JlO3HrQAWozEvfHy1Z5z2zVe1JEhU8A/pVphjigCaDpWlD1HBrOgHHatKHqCKALKjtS/j/8AXoQUuMjk0AKnrn8Kfg+vPpTVxjnrSk8+vNACscdjSZ7/AJDHWg844wKOvfigAz9BR19aXt60Y6+lAEZ5Of8AJplPbr7imHrQA09/WoG5NWG6VA4596AIn5B9axvEnMGlcf8AMZ0v/wBLoK2yKxfEgxDpf/YZ0v8A9LoKAPZqKKKAPF/2qP8AkTfD/wD2Gk7/APTtcV8/W8gabHYDJ9q+gf2qt3/CF6BsGW/tlf8A0lua+ebIBY92Rk+9AGwGHyjPoDWtaKBAASMHmsKABp0+YkZGR0rbsUe4kEMSbnboOw9/agDtdIRZre2LgO6woM/nW7bRERk9gOcVl6PEYJrYKoKG3RTnpxnmt9H2oVfHTjjpQA6A9uA2Bwf51YkURrvALKfvqOciqxYKAVG7jP51btir27q2MlCeO1AGBqEQiE0Z2vG/3gejqema5nX9OazvHZcm2kIKP12EKOG/xrr9SjLQRtHyHQgkHrjkcVDcmNnkjkVXRwAy9ugoA88MgRwHJI575Iq1a2m8o7EBT0VT2rVu/DB3tJp8yODz5bnBH496iSzvbMHzLaUcfwjOKAK6Rb5MgMEVto4yT68elPhBilBxyzAEL9e9TpPI2cwyIR6qaW3HmSDA+YkcYwTQBJdzqbiYMGO1mGc8feNQi88oKQAwz0NW7u3Mt1KsUTEl2B46801tIuHI2x4weQxGMe1ADhebgMgxsDjHb68Un2kMwCfM7HHA5P0qSDw9Nv8A3lxGinPAJOfrW5pumWljhxmaUdGft9BQBHo9mbQpLMB9pkYDB/hX0+vrWparsViep+UHv70wKXuIMr95gcenNXIECQykgjYSSKAElXYp44AycVVVdxyR74zUkzAnjOD6daYrkAEBcHjk0AQXC7Y2c545FczcjE37wYBDdPdTXS3jAwMe54yPSsZ4la4UHhSGB/75NAHFXv8AqgwHv9K6H4fHPxH8Hd83s5/8krmue1CKS3JhlGB1VscMPat/4cY/4WH4OGMEX0//AKRXNAFv48Fl+KwZASw0W2wB6+dd15isZlkAH3TgkHnj3r0749sU+Jzumdy6NaEe37+65rh7GASSmVRjn5l9/Y+ntQBe0aCKLB8tdx5yBz/9aupt5sYDnkEYHYVkW0CohfkMfQVdtkYTD5uc9+poA3QS88uD0Yj361oIwdVAG0+nestd4nlOOrt0+tPs9TRdWS2ID5yX54TjvQBrGP5sHjb2HrVi2YNeRoCN3JJP0qrJI6hsEYJ7Gktm2vuI+Y5/lQAy8vYYLyGLZJ87Bt46deBiqsIhuGYW8oLdQnf6YqhqUxn1dcEbVdVH4Hms5vkYOrFWB4OcEfjQB0m91UqyhgezDI/WqctlaOcmEID3RiKZYaqtyohvB+/HG8fxY9R61NJIhP3yM+3JoAyruwiJKhnU5BGWzVG1t3j1WPeQRhgAP901r3D/ACcfN2PrWdHIo1FAeD8x45/hNAE9nZo8cbShiMAkA4xWvbW0KH/j3QjsXGTWbp5LIGUbeB71sRuAAz5z2/xoAtxM6KqrgAcccZp5EccfmTnanYd2PsKgN0scRcgEL+p9BWY129zMzyvljx0yAPQUAacd+fMmMUYU+U2Cx+la+nXBntg0gALRkEjuRXOx8rJg5PlsOv0rT0qTdasv90kZ/CgC1E4YHecH17fSnoMoT2HUYqi7gKBkg96c1yY7K4aE/OFyB2zQAty+cjOMVTmf91MMY+7z+NNgl+0WqzKT83BB7Gq82RFPkYxs6f71AE9i3mKN4DKeMGtSyAX9nHxeF6C318D/AMCLqs/TY84J5OK0bbj9nTxj/wBcdf8A/Si7oA5NtPlKf6mT2+Q1m6pp8/2S0AgkyPM6If71bTF9h+Y5+pqlqYb7NbfM/R+/+1QBi6TbzW+q2sphkH7wA/IenQ16KY2CEbW/KvO2DqitubIbP3jXe2c5ntIpMk7lB5NAEioysMhgasHBPFQp16nPFSK2Dzz9aALluudtaMI9ao2oyOvb860YV6f0oAsIvHuadgcfzpV6UvbFADR075pAOcinAcUY59qAEPWjH4UuMe9HagBOOBS9iKU9s0Y46UARsPU89qiNTPz/AJ61G/WgCM1A45qxUcg6k5NAENYvicfudK/7DOl/+l0FbXfFZHicf6NpfH/Ma0vn/t/goA9iooooA8i/aUlEHhvw3IyLIo1oZRhww+yXIIr591HT44b9obclI9+5c8gDrXv37Tnl/wDCK+HRMxWM60oJGM/8etz68V41iwmuVmWeUnb82Nhwcd+eOlAFXTdLaWT/AFqhM5yqnOPxrtNEtoLJGEYJdhhmbnP/ANasqzWzWRFS5k5GQCU/xq9a3cD37QmRxBGoIfcuSx7dcYxj3oA6i3ZQ1u2BkQr0/HitfI8vgjGM1gxS2TvEi3J3rboSNydOeetaEN9YbzA1ztdQGJZ0B56d6ALa5znOB2B9fT/61WLQss8Yf7rNgAe9Uvt+nNJII7vf5PyOuUHPpyf1ohv7K5voQtwu6OUZXenynj35+tAEOsajb2dk+3FxKGaL92RhX/iyfYfzqgNatGupIbmKRE4wyjOPlHOKx5bm1NjJHLMytJeTyYDJ93PB5NV7uexa7mkjuXZCByGQD7oz1NAHYPbqYVlhZXjPIePkGqTs8bcksPU96x9O1S1tgWjuJxAeSMoNvvjP5ir9zqVl5e9rnKYyr5Tp275/CgCaSdPKDKw8zuD1xWW0oI3qSrlxx681Xvr6BLaaSOR2mVMxqxQhjxjoc0kV5aMNxmkUEK3ysh64OODQBtC5CzSLyzGRiPbk1owt5h3+3AP9awmvrBZZW+0NjzGBIdDgkn3rQhvrQKvnT7Qx2jLp1+meB70AaqjAG7IOegweabdXkFiEMuHncExQk4L46/hVP+0LKJQZLjgnABdCWPp1rmr+4hudbt5pZnYYO75k+UdhwcD8aAN2K9u7m+id5tg3D5VHHXpXQaNPNPphFw+7KHDY5yDXNWk1iLqGM3BEjMDjenb8a09G1Cy+yS24ugJMMwUugYgHORzQBbWTf9cHHuP8aasq4IGOPSsue+tGkaFJiWGGZd6Dj65p8V3bxrcO13l4lDOjMnQ9Mc0AWLqbKYA4xknOcVUVv3y7s8g89f4TUFjqUN7NcqxCRRhdr71yc9c846+lL59k10UWb5k3KfnQYO08daAMrUQskYWQBo8Z5GateCLWOD4h+DGjDDdfTgg9v9Buaglks5gdszkdM70rU8Itbt448Fm3mMmdRmz8yn/lxuvSgCp8dlz8TZjjO3RbT8P393XI6XHtUHAz1IHb3rs/jhsPxNnV2Rd2i2mNzY/5b3dctYmHaEWSPIGWw46fX+lAGrbpkKRxx3NaMCAkEc4P3j9apwtAWCCaHcqg8OM/XrzV/S7hLq4vIt8KpBKI1JkHz8ZJ60AXdRZbK1uJh/rNxCD3Jrl9MJXVF3khtjMze+RWx4nvrdpxax3ELGOQmTEg4PpWRoxhl1UMs0W0hlALgf1/XpQB0zXJGPMHXoxq1C4WLJYHBzu9qz0ltnjLR3MBXkZ8wDp2OaoXF4kdlO8FxEytG3ylxjofXkUAQJcJLfCSJgyNNkEcg89qrNINpOSQM9azdMu4YYrZZJo1ZGViCwBAJpftSywnawKjOTuFADpZmWQSJw2dwxXRySCZVKnLHk/XvXOCCNFSS5niUD5giuGJ7jNXYLmERb3uIlTsd46+1AFyZ2AYHIP8qqxFDqcZXOQrde/ymoNT1GK2t3ZHhkdSMjcM479DTrO4hbUk3yxYweQ45+U80AatjJtijx90gHPTtV+JgW3MeKwIdRt4JUjkmhHAwd42+30q8b2DtcQF2BIAkFAFvU58eWg6AndjrmqsMqCUxhxvC7tnfHrTFmtpwsLXMQkYFh84NUoFMWt3XzxMPKXBDjBoA34JeJhkf6pun4Ve02ULDJk/xjg/SuZGpQIZ0SWMyrE2fmGB0/WrujTLKv7y4i80ncVLgYGOMc9KANxpTI3A4Pf/AD3pjkrBKO5Q5/KnWb2rPJtuYWMZ2uBIBg/nSzzW7wzmK5t2ZMowEi8H8/8A61AFTQciSSIn5WXcB6GtCSIbZgT/AHce/Nc/oWoRyXEUrtDHiUx4Mg+70zya6aWa1mgeaG6t2R8fMJVA4bHegBunRlX65GTVqD/k3Xxl/wBcfEH/AKUXdQ6ZPbPGHSeAxMC27zAARUllJHN+zj4vkhdXie319kZejA3F1gigDDmVUiZ5GVI1GSzdAB3qpfR77a2IwQVYgj0LVY1poZdA1AwzQyYjZTtcfeHb3qWUQrY6crzQKzxYUFxycAn8aAObnhIbGDiug8PTE2vlFvmjPH0qhcrCJHTz4SyLlh5g4FMsLyC2njk8+IxynA+cc5/z3oA6mM/MPrUpGT/hWba3yyau9opiMKwrKJPMHzMWxj0/rV8XdoYGuPtdv5Ck7n8wfLg4Oe/WgDStOAB2rTV0jQySsqRqCzMxwFAHJJ9Ky7ee3EscJubfzpFLovmrllHU9aTXLi2l0HWI4rmCRooHR1WQEq2wkD60Ab0bK8aujBkYAqw6EHkGlrO0i5totJ0qOW6t0klgjSNWkUFmCAkdetXRdWpmlhF3bebGod081flU9CefY0ASikqv/aFj9kjuvt1r9mkwEl80YbJwPfk1WOpgeIv7NxB5f2Xz/N80Z379u3rjp+NAGiaMVW/tGw+ySXX261+zRlg8gkGFIOD78GpGu7VZ44Td23myqXRfNXLAdSOenNAEjsqRs7kKigszE4AA5JNEbrJGskbK8bgMrKchgeQRWfqt1bTaTq0cV1bvJFBIkirIuVYoSB164qDw7cW0Hh/RYpbm3jklgjjRGkALNtztxnrQBrnnAzTCOMdKaLq1a4eAXdt5sah3TzVBUHoetRHULD7Il19utRbOQFk80YJJwPfrQAp96a4yPpVSfUVj1+HTgYDHJbNOZPNHDBsbfTp+NSf2hYm2luPttt9ni3B5PNGFwcH8qAFI6c96yPFAxbaZ/wBhrS//AEvgrWa6tVkiia6tt8oJRfNXLADJPX0xWP4luLeWCwjiuIZJYtb0pXVZASpN9AQPyoA9iooooA5f4g+C7LxxpdpY6jeX1mtrdC7jls2QPvCOmDvRhjEjdvSuFPwB0IzRynxD4jMkYIVi1ocA9f8Al39qKKAHH4CaGZllPiDxCZFBUMfsfAPX/l39qUfAXRBP53/CQeIPN2hN2LPpnOP+Pf3oooAcvwI0RZmlGva75jKFLbLLJA6f8u3vSf8ACh9E89phr+vrI2NxVbIZx0yBb89aKKAHJ8CdER5GTXtcVpG3NiOxGT/4De1JD8B9EhZzHr2vKXYu3yWXJPf/AI9qKKAGp8BtDTf5ev8AiBN7Fm2izGSep4t6SH4CaHDGEi1/xCiDoo+x4/L7PRRQAkPwD0KGFYo/EHiFY1GAv+iYx/4D0D4BaCLX7ONe1/yNuzZizxj0/wCPeiigBZPgJockDQPr/iFomXaVP2Pp/wCA9E3wE0OeJopfEHiFo24Kn7Hj/wBJ6KKAFl+Auhy4Emv+IGAYOARZ4BHT/l3pZfgNoc2zzdf19tjB1ytnwR0P/HvRRQAsvwI0SXZ5mv68xjbep2WWQfX/AI9/emt8BdEaWOVvEHiAyR52sRZ8Z6/8u9FFACn4D6I0ySnX9eMiZCnbZcZ6/wDLv7Uo+BGiCbzf7f14yBSoYpZEgHqObeiigAX4EaIszSjXtd8xlCltllnA6D/j296UfAnRVkkkXXtdDuArMI7LJA6c/ZveiigBsXwH0OKWSRNe17fJjexSyJOBgdbeli+BGiRFzHr2uqXYs2EsuTjGf+PaiigBIvgNocO/ytf19d7F2wtlyT3/AOPetPwp8HdG8NeIbDV7XVdXuJrKSSaOKcWwjLvG8ZLeXCrHiRu/XFFFAFvxz8LNK8YeIk1m81PVbK7W1SzxaGDaUV3cf6yJznMh6EdqwF+AuiLM0o8QeIfMZQpb/QzkDoP+PeiigBw+BGiiVpB4g1/zGUKW22WSB0/5d6dF8CtFieR01/XQ0hDOTHZHccYyf9GoooAYPgPoiySuviDxArSNufatmAT0zgW9EHwG0SBmaLxB4gBZi5yLM5J7829FFADofgTosMYSPX9eVMk4CWXUnJ/5dqSP4EaJHEscev68qKMABLIf+29FFAEa/ALQltxANf8AEIhC7Qv+iYx6f8e9Of4C6I8BhbxB4hMRXYV/0Pp6f8e9FFACS/ATQ5YWik8QeIjGy7SubTken/HvRN8BNDmj2SeIPETICGAzacEHI/5d6KKAEm+AWhzBRL4h8RsFYOMtafeHQ/8AHvTn+A2iOyF/EHiFijB1z9jOD6/8e9FFACP8BNDd43fxB4iLRklT/onGRg/8u9B+AmhmWOQ+IPEReMEKc2nGev8Ay70UUAOPwG0QzLKfEHiAyKCobFnwD1H/AB70v/CiNE80yjxBr4kKhCwWzztznH/HvRRQAJ8CNFSd5h4g8QeY6hSStmcgdP8Al3pV+BWirK8o17XfMcAMfLsuQOn/AC7UUUALH8C9FjaRk17XA0jbmPl2PJxj/n2oT4F6KnmbNe1xd7F2IjseT6/8e1FFADYvgRokO7ytf15dzFzhLLknqf8Aj3qSL4G6NFEI49d1pUGeBDYfX/n2oooASH4GaNBCsUWva2I1GAvlWJwP/Aaut0rwJpmmfDq48GQ3F4+mT29zbvKxQTbZ2cuRtQICDI2PlwOODRRQBx4+BGhLFLENb1ry5SS6+TY/MT1/5dqVvgTojNCx1zW8w58s+TY/Lxj/AJ9vSiigBB8CNEEkkg13XA8oAciOy5A6f8u1MHwD0ERQxjXdd2QkMg2WXykdP+XeiigCRfgVoqzmYa9rnmldu4xWJOM5x/x7U0/AfQTbNbnWtZ8hs5TyLHBycn/l29aKKAJT8DtGMySnXNZMiAhW8iwyAev/AC7e1J/wozRNsy/21q+Jv9Z/o9h83GOf9F9KKKAF/wCFG6L+5/4nWr/uvuf6Np/y8Y4/0X0pV+B+jLK8i63q4kcAM32bT+QOn/Lr70UUAM/4UVof2dIP7Z1byUwVT7Np+Bg5H/LrT/8AhR+jef539t6v5u3Zu+zafnGc4/49aKKAGf8ACitD8h4P7Z1bynzuT7Np+Dk5P/LrT2+B+jNLHI2t6uXjBCt9m0/gHr/y6+1FFACf8KN0X99/xOtX/ff6z/RtP+bjHP8AovpSf8KM0TEI/trV8Q/6sfZtP+XjHH+i+lFFADl+B+jLK8o1vVxI4AZvs2n5IHT/AJdfemD4E6ELZbcazq3kLjCfZtPwMHI/5dfWiigB/wDwo7RvO87+3NY8zbs3fZ7DOM5x/wAe1M/4UVofkSQ/21q/lOSWX7PYYOev/LtRRQA5vgborSxSHW9Y3xAhD9nsPlz1/wCXaptP+CeiWWq2t+NX1eSSC6gvNrRWaCR4nV03FLdWxlBnBHFFFAHqdFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pre-operative posteroanterior (PA) and post-operative PA and lateral radiographs (panels A, B, and C, respectively) of a patient who underwent posterior spinal fusion and segmental spinal instrumentation with pedicle screws. Note on the post-operative lateral how the use of segmental instrumentation allows contoured rods to be attached to the spine to better maintain normal physiologic sagittal plane curves (thoracic kyphosis and lumbar lordosis). By orthopaedic convention, scoliosis images are viewed as if looking from the patient's back; the left side of the image is the left side of the patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Phillips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32136=[""].join("\n");
var outline_f31_24_32136=null;
var title_f31_24_32137="Cervical fascial spaces anatomy";
var content_f31_24_32137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Relationship of various cervical fascial spaces to the superficial and deep layers of the cervical fascia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 672px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Sagittal section of the neck.",
"    <br>",
"     (B) Coronal section at the level of C7.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Adapted with permission from: Chow, AW. Life-threatening infections of the head, neck, and upper respiratory tract. In: Principles of Critical Care, 2nd ed. Hall, JB, Schmidt, GA, Wood, LH (Eds), McGraw-Hill, New York 1998. p.888. Copyright &copy; 1998 McGraw-Hill.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32137=[""].join("\n");
var outline_f31_24_32137=null;
var title_f31_24_32138="Anterior cruciate ligament injury";
var content_f31_24_32138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anterior cruciate ligament injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/24/32138/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/24/32138/contributors\">",
"     Ryan P Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/24/32138/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/24/32138/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/24/32138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/24/32138/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/24/32138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior cruciate ligament (ACL) is an important stabilizing ligament of the knee that is frequently injured by athletes and trauma victims. There are between 100,000 and 200,000 ACL ruptures per year in the United States (US) alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the presentation, evaluation, and management of ACL injuries. A discussion of the general approach to the patient with knee pain, including descriptions of examination techniques, and discussions of other specific knee injuries are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/11/3257?source=see_link\">",
"     \"Medial collateral ligament injury of the knee\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/15/16632?source=see_link\">",
"     \"Meniscal injury of the knee\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21157?source=see_link\">",
"     \"Patella fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=see_link\">",
"     \"Patellofemoral pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary function of the anterior cruciate ligament (ACL) is to control anterior translation of the tibia. The ACL also is a secondary restraint to tibial rotation as well as varus or valgus stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/3\">",
"     3",
"    </a>",
"    ]. The ACL originates at the posteromedial aspect of the lateral femoral condyle. It courses distally in an anterior and medial fashion to the anteromedial aspect of the tibia between the condyles. The position on the tibia is approximately 15 mm behind the anterior border of the tibial articular surface, and medial to the attachment of the anterior horn of the lateral meniscus (",
"    <a class=\"graphic graphic_figure graphicRef69611 \" href=\"mobipreview.htm?34/27/35251\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/4\">",
"     4",
"    </a>",
"    ]. The ACL is often said to be comprised of two bundles: an anteromedial bundle that is tight in flexion and a posterolateral bundle that is tight in extension. The blood supply to the ACL is from branches of the middle geniculate artery and its innervation comes from the posterior articular nerve, a branch of the tibial nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior cruciate ligament (ACL) is the most commonly injured knee ligament. In the United States (US) there are between 100,000 and 200,000 ACL ruptures per year, with an annual incidence in the general population of approximately 1 in 3500, although the actual incidence may be higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/1,2,6-8\">",
"     1,2,6-8",
"    </a>",
"    ]. Data are limited by the absence of any standard surveillance mechanism for the general population. Registries exist for injuries sustained by US college and high school athletes, but these account for a small percentage of the total number of injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The great majority of ACL tears occur from noncontact athletic injuries. According to the National Collegiate Athletic Association (NCAA) injury surveillance system, which has tracked all injuries associated with US college athletics since 1988, American football players sustain the greatest number of ACL tears (53 percent of total), but female gymnasts sustain the highest rate of injury (0.33 ACL",
"    <span class=\"nowrap\">",
"     injuries/1000",
"    </span>",
"    athletic exposures). One athlete participating in a single game or practice equals one exposure. Among skiers, recreational alpine skiers have the highest incidence of ACL rupture, while expert recreational skiers the lowest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/11\">",
"     11",
"    </a>",
"    ]. Competitive alpine skiers sustain ACL injuries at a high rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/12\">",
"     12",
"    </a>",
"    ]. Participants in women's ice hockey and men's baseball have a low incidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With certain sports, female gender confers significantly greater risk of ACL rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/14-21\">",
"     14-21",
"    </a>",
"    ]. In addition to gymnasts, female soccer and basketball players sustain significantly more ACL injuries than their male counterparts (incidence ratios 3.5 and 2.7 for each sport respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Although the overall incidence of ACL injuries is roughly equal for female and male US college athletes, this stems from the disproportionate number of injuries among male American football players. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gender-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains unclear which factors most predispose athletes to ACL injury. Overall, women engaged in pivoting sports sustain ACL tears at significantly higher rates than men participating in the same activity. Researchers have proposed several explanations to account for this disparity, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Quadriceps-dominant deceleration",
"     </li>",
"     <li>",
"      Increased valgus knee angulation with pivoting or deceleration",
"     </li>",
"     <li>",
"      Effects of estrogen",
"     </li>",
"     <li>",
"      Discrepancies in Q angle and bone length",
"     </li>",
"     <li>",
"      Decreased intercondylar notch width",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Quadriceps dominance refers to the muscle group used preferentially to control deceleration. Several biomechanical studies have found that in female athletes the quadriceps group generally contracts first during deceleration, while in men the hamstring group generally contracts first [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The quadriceps muscles are less effective at preventing anterior tibial translation, thereby increasing the stress placed on the ACL. Studies also suggest that women generally have weaker hamstrings and greater strength imbalances between the two muscle groups, and such imbalances increase knee instability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. These findings suggest an important role for injury prevention training designed to correct relative muscle weakness and imbalance. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Increased valgus angulation of the knee (ie, knee bent inward) during sudden changes in direction substantially increases the stress placed on the ACL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/29\">",
"     29",
"    </a>",
"    ]. Several biomechanical studies, including some using video analysis, have found that female athletes are more likely to place their knees in positions of increased valgus angulation when changing direction during a sporting event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. Thus, training to correct faulty biomechanics may limit susceptibility to ACL injury. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Serum estrogen and relaxin exert effects upon the strength and flexibility of soft tissues, including ligaments, and may influence neuromuscular function, although this remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/29,35,36\">",
"     29,35,36",
"    </a>",
"    ]. The direct role of estrogen in ACL injury, however, remains unclear. One systematic review and several studies differ in their conclusions about the relationship between ACL injury risk and the different levels of estrogen during the menstrual cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]. Oral contraceptives modulate hormonal effects on soft tissue and several observational studies suggest that they may reduce the risk of ACL rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/15,29,41\">",
"     15,29,41",
"    </a>",
"    ]. However others refute this idea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/43\">",
"     43",
"    </a>",
"    ]. The use of oral contraceptives to decrease the risk of ACL injuries remains controversial and requires further study.",
"   </p>",
"   <p>",
"    Although some researchers claim an association exists between a larger Q angle and increased risk of ACL tear, no convincing evidence exists to substantiate this claim [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/29,44\">",
"     29,44",
"    </a>",
"    ]. The Q angle is made by drawing a line from the anterior superior iliac spine to the patella and a second line from the patella to the tibial tubercle (",
"    <a class=\"graphic graphic_figure graphicRef55389 \" href=\"mobipreview.htm?5/4/5184\">",
"     figure 2",
"    </a>",
"    ). The relatively wide pelvis and short femur of women creates a larger Q angle.",
"   </p>",
"   <p>",
"    Some researchers claim that decreased width of the intercondylar notch of the distal femur is associated with ACL tear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Others refute this [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/48\">",
"     48",
"    </a>",
"    ]. The role of notch width remains debatable and unmodifiable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Additional factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of factors ranging from playing surface to genetics may predispose particular athletes to ACL injury. Our understanding of which factors play a major role is limited by the dearth of controlled studies. Potential risk factors under investigation include external factors (eg, shoe-surface interface) and intrinsic factors (eg, joint laxity, hamstring weakness).",
"   </p>",
"   <p>",
"    Among extrinsic factors, footwear and field surface are the subject of several studies. One review found no clear association between footwear or playing surface and ACL injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/49\">",
"     49",
"    </a>",
"    ], while other studies suggest increased risk for athletes playing on surfaces with increased traction (eg, synthetic gym floors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/29,32,50,51\">",
"     29,32,50,51",
"    </a>",
"    ]. A survey of noncontact injuries among professional American football players found that fewer than 5 percent occurred on a wet playing surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improper biomechanics likely contribute to ACL tears. One study using video analysis found that athletes were more likely to be in an unstable or unbalanced position just prior to sustaining an ACL injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Mechanism and presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Intrinsic factors that may predispose to ACL tear include increased knee joint laxity, hamstring weakness or laxity, smaller ACL, increased body mass index (BMI), core muscle weakness, impaired proprioception, and genetic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/29,45,53-57\">",
"     29,45,53-57",
"    </a>",
"    ]. Further research is needed to clarify the role of such factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MECHANISM AND PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior cruciate ligament (ACL) injuries can occur by a variety of mechanisms, including both high-energy (eg, motor vehicle collision) and low-energy (ie, noncontact field sports). Low-energy injuries may involve contact (eg, blow to the lateral knee), but noncontact injuries are more common, accounting for approximately 70 percent of ACL tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/21,54\">",
"     21,54",
"    </a>",
"    ]. The most common mechanism involves a low-energy, noncontact injury sustained during an athletic activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Noncontact mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical mechanism for a noncontact ACL injury involves a running or jumping athlete who suddenly decelerates and changes direction (eg, cutting) or pivots in a way that involves rotation or lateral bending (ie, valgus stress) of the knee. Researchers using video to assess the biomechanics of ACL tears have found that the majority of injuries occur when an athlete moves her leg forcefully into a valgus position with the knee extended and the tibia rotated internally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/32,33,58\">",
"     32,33,58",
"    </a>",
"    ]. Sports associated with ACL injuries often involve pivoting and sudden changes in direction, and include alpine skiing, soccer (football), basketball, and tennis (",
"    <a class=\"graphic graphic_table graphicRef70676 \" href=\"mobipreview.htm?0/32/523\">",
"     table 1",
"    </a>",
"    ). Women are more prone to ACL tears than men. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Contact mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact-related ACL injuries usually occur from a direct blow causing hyperextension or valgus stress to the knee. This is often seen in American football when a player's foot is planted and an opponent strikes him on the lateral aspect of the planted leg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACL injuries also occur during high speed motor vehicle collisions. Such injuries are often missed in the multiple trauma patient because clinicians concentrate appropriately on managing life-threatening injuries, and the tertiary trauma exam may be delayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who sustain a noncontact ACL injury often complain of feeling a \"pop\" in their knee at the time of injury, acute swelling thereafter, and a feeling that the knee is unstable or \"giving out.\" Nearly all patients with an acute ACL injury manifest a knee effusion from hemarthrosis. Conversely, approximately 67 to 77 percent of patients presenting with acute traumatic knee hemarthrosis have an ACL injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Often after the initial swelling has improved, patients are able to bear weight but complain of instability. Movements such as squatting, pivoting, and stepping laterally, and activities such as walking down stairs, in which the entire body weight is placed on the affected leg, most often elicit such instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other structures are often damaged during an acute ACL injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/62\">",
"     62",
"    </a>",
"    ]. Associated structures that are commonly injured include the meniscus, joint capsule, articular cartilage, subchondral bone (bone bruise), and other ligaments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Such injuries may be more frequent if the mechanism involves significant force (eg, contact injury). One small study suggests that weightbearing motion in the uninjured knee does not appear to be adversely affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the knee includes an appropriate history and physical examination. In patients with a possible anterior cruciate ligament (ACL) injury, the clinician should inquire about the timing of the injury, the mechanism, joint swelling, functional ability (eg, can the patient walk, climb stairs), joint instability (eg, is the knee giving out), and associated injuries. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Mechanism and presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An appropriate examination includes inspection, palpation, testing of mobility, strength, and stability, and performance of special tests of ACL integrity. Depending upon the patient and the time elapsed since the acute injury, the knee examination may be limited by pain or hemarthrosis. Although an ACL tear can generally be diagnosed clinically, MRI is often used to assist diagnosis. Performance of the knee examination is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One key to an accurate knee examination is to evaluate the unaffected knee for comparison. Many patients have increased laxity that is not pathologic. When evaluating for an ACL injury, it is often best to examine the patient immediately after the injury is sustained. This avoids the difficulty of trying to evaluate a knee with a significant hemarthrosis, which can develop within a few hours.",
"   </p>",
"   <p>",
"    Many tests to delineate ACL injury are described. Three such tests, the Lachman, the Pivot Shift, and the Anterior drawer, are the most sensitive and specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. We suggest the clinician perform these tests whenever possible to assess patients at risk for ACL injury.",
"   </p>",
"   <p>",
"    The Lachman test is performed by placing the knee in 30 degrees of flexion and then stabilizing the distal femur with one hand while pulling the proximal tibia anteriorly with the other hand, thereby attempting to produce anterior translation of the tibia (",
"    <a class=\"graphic graphic_picture graphicRef65914 \" href=\"mobipreview.htm?16/54/17251\">",
"     picture 1",
"    </a>",
"    ). An intact ACL limits anterior translation and provides a distinct endpoint. Increased translation compared with the uninjured knee and a vague endpoint suggests ACL injury.",
"   </p>",
"   <p>",
"    The pivot shift test can be difficult to perform in the awake patient due to guarding, and is sensitive only in a fully relaxed and cooperative patient. A positive test is highly specific, albeit insensitive, for ACL rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/66,68\">",
"     66,68",
"    </a>",
"    ]. The test is performed with the knee starting in extension. The clinician holds the lower leg with one hand and internally rotates the tibia, while placing a valgus stress on the knee using the other hand (",
"    <a class=\"graphic graphic_figure graphicRef52976 \" href=\"mobipreview.htm?28/14/28899\">",
"     figure 3",
"    </a>",
"    ). This causes subluxation in the ACL-deficient knee. While maintaining the forces described, the clinician flexes the knee. In the ACL-deficient knee this causes a reduction of the subluxed tibia, which the clinician senses as a 'clunk,' and which constitutes a positive test.",
"   </p>",
"   <p>",
"    The anterior drawer test is performed with the patient lying supine and the knee flexed at 90 degrees. The proximal tibia is gripped with both hands and pulled anteriorly, checking for anterior translation. Often the clinician sits on the foot while performing the test to provide stability (",
"    <a class=\"graphic graphic_picture graphicRef73963 \" href=\"mobipreview.htm?6/30/6628\">",
"     picture 2",
"    </a>",
"    ). The test is positive if there is anterior translation. Comparing the degree of translation to the uninjured knee is helpful.",
"   </p>",
"   <p>",
"    It is important to evaluate for posterior translation of the tibia prior to performing the drawer test. A false positive anterior drawer test can occur if a posterior cruciate ligament (PCL) injury exists. Posterior sag from the PCL injury will give the clinician the sensation of anterior tibial translation, when in fact the knee is returning to a neutral position. Sag exists if one tibia lies below the other when observing the legs from the side with the knees flexed to 90 degrees.",
"   </p>",
"   <p>",
"    A metaanalysis of the efficacy of these tests shows the Lachman is the most useful, with a sensitivity of 85 percent and a specificity of 94 percent for ACL rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/66\">",
"     66",
"    </a>",
"    ]. The pivot shift has a sensitivity of 24 percent and specificity of 98 percent. The anterior drawer has a sensitivity of 92 percent and specificity of 91 percent in chronic conditions, but is not accurate in acute injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/59,66\">",
"     59,66",
"    </a>",
"    ]. Other reviews have reported similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The KT-1000 knee ligament arthrometer is a device that provides an objective measurement of anterior-posterior translation and is often used in studies evaluating ACL tears. This machine is seldom used in clinical practice because physical examination is generally reliable. Due to the high sensitivity of the Lachman and the high specificity of the pivot shift, we suggest performing both tests to confirm an ACL rupture. The combination of a positive Lachman and a negative pivot shift can mean the ACL is partially torn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to evaluate the other knee structures that can sustain injury in conjunction with the ACL. Test the stability of the medial and lateral collateral ligaments by applying gradual varus and valgus stress. Test the posterior collateral ligament by performing a posterior drawer test. Assess for meniscal injury by palpating the medial and lateral joint lines, and performing the appropriate examination maneuvers. Examination techniques for meniscal injury are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are often performed following traumatic knee injuries to rule out fractures, but cannot be used to diagnose ACL tears. In some cases, an avulsion fracture of the anterolateral tibial plateau at the site of attachment of the lateral capsular ligament (the so-called Segond fracture) is identified on plain film (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59018 \" href=\"mobipreview.htm?14/16/14607\">",
"     image 1",
"    </a>",
"    ). Such an injury suggests the presence of an associated ACL rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, magnetic resonance imaging (MRI) is the primary modality used to diagnose ACL rupture. In parts of Europe, ultrasound is often used to assist in the diagnosis. Knee arthrograms are only performed in patients in whom MRI is contraindicated and physical examination is inconclusive.",
"   </p>",
"   <p>",
"    MRI is both highly sensitive and specific in the diagnosis of complete ACL rupture. A systematic review using arthroscopy as a gold standard found MRI to have a sensitivity of 86 percent and a specificity of 95 percent for ACL tear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/62\">",
"     62",
"    </a>",
"    ]. Diagnostic studies, again using arthroscopy as the gold standard, describe sensitivities as high as 92 to 100 percent and specificities as high as 95 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. MRI is less accurate in differentiating complete tears from partial tears, and in detecting chronic tears.",
"   </p>",
"   <p>",
"    In some parts of Europe, ultrasound is widely used to aid in the diagnosis of ACL tear. Like MRI, ultrasound is best at detecting complete ACL rupture. Ultrasound is inexpensive, rapid, and painless, and several studies purport high specificity and positive predictive value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/74,76-80\">",
"     74,76-80",
"    </a>",
"    ]. Sensitivity is likely more limited than MRI. The accuracy of ultrasound is highly user-dependent.",
"   </p>",
"   <p>",
"    Multidetector computed tomography (MDCT) is not used to evaluate ACL injury. Data suggest MDCT is accurate at detecting an intact ACL, but is unreliable for determining ACL tear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute management consists of rest, ice, compression of the injured knee, and elevation of the affected lower extremity. Crutches may be needed acutely to avoid weight-bearing, particularly if the knee is unstable. Over the counter analgesics are generally sufficient to control pain. While NSAIDs provide effective short-term pain relief, their effect on ligament and bone healing remains unclear. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link&amp;anchor=H24#H24\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Possible effect on tendon injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Operative or nonoperative treatment?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate treatment for an ACL injury depends upon the extent of injury, patient characteristics and activities, and available resources. These issues are reviewed below. It is important that the patient feel comfortable discussing the available treatment options with their surgeon and that issues such as patient expectations, rehabilitation, and potential complications are addressed in such discussions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Determining the need for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACL injuries can be managed operatively or nonoperatively. Most active, younger patients and high-level athletes opt for surgical reconstruction. In general, patients with an ACL injury should be referred to an orthopedist to discuss treatment options. Patients who decide not to pursue surgical management should be referred to a knowledgeable physical therapist or athletic trainer for rehabilitation. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Rehabilitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The decision to have surgery is based upon multiple factors, including the patient&rsquo;s level of activity, functional demands placed on the knee, and the presence of associated injuries to the meniscus or other knee ligaments. Other factors such as age and occupation also play a role.",
"   </p>",
"   <p>",
"    Patients with injuries to multiple knee structures (eg, ACL plus meniscus or medial collateral ligament) generally need surgical reconstruction, in part due to their increased risk for developing osteoarthritis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Risk of osteoarthritis or subsequent injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, surgical reconstruction of the ACL is appropriate for patients who:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Participate in high-demand sports or occupations (ie, those involving cutting, jumping, pivoting, and quick deceleration)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Experience significant knee instability (eg, knee gives out while climbing stairs).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Traditionally, anterior translation of more than 5 mm with testing on a KT1000&trade; or comparable device has been used as a criterion for surgery. However, some studies question the use of static translation as an accurate predictive tool for knee function and the need for surgical reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/82\">",
"     82",
"    </a>",
"    ]. Some experts believe a positive pivot shift test three months following injury best predicts the future need for surgical repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no long term studies that directly compare the rates of return to sport between athletes treated operatively and nonoperatively. Nevertheless, in our experience, athletes who participate in sports involving rapid deceleration, pivoting, and change in direction have a better chance of returning to play if they undergo ACL reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to a systematic review of 48 studies involving 5770 participants, 82 percent of patients treated with ACL reconstruction returned to some type of athletic activity, while 63 percent attained their preinjury level of competition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/85\">",
"     85",
"    </a>",
"    ]. These rates are relatively low given that 90 percent of patients achieved normal or near normal knee function following surgery, suggesting that other factors, such as fear of reinjury, play an important role in athletes&rsquo; decision-making about return to play.",
"   </p>",
"   <p>",
"    Less active patients who do not participate in sports that involve squatting, pivoting, and lateral movement have less risk of developing further injury. Patients who fare worst with nonoperative treatment are high level athletes and young athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/63\">",
"     63",
"    </a>",
"    ]. The patients best suited for nonoperative management are described below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Patients amenable to nonoperative treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Theoretically there is no age cut-off for surgery. Although patients older than 55 years rarely undergo ACL reconstruction, the decision whether to perform surgery depends upon the patient's condition including symptomatic knee instability, activity level, and the surgeon's judgment. Observational studies suggest that ACL reconstruction is generally successful in patients older than 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Risk of osteoarthritis or subsequent injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;When deciding to treat a complete ACL rupture nonoperatively, it is important to understand the possible sequelae. Although rigorous prospective studies are lacking, the ACL-deficient knee may place patients at increased risk for osteoarthritis (OA), meniscal tear, articular cartilage injury, chronic knee pain, and decreased level of activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/63,88-91\">",
"     63,88-91",
"    </a>",
"    ]. Partial or complete meniscectomy at the time of surgical repair of the ACL is associated with a substantial increase in the risk of knee OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review performed to determine the risk of developing OA following ACL injury, which included patients who underwent surgical repair and those treated conservatively, noted the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/93\">",
"     93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher quality studies found the prevalence of knee OA in patients with",
"      <strong>",
"       isolated",
"      </strong>",
"      ACL injury to range from 0 to 13 percent, lower than previously thought. Radiographic follow-up was performed a minimum of 10 years following injury.",
"     </li>",
"     <li>",
"      The prevalence of knee OA is higher (between 21 and 48 percent) in patients with associated injuries (eg, meniscal tear). The findings of a subsequent prospective cohort study of patients who underwent ACL reconstruction (n = 181) support this conclusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most studies to investigate this problem were retrospective and of limited quality. Moreover, the seven radiologic classification schemes used to determine the presence of OA are inconsistent, making comparisons among studies difficult.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another systematic review noted that surveillance studies suggest degenerative OA may occur regardless of the treatment approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/95\">",
"     95",
"    </a>",
"    ]. Subsequent studies support this notion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. As examples, a prospective observational study of 40 patients with acute ACL tear noted that all participants sustained longitudinal chondral degradation in compartments unaffected by any initial bone bruise, although nonoperative management was associated with greater risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/96\">",
"     96",
"    </a>",
"    ]. A prospective cohort study of 94 patients with ACL tear reported that OA developed infrequently among those managed with activity modification and physical therapy, provided meniscectomy was not performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/98\">",
"     98",
"    </a>",
"    ]. One important limitation of many surveillance studies is their limited time frame; a longer period (eg, over 20 years from the time of injury) may be needed to reveal signs of OA in patients managed conservatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Patients amenable to nonoperative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients with ACL injury are capable of returning to sustained, high-level athletic activity without surgical repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/99\">",
"     99",
"    </a>",
"    ]. Assessment to identify these patients soon after their injury is likely to be more accurate when several tests of dynamic neuromuscular function are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/82,100,101\">",
"     82,100,101",
"    </a>",
"    ]. While a significant number of these athletes may later choose to undergo surgical repair, identification of those capable of performing without surgery gives them the option of continuing to compete, once symptoms have subsided, while surgery would preclude early participation in competitive sports.",
"   </p>",
"   <p>",
"    This approach is supported by a prospective observational study of 345 consecutive patients, all active in sports that place significant demands on the knee, who sustained an isolated ACL rupture, and were tested within seven months of injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/82\">",
"     82",
"    </a>",
"    ]. Dynamic functional testing (a series of specific hopping tests) better predicted those patients capable of returning to preinjury levels of athletic performance without ACL repair than did traditional isolated testing of joint laxity or strength.",
"   </p>",
"   <p>",
"    In this study, 88 of 146 athletes who attained a minimum level of strength and knee mobility with preliminary rehabilitation and passed dynamic functional testing chose rehabilitation as the primary treatment for their ACL injury. Ten-year follow-up data were available in 61 of 63 athletes who returned to full sporting activity: 25 continued without surgical repair, while 36 ultimately underwent ACL reconstruction. Long-term follow-up studies are needed to confirm these results. The results of this study and a randomized trial described elsewhere in this review suggest that there is a subset of active patients, albeit not yet clearly defined, for whom nonoperative treatment is a viable approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/82,102\">",
"     82,102",
"    </a>",
"    ]. Further research is needed to delineate this group of patients.",
"   </p>",
"   <p>",
"    Patients with low functional demands and athletes who participate in sports that do not place high demands on the knee, such as those involving linear, nondeceleration activities, may be treated nonoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/5\">",
"     5",
"    </a>",
"    ]. With some activity modification and proper rehabilitation, such patients can achieve good results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. We believe such patients should work with a qualified physical therapist following their injury to improve the strength and proprioception needed to support the injured knee, and thereby reduce the risk of degenerative disease and further injury. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Rehabilitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Graft selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACL reconstruction is generally performed with arthroscopy using a graft to replace the ruptured ACL. Graft selection remains a source of debate among orthopedic surgeons. Native grafts may be taken from the patellar tendon, hamstring tendon (semitendinosus and gracilis), or quadriceps tendon, or an allograft may be used. Allografts are usually taken from an Achilles or patellar tendon, but the quadriceps, hamstring, and tibialis tendons may also be used. No particular graft has clearly demonstrated superior functional outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The three most common grafts are the patellar tendon graft, the hamstring tendon graft, and the allograft. The theoretical advantages of the patellar graft include increased initial strength and stiffness compared with the normal ACL and potential bone-to-bone healing in the femoral and tibial tunnels made during surgery, which promotes earlier graft fixation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/108\">",
"     108",
"    </a>",
"    ]. Systematic reviews confirm that reconstruction using the patellar tendon graft results in greater anterior knee pain compared with other grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/105,109,110\">",
"     105,109,110",
"    </a>",
"    ]. Such pain usually resolves after the first year. Patellar tendon grafts provide greater stability than traditional hamstring grafts, but this may no longer be the case with four stranded hamstring grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/110\">",
"     110",
"    </a>",
"    ]. Patellar tendon grafts may increase the long-term risk for osteoarthritis of the knee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/111,112\">",
"     111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hamstring graft has several advantages. Use of the hamstring tendon eliminates patellar tendon morbidity, primarily anterior knee pain. A systematic review found that hamstring donor site pain usually resolved by three months, while hamstring strength returned to normal by 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/109,113\">",
"     109,113",
"    </a>",
"    ]. The hamstring graft is stronger and stiffer when quadruple strands are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/114\">",
"     114",
"    </a>",
"    ]. Studies are underway using eight-stranded tendon grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/115\">",
"     115",
"    </a>",
"    ], and double-bundle reconstructions, which appear to yield greater strength and stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. Studies of these techniques are ongoing.",
"   </p>",
"   <p>",
"    Patellar tendon grafts include a portion of bone at either end, while hamstring grafts are comprised entirely of tendon. A potential disadvantage of hamstring grafts is the need for healing between a tendon and an osseous tunnel. As a result, initial fixation may be slower and ultimately weaker than the bone-to-bone healing of a patellar tendon graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/108,119\">",
"     108,119",
"    </a>",
"    ], although techniques (eg, endo-button) are being developed to address this [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allografts are commonly used for ACL reconstruction. The advantages of allograft include reduced surgical time, reduced harvest site morbidity, and the availability of a range of sizes. Possible disadvantages include potential disease transmission, immunologic reactions, slower remodeling and integration, and cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of infection from an allograft is extremely low. Although reports exist of HIV and hepatitis transmission, no transmissions have been reported since 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/108,121\">",
"     108,121",
"    </a>",
"    ]. Clinically significant bacterial infections occur in less than 1 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. Animal models and radiologic studies suggest allografts may require three years or longer for complete cellular remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. Theoretically, native tissue heals more rapidly enabling the patient to begin rehabilitation and activities sooner, but this is unproven and the clinical significance of the prolonged period required for the integration of allografts remains unclear.",
"   </p>",
"   <p>",
"    The quadriceps tendon graft is a less common approach to ACL reconstruction. Its primary advantages lie in avoiding injury to the infrapatellar branch of the saphenous nerve, which can occur with patellar tendon grafts, and sparing the area around the tibial tubercle. The quadriceps tendon can be made into a double bundle, thereby improving graft strength, and allows for bone-to-bone healing at one end of the graft. Several studies show no difference in outcome between patellar and quadriceps tendon repairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/126-128\">",
"     126-128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No specific graft has proven superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. In our practice, most young patients active in high-demand sports receive patellar tendon autograft reconstructions because of their strength and relatively rapid healing. However, improvements in surgical technique have reduced concerns over the fixation of hamstring grafts and these are now more common, in part because they reduce graft site morbidity (ie, anterior knee pain). Allografts are usually reserved for middle-aged athletes who engage in low-impact sports, but they have not been found to be inferior to autografts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best time to undergo ACL reconstruction remains unclear. We believe the condition of the injured knee is the most important factor when determining the timing of surgery. The knee should exhibit full range of motion with no significant effusion and adequate strength at the time of reconstruction. Observational studies suggest that surgery performed prematurely increases the risk of arthrofibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. One such study found that 70 percent of patients with signs of knee swelling and inflammation at the time of ACL reconstruction went on to develop arthrofibrosis. Early repair may result in better long-term knee motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/131\">",
"     131",
"    </a>",
"    ]. Often, our patients undergo two to four weeks of \"prehabilitation\" to maximize strength and motion prior to surgery.",
"   </p>",
"   <p>",
"    In one randomized trial involving young healthy adults with acute uncomplicated ACL injuries, no difference in symptoms or patient perceptions of knee function were noted at two year follow-up between patients treated with structured rehabilitation and early reconstruction and those treated with structured rehabilitation and optional delayed reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/102\">",
"     102",
"    </a>",
"    ]. The authors claim that the latter approach could substantially reduce the number of ACL surgeries without adversely affecting outcomes. However, the accompanying editorial notes that functional assessment at two years, even using a well-validated score, does not accurately reflect long-term knee function or injury risk and that many ACL reconstructions are performed more than two years following the initial injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/132\">",
"     132",
"    </a>",
"    ]. Delayed reconstruction may increase the risk of further knee injury (eg, medial meniscal tear) and prolong the time before an athlete can return to full activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/133-135\">",
"     133-135",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Risk of osteoarthritis or subsequent injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Partial tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, incomplete tears of the ACL can be managed nonoperatively with an emphasis upon physical therapy and proper sport-specific biomechanics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/136\">",
"     136",
"    </a>",
"    ]. Clinical findings suggestive of a partial ACL tear include an asymmetric Lachman test, a negative pivot shift test, and KT-1000 arthrometer testing that demonstrates no more than 3 mm of anterior-posterior translation.",
"   </p>",
"   <p>",
"    A hinged knee brace may be worn during the early stages of rehabilitation. There is no evidence that wearing a brace upon returning to full activity reduces the risk of progression to a complete tear, but some clinicians suggest bracing. Once the strength and motion of the injured leg equals that of the opposite leg, the patient may return to sports. Symptom progression depends upon the extent of the tear and the patient's activities. Patients should be referred to an orthopedic surgeon if symptomatic instability develops. Preliminary studies of primary repair of partial ACL tears are ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/137\">",
"     137",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Rehabilitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     REHABILITATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1092550\">",
"    <span class=\"h2\">",
"     Principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel approaches to ACL rehabilitation develop continually. Nevertheless, several principles of rehabilitation have been shown consistently to be important for complete recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/138\">",
"     138",
"    </a>",
"    ]. Full range of motion, especially in knee extension, should be promoted immediately following ACL reconstruction. The inability to regain normal knee motion is associated with an increased risk of osteoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Closed kinetic chain exercises to strengthen the hamstring and quadriceps muscles are effective for initial rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/1,140\">",
"     1,140",
"    </a>",
"    ]. Closed chain exercises require that both feet be planted and remain in a fixed position throughout the exercise (eg, squat). Closed chain exercises may place less stress on a new ACL graft than open kinetic chain exercises, in which the feet change position during the activity.",
"   </p>",
"   <p>",
"    Controversy continues about the role of open chain exercises in ACL rehabilitation. Based upon limited evidence, we believe that open chain exercises may be added to the rehabilitation program no sooner than six weeks following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/140,141\">",
"     140,141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercises to enhance balance, proprioception, and core strength should be incorporated into postoperative rehabilitation, as should training to improve sport-specific biomechanics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/138,142\">",
"     138,142",
"    </a>",
"    ]. Patients who opt for nonoperative management also benefit from such exercises and should participate in a comprehensive rehabilitation program following injury.",
"   </p>",
"   <p>",
"    Motivated patients can perform postoperative rehabilitation effectively on their own with no difference in long-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/143\">",
"     143",
"    </a>",
"    ]. Patients wishing to perform rehabilitation independently must be given clear instructions explaining how to perform the exercises correctly and should demonstrate proper technique to a knowledgeable clinician before beginning. Different muscle groups manifest relatively greater weakness postoperatively depending upon the site of the autograft. Specific rehabilitation protocols based on the autograft site have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of devices have been used as part of rehabilitation, but often there is little evidence of effectiveness. A systematic review found no benefit from the use of passive-motion machines following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/145\">",
"     145",
"    </a>",
"    ]. Use of a brace after surgery is based upon surgeon and patient preference. A systematic review of bracing following ACL reconstruction, which included 12 randomized controlled trials, found no evidence of improved outcome or reduced risk of subsequent injury among patients using a brace [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1092543\">",
"    <span class=\"h2\">",
"     Return to activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little high quality research is available to help determine when patients can safely return to full activity and sport. A premature return increases the risk for reinjury and graft failure. We believe that athletes may safely return to sport once their repaired knee demonstrates strength, proprioception, and function roughly equal to the unaffected knee. We tell patients to expect a return to full activity and sports between 6 and 12 months following surgery, depending upon the sport and their compliance with a sound rehabilitation program.",
"   </p>",
"   <p>",
"    A systematic review of over 264 studies addressing return to play after ACL reconstruction identified only 35 studies with objective criteria for return [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/147\">",
"     147",
"    </a>",
"    ]. In many studies, time from surgery was the sole factor. Additional research is needed to identify the most useful criteria for determining when an athlete is ready to return to sport with minimal risk of reinjury or graft failure. Such criteria are likely to involve a combination of factors involving knee motion, strength of supporting muscles, and neuromuscular function.",
"   </p>",
"   <p>",
"    Some patients are now returning to full activity at six months (and some high-level athletes sooner) following reconstructive surgery. For selected athletes eager to return to competition, early participation may not be disadvantageous, provided an appropriate and rigorous rehabilitation program is followed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/140\">",
"     140",
"    </a>",
"    ]. However, studies supporting early participation involve small numbers of patients and athletes should be aware that this approach entails some risk of reinjury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/148\">",
"     148",
"    </a>",
"    ]. Expedited returns occur before reconstructed ACL grafts are completely incorporated into the knee. Athletes who participate in accelerated rehabilitation programs may continue to demonstrate some abnormal joint motion and relative weakness for up to 22 months following surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall toll of ACL reconstruction is high and this has stimulated research into the prevention of noncontact ACL injuries. Studies have focused on various aspects of physical training, particularly neuromuscular training, and on extrinsic supports (ie, braces).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neuromuscular training",
"    </span>",
"    &nbsp;&mdash;&nbsp;We concur with the consensus statement issued jointly by numerous organizations, including the American Academy of Orthopaedic Surgeons and the American College of Sports Medicine, that supports the use of ACL injury prevention programs for female athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/149\">",
"     149",
"    </a>",
"    ]. Although the benefit of such programs is likely to be greatest among young female athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/150\">",
"     150",
"    </a>",
"    ], we believe well-designed programs are likely to help",
"    <strong>",
"     all",
"    </strong>",
"    athletes, male and female, that participate in high-risk sports (",
"    <a class=\"graphic graphic_table graphicRef70676 \" href=\"mobipreview.htm?0/32/523\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/151,152\">",
"     151,152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of prospective studies (n = 6) found that the overall risk of ACL injury was reduced in female athletes that participated in neuromuscular training programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/151\">",
"     151",
"    </a>",
"    ]. A total of 29 ACL injuries occurred among program participants compared with 100 injuries among nonparticipant athletes (OR 0.40; 95 percent CI 0.26-0.61). The reviewers noted the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All four programs that incorporated high-intensity jumping plyometric exercises reduced injury rates.",
"     </li>",
"     <li>",
"      All three programs that included biomechanical analysis and provided direct feedback to the athletes about proper position and movement reduced injury rates.",
"     </li>",
"     <li>",
"      Programs that incorporated strength training reduced injury rates, although strength training alone did not.",
"     </li>",
"     <li>",
"      Balance training alone is unlikely to reduce injury rates, although it may enhance other prevention techniques.",
"     </li>",
"     <li>",
"      Athletes must participate in prevention training at least two times per week for a minimum of six consecutive weeks to accrue any benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent meta-analysis of 8 prospective studies did not comment on the best methods for ACL injury prevention but reported a significant reduction in injury rates for athletes who participate regularly in well-designed neuromuscular prevention programs (pooled risk ratio (RR) 0.38, 95% CI 0.20-0.72) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/153\">",
"     153",
"    </a>",
"    ]. The reduction in injury risk was greatest for male athletes (RR 0.15, 95% CI 0.08-0.28) but remained statistically significant for female athletes (RR 0.48, 95% CI 0.26-0.89). Of note, the results of negative studies included in the review suggest that neither plyometric training (20 minutes twice weekly) nor balance board training (15 minutes three times weekly), when performed alone, reduce the risk of ACL injury.",
"   </p>",
"   <p>",
"    Females in early adolescence, or possibly preadolescence, may benefit the most from neuromuscular training prevention programs, according to a meta-analysis of 14 randomized trials involving thousands of athletes that looked specifically at this issue. According to this meta-analysis, females in their mid-teens had greater reductions in their rate of ACL injury (OR 0.28; 95% CI 0.18-0.42) than females in their late teens (OR 0.48; 95% CI 0.21-1.07) or early adulthood (OR 1.01; 95% CI 0.62-1.64) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/150\">",
"     150",
"    </a>",
"    ]. These results suggest that it is important to implement prevention programs before female athletes develop poor mechanics during movements associated with an increased risk of ACL injury (eg, suddenly changing direction while running, landing from a jump). The authors advocate early use of neuromuscular training, and we concur.",
"   </p>",
"   <p>",
"    Individual trials have focused on particular elements of prevention. In one such trial, high-level intercollegiate women&rsquo;s soccer (football) teams in the United States were randomly assigned to participate three times per week before practice in a neuromuscular training program designed to reduce the rate of noncontact ACL injuries or to engage in their standard team warm-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/154\">",
"     154",
"    </a>",
"    ]. Athletes participating in the program (n = 583) sustained only two noncontact ACL injuries over the course of one season while those following their team&rsquo;s standard warm-up (n = 852) sustained 10. The program, known as PEP for Prevent injury and Enhance Performance, requires about 10 to 15 minutes to perform and consists of a warm-up followed by several strength, agility, plyometric, and flexibility exercises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/155\">",
"     155",
"    </a>",
"    ]. The goal is to increase lower extremity and core muscle fitness and to improve neuromuscular function such that athletes avoid positions that increase their susceptibility to ACL injury. A similar trial performed in adolescent female soccer players reported similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/156\">",
"     156",
"    </a>",
"    ]. Other smaller studies involving athletes in a number of high-risk sports (eg, basketball, soccer) have demonstrated decreased rates of ACL tear among athletes who participate in similar well-designed prevention programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/38,154,155,157-161\">",
"     38,154,155,157-161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different prevention programs incorporate specific drills that more closely approximate the demands of particular sports, and may hold advantages for athletes engaged primarily in these sports. The Henning program, based on video analysis of ACL injuries, teaches specific landing, cutting, and stopping maneuvers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/162\">",
"     162",
"    </a>",
"    ]. The Caraffa program focuses on proprioceptive training for soccer players [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/157\">",
"     157",
"    </a>",
"    ]. FIFA (F&eacute;d&eacute;ration Internationale de Football Association), the governing body of international soccer, includes a program for ACL injury prevention on its website. The Sportsmetrics training program includes a large number of volleyball athletes and includes jumping and plyometric training to increase strength and to inculcate safer landing positions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/160\">",
"     160",
"    </a>",
"    ]. A program developed by the Vermont Safety Research group, based in part on video analysis, teaches downhill skiers to avoid certain high-risk positions and movements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest ACL prevention programs be taught and supervised initially by knowledgeable athletic trainers, physical therapists, or comparable professionals, until players are able to perform the program with consistent proficiency. Prevention exercises that address the specific biomechanical faults of individual athletes as determined by such experts may be useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Extrinsic supports",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized and observational studies suggest that prophylactic knee bracing does not prevent ACL tears, and one observational study suggests that such bracing may increase morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/146,164-166\">",
"     146,164-166",
"    </a>",
"    ]. A small laboratory study suggests medially posted orthotics may reduce the risk of valgus knee angulation, and thereby ACL injury, but further research is needed before this intervention can be recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/167\">",
"     167",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     FUTURE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Future developments in ACL reconstruction may include repair of the injured ACL, synthetic replacements, and bioengineered ACL reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/24/32138/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/12/7362?source=see_link\">",
"       \"Patient information: Anterior cruciate ligament tear (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/36/7747?source=see_link\">",
"       \"Patient information: Knee pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1797?source=see_link\">",
"       \"Patient information: Anterior cruciate ligament injury (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24642?source=see_link\">",
"       \"Patient information: Knee pain (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior cruciate ligament (ACL) is the most commonly injured knee ligament. Noncontact, low-energy injuries incurred during athletic activity account for the majority of ACL tears. Female athletes are at increased risk. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical mechanism for a noncontact ACL injury involves a running or jumping athlete who suddenly decelerates and changes direction (eg, cutting) or pivots in a way that involves rotation or lateral bending (ie, valgus stress) of the knee. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mechanism and presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who sustain an ACL injury often complain of feeling a \"pop\" in their knee at the time of injury, acute swelling thereafter, and a feeling that the knee is unstable or \"giving out.\" Nearly all patients with an acute ACL injury manifest a knee effusion from hemarthrosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mechanism and presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Lachman, Pivot Shift, and Anterior drawer tests are the most useful examination techniques for detecting ACL injury. When evaluating a patient for ACL injury it is important to look for associated injuries (eg, meniscal tear) and to examine the unaffected knee for comparison. Many patients have increased laxity that is not pathologic. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs cannot be used to diagnose ACL rupture. MRI is both highly sensitive and specific. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACL injuries can be managed operatively or nonoperatively. Although rigorous studies are lacking, the ACL-deficient knee may place patients at increased risk for further injury (eg, meniscal tear), chronic pain, and decreased level of activity. Degenerative osteoarthritis may occur regardless of the treatment approach. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Operative or nonoperative treatment?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with injuries to multiple knee structures (eg, ACL plus meniscus or medial collateral ligament) or who experience significant knee instability (eg, knee gives out while climbing stairs) generally need surgical reconstruction. Young athletes and athletes who participate and wish to continue in high-demand sports (ie, those involving cutting, jumping, pivoting, and quick deceleration) generally need surgical reconstruction.",
"     </li>",
"     <li>",
"      Different tissue grafts can be used for ACL reconstruction. Graft selection and the timing of surgery are discussed in the text. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Graft selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Focused neuromuscular training designed to prevent ACL rupture may reduce risk, particularly among women participating in high-risk sports. We strongly encourage athletes who participate in sports that place them at high risk for ACL injury to participate in a well-designed, neuromuscular, injury-prevention program. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gordon MD, Steiner ME.. Anterior cruciate ligament injuries. In: Orthopaedic Knowledge Update Sports Medicine III, Garrick JG.  (Ed), American Academy of Orthopaedic Surgeons, Rosemont 2004. p.169.",
"    </li>",
"    <li>",
"     Albright JC, Carpenter JE, Graf BK, et al.. Knee and leg: soft tissue trauma. In: Orthopaedic Knowledge Update 6, Beaty JH.  (Ed), American Academy of Orthopaedic Surgeons, Rosemont 1999. p.533.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/3\">",
"      Markolf KL, Mensch JS, Amstutz HC. Stiffness and laxity of the knee--the contributions of the supporting structures. A quantitative in vitro study. J Bone Joint Surg Am 1976; 58:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/4\">",
"      Fu FH, Bennett CH, Lattermann C, Ma CB. Current trends in anterior cruciate ligament reconstruction. Part 1: Biology and biomechanics of reconstruction. Am J Sports Med 1999; 27:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/5\">",
"      Kennedy JC, Alexander IJ, Hayes KC. Nerve supply of the human knee and its functional importance. Am J Sports Med 1982; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/6\">",
"      Muneta T, Sekiya I, Yagishita K, et al. Two-bundle reconstruction of the anterior cruciate ligament using semitendinosus tendon with endobuttons: operative technique and preliminary results. Arthroscopy 1999; 15:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/7\">",
"      Miyasaka, KC, Daniel, DM, Stone, ML. The incidence of knee ligament injuries in the general population. Am J Knee Surg 1991; 4:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/8\">",
"      Daniel DM, Stone ML, Dobson BE, et al. Fate of the ACL-injured patient. A prospective outcome study. Am J Sports Med 1994; 22:632.",
"     </a>",
"    </li>",
"    <li>",
"     National Collegiate Athletic Association. NCAA Injury Surveillance System Summary. Indianapolis, Ind: National Collegiate Athletic Association; 2002.",
"    </li>",
"    <li>",
"     National Federation of State High School Associations. 2002 High School Participation Survey. Indianapolis, Ind: National federation of State High School Associations; 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/11\">",
"      Prodromos CC, Han Y, Rogowski J, et al. A meta-analysis of the incidence of anterior cruciate ligament tears as a function of gender, sport, and a knee injury-reduction regimen. Arthroscopy 2007; 23:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/12\">",
"      Pujol N, Blanchi MP, Chambat P. The incidence of anterior cruciate ligament injuries among competitive Alpine skiers: a 25-year investigation. Am J Sports Med 2007; 35:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/13\">",
"      Hootman JM, Dick R, Agel J. Epidemiology of collegiate injuries for 15 sports: summary and recommendations for injury prevention initiatives. J Athl Train 2007; 42:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/14\">",
"      Ireland ML. The female ACL: why is it more prone to injury? Orthop Clin North Am 2002; 33:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/15\">",
"      Arendt E, Dick R. Knee injury patterns among men and women in collegiate basketball and soccer. NCAA data and review of literature. Am J Sports Med 1995; 23:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/16\">",
"      Arendt, EA, Grossfeld, SL. Patient selection for ACL reconstruction. Sports Med Arthrosc Rev 1996; 4:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/17\">",
"      Gwinn DE, Wilckens JH, McDevitt ER, et al. The relative incidence of anterior cruciate ligament injury in men and women at the United States Naval Academy. Am J Sports Med 2000; 28:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/18\">",
"      Lindenfeld TN, Schmitt DJ, Hendy MP, et al. Incidence of injury in indoor soccer. Am J Sports Med 1994; 22:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/19\">",
"      Myklebust G, Maehlum S, Holm I, Bahr R. A prospective cohort study of anterior cruciate ligament injuries in elite Norwegian team handball. Scand J Med Sci Sports 1998; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/20\">",
"      Strickland SM, MacGillivray JD, Warren RF. Anterior cruciate ligament reconstruction with allograft tendons. Orthop Clin North Am 2003; 34:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/21\">",
"      Mountcastle SB, Posner M, Kragh JF Jr, Taylor DC. Gender differences in anterior cruciate ligament injury vary with activity: epidemiology of anterior cruciate ligament injuries in a young, athletic population. Am J Sports Med 2007; 35:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/22\">",
"      Huston LJ, Greenfield ML, Wojtys EM. Anterior cruciate ligament injuries in the female athlete. Potential risk factors. Clin Orthop Relat Res 2000; :50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/23\">",
"      Chappell JD, Creighton RA, Giuliani C, et al. Kinematics and electromyography of landing preparation in vertical stop-jump: risks for noncontact anterior cruciate ligament injury. Am J Sports Med 2007; 35:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/24\">",
"      Myer GD, Ford KR, Barber Foss KD, et al. The relationship of hamstrings and quadriceps strength to anterior cruciate ligament injury in female athletes. Clin J Sport Med 2009; 19:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/25\">",
"      Zebis MK, Andersen LL, Bencke J, et al. Identification of athletes at future risk of anterior cruciate ligament ruptures by neuromuscular screening. Am J Sports Med 2009; 37:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/26\">",
"      Cowling EJ, Steele JR. Is lower limb muscle synchrony during landing affected by gender? Implications for variations in ACL injury rates. J Electromyogr Kinesiol 2001; 11:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/27\">",
"      Wild CY, Steele JR, Munro BJ. Insufficient hamstring strength compromises landing technique in adolescent girls. Med Sci Sports Exerc 2013; 45:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/28\">",
"      Hewett TE, Stroupe AL, Nance TA, Noyes FR. Plyometric training in female athletes. Decreased impact forces and increased hamstring torques. Am J Sports Med 1996; 24:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/29\">",
"      Hewett TE, Myer GD, Ford KR. Anterior cruciate ligament injuries in female athletes: Part 1, mechanisms and risk factors. Am J Sports Med 2006; 34:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/30\">",
"      Hewett TE, Myer GD, Ford KR, et al. Biomechanical measures of neuromuscular control and valgus loading of the knee predict anterior cruciate ligament injury risk in female athletes: a prospective study. Am J Sports Med 2005; 33:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/31\">",
"      Ford KR, Myer GD, Toms HE, Hewett TE. Gender differences in the kinematics of unanticipated cutting in young athletes. Med Sci Sports Exerc 2005; 37:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/32\">",
"      Olsen OE, Myklebust G, Engebretsen L, Bahr R. Injury mechanisms for anterior cruciate ligament injuries in team handball: a systematic video analysis. Am J Sports Med 2004; 32:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/33\">",
"      Krosshaug T, Nakamae A, Boden BP, et al. Mechanisms of anterior cruciate ligament injury in basketball: video analysis of 39 cases. Am J Sports Med 2007; 35:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/34\">",
"      Boden BP, Torg JS, Knowles SB, Hewett TE. Video analysis of anterior cruciate ligament injury: abnormalities in hip and ankle kinematics. Am J Sports Med 2009; 37:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/35\">",
"      Hertel J, Williams NI, Olmsted-Kramer LC, et al. Neuromuscular performance and knee laxity do not change across the menstrual cycle in female athletes. Knee Surg Sports Traumatol Arthrosc 2006; 14:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/36\">",
"      Park SK, Stefanyshyn DJ, Loitz-Ramage B, et al. Changing hormone levels during the menstrual cycle affect knee laxity and stiffness in healthy female subjects. Am J Sports Med 2009; 37:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/37\">",
"      Hewett TE, Zazulak BT, Myer GD. Effects of the menstrual cycle on anterior cruciate ligament injury risk: a systematic review. Am J Sports Med 2007; 35:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/38\">",
"      Myklebust G, Engebretsen L, Braekken IH, et al. Prevention of anterior cruciate ligament injuries in female team handball players: a prospective intervention study over three seasons. Clin J Sport Med 2003; 13:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/39\">",
"      Slauterbeck JR, Fuzie SF, Smith MP, et al. The Menstrual Cycle, Sex Hormones, and Anterior Cruciate Ligament Injury. J Athl Train 2002; 37:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/40\">",
"      Beynnon BD, Johnson RJ, Braun S, et al. The relationship between menstrual cycle phase and anterior cruciate ligament injury: a case-control study of recreational alpine skiers. Am J Sports Med 2006; 34:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/41\">",
"      Wojtys EM, Huston LJ, Boynton MD, et al. The effect of the menstrual cycle on anterior cruciate ligament injuries in women as determined by hormone levels. Am J Sports Med 2002; 30:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/42\">",
"      Adachi N, Nawata K, Maeta M, Kurozawa Y. Relationship of the menstrual cycle phase to anterior cruciate ligament injuries in teenaged female athletes. Arch Orthop Trauma Surg 2008; 128:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/43\">",
"      Bell DR, Blackburn JT, Ondrak KS, et al. The effects of oral contraceptive use on muscle stiffness across the menstrual cycle. Clin J Sport Med 2011; 21:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/44\">",
"      Pantano KJ, White SC, Gilchrist LA, Leddy J. Differences in peak knee valgus angles between individuals with high and low Q-angles during a single limb squat. Clin Biomech (Bristol, Avon) 2005; 20:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/45\">",
"      Uhorchak JM, Scoville CR, Williams GN, et al. Risk factors associated with noncontact injury of the anterior cruciate ligament: a prospective four-year evaluation of 859 West Point cadets. Am J Sports Med 2003; 31:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/46\">",
"      LaPrade RF, Burnett QM 2nd. Femoral intercondylar notch stenosis and correlation to anterior cruciate ligament injuries. A prospective study. Am J Sports Med 1994; 22:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/47\">",
"      Shelbourne KD, Davis TJ, Klootwyk TE. The relationship between intercondylar notch width of the femur and the incidence of anterior cruciate ligament tears. A prospective study. Am J Sports Med 1998; 26:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/48\">",
"      Lombardo S, Sethi PM, Starkey C. Intercondylar notch stenosis is not a risk factor for anterior cruciate ligament tears in professional male basketball players: an 11-year prospective study. Am J Sports Med 2005; 33:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/49\">",
"      Baker MM. Anterior cruciate ligament injuries in the female athlete. J Womens Health 1998; 7:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/50\">",
"      Orchard JW, Powell JW. Risk of knee and ankle sprains under various weather conditions in American football. Med Sci Sports Exerc 2003; 35:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/51\">",
"      Dowling AV, Corazza S, Chaudhari AM, Andriacchi TP. Shoe-surface friction influences movement strategies during a sidestep cutting task: implications for anterior cruciate ligament injury risk. Am J Sports Med 2010; 38:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/52\">",
"      Scranton PE Jr, Whitesel JP, Powell JW, et al. A review of selected noncontact anterior cruciate ligament injuries in the National Football League. Foot Ankle Int 1997; 18:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/53\">",
"      Ramesh R, Von Arx O, Azzopardi T, Schranz PJ. The risk of anterior cruciate ligament rupture with generalised joint laxity. J Bone Joint Surg Br 2005; 87:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/54\">",
"      Boden BP, Dean GS, Feagin JA Jr, Garrett WE Jr. Mechanisms of anterior cruciate ligament injury. Orthopedics 2000; 23:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/55\">",
"      Zazulak BT, Hewett TE, Reeves NP, et al. The effects of core proprioception on knee injury: a prospective biomechanical-epidemiological study. Am J Sports Med 2007; 35:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/56\">",
"      Flynn RK, Pedersen CL, Birmingham TB, et al. The familial predisposition toward tearing the anterior cruciate ligament: a case control study. Am J Sports Med 2005; 33:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/57\">",
"      Chaudhari AM, Zelman EA, Flanigan DC, et al. Anterior cruciate ligament-injured subjects have smaller anterior cruciate ligaments than matched controls: a magnetic resonance imaging study. Am J Sports Med 2009; 37:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/58\">",
"      Myer GD, Ford KR, Hewett TE. The effects of gender on quadriceps muscle activation strategies during a maneuver that mimics a high ACL injury risk position. J Electromyogr Kinesiol 2005; 15:181.",
"     </a>",
"    </li>",
"    <li>",
"     Sellards RA, Bach Jr BR. Management of Acute Anterior Cruciate Ligament Injuries. In: The Adult Knee, Callaghan JJ, Rosenberg AG, et al.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003. Vol 1, p.663.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/60\">",
"      Maffulli N, Binfield PM, King JB, Good CJ. Acute haemarthrosis of the knee in athletes. A prospective study of 106 cases. J Bone Joint Surg Br 1993; 75:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/61\">",
"      Noyes FR, Bassett RW, Grood ES, Butler DL. Arthroscopy in acute traumatic hemarthrosis of the knee. Incidence of anterior cruciate tears and other injuries. J Bone Joint Surg Am 1980; 62:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/62\">",
"      Spindler KP, Wright RW. Clinical practice. Anterior cruciate ligament tear. N Engl J Med 2008; 359:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/63\">",
"      Fithian DC, Paxton LW, Goltz DH. Fate of the anterior cruciate ligament-injured knee. Orthop Clin North Am 2002; 33:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/64\">",
"      Hardaker WT Jr, Garrett WE Jr, Bassett FH 3rd. Evaluation of acute traumatic hemarthrosis of the knee joint. South Med J 1990; 83:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/65\">",
"      Kozanek M, Van de Velde SK, Gill TJ, Li G. The contralateral knee joint in cruciate ligament deficiency. Am J Sports Med 2008; 36:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/66\">",
"      Benjaminse A, Gokeler A, van der Schans CP. Clinical diagnosis of an anterior cruciate ligament rupture: a meta-analysis. J Orthop Sports Phys Ther 2006; 36:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/67\">",
"      Solomon DH, Simel DL, Bates DW, et al. The rational clinical examination. Does this patient have a torn meniscus or ligament of the knee? Value of the physical examination. JAMA 2001; 286:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/68\">",
"      Ostrowski JA. Accuracy of 3 diagnostic tests for anterior cruciate ligament tears. J Athl Train 2006; 41:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/69\">",
"      Jackson JL, O'Malley PG, Kroenke K. Evaluation of acute knee pain in primary care. Ann Intern Med 2003; 139:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/70\">",
"      Dietz GW, Wilcox DM, Montgomery JB. Segond tibial condyle fracture: lateral capsular ligament avulsion. Radiology 1986; 159:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/71\">",
"      Goldman AB, Pavlov H, Rubenstein D. The Segond fracture of the proximal tibia: a small avulsion that reflects major ligamentous damage. AJR Am J Roentgenol 1988; 151:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/72\">",
"      Cosgrave CH, Burke NG, Hollingsworth J. The Segond fracture: a clue to intra-articular knee pathology. Emerg Med J 2012; 29:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/73\">",
"      Lee JK, Yao L, Phelps CT, et al. Anterior cruciate ligament tears: MR imaging compared with arthroscopy and clinical tests. Radiology 1988; 166:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/74\">",
"      Moore SL. Imaging the anterior cruciate ligament. Orthop Clin North Am 2002; 33:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/75\">",
"      Mellado JM, Calmet J, Olona M, et al. Magnetic resonance imaging of anterior cruciate ligament tears: reevaluation of quantitative parameters and imaging findings including a simplified method for measuring the anterior cruciate ligament angle. Knee Surg Sports Traumatol Arthrosc 2004; 12:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/76\">",
"      Friedl W, Glaser F. Dynamic sonography in the diagnosis of ligament and meniscal injuries of the knee. Arch Orthop Trauma Surg 1991; 110:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/77\">",
"      Ritzmann C, Weyand F. [The value of sonographic diagnosis of the injured knee joint in trauma-surgical practice]. Unfallchirurgie 1992; 18:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/78\">",
"      Richter J, D&agrave;vid A, Pape HG, et al. [Diagnosis of acute rupture of the anterior cruciate ligament. Value of ultrasonic in addition to clinical examination]. Unfallchirurg 1996; 99:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/79\">",
"      Skovgaard Larsen LP, Rasmussen OS. Diagnosis of acute rupture of the anterior cruciate ligament of the knee by sonography. Eur J Ultrasound 2000; 12:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/80\">",
"      Ptasznik R, Feller J, Bartlett J, et al. The value of sonography in the diagnosis of traumatic rupture of the anterior cruciate ligament of the knee. AJR Am J Roentgenol 1995; 164:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/81\">",
"      Mustonen AO, Koivikko MP, Haapamaki VV, et al. Multidetector computed tomography in acute knee injuries: assessment of cruciate ligaments with magnetic resonance imaging correlation. Acta Radiol 2007; 48:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/82\">",
"      Hurd WJ, Axe MJ, Snyder-Mackler L. A 10-year prospective trial of a patient management algorithm and screening examination for highly active individuals with anterior cruciate ligament injury: Part 2, determinants of dynamic knee stability. Am J Sports Med 2008; 36:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/83\">",
"      Kostogiannis I, Ageberg E, Neuman P, et al. Clinically assessed knee joint laxity as a predictor for reconstruction after an anterior cruciate ligament injury: a prospective study of 100 patients treated with activity modification and rehabilitation. Am J Sports Med 2008; 36:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/84\">",
"      Giove TP, Miller SJ 3rd, Kent BE, et al. Non-operative treatment of the torn anterior cruciate ligament. J Bone Joint Surg Am 1983; 65:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/85\">",
"      Ardern CL, Webster KE, Taylor NF, Feller JA. Return to sport following anterior cruciate ligament reconstruction surgery: a systematic review and meta-analysis of the state of play. Br J Sports Med 2011; 45:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/86\">",
"      Barrett G, Stokes D, White M. Anterior cruciate ligament reconstruction in patients older than 40 years: allograft versus autograft patellar tendon. Am J Sports Med 2005; 33:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/87\">",
"      Legnani C, Terzaghi C, Borgo E, Ventura A. Management of anterior cruciate ligament rupture in patients aged 40 years and older. J Orthop Traumatol 2011; 12:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/88\">",
"      Strehl A, Eggli S. The value of conservative treatment in ruptures of the anterior cruciate ligament (ACL). J Trauma 2007; 62:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/89\">",
"      Linko E, Harilainen A, Malmivaara A, Seitsalo S. Surgical versus conservative interventions for anterior cruciate ligament ruptures in adults. Cochrane Database Syst Rev 2005; :CD001356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/90\">",
"      Dunn WR, Lyman S, Lincoln AE, et al. The effect of anterior cruciate ligament reconstruction on the risk of knee reinjury. Am J Sports Med 2004; 32:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/91\">",
"      Mihelic R, Jurdana H, Jotanovic Z, et al. Long-term results of anterior cruciate ligament reconstruction: a comparison with non-operative treatment with a follow-up of 17-20 years. Int Orthop 2011; 35:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/92\">",
"      Magnussen RA, Mansour AA, Carey JL, Spindler KP. Meniscus status at anterior cruciate ligament reconstruction associated with radiographic signs of osteoarthritis at 5- to 10-year follow-up: a systematic review. J Knee Surg 2009; 22:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/93\">",
"      &Oslash;iestad BE, Engebretsen L, Storheim K, Risberg MA. Knee osteoarthritis after anterior cruciate ligament injury: a systematic review. Am J Sports Med 2009; 37:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/94\">",
"      Oiestad BE, Holm I, Aune AK, et al. Knee function and prevalence of knee osteoarthritis after anterior cruciate ligament reconstruction: a prospective study with 10 to 15 years of follow-up. Am J Sports Med 2010; 38:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/95\">",
"      Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med 2007; 35:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/96\">",
"      Potter HG, Jain SK, Ma Y, et al. Cartilage injury after acute, isolated anterior cruciate ligament tear: immediate and longitudinal effect with clinical/MRI follow-up. Am J Sports Med 2012; 40:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/97\">",
"      Li RT, Lorenz S, Xu Y, et al. Predictors of radiographic knee osteoarthritis after anterior cruciate ligament reconstruction. Am J Sports Med 2011; 39:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/98\">",
"      Neuman P, Englund M, Kostogiannis I, et al. Prevalence of tibiofemoral osteoarthritis 15 years after nonoperative treatment of anterior cruciate ligament injury: a prospective cohort study. Am J Sports Med 2008; 36:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/99\">",
"      Hurd WJ, Axe MJ, Snyder-Mackler L. A 10-year prospective trial of a patient management algorithm and screening examination for highly active individuals with anterior cruciate ligament injury: Part 1, outcomes. Am J Sports Med 2008; 36:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/100\">",
"      Eastlack ME, Axe MJ, Snyder-Mackler L. Laxity, instability, and functional outcome after ACL injury: copers versus noncopers. Med Sci Sports Exerc 1999; 31:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/101\">",
"      Fitzgerald GK, Axe MJ, Snyder-Mackler L. A decision-making scheme for returning patients to high-level activity with nonoperative treatment after anterior cruciate ligament rupture. Knee Surg Sports Traumatol Arthrosc 2000; 8:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/102\">",
"      Frobell RB, Roos EM, Roos HP, et al. A randomized trial of treatment for acute anterior cruciate ligament tears. N Engl J Med 2010; 363:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/103\">",
"      Ageberg E, Pettersson A, Frid&eacute;n T. 15-year follow-up of neuromuscular function in patients with unilateral nonreconstructed anterior cruciate ligament injury initially treated with rehabilitation and activity modification: a longitudinal prospective study. Am J Sports Med 2007; 35:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/104\">",
"      Kostogiannis I, Ageberg E, Neuman P, et al. Activity level and subjective knee function 15 years after anterior cruciate ligament injury: a prospective, longitudinal study of nonreconstructed patients. Am J Sports Med 2007; 35:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/105\">",
"      Biau DJ, Tournoux C, Katsahian S, et al. ACL reconstruction: a meta-analysis of functional scores. Clin Orthop Relat Res 2007; 458:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/106\">",
"      Goldblatt JP, Fitzsimmons SE, Balk E, Richmond JC. Reconstruction of the anterior cruciate ligament: meta-analysis of patellar tendon versus hamstring tendon autograft. Arthroscopy 2005; 21:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/107\">",
"      Foster TE, Wolfe BL, Ryan S, et al. Does the graft source really matter in the outcome of patients undergoing anterior cruciate ligament reconstruction? An evaluation of autograft versus allograft reconstruction results: a systematic review. Am J Sports Med 2010; 38:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/108\">",
"      Miller SL, Gladstone JN. Graft selection in anterior cruciate ligament reconstruction. Orthop Clin North Am 2002; 33:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/109\">",
"      Poolman RW, Farrokhyar F, Bhandari M. Hamstring tendon autograft better than bone patellar-tendon bone autograft in ACL reconstruction: a cumulative meta-analysis and clinically relevant sensitivity analysis applied to a previously published analysis. Acta Orthop 2007; 78:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/110\">",
"      Li S, Su W, Zhao J, et al. A meta-analysis of hamstring autografts versus bone-patellar tendon-bone autografts for reconstruction of the anterior cruciate ligament. Knee 2011; 18:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/111\">",
"      Pinczewski LA, Lyman J, Salmon LJ, et al. A 10-year comparison of anterior cruciate ligament reconstructions with hamstring tendon and patellar tendon autograft: a controlled, prospective trial. Am J Sports Med 2007; 35:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/112\">",
"      Sajovic M, Vengust V, Komadina R, et al. A prospective, randomized comparison of semitendinosus and gracilis tendon versus patellar tendon autografts for anterior cruciate ligament reconstruction: five-year follow-up. Am J Sports Med 2006; 34:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/113\">",
"      Yasuda K, Tsujino J, Ohkoshi Y, et al. Graft site morbidity with autogenous semitendinosus and gracilis tendons. Am J Sports Med 1995; 23:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/114\">",
"      Brown CH Jr, Steiner ME, Carson EW. The use of hamstring tendons for anterior cruciate ligament reconstruction. Technique and results. Clin Sports Med 1993; 12:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/115\">",
"      Zhao J, He Y, Wang J. Double-bundle anterior cruciate ligament reconstruction: four versus eight strands of hamstring tendon graft. Arthroscopy 2007; 23:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/116\">",
"      Kondo E, Yasuda K, Azuma H, et al. Prospective clinical comparisons of anatomic double-bundle versus single-bundle anterior cruciate ligament reconstruction procedures in 328 consecutive patients. Am J Sports Med 2008; 36:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/117\">",
"      Branch TP, Siebold R, Freedberg HI, Jacobs CA. Double-bundle ACL reconstruction demonstrated superior clinical stability to single-bundle ACL reconstruction: a matched-pairs analysis of instrumented tests of tibial anterior translation and internal rotation laxity. Knee Surg Sports Traumatol Arthrosc 2011; 19:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/118\">",
"      Schreiber VM, van Eck CF, Fu FH. Anatomic Double-bundle ACL Reconstruction. Sports Med Arthrosc 2010; 18:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/119\">",
"      Poolman RW, Abouali JA, Conter HJ, Bhandari M. Overlapping systematic reviews of anterior cruciate ligament reconstruction comparing hamstring autograft with bone-patellar tendon-bone autograft: why are they different? J Bone Joint Surg Am 2007; 89:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/120\">",
"      Peterson RK, Shelton WR, Bomboy AL. Allograft versus autograft patellar tendon anterior cruciate ligament reconstruction: A 5-year follow-up. Arthroscopy 2001; 17:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/121\">",
"      Conrad EU, Gretch DR, Obermeyer KR, et al. Transmission of the hepatitis-C virus by tissue transplantation. J Bone Joint Surg Am 1995; 77:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/122\">",
"      Guelich DR, Lowe WR, Wilson B. The routine culture of allograft tissue in anterior cruciate ligament reconstruction. Am J Sports Med 2007; 35:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/123\">",
"      Crawford C, Kainer M, Jernigan D, et al. Investigation of postoperative allograft-associated infections in patients who underwent musculoskeletal allograft implantation. Clin Infect Dis 2005; 41:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/124\">",
"      Malinin TI, Levitt RL, Bashore C, et al. A study of retrieved allografts used to replace anterior cruciate ligaments. Arthroscopy 2002; 18:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/125\">",
"      Lomasney LM, Tonino PM, Coan MR. Evaluation of bone incorporation of patellar tendon autografts and allografts for ACL reconstruction using CT. Orthopedics 2007; 30:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/126\">",
"      Griffith, P, Shelton, W, Bomboy, A. A comparison of quadriceps and patellar tendon for ACL reconstruction: one year functional results (abstract). Arthroscopy 1998; 14:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/127\">",
"      DeAngelis JP, Fulkerson JP. Quadriceps tendon--a reliable alternative for reconstruction of the anterior cruciate ligament. Clin Sports Med 2007; 26:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/128\">",
"      Lee S, Seong SC, Jo H, et al. Outcome of anterior cruciate ligament reconstruction using quadriceps tendon autograft. Arthroscopy 2004; 20:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/129\">",
"      Beynnon BD, Johnson RJ, Abate JA, et al. Treatment of anterior cruciate ligament injuries, part I. Am J Sports Med 2005; 33:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/130\">",
"      Mayr HO, Weig TG, Plitz W. Arthrofibrosis following ACL reconstruction--reasons and outcome. Arch Orthop Trauma Surg 2004; 124:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/131\">",
"      Isberg J, Fax&eacute;n E, Laxdal G, et al. Will early reconstruction prevent abnormal kinematics after ACL injury? Two-year follow-up using dynamic radiostereometry in 14 patients operated with hamstring autografts. Knee Surg Sports Traumatol Arthrosc 2011; 19:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/132\">",
"      Levy BA. Is early reconstruction necessary for all anterior cruciate ligament tears? N Engl J Med 2010; 363:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/133\">",
"      Sri-Ram K, Salmon LJ, Pinczewski LA, Roe JP. The incidence of secondary pathology after anterior cruciate ligament rupture in 5086 patients requiring ligament reconstruction. Bone Joint J 2013; 95-B:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/134\">",
"      Tandogan RN, Taer O, Kayaalp A, et al. Analysis of meniscal and chondral lesions accompanying anterior cruciate ligament tears: relationship with age, time from injury, and level of sport. Knee Surg Sports Traumatol Arthrosc 2004; 12:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/135\">",
"      Dumont GD, Hogue GD, Padalecki JR, et al. Meniscal and chondral injuries associated with pediatric anterior cruciate ligament tears: relationship of treatment time and patient-specific factors. Am J Sports Med 2012; 40:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/136\">",
"      DeFranco MJ, Bach BR Jr. A comprehensive review of partial anterior cruciate ligament tears. J Bone Joint Surg Am 2009; 91:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/137\">",
"      Gobbi A, Bathan L, Boldrini L. Primary repair combined with bone marrow stimulation in acute anterior cruciate ligament lesions: results in a group of athletes. Am J Sports Med 2009; 37:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/138\">",
"      van Grinsven S, van Cingel RE, Holla CJ, van Loon CJ. Evidence-based rehabilitation following anterior cruciate ligament reconstruction. Knee Surg Sports Traumatol Arthrosc 2010; 18:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/139\">",
"      Shelbourne KD, Urch SE, Gray T, Freeman H. Loss of normal knee motion after anterior cruciate ligament reconstruction is associated with radiographic arthritic changes after surgery. Am J Sports Med 2012; 40:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/140\">",
"      Wright RW, Preston E, Fleming BC, et al. A systematic review of anterior cruciate ligament reconstruction rehabilitation: part II: open versus closed kinetic chain exercises, neuromuscular electrical stimulation, accelerated rehabilitation, and miscellaneous topics. J Knee Surg 2008; 21:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/141\">",
"      Mikkelsen C, Werner S, Eriksson E. Closed kinetic chain alone compared to combined open and closed kinetic chain exercises for quadriceps strengthening after anterior cruciate ligament reconstruction with respect to return to sports: a prospective matched follow-up study. Knee Surg Sports Traumatol Arthrosc 2000; 8:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/142\">",
"      Risberg MA, Holm I, Myklebust G, Engebretsen L. Neuromuscular training versus strength training during first 6 months after anterior cruciate ligament reconstruction: a randomized clinical trial. Phys Ther 2007; 87:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/143\">",
"      Grant JA, Mohtadi NG. Two- to 4-year follow-up to a comparison of home versus physical therapy-supervised rehabilitation programs after anterior cruciate ligament reconstruction. Am J Sports Med 2010; 38:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/144\">",
"      Hiemstra LA, Webber S, MacDonald PB, Kriellaars DJ. Knee strength deficits after hamstring tendon and patellar tendon anterior cruciate ligament reconstruction. Med Sci Sports Exerc 2000; 32:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/145\">",
"      Wright RW, Preston E, Fleming BC, et al. A systematic review of anterior cruciate ligament reconstruction rehabilitation: part I: continuous passive motion, early weight bearing, postoperative bracing, and home-based rehabilitation. J Knee Surg 2008; 21:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/146\">",
"      Wright RW, Fetzer GB. Bracing after ACL reconstruction: a systematic review. Clin Orthop Relat Res 2007; 455:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/147\">",
"      Barber-Westin SD, Noyes FR. Factors used to determine return to unrestricted sports activities after anterior cruciate ligament reconstruction. Arthroscopy 2011; 27:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/148\">",
"      Salmon L, Russell V, Musgrove T, et al. Incidence and risk factors for graft rupture and contralateral rupture after anterior cruciate ligament reconstruction. Arthroscopy 2005; 21:948.",
"     </a>",
"    </li>",
"    <li>",
"     Female athlete issues for the team physician: A consensus statement. American Academy of Orthopaedic Surgeons 2003. Available online at www.aaos.org/about/papers/advistmt/1024.asp (Accessed on February 04, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/150\">",
"      Myer GD, Sugimoto D, Thomas S, Hewett TE. The influence of age on the effectiveness of neuromuscular training to reduce anterior cruciate ligament injury in female athletes: a meta-analysis. Am J Sports Med 2013; 41:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/151\">",
"      Hewett TE, Ford KR, Myer GD. Anterior cruciate ligament injuries in female athletes: Part 2, a meta-analysis of neuromuscular interventions aimed at injury prevention. Am J Sports Med 2006; 34:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/152\">",
"      Yoo JH, Lim BO, Ha M, et al. A meta-analysis of the effect of neuromuscular training on the prevention of the anterior cruciate ligament injury in female athletes. Knee Surg Sports Traumatol Arthrosc 2010; 18:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/153\">",
"      Sadoghi P, von Keudell A, Vavken P. Effectiveness of anterior cruciate ligament injury prevention training programs. J Bone Joint Surg Am 2012; 94:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/154\">",
"      Gilchrist J, Mandelbaum BR, Melancon H, et al. A randomized controlled trial to prevent noncontact anterior cruciate ligament injury in female collegiate soccer players. Am J Sports Med 2008; 36:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/155\">",
"      Mandelbaum BR, Silvers HJ, Watanabe DS, et al. Effectiveness of a neuromuscular and proprioceptive training program in preventing anterior cruciate ligament injuries in female athletes: 2-year follow-up. Am J Sports Med 2005; 33:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/156\">",
"      Wald&eacute;n M, Atroshi I, Magnusson H, et al. Prevention of acute knee injuries in adolescent female football players: cluster randomised controlled trial. BMJ 2012; 344:e3042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/157\">",
"      Caraffa A, Cerulli G, Projetti M, et al. Prevention of anterior cruciate ligament injuries in soccer. A prospective controlled study of proprioceptive training. Knee Surg Sports Traumatol Arthrosc 1996; 4:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/158\">",
"      Ettlinger CF, Johnson RJ, Shealy JE. A method to help reduce the risk of serious knee sprains incurred in alpine skiing. Am J Sports Med 1995; 23:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/159\">",
"      Heidt RS Jr, Sweeterman LM, Carlonas RL, et al. Avoidance of soccer injuries with preseason conditioning. Am J Sports Med 2000; 28:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/160\">",
"      Hewett TE, Lindenfeld TN, Riccobene JV, Noyes FR. The effect of neuromuscular training on the incidence of knee injury in female athletes. A prospective study. Am J Sports Med 1999; 27:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/161\">",
"      Herman DC, O&ntilde;ate JA, Weinhold PS, et al. The effects of feedback with and without strength training on lower extremity biomechanics. Am J Sports Med 2009; 37:1301.",
"     </a>",
"    </li>",
"    <li>",
"     Griffen LY.. The Henning Program. In: Prevention of Noncontact ACL Injuries, American Academy of Orthopaedic Surgeons, Rosemont 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/163\">",
"      DiStefano LJ, Padua DA, DiStefano MJ, Marshall SW. Influence of age, sex, technique, and exercise program on movement patterns after an anterior cruciate ligament injury prevention program in youth soccer players. Am J Sports Med 2009; 37:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/164\">",
"      Rovere GD, Haupt HA, Yates CS. Prophylactic knee bracing in college football. Am J Sports Med 1987; 15:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/165\">",
"      Sitler M, Ryan J, Hopkinson W, et al. The efficacy of a prophylactic knee brace to reduce knee injuries in football. A prospective, randomized study at West Point. Am J Sports Med 1990; 18:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/166\">",
"      Rishiraj N, Taunton JE, Lloyd-Smith R, et al. The potential role of prophylactic/functional knee bracing in preventing knee ligament injury. Sports Med 2009; 39:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/167\">",
"      Joseph M, Tiberio D, Baird JL, et al. Knee valgus during drop jumps in National Collegiate Athletic Association Division I female athletes: the effect of a medial post. Am J Sports Med 2008; 36:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/24/32138/abstract/168\">",
"      Weitzel PP, Richmond JC, Altman GH, et al. Future direction of the treatment of ACL ruptures. Orthop Clin North Am 2002; 33:653.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 243 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32138=[""].join("\n");
var outline_f31_24_32138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gender-related",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Additional factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MECHANISM AND PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Noncontact mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Contact mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Operative or nonoperative treatment?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Determining the need for surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Risk of osteoarthritis or subsequent injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Patients amenable to nonoperative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Graft selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Partial tear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1092550\">",
"      Principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1092543\">",
"      Return to activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neuromuscular training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Extrinsic supports",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      FUTURE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/243\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/243|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/16/14607\" title=\"diagnostic image 1\">",
"      Segond fx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/243|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/27/35251\" title=\"figure 1\">",
"      Anterior anatomy of knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/4/5184\" title=\"figure 2\">",
"      Q angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/14/28899\" title=\"figure 3\">",
"      Pivot shift test A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/243|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/54/17251\" title=\"picture 1\">",
"      Lachman test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/30/6628\" title=\"picture 2\">",
"      Ant drawer test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/243|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/32/523\" title=\"table 1\">",
"      ACL hi risk sports",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/11/3257?source=related_link\">",
"      Medial collateral ligament injury of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/15/16632?source=related_link\">",
"      Meniscal injury of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21157?source=related_link\">",
"      Patella fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=related_link\">",
"      Patellofemoral pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1797?source=related_link\">",
"      Patient information: Anterior cruciate ligament injury (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/12/7362?source=related_link\">",
"      Patient information: Anterior cruciate ligament tear (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/36/7747?source=related_link\">",
"      Patient information: Knee pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_24_32139="NCI CTCAE for NV v4";
var content_f31_24_32139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Cancer Institute Common Terminology Criteria for Adverse Events, nausea and vomiting",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nausea",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Loss of appetite without alteration in eating habits",
"       </td>",
"       <td>",
"        One to two episodes (separated by five minutes) in 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Oral intake decreased without significant weight loss, dehydration, or malnutrition",
"       </td>",
"       <td>",
"        Three to five episodes (separated by five minutes) in 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Inadequate oral caloric or fluid intake; tube feedings, TPN, or hospitalization indicated",
"       </td>",
"       <td>",
"        &ge;6 episodes (separated by five minutes) in 24 hours; tube feeding, TPN, or hospitalization indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TPN: total parenteral nutrition.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32139=[""].join("\n");
var outline_f31_24_32139=null;
var title_f31_24_32140="Food poisoning GI sxs";
var content_f31_24_32140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major foodborne microbes by the principal presenting gastrointestinal symptom",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Major presenting symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Likely microbes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Likely food sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Vomiting",
"       </td>",
"       <td>",
"        S. aureus",
"       </td>",
"       <td>",
"        1 to 6 hours",
"       </td>",
"       <td>",
"        Prepared food, eg, salads, dairy, meat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. cereus",
"       </td>",
"       <td>",
"        1 to 6 hours",
"       </td>",
"       <td>",
"        Rice, meat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norwalk-like viruses",
"       </td>",
"       <td>",
"        24 to 48 hours",
"       </td>",
"       <td>",
"        Shellfish, prepared foods, salads, sandwiches, fruit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Watery diarrhea",
"       </td>",
"       <td>",
"        C. perfringens",
"       </td>",
"       <td>",
"        8 to 16 hours",
"       </td>",
"       <td>",
"        Meat, poultry, gravy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterotoxigenic E. coli",
"       </td>",
"       <td>",
"        1 to 3 days",
"       </td>",
"       <td>",
"        Fecally contaminated food or water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteric viruses",
"       </td>",
"       <td>",
"        10 to 72 hours",
"       </td>",
"       <td>",
"        Fecally contaminated food or water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. parvum",
"       </td>",
"       <td>",
"        2 to 28 days",
"       </td>",
"       <td>",
"        Vegetables, fruit, unpasteurized milk, water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. cayetanensis",
"       </td>",
"       <td>",
"        1 to 11 days",
"       </td>",
"       <td>",
"        Imported berries, basil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Inflammatory diarrhea",
"       </td>",
"       <td>",
"        Campylobacter spp",
"       </td>",
"       <td>",
"        2 to 5 days",
"       </td>",
"       <td>",
"        Poultry, unpasteurized milk, water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-typhoidal salmonella",
"       </td>",
"       <td>",
"        1 to 3 days",
"       </td>",
"       <td>",
"        Eggs, poultry, meat, unpasteurized milk or juice, fresh",
"produce",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shiga toxin-producing E. coli",
"       </td>",
"       <td>",
"        1 to 8 days",
"       </td>",
"       <td>",
"        Ground beef, unpasteurized milk and juice, raw",
"vegetables, water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shigella spp",
"       </td>",
"       <td>",
"        1 to 3 days",
"       </td>",
"       <td>",
"        Fecal contamination of food and water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V. parahemolyticus",
"       </td>",
"       <td>",
"        2 to 48 hours",
"       </td>",
"       <td>",
"        Raw shellfish",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Incubation period and likely food sources are shown for each.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Centers for Disease Control and Prevention. Diagnosis and management of food borne illness, a primer for physicians. MMWR Recomm Rep 2001; 50:(RR-2):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32140=[""].join("\n");
var outline_f31_24_32140=null;
var title_f31_24_32141="Disability definitions";
var content_f31_24_32141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disability definitions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Definitions of impairment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; \"A loss, loss of use or derangement of any body part, organ system or organ function.\" AMA \"Guides\" Fifth edition",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; \"A significant deviation, loss, or loss of use of any body structure or body function in an individual with a health condition, disorder or disease.\" AMA \"Guides\" Sixth edition",
"       <sup>",
"        [2]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; \"Results from anatomical, physiological, or psychological abnormalities which can be shown by medically acceptable clinical and laboratory diagnostic techniques. A physical or mental impairment must be established by medical evidence consisting of signs, symptoms, and laboratory findings - not only by the individual's statement of symptoms.\" For an impairment to be considered \"severe\" by Social Security, it must only cause more than a mild limitation on the ability to function and work. The Social Security Administration (SSA)",
"       <sup>",
"        [3]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; \"[A]ny physiological disorder or condition, cosmetic disfigurement, or anatomical loss affecting one or more of the following body systems: neurological, musculoskeletal, special sense organs, respiratory (including speech organs), cardiovascular, reproductive, digestive, genitourinary, hemic and lymphatic, skin, and endocrine.\" The Americans with Disabilities Act",
"       <sup>",
"        [4]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; \"[A]ny mental or psychological disorder, such as mental retardation, organic brain syndrome, emotional or mental illness, and specific learning disabilities.\" Neither the statute nor the regulation lists all diseases or conditions that make up \"physical or mental impairments,\" because it would be impossible to provide a comprehensive list, given the variety and expanding number of possible impairments. For example, a person suffering from general \"stress\" because of job or personal life pressures would not be considered to have an impairment. However, if this person is diagnosed by a psychiatrist as having an identifiable stress disorder, she or he would have an impairment that may be a disability. The Americans with Disabilities Act",
"       <sup>",
"        [4]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; \"A problem in body function or structure such as a significant deviation or loss.\" \"Body functions are the physiological functions of body systems (including psychological functions). Body structures are anatomical parts of the body such as organs, limbs and their components.\" WHO's International Classification of Functioning, Disability and Health (ICF)",
"       <sup>",
"        [5]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Definitions of disability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; \"An alteration of an individual's capacity to meet personal, social or occupational demands or statutory or regulatory requirements because of an impairment.\" AMA \"Guides\" Fifth edition",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; \"Activity limitations and/or participation restrictions in an individual with a health condition disorder or disease.\" AMA \"Guides\" Sixth edition",
"       <sup>",
"        [2]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; \"The inability to engage in any substantial, gainful activity (SGA) by reason of a medically determinable physical or mental impairment(s), which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months.\" The Social Security Administration (SSA)",
"       <sup>",
"        [3]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; A physical or mental impairment that substantially limits one or more major life activities; has a record of such an impairment; or is regarded as having such an impairment. The Americans with Disabilities Act",
"       <sup>",
"        [4]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       &bull; A restriction or lack (resulting from an impairment) of ability to perform an activity in the manner or within the range considered normal for a human being. The ICF identifies three components of disability:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       - Impairments - Problems in body function or structure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       - Activity - Execution of a task or action",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       - Participation - Involvement in a life situation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       WHO's International Classification of Functioning, Disability and Health (ICF)",
"       <sup>",
"        [5]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; The IOM, in evaluating the definition of disability, notes that it is \"complex, with medical, functional, and vocational components.\" A complete and comprehensive assessment of all aspects of the definition would require a detailed clinical evaluation of the underlying medical cause(s) for the impairment; analysis of the expected duration of the impairment (prognosis); a comprehensive assessment of the work-related functional limitations attributable to the impairment, the individual's remaining functional capacity; a detailed vocational analysis of the individual's work history and acquired work skills, educational background, and age; and a thorough analysis of the individual's current vocational prospects",
"       <sup>",
"        [5]",
"       </sup>",
"       .",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Cocchiarella, L, Anderson, GBJ. Guides to the Evaluation of Permanent Impairment, 5th Ed, American Medical Association 2001. p.565.",
"     <br>",
"      2. Rondinelli, R. Medical Editor AMA Guides to the Evaluation of Permanent Impairment, Sixth Ed, 2007.",
"      <br>",
"       3. SSA Pub. No. 64-039 ICN 468600 September 2008 Disability Evaluation Under Social Security (Blue Book-September 2008).",
"       <br>",
"        4. What is the ADA: Definition of Disability: www.adata.org/whatsada-definition.aspx.",
"        <br>",
"         5. World Health Organization. International Classification of Impairments, Disability and Health. Geneva, Switzerland 2001.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32141=[""].join("\n");
var outline_f31_24_32141=null;
var title_f31_24_32142="How to stretch the backs of your legs PI";
var content_f31_24_32142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    How to stretch the backs of your legs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 234px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stand facing the wall, feet together, about 2 feet from the wall. With your heels firmly on the floor and your shoulders, hips, and knees lined up straight, lean forward into the wall. This should stretch the backs of your legs. Hold this position for 10 to 30 seconds. Repeat 5 times each session, at least twice a day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32142=[""].join("\n");
var outline_f31_24_32142=null;
var title_f31_24_32143="Proper movement avoid twisting";
var content_f31_24_32143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proper mechanics: Move entire body forward and avoid twisting at the waist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sharon Alzner, MPT.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_24_32143=[""].join("\n");
var outline_f31_24_32143=null;
